52Nd Annual Meeting

Home , Azapirone, Daniel Levey, Dickson Prize, Godfrey Phillips India, Opioid modulator

ACNP 52nd Annual Meeting

Final Program

December 8-12, 2013 The Westin Diplomat Resort & Spa Hollywood, Florida

President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D.

This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology. Dear ACNP Members and Guests, It is a distinct pleasure to welcome you to the 2014 meeting of the American College of Neuropsychopharmacology! This 52nd annual meeting will again provide opportunities for the exercise of the College’s core values: the spirit of Collegiality, promoting in each other the best in science, training and service; participation in Community, pursuing together the goals of understanding the neurobiology of brain diseases and eliminating their burden on individuals and our society; and engaging in Celebration, taking the time to recognize and enjoy the contributions and accomplishments of our members and guests. Under the excellent leadership of Randy Blakely and Pat Levitt, the Program Committee has done a superb job in assembling an outstanding slate of scientific presentations. Based on membership feedback, the meeting schedule has been designed with the goals of achieving an optimal mix of topics and types of sessions, increasing the diversity of participating scientists and creating more time for informal interactions. The presentations will highlight both the breadth of the investigative interests of ACNP membership and the unprecedented depth of studies examining disease mechanisms and new strategies for treating these illnesses. Accordingly, the theme of this year’s meeting, reflected in the title of the Plenary Session, is “Neural Circuitry Structure and Plasticity: Substrate for Brain Disorders and Novel Therapeutics.” I believe you will experience at this meeting ample evidence of the continued efforts of ACNP Council and staff to ensure the College’s successful leadership in shaping the future of our field, in facilitating the engagement of a broader group of investigators and in preserving the distinctive features that define us as a unique community of scientists and clinicians. I would like to extend a special note of thanks to Ronnie Wilkins, Sarah Timm, Laura Bersacola-Hill and the rest of the ACNP staff for their tremendous help and good humor over the past year. It has been a pleasure and honor to serve as president of the ACNP. I hope you find the meeting enlightening, energizing and enjoyable!

David A. Lewis, M.D. President, 2013 ACNP AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY 52nd ANNUAL MEETING

GENERAL PROGRAM

HOLLYWOOD, FLORIDA WESTIN DIPLOMAT RESORT & SPA

DECEMBER 8-12, 2013

Disclosures for 2013 speakers (mini-panel, panel, study group, and plenary) and poster presenters may be found online at: www.acnp.org (click the Annual Meeting tab). Vanderbilt CME has determined that there is no conflict of interest.

ACNP Annual Meeting Book 2013 rev8.indd 1 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2nd Floor Convention Center

THE WESTIN CONVENTION SERVICE FREIGHT DIPLOMAT CENTER ELEVATORS ELEVATOR

ATLANTIC REGENCY BALLROOM BALLROOM 54 3 3 GRAND GRAND ATLANTIC BALLROOM BALLROOM RRIDOR BALLROOM REGENCY RRIDOR DIPLOMAT EAST WEST 2 BALLROOM BALLROOM 2 3 VICE CO

ATLANTIC VICE CO

SER BALLROOM 1 REGENCY SER 1 2 BALLROOM M W 1 S REGISTRATION ESCALATOR ELEVATORS

E W

TERRACE N

WALKWAY TO RESORT

Meeting rooms for panels, mini-panels, plenaries, and study groups are on the 2nd floor of the Convention Center (map above). Poster sessions and group lunches are on the 3rd floor (map below).

3rd Floor Convention Center

THE WESTIN CONVENTION SERVICE DIPLOMAT CENTER ELEVATORS

FREIGHT ELEVATOR M W

GREAT HALL GREAT HALL M 6 2

GREAT HALL GREAT HALL TERRACE 4 3

GREAT HALL GREAT HALL W 5 1

ELEVATORS REGISTRATION E W

ESCALATOR

ACNP Annual Meeting Book 2013 rev8.indd 2 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Resort, Second Floor

THE WESTIN CONVENTION NORTH SOUTH DIPLOMAT CENTER TOWER TERRAC TOWER TERRACE E

203 218 202 201 220 219 204 217 ESCALATORS

205 216

SERVICE ELEVATORS SERVICE WALKWAY TO ELEVATORS ELEVATORS ELEVATORS SKYWALK CONVENTION CENTER

MW 209 WM

206 208 215 E 207 212 213 214

N S EXECUTIVE BUSINESS OFFICES CENTER TERRACE W

Conference rooms for committee and board meetings are located on the 2nd and 3rd floor of the hotel. Most small meetings have been scheduled on the hotel side.

Resort, Third Floor

THE WESTIN CONVENTION NORTH SOUTH TERRAC DIPLOMAT CENTER TOWER TOWER TERRACE E 318 302 301 320319 303 317 322 321

305 316 ESCALATOR ESCALATOR

SERVICE ELEVATORS SERVICE ELEVATORS SKYWALK ELEVATORS ELEVATORS

MW 309 310 WM

306 308 311 315 E 312 313 314 307 N S EXECUTIVE OFFICES TERRACE W

iii

ACNP Annual Meeting Book 2013 rev8.indd 3 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Program at a Glance Saturday, December 7, 2013 Monday, December 9, 2013 Tuesday, December 10, 2013

8:00 AM – 3:00 PM Room 319 & 320 12:00 PM – 1:00 PM Room 206 6:45 AM – 8:00 AM Room 220 ACNP Council Meeting CNS Spectrums Field Editor/Deputy Editor CDI Booster Session Meeting 8:00 AM – 5:00 PM Diplomat Ballroom 5 7:00 AM – 8:00 AM Room 207 ACNP Membership Committee Meeting 1:30 PM – 3:00 PM Grand Ballroom ACNP Leadership & Institute Directors Distinguished Lecture: “The Story of Rett 8:00 AM – 8:00 PM Diplomat Ballroom 1 & 2 Syndrome and the Insight it Provides into 7:00 AM – 8:00 AM Room 218 Schizophrenia Prodome Meeting Neuropsychiatric Disorders” CME Institute Executive Directors Meeting

2:00 PM – 4:00 PM Room 208 Mini-Panel Sessions 7:00 AM – 8:30 AM Diplomat Ballroom 4 Neuropsychopharmacology & 3:00 PM – 4:15 PM Diplomat Ballroom 1 & 2 ACNP Education & Training Committee Neuropsychopharmacology Reviews Neuronal Immaturity in Schizophrenia Meeting EIC & Deputy Editors Meeting 4:15 PM – 5:30 PM Diplomat Ballroom 1 & 2 7:00 AM – 8:30 AM Room 203 4:00 PM – 5:00 PM Room 218 Social Processes Initiative in ACNP Membership Advisory Task Force ACNP Website Editors Meeting Neurobiology of the Schizophrenia(s) Meeting 4:00 PM – 5:30 PM Room 202 Panel Sessions ACNP Ethics Committee Meeting 7:00 AM – 8:30 AM Room 316 3:00 PM – 5:30 PM Atlantic Ballroom 1 American Journal of Psychiatry Editorial 5:00 PM – 6:30 PM Room 208 Kicking Over the Traces – Noncatecholic Board Meeting ACNP Publications Committee Meeting Biogenic Amines and Their Receptors Mini-Panel Sessions 6:30 PM – 8:30 PM Great Hall 5 3:00 PM – 5:30 PM Regency Ballroom 2 8:30 AM – 9:45 AM Diplomat Ballroom 1 & 2 ACNP Travel Award Reception Can Biology Inform Treatment Prediction and Biochemical and Behavioral Pharmacology (by invitation only) Selection in Depression? of Synthetic Cathinone Derivatives Found in Psychoactive Bath Salts Products Sunday, December 8, 2013 3:00 PM – 5:30 PM Atlantic Ballroom 2 Autism Spectrum Disorders: From Rare 9:45 AM – 11:00 AM Diplomat Ballroom 1 & 2 8:30 AM – 11:30 AM Regency Ballroom 1 & 2 Chromosomal Abnormalities to Common After the Trauma: Developmental Trajectories Neuropsychopharmacology Reviews Molecular Targets from Childhood to Adult Psychiatric Disorders Plenary: “Frontiers in Discovery and 3:00 PM – 5:30 PM Atlantic Ballroom 3 Neurotherapeutics” Panel Sessions Circuitry Underlying Obsessive-compulsive 8:30 AM – 11:00 AM Regency Ballroom 3 Disorder: Lessons from Deep Brain 11:30 AM – 1:00 PM Room 212 & 213 Augmentation of Antidepressant Response by Stimulation and Ablative Surgery Past Presidents’ Luncheon Autoreceptor-mediated Mechanisms: Clinical Experience and Mechanisms of Action 11:30 AM – 1:00 PM Diplomat Ballroom 5 3:00 PM – 5:30 PM Regency Ballroom 1 ACNP Program Committee Meeting The Role of Inflammation in the Pathophysiology of Mood, Aggressive and 8:30 AM – 11:00 AM Regency Ballroom 2 11:30 AM – 1:00 PM Diplomat Ballroom 4 Medical Disorders: A Deadly Combination Neuroactive Steroids and Oxysterols as ACNP Liaison Committee Meeting Endogenous Modulators of GABA and 3:00 PM – 5:30 PM Regency Ballroom 3 Glutamate Receptors: Basic Mechanisms and 11:30 AM – 1:00 PM Diplomat Ballroom 1 Structural and Functional Brain Changes Therapeutic Implications FNIH Biomarkers Consortium in Young People at Risk for Severe Mental Illness 8:30 AM – 11:00 AM Atlantic Ballroom 1 11:30 AM – 1:00 PM Diplomat Ballroom 2 The Future of Translational Research in Neuropsychopharmacology Editorial Board 5:30 PM – 7:30 PM Great Hall 1-4 Addiction Poster Session I with Reception 1:00 PM – 2:30 PM Regency Ballroom 1 & 2 8:30 AM – 11:00 AM Atlantic Ballroom 2 NIH Institutes Directors’ Briefing Study Groups At the Crossroads of Physics, Physiology, and 7:30 PM – 9:00 PM Regency Ballroom 1 Psychiatry: Rational Design of Noninvasive 2:30 PM – 6:30 PM Regency Ballroom 1 & 2 The Challenges of Designing and Interpreting Neuromodulation Therapies Hot Topics Clinical Trials with Depot Antipsychotics 8:30 AM – 11:00 AM Atlantic Ballroom 3 6:30 PM – 7:30 PM Room 201 & 202 7:30 PM – 9:00 PM Regency Ballroom 2 Nutrition, Neurodevelopment, and Risk Associate Member Reception Mental Illness, Violence and the Gun Control for Schizophrenia and Autism: From (by invitation only) Debate: Evidence, Policy, Privacy and Stigma Epidemiology to Epigenetics 7:00 PM – 9:00 PM Infinity Pool “T” Area – On Behalf of the ACNP Ethics Committee Opening Night Reception 8:30 AM – 11:00 AM Regency Ballroom 1 7:30 PM – 9:00 PM Regency Ballroom 3 Peripheral Immune and Endocrine Pathways New Models of Open Innovation to Monday, December 9, 2013 as Markers of PTSD Risk and Symptom Rejuvenate the Biopharmaceutical Development: Evidence from Prospective 6:45 AM – 8:00 AM Room 220 Ecosystem, A Proposal by the ACNP Liaison Studies CDI Booster Session Committee 10:30 AM – 4:30 PM Great Hall 1 – 4 8:00 AM – 11:30 AM Grand Ballroom 7:30 PM – 9:00 PM Atlantic Ballroom 2 Poster Viewing President’s Plenary: “Neural Circuitry Medical and Non-Medical Use of Stimulant Structure and Plasticity: Substrate for Brain Drugs for Cognitive Enhancement 11:00 AM – 12:30 PM Diplomat Ballroom 4 ACNP Corporate Liaison Luncheon Disorders and Novel Therapeutics” 7:30 PM – 9:00 PM Atlantic Ballroom 1 (by invitation only) 10:30 AM – 4:30 PM Great Hall 1-4 The Assessment of Suicidal Ideation, Poster Viewing Behavior & Risk: At Baseline; As a Measure 11:00 AM – 12:30 PM Room 217 of Clinical Outcome, and/or as a Treatment ACNP Public Information Committee Meeting 11:30 AM – 1:00 PM Great Hall 5 & 6 Emergent SAE Women’s Luncheon iv

ACNP Annual Meeting Book 2013 rev8.indd 4 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Program at a Glance Tuesday, December 10, 2013 Wednesday, December 11, 2013 Thursday, December 12, 2013 11:30 AM – 1:30 PM Regency Ballroom 2 8:30 AM – 11:00 AM Regency Ballroom 1 7:00 AM – 8:00 AM Room 212 Data Blitz Session The Ventromedial Prefrontal Cortex in ACNP/AsCNP/CINP/ECNP Meeting Conditioning and Extinction in Chronically 1:30 PM – 3:00 PM Regency Ballroom 1 Relapsing Disorders Panel Sessions Career Development Session 8:00 AM – 10:30 AM Diplomat Ballroom 1 & 2 8:30 AM – 11:00 AM Atlantic Ballroom 3 Molecular Regulation and Clinical Mini-Panel Sessions α4β2-Nicotinic Acetylcholine Receptors in Applications of Phosphodiesterase 4, the 3:00 PM – 4:15 PM Diplomat Ballroom 1 & 2 Schizophrenia: Implications for Smoking Major Enzyme for Degrading cAMP Emerging Role of the Primary Cilium in Cessation and Therapeutics Neuropsychiatric Disorders 8:00 AM – 10:30 AM Regency Ballroom 1 8:30 AM – 11:00 AM Regency Ballroom 2 Naltrexone Revisited: New Findings Beyond 4:15 PM – 5:30 PM Diplomat Ballroom 1 & 2 New Directions for Optogenetics: Mu, Beyond Dopamine and Beyond Addiction Adolescent Brain Development and Affective Investigating Plasticity Mechanisms Disorders: The Role of Reward and Threat Underlying Psychiatric Disorders 8:00 AM – 10:30 AM Regency Ballroom 3 Circuitry Understanding Neurodevelopmental Risk 8:30 AM – 11:00 AM Regency Ballroom 3 Factors Leading to Anxiety and Depression to Alterations of the Glutamate Cycle in Severe Panel Sessions Inform Novel Early Interventions in Vulnerable Mental Illness 3:00 PM – 5:30 PM Regency Ballroom 1 Children Treating Addiction: Should We Aim High or Low? 8:30 AM – 11:00 AM Atlantic Ballroom 1 8:00 AM – 10:30 AM Atlantic Ballroom 1 3:00 PM – 5:30 PM Atlantic Ballroom 3 Epigenetic Mechanisms in Neuropsychiatric Disorders Brain on Fire: Inflammation in Neurological Anxiety and the Striatum, an Unusual and Psychiatric Illness Suspect 10:30 AM – 4:30 PM Great Hall 1 – 4 Poster Viewing 8:00 AM – 10:30 AM Atlantic Ballroom 2 3:00 PM – 5:30 PM Atlantic Ballroom 2 Melatonin and Its Receptors: Important Posttraumatic Stress Disorder: From Markers 11:15 AM – 12:30 PM Regency Ballroom 2 Players in Major Depressive Disorder to Mechanisms ACNP Business Meeting (ACNP Fellows, Members, and Associate Members Only) 8:00 AM – 10:30 AM Atlantic Ballroom 3 3:00 PM – 5:30 PM Atlantic Ballroom 1 Building a More Predictive Mouse: Pathophysiology and Treatment of Obesity 12:30 PM – 2:00 PM Diplomat Ballroom 4 Humanized Mouse Models for and Glucose Dysregulation in Schizophrenia SOBP Program Committee Meeting Neuropsychiatric Disorders 3:00 PM – 5:30 PM Regency Ballroom 2 12:30 PM – 2:00 PM Great Hall 5 8:00 AM – 10:30 AM Regency Ballroom 2 Biotypes of Psychosis Travel Awardee Luncheon (by Invitation Only) Broadening the Trajectories of Risk: Specific and Non-specific Markers of Risk of 3:00 PM – 5:30 PM Regency Ballroom 3 2:00 PM – 3:00 PM Room 209 Psychopathology An Update from the Clinic on mGluR2/3 PMG Board Meeting Approaches for Treating Schizophrenia – Mini-Panel Sessions 9:00 AM – 12:00 PM Room 319 & 320 Understanding Human Circuit Engagement 3:00 PM – 4:15 PM Diplomat Ballroom 1 & 2 ACNP Council Meeting through to Recent Clinical Trials Human Brain Evolution and Comparative Epigenomics Panel Sessions 5:30 PM – 7:30 PM Great Hall 1-4 12:00 PM – 2:30 PM Regency Ballroom 2 Poster Session II with Reception 4:15 PM – 5:30 PM Diplomat Ballroom 1 & 2 Experimental Therapeutics and Drug Intergenerational Transmission of Trauma – Development Targeting Inflammation in 6:00 PM – 11:00 PM Room 319 & 320 From Animal Models to Humans Developmental Disorders ACNP Council – Committee Chairs Panel Sessions 12:00 PM – 2:30 PM Atlantic Ballroom 3 6:00 PM – 11:00 PM Room 318 3:00 PM – 5:30 PM Regency Ballroom 2 Applying Animal and Human Models of Risk ACNP Committee Chairs Waiting Room Legal Damages: New Insights into Chronic Avoidance and Impulsivity to Understanding Marijuana Effects on Human Brain Structure Eating Disorders Wednesday, December 11, 2013 and Function 12:00 PM – 2:30 PM Diplomat Ballroom 1 & 2 3:00 PM – 5:30 PM Atlantic Ballroom 3 6:45 AM – 8:00 AM Room 220 Novel Molecules and Mechanisms in Glutamate-dopamine Interactions in Nicotine CDI Booster Session Vulnerability and Resilience Throughout Life and Cocaine Dependence: Biomarkers and 7:00 AM – 8:30 AM Room 201 Therapy Opportunities 12:00 PM – 2:30 PM Regency Ballroom 1 ASCP Board of Director’s Meeting Cognition, Biomarkers, and Longitudinal 3:00 PM – 5:30 PM Regency Ballroom 1 Outcomes in Geriatric Mood Disorders Mini-Panel Sessions Public-private Repositioning Partnerships: A 8:30 AM – 9:45 AM Diplomat Ballroom 1 & 2 New Path to Achieve Target Validation and 12:00 PM – 2:30 PM Regency Ballroom 3 Are the Putative Therapeutic Effects of Proof of Concept for Novel CNS Indications The Insula Salience Network: Alterations in Its Connectivity in Developmental, Anxiety, Kappa-opioid Antagonists Explained by 3:00 PM – 5:30 PM Atlantic Ballroom 2 Mood and Personality Disorders Anti-Stress Actions? Multidimensional Data Integration and Causality: A Systems Approach for 9:45 AM – 11:00 AM Diplomat Ballroom 1 & 2 12:00 PM – 2:30 PM Atlantic Ballroom 1 Unraveling the Molecular Architecture of Developing Imaging Biomarkers for Strategies for the Development of Novel Mental Disorders Treatment Development: Beyond CNTRICS, Therapies for Schizophrenia: From Clinic to CNTRaCs and NEWMEDS 3:00 PM – 5:30 PM Regency Ballroom 3 Laboratory (And Back Again) Early Stress and Emotion Dysregulation Panel Sessions 12:00 PM – 2:30 PM Atlantic Ballroom 2 8:30 AM – 11:00 AM Atlantic Ballroom 2 3:00 PM – 5:30 PM Atlantic Ballroom 1 Behavioral, Endocrine, and Neural Plasticity Manipulating BDNF-TrkB Signaling in Brain Neurobiological Regulation of Palatable Food Changes Reflecting Stress Associated with Disorders: Complex Regulation and Cellular Binging and Seeking Mouse and Monkey Models of Heavy Alcohol and Systems Level Interactions as Novel Drinking Substrates for Translational Medicine? 5:30 PM – 7:30 PM Great Hall 1-4 Poster Session III with Reception v

ACNP Annual Meeting Book 2013 rev8.indd 5 11/15/13 4:10 PM ACNP Annual Meeting Book 2013 rev8.indd 6 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Tuesday, December 10th Morning Mini-Panel Sessions • After the Trauma: Developmental Trajectories from Childhood to Adult Psychiatric Disorders ...... 89 • Biochemical and Behavioral Pharmacology of Synthetic Cathinone Derivatives Found in Psychoactive Bath Salts Products. . . . 90

Morning Panel Sessions • At the Crossroads of Physics, Physiology, and Psychiatry: Rational Design of Noninvasive Neuromodulation Therapies...... 91 • Augmentation of Antidepressant Response by Autoreceptor-Mediated Mechanisms: Clinical Experience and Mechanisms of Action. . . . 92 • Neuroactive Steroids and Oxysterols as Endogenous Modulators of GABA and Glutamate Receptors: Basic Mechanisms and Therapeutic Implications ...... 93 • Nutrition, Neurodevelopment, and Risk for Schizophrenia and Autism: From Epidemiology to Epigenetics...... 94 • Peripheral Immune and Endocrine Pathways as Markers of PTSD Risk and Symptom Development: Evidence from Prospective Studies...... 95 • The Future of Translational Research in Addiction ...... 96 Data Blitz Session • Can Serotonin Put Your Mind at Rest?...... 99 • Effects of Pharmacogenetic Manipulation of the Nucleus Accumbens on Neuronal Activity and Alcohol-Related Behaviors. . . . 101 • Feedforward and Feedback Control Abnormalities During Precision Grasping Implicate Cerebellar Dysfunction in Autism Spectrum Disorder...... 103 • Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-NMDA Receptor Encephalitis...... 105 • Genetic Background Regulates the Effect of Antidepressant Treatment on Behavioral Despair and Hippocampal Neurogenesis in Mice...... 107 • High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish...... 108 • Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders...... 110 • Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants...... 113

vii

ACNP Annual Meeting Book 2013 rev8.indd 7 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

• Poverty and the Past: The Relation Between Hippocampus Function and Memory Performance is Linked to Childhood Poverty...... 116 • Rare Genetic Variants in VMAT1 (SLC18A1) Are Functional in Vitro and Associated with Bipolar Disorder...... 118 • Real-time Functional MRI Feedback, Compared to Sham, Reduces Cue-Induced Nicotine Craving in Smokers: Results from the First Clinical Trial...... 120 • Substrate-selective COX-2 Inhibition Decreases Anxiety via Endocannabinoid Activation...... 122 Afternoon Mini-Panel Sessions • Emerging Role of the Primary Cilium in Neuropsychiatric Disorders...... 123 • Adolescent Brain Development and Affective Disorders: The Role of Reward and Threat Circuitry ...... 123 Afternoon Panel Sessions • An Update from the Clinic on mGluR2/3 Approaches for Treating Schizophrenia – Understanding Human Circuit Engagement through to Recent Clinical Trials...... 124 • Anxiety and the Striatum, an Unusual Suspect...... 125 • Biotypes of Psychosis...... 126 • Pathophysiology and Treatment of Obesity and Glucose Dysregulation in Schizophrenia...... 127 • Posttraumatic Stress Disorder: From Markers to Mechanisms. . . . 128 • Treating Addiction: Should We Aim High or Low?...... 129

viii

ACNP Annual Meeting Book 2013 rev8.indd 8 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Wednesday, December 11th

Morning Mini-Panel Sessions • Are the Putative Therapeutic Effects of Kappa-opioid Antagonists Explained by Anti-stress Actions? ...... 131 • Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS, CNTRaCs and NEWMEDS...... 131

Morning Panel Sessions • Alterations of the Glutamate Cycle in Severe Mental Illness...... 132 • Epigenetic Mechanisms in Neuropsychiatric Disorders...... 133 • α4β2-Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics ...... 134 • Manipulating BDNF-TrkB Signaling in Brain Disorders: Complex Regulation and Cellular & Systems Level Interactions as Novel Substrates for Translational Medicine...... 135 • New Directions for Optogenetics: Investigating Plasticity Mechanisms Underlying Psychiatric Disorders...... 136 • The Ventromedial Prefrontal Cortex in Conditioning and Extinction in Chronically Relapsing Disorders ...... 137

Afternoon Mini-Panel Sessions • Human Brain Evolution and Comparative Epigenomics...... 138 • Intergenerational Transmission of Trauma – From Animal Models to Humans ...... 138

Afternoon Panel Sessions • Legal Damages: New Insights into Chronic Marijuana Effects on Human Brain Structure and Function ...... 139 • Early Stress and Emotion Dysregulation ...... 140 • Glutamate-dopamine Interactions in Nicotine and Cocaine Dependence: Biomarkers and Therapy Opportunities...... 141 • Multidimensional Data Integration and Causality: A Systems Approach for Unraveling the Molecular Architecture of Mental Disorders...... 142 • Neurobiological Regulation of Palatable Food Binging and Seeking...... 143 • Public-private Repositioning Partnerships: A New Path to Achieve Target Validation and Proof of Concept for Novel CNS Indications...... 144

ACNP Annual Meeting Book 2013 rev8.indd 9 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Thursday, December 12th

Morning Panel Sessions • Brain on Fire: Inflammation in Neurological and Psychiatric Illness ...... 147 • Broadening the Trajectories of Risk: Specific and Non-Specific Markers of Risk of Psychopathology...... 148 • Building a More Predictive Mouse: Humanized Mouse Models for Neuropsychiatric Disorders...... 149 • Melatonin and its Receptors: Important Players in Major Depressive Disorder...... 150 • Molecular Regulation and Clinical Applications of Phosphodiesterase 4, the Major Enzyme for Degrading cAMP. . . . . 151 • Naltrexone Revisited: New Findings Beyond Mu, Beyond Dopamine and Beyond Addiction...... 152 • Understanding Neurodevelopmental Risk Factors Leading to Anxiety and Depression to Inform Novel Early Interventions in Vulnerable Children...... 153

Afternoon Panel Sessions • Applying Animal and Human Models of Risk Avoidance and Impulsivity to Understanding Eating Disorders...... 154 • Behavioral, Endocrine, and Neural Plasticity Changes Reflecting Stress Associated with Mouse and Monkey Models of Heavy Alcohol Drinking...... 155 • Cognition, Biomarkers, and Longitudinal Outcomes in Geriatric Mood Disorders...... 156 • Experimental Therapeutics and Drug Development Targeting Inflammation in Developmental Disorders...... 157 • Novel Molecules and Mechanisms in Vulnerability and Resilience Throughout Life...... 158 • Strategies for the Development of Novel Therapies for Schizophrenia: From Clinic To Laboratory (And Back Again). . . . . 159 • The Insula Salience Network: Alterations in its Connectivity in Developmental, Anxiety, Mood and Personality Disorders...... 160

ACNP Annual Meeting Book 2013 rev8.indd 10 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Sessions Poster Session I...... 163 Poster Session II...... 201 Poster Session III ...... 239

Nonmember Participant List...... 277 Disclosures...... 289 Author Index...... 311

ACNP Annual Meeting Book 2013 rev8.indd 11 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Acknowledgments

The American College of Neuropsychopharmacology appreciates the support of our supporting corporations:

AbbVie, Inc . Alkermes, Inc . Amgen, USA Astellas Pharma Eisai Medical Research, Inc . Envivo Pharmaceuticals Forest Laboratories, Inc . Genentech H . Lundbeck A/S, Denmark Hoffmann-LaRoche, Inc . Janssen Pharmaceuticals, Inc . Lilly USA, LLC Merck Novartis Pharmaceuticals Corporation Otsuka America Pharmaceutical, Inc . Otsuka Pharmaceutical Development and Commercialization, Inc . Sunovion Pharmaceuticals, Inc . Takeda Pharmaceuticals Targacept, Inc .

Vanderbilt University School of Medicine Department of Psychiatry and the American College of Neuropsychopharmacology express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

Lilly USA, LLC Otsuka America Pharmaceutical, Inc .

xii

ACNP Annual Meeting Book 2013 rev8.indd 12 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Council

Officers and Council President David A . Lewis President-Elect Peter W . Kalivas President-Elect Designate Raquel E . Gur Secretary Alan Frazer Treasurer David J . Kupfer Council Karen F . Berman Linda S . Brady John G . Csernansky Ronald S . Duman Suzanne N . Haber John H . Krystal Robert C . Malenka Eric J . Nestler

Program Committee

2013 Program and Scientific Communications Committee Chair Randy Blakely Co-Chair Pat Levitt Council Liaison Peter W . Kalivas Members Ted Abel Kalpana Merchant Matthew State Anissa Abi-Dargham Andreas Meyer- Trisha Suppes Gary Aston-Jones Lindenberg Audrey Tyrka Hilary Blumberg Karoly Mirnics Rachel Yehuda John Bruno Bita Moghaddam Carlos Zarate Kristin Cadenhead Lisa Monteggia Ariel Deutch Uma Rao Ad Hoc: Stephen Deutsch Kerry Ressler Joseph Callicott Rita Goldstein John Rubenstein David Grandy Paul Kenny Akira Sawa Robert Greene Henry Kranzler Darryle Schoepp James Sutcliffe Stephen Marder Thomas Schulze Barbara Mason Etienne Sibille Jeremy Veenstra- Daniel Mathalon Pamela Sklar Vander Weele Colleen McClung Arielle Stanford

ACNP Annual Meeting Book 2013 rev8.indd 1 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

General Information

Dates and Location

Dates Sunday, December 8, 2013 - Thursday, December 12, 2013 Location The Westin Diplomat, Hollywood, Florida

Program Book

All scientific registrants will receive a Program Book as part of their registration material . The Program Book is also available on the ACNP website, www .acnp .org .

Itinerary Planner

All scientific registrants will be able to access the itinerary planner for the 52nd ACNP Annual Meeting at http://www .eventscribe .com/2013/ACNP .

ACNP Executive Office

ACNP Executive Office 5034A Thoroughbred Lane Brentwood, Tennessee 37027 USA

Phone: 615-324-2360 Fax: 615-523-1715 E-mail: acnp@acnp .org

ACNP Annual Meeting Book 2013 rev8.indd 2 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Continuing Medical Education

The 2013 ACNP Annual Meeting is jointly sponsored by the Vanderbilt University School of Medicine and the ACNP . This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for CME (ACCME) through the joint sponsorship of Vanderbilt University School of Medicine and the ACNP .

Vanderbilt University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians .

Vanderbilt University School of Medicine designates this live activity for a maximum of 36 .25 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity .

There will be a $40.00 charge for scientific registrants to obtain CME credits. CME instructions will be available at the meeting registration desk and on the ACNP website (www .acnp .org) .

It is the policy of Vanderbilt University School of Medicine and the ACNP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity . Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations .

Program Overview/Statement of Need

The Annual Meeting of the American College of Neuropsychopharmacology is designed to meet the educational needs of ACNP members and invited non-member colleagues . Current data suggests that in any given year more than 20% of the U .S . adult population suffers from a diagnosable mental disorder . Four of the ten leading causes of disability in the U .S . are psychiatric disorders, including schizophrenia, depression, bipolar disorder, and obsessive-compulsive disorder . ACNP members have been among the leaders in identifying underlying mechanisms for these disorders and developing new treatment strategies . The desired results for the meeting are that ACNP members and their invited guests learn of the latest developments in preclinical and clinical research being performed by their colleagues and world experts in order to 1) enhance understanding of the neurobiological bases of current best practice approaches, 2) enhance understanding of neurobiological and clinical science underpinnings in development of novel therapeutic strategies, particularly for treatment-resistant forms of illness, and 3) lead to improvements in study designs for proposed clinical and basic studies .

ACNP Annual Meeting Book 2013 rev8.indd 3 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Continuing Medical Education (continued)

Target Audience The target audience includes members of the American College of Neuropsycho- pharmacology and invited experts . The audience includes physicians, psychologists, and basic neuroscientists from across the United States as well as Europe and Asia . The physicians include a number of specialties, with psychiatrists representing the majority of attendees, and neurologists next most common . Psychologists include clinical psychologists and neuropsychologists .

Learning Objectives: After participating in this CME activity, participants should be able to: • Describe and discuss how the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area impact your current or potential future research projects . • Describe and discuss how you will change or modify a current approach or strategy in your current or potential future research projects based on what you learned from the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area . • Describe and discuss how recent progress in identifying genetic variations that are risk factors for the development of psychiatric disorders affect your current or potential future research projects .

Americans with Disabilities Act It is the policy of Vanderbilt University School of Medicine not to discriminate against any person on the basis of disabilities . If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-324-2360 or send an email to acnp@acnp .org .

Meeting Evaluation

All meeting attendees are urged to complete an evaluation of the meeting . Attendees who are requesting CME credit for the meeting are required to complete the evaluation . This form is available online only . You may complete the evaluation in the ACNP Computer Center located in Diplomat 1 & 2 foyer or on-line at www .acnp .org (click the Annual Meeting tab) . All evaluations must be completed by January 23, 2014 .

ACNP Annual Meeting Book 2013 rev8.indd 4 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Future ACNP Annual Meetings

Dates Hotel Location

December 7 - 11, 2014 JW Marriott Desert Ridge Resort Phoenix, Arizona

December 6 - 10, 2015 The Westin Diplomat Hollywood, Florida

December 4 - 8, 2016 The Westin Diplomat Hollywood, Florida

December 3 - 7, 2017 JW Marriott Desert Springs Resort Palm Springs, California

In Memoriam

Sydney Spector October 26, 2012

Peter B . Dews November 2, 2012

Svein G . Dahl December 8, 2012

Daniel W . Hommer January 2, 2013

Albert Weissman July 11, 2013

Ernest Hartmann August 7, 2013

Candace B . Pert September 12, 2013

ACNP Annual Meeting Book 2013 rev8.indd 5 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

ACNP Annual Meeting Book 2013 rev8.indd 6 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Neuropsychopharmacology Reviews Plenary

“Frontiers in Discovery and Neurotherapeutics”

Co-Chairs: Carol Nilsson and Kathryn Cunningham

8:30 a .m . Integrated Omics Approach to Neuropharmacological Studies Mark Emmett

8:55 a .m . Approaches for the Small-volume Analysis of Cell–cell Signaling Molecules in the Brain Jonathan Sweedler

9:20 a .m . Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Relevance to Neuropsychiatric Disease Susan R. George

9:45 a .m . Use of CSF Biomarkers for Alzheimer’s Disease in Clinical Trials Kaj Blennow

10:10 a .m . New Technologies Promise Revitalization of Psychiatric Therapeutics Steven E. Hyman

10:35 a .m . Discussion Carol Nilsson and Kathryn Cunningham

ACNP Annual Meeting Book 2013 rev8.indd 7 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Integrated Omics Approach to Neuropharmacological Studies

Mark Emmett University of Texas Medical Branch-Galveston (UTMB)

Understanding the response of neurological cell populations (normal vs . diseased, treated vs . untreated, etc .) and evidence that these cell populations are “drivers” of disease underscores the importance of understanding detailed biology at the molecular level of these cells . Utilizing an integrated omics (systems biology) approach to probe the response of these cells will guide the rational design of therapeutic treatment(s) . Due to the complexity of the system biology approach, this research is most often accomplished through multi-disciplinary and inter- institutional collaborations because no one laboratory has expertise in all the technologies required .

Systems biology research is built on knowledge derived from global datasets measured in patterns of response of the transcriptome, proteome, glycome, lipidome, and metabolome . To obtain knowledge of the signaling pathways involved in the maintenance of the normal vs . diseased state or treated vs . untreated states, quantitative phosphoproteomic, glycomic, transcriptomic, lipidomic and metabolomic data sets are collected on each sample (with biological and analytical replicates) . These large data sets are then processed with innovative mathematical- computational algorithms tailored to define correlations between the data sets and graphical modeling to reconstruct pathways that are not yet defined in the scientific literature. The focus is to identify and characterize pathway reactions that will bridge the final gap and, for the first time, enable a mechanism to a) understand cellular responses, b) identify new targets and diagnostic biomarkers and c) design appropriate therapeutic interventions specifically targeting disease.

This approach has been developed and applied to the study of glioma and data will be presented linking omics technologies in these studies . All of the technologies developed for these glioma studies, can be directly applied to other neurological disease states as well .

ACNP Annual Meeting Book 2013 rev8.indd 8 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Integrated Omics Approach to Neuropharmacological Studies (continued)

Mark Emmett

Dr . Emmett’s research experience is diverse, ranging from a Master’s in Microbiology/Molecular Biology to a PhD in Biochemistry/Neuropharmacolgy . He has substantial research experience in the pharmaceutical industry in neuroscience drug discovery groups . He has extensive mass spectrometry experience with emphasis on ultra-high sensitivity analysis of biological samples using Nano-scale Liquid Chromatography, Microelectrospray Mass Spectrometry, which he specifically developed for his Ph.D. research. At the NHMFL, he applied this technology to Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass Spectrometry in the analysis of endogenous biological compounds . Has has spent the last 17 years in the FT-ICR group at the NHMFL developing applications for and modifications of high-resolution FT-ICR MS instrumentation with an emphasis on interfacing chromatography to MS (LC, CE, SFC, etc), thus he is well versed in analytical methodology and instrumentation . While at the NHMFL, he began working in the field of cancer research (1997-present) he has focused mainly on Neuro-Oncology, but has also worked in breast, prostate and gastro-intestinal stromal tumors (GIST) . He established a program of lipidomics in cancer research and with collaborators established a multi-disciplinary research group enabling a systems biological approach integrating genomics, transcriptomics, proteomics, glycomics, lipidomics, metabolomics and phenotypic responses to the study of cancer focusing on the identification of novel biomarkers and therapeutic targets.

ACNP Annual Meeting Book 2013 rev8.indd 9 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Approaches for the Small-volume Analysis of Cell-cell Signaling Molecules in the Brain

Jonathan Sweedler University of Illinois

The interactions between neurons in our brain are partially controlled by the chemicals that surround the neurons . In the postgenomic era, one expects the suite of chemical players in a brain region to be known and their functions uncovered . However, many cell-to-cell signaling molecules remain poorly characterized and for those that are known, their localization and dynamics are oftentimes unknown. Significant challenges in the characterization of intercellular signaling molecules arise in part from their large chemical diversity and their broad range of concentrations . Neurotransmitters and neuromodulators vary from small gaseous molecules such as nitric oxide to larger peptides that are only bioactive with particular posttranslational modifications. The enormous biochemical complexity of nervous system where even adjacent cells often have very different and dynamic metabolic profiles necessitates development and application of technologies capable characterization of the neurometabolome on the individual cell level .

Here, we present a suite of bioanalytical approaches that allow the investigation of defined brain regions down to individual neurons. These approaches include capillary electrophoresis with laser induced fluorescence and mass spectrometric detection, and direct mass spectrometric-based profiling and imaging. Several applications of single cell microanalysis are highlighted: investigating novel indolamine neurochemistry, determining the role of d-amino acids in the brain, and uncovering novel neuropeptides. Specifically, new serotonin-related compounds and literally hundreds of new neuropeptides have been characterized in well- defined neuronal networks, and in several cases, the functional roles ofthese molecules described . Discovery of new neurochemical pathways often relies not only on structural information provided by traditional mass spectrometry but also requires knowledge on the spatial and temporal dynamics of these signaling molecules in the brain . Imaging mass spectrometry and dynamic sampling of the extracellular environment are used for elucidating novel cell to cell signaling

ACNP Annual Meeting Book 2013 rev8.indd 10 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Approaches for the Small-volume Analysis of Cell-cell Signaling Molecules in the Brain

Jonathan Sweedler

molecules in a range of neuronal model systems . Our overarching goal is to uncover the complex chemical mosaic of the brain and pinpoint key cellular players in physiological and pathological processes .

Prof . Jonathan Sweedler’s research involves analytical neurochemistry . He develops new measurement tools that enable small scale chemical analysis, and applies these tools to understanding the chemistry occurring in the brain . Sweedler is the Director of the School of Chemical Sciences, holds the James R. Eiszner Family Chair in Chemistry and is affiliated with the Departments of Molecular and Integrative Physiology and Bioengineering, the Neuroscience program, the Beckman Institute of Science and Technology, and the Institute of Genomic Biology . Sweedler has authored or coauthored over 320 peer- reviewed publications, has 14 patents issued, and has delivered over 380 invited lectures to universities, companies, and at scientific meetings. His scientific contributions have been recognized by numerous awards including the Ralph N . Adams Award, the Heinrich-Emanuel Merck Prize, and the American Chemical Society’s Analytical Chemistry Award . Sweedler is currently the Editor-in-Chief of Analytical Chemistry .

ACNP Annual Meeting Book 2013 rev8.indd 11 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Relevance to Neuropsychiatric Disease

Susan R. George University of Toronto

The involvement of the dopaminergic system in many mental health disorders has resulted in the pharmacological targeting of dopamine transmission as the mainstay of the treatment of several disorders, such as schizophrenia, addiction, depression and ADHD . However, the currently available therapies mostly target a single dopamine receptor, limiting the scope of treatment . The recognition that dopamine receptors participate in forming heteromeric complexes, often with distinct anatomical localization in brain as well as signaling and functional properties has significantly expanded the range of physiologically relevant signaling complexes present beyond the five known dopamine receptors. Furthermore, as the physiology and disease relevance of these receptor heteromers is further understood, their ability to exhibit pharmacological and functional properties distinct from their constituent receptors, or ability to modulate the function of endogenous homomeric receptor complexes, may allow for the development of alternate therapeutic strategies and provide new avenues for rational drug design . The emerging neurobiology of the best characterized dopamine receptor heteromers such as the D1-D2, D2-D4 and other complexes, their physiological relevance in brain, and the potential role of these receptor complexes in neuropsychiatric disease will be discussed . The value of these heteromers as targets for future drug development is highlighted and how designing drugs to selectively activate or inactivate these dopamine receptor heteromers may have enormous potential to aid in the search for novel and clinically efficacious pharmacotherapies for these often difficult to treat clinical disorders.

Dr . Susan George is a clinician-scientist with a particular interest in G protein coupled receptor signaling in brain mediated by dopamine and opioid receptors, as they relate to neuropsychiatric disease mechanisms, especially related to drug addiction and schizophrenia .

ACNP Annual Meeting Book 2013 rev8.indd 12 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Use of CSF Biomarkers for Alzheimer’s Disease in Clinical Trials

Kaj Blennow University of Gothenburg

Research advances have given detailed knowledge on AD molecular pathogenesis, which has been translated into new drug candidates with disease-modifying potential . The majority of the drug candidates evaluated in clinical trials are directed against amyloid-β (Aβ). The main principles for anti-Aβ drugs include active and passive Aβ immunotherapy and Aβ lowering drugs (BACE1 and γ-secretase inhibitors). However, there is a growing list of anti-Aβ clinical trials in which it has not been possible to identify any clinical benefit. This has caused concern that Aβ deposition may merely be a bystander, and not the cause, of the disease, and that the amyloid hypothesis only is valid for the familial form of AD . A more optimistic view is that the design of anti-Aβ trials will need refinement to give the drug a fair chance to show a positive clinical effect . There is a growing consensus that biomarkers (CSF tests, amyloid PET and MRI measurements) will have a critical role in this new era in AD drug development . Diagnostic biomarkers will be essential to allow initiation of treatment in the pre-dementia stages, before neurodegeneration is too advanced . Primary biomarkers applied in early clinical phases to study the pharmacodynamic effects of a drug will be important to guide the decision to only advance compounds with target engagement proven in man on Aβ metabolism into large and expensive phase II or III clinical trials. Downstream biomarkers will provide evidence that the drug candidate affects the central neuropathology, which, together with a positive effect on cognition, will be necessary to claim a label as a disease-modifying drug .

Kaj Blennow took his medical degree (MD) in 1984, and holds a Specialist Competence in both General Psychiatry and in Cinical Chemistry . He is Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden, and Professor in Clinical Neurochemistry at the Sahlgrenska Academy, Mölndal campus at University of Gothenburg, Sweden . The Clinical Neurochemistry research group includes 15 post-docs and 6 PhD students, 8 laboratory technicians. The major research areas are cerebrospinal fluid biochemical markers, clinical proteomics, and the neurochemical pathogenesis of Alzheimer’s disease and other brain disorders . Blennow has published more than

ACNP Annual Meeting Book 2013 rev8.indd 13 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

Use of CSF Biomarkers for Alzheimer’s Disease in Clinical Trials (continued)

Kaj Blennow

550 original research papers and 80 review articles in peer-reviewed journals, and has a H-index above 80. He has received a number of scientific awards, such as The CINP Award (1992), the IPA Research Award (1993), the Alois Alzheimer Research Award (2001), the ECNP Clinical Research Award (2010), the Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research (2011), and the International Federation of Research in Alzheimer’s Disease Grand Prix in Research (2013)

ACNP Annual Meeting Book 2013 rev8.indd 14 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:30 a.m. Neuropsychopharmacology Reviews Plenary Regency Ballroom 1 & 2 PL

New Technologies Promise Revitalization of Psychiatric Therapeutics

Steven E . Hyman Broad Institute of Harvard and MIT

To the detriment of patients, the pharmaceutical industry has de-emphasized psychiatric illness . Reasons include a dearth of convincing new molecular targets, disillusionment with current animal “models”, and lack of treatment biomarkers . Yet there is reason for optimism . Unbiased genomic methods are beginning to identify pathways . New stem cell and genome engineering technologies promise cellular models to complement animals . Recognition that psychiatric disorders are better conceptualized as spectra and dimensionally should help clear away the obstacles to progress posed by current fictive diagnostic categories

Steven E . Hyman, M .D . is Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and also serves as Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology . From 2001 to 2011, Hyman served as Provost of Harvard University, the University’s chief academic officer. From 1996 to 2001, he served as director of theU.S. National Institute of Mental Health (NIMH), where he emphasized investment in neuroscience and emerging genetic technologies, and initiated a series of large practical clinical trials to inform practice . Hyman is the editor of the Annual Review of Neuroscience, President of the International Neuroethics Society, and a member of the Institute of Medicine of the U .S . National Academies where he serves on the governing Council, the Board of Health Science Policy, and chairs the Forum on Neuroscience and Nervous System Disorders . He is a fellow of the American College of Neuropsychopharmacology, a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, and a Distinguished Life Fellow of the American Psychiatric Association .

ACNP Annual Meeting Book 2013 rev8.indd 15 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

1:00 p.m. – 2:30 p.m. Institute Director’s Session Regency Ballroom 1 & 2 PL

NIH Institute Director’s Session

Chair: David Lewis

Panelists:

Kenneth Warren NIAAA

Thomas Insel NIMH

Nora Volkow NIA

ACNP Annual Meeting Book 2013 rev8.indd 16 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Hot Topics

Co-Chairs: Randy Blakely and Pat Levitt

2:30 p .m . Dysregulated Neural Response to Social Evaluation In Bullied Adolescents: A Potential Mechanism that Promotes Risk for Social Anxiety Disorder Johanna Jarcho

2:41 p .m . Buspirone Blocks Dopamine D3 Receptors in the Non-Human Primate Brain When Administered Orally Nora Volkow

2:52 p .m . Naloxone-Reversible Modulation of Pain Circuitry by Left Prefrontal Repetitive Transcranial Magnetic Stimulation Joseph Taylor

3:03 p .m . DREADDs in Drosophila: Pharmacogenetic Control of Neurons and Behavior in the Fly Charles Nichols

3:14 p .m . Striatal Activation Induced by mGluR2 Positive Allosteric Modulation Correlates with Negative Symptom Reduction in Schizophrenia Daniel Wolf

3:25 p .m . Prenatal Exposure to Maternal Infection Alters Neonatal Brain Structure John Gilmore

3:36 p.m. Application of Sequencing, Fatty Acid Profiling, and Metabolomics Investigations to Explore Pathogenesis and Treatment Strategy for Anorexia Nervosa Pei-an Betty Shih

ACNP Annual Meeting Book 2013 rev8.indd 17 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Hot Topics

Co-Chairs: Randy Blakely and Pat Levitt

3:47 p .m . Retinoid-Related Orphan Receptor Alpha: A Novel Candidate Gene for Psychiatric Disease Joseph Friedman

3:58 p .m . Automated Analysis of Disorganized Communication Predicts Transition to Psychosis Among Clinical High Risk Patients Cheryl Corcoran

4:09 p .m . Dissecting Nucleus Accumbens Dynorphin Neurons in Aversion and Reward Michael Bruchas

4:40 p .m . Mismatch Negativity Predicts Psychosis Onset and is Associated with Plasma Markers of Inflammation in Youth at Clinical High Risk for Psychosis Daniel Mathalon

4:51 p .m . Age-related Sperm DNA Methylation Changes are Transmitted to Offspring and Associated with Abnormal Behavior and Dysregulated Gene Expression Maria Milekic

5:02 p .m . Prospective Examination Of Prepulse Inhibition In OIF/OEF Marines Suggests Reduced Sensorimotor Gating Is A Pre- existing Factor In Those That Develop PTSD After Combat Deployment Dean Acheson

5:13 p .m . Disrupting AMPA Receptor Endocytosis Restores the Ability to Form New, and Enables the Recovery of Old, Memories in Mice Genetically Designed to Mimic Alzheimer’s Disease Sheena Josselyn

ACNP Annual Meeting Book 2013 rev8.indd 18 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Hot Topics

Co-Chairs: Randy Blakely and Pat Levitt

5:24 p .m . Selective Effects of the 5-HT2C Receptor Agonist Meta- chlorophenylpiperazine (mCPP) on Intake of a Palatable Snack Food in Healthy Female Volunteers: Correlation with Regional Brain Activations Measured by BOPLD fMRI Colin Dourish

5:35 p.m. Locus Specific Epigenetic Reprogramming: Bidirectional Regulation of the FosB Gene Using Synthetic Transcription Factors In Vivo Elizabeth Heller

5:46 p .m . Suicidal Ideation in Depressed New Mothers: Relationship with Childhood Trauma and Sleep Disturbance Dorothy Sit

5:57 p .m . The Contribution of Adult Hippocampal Neurogenesis to Fear Memory Generalization Mazen Kheirbek

6:08 p .m . Intranasal Ketamine in Treatment-Resistant Depression Kyle Lapidus

6:19 p.m. Specific Elevation of βCaMKII in the Lateral Habenula Lead to Core Symptoms of Depression Fritz Henn

ACNP Annual Meeting Book 2013 rev8.indd 19 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Dysregulated Neural Response to Social Evaluation In Bullied Adolescents: A Potential Mechanism that Promotes Risk for Social Anxiety Disorder Monday, Poster #48

Johanna M . Jarcho, Megan Davis, Ellen Leibenluft, Nathan Fox, Tomer Shechner, Daniel S . Pine, Eric Nelson National Institute of Mental Health Background: Peer victimization is a risk factor for social anxiety disorder (SAD) that engenders fear of negative evaluation, the primary symptom of SAD . While available treatments for SAD can reduce symptoms, they rarely result in full remission . Interventions that target neural circuits dysregulated in adolescent SAD may enhance treatment efficacy. An important first step toward developing such interventions is to isolate dysregulated neural circuits shared by early adolescents with SAD, and at risk for SAD due to peer victimization . Treating early adolescents may alleviate acute symptoms before they become chronic, thereby facilitating normative development, and preventing the high cost of adult SAD . Progress toward this goal has been hindered by limitations in neuroimaging paradigms, which bear little resemblance to contexts that precipitate the primary symptoms of adolescent SAD, or to contexts in which peer victimization occurs . An fMRI paradigm that evokes fear of negative evaluation while modeling an ecologically valid context for bullying may address these limitations, and thereby facilitate the development of novel interventions . To this end, we developed the Virtual School paradigm, which explicitly models unpredictable social evaluation in an ecologically valid classroom setting . Here we present data from the first fMRI study to utilize the Virtual School paradigm. In this study, we assess brain function as healthy adolescents with high or low exposure to victimization anticipate social evaluation from predictable and unpredictable peers . We hypothesize that adolescents with high, relative to low, exposure to peer victimization will differentially engage fronto-striatal-amygdala circuits, implicated in self-reflection, reward, and threat processing, when anticipating unpredictable social feedback from peers . Methods: Healthy adolescents (N = 22; M = 10 .73 years; SD = .46) with high and low exposure to peer victimization are told that they are the “New Kid” at our

ACNP Annual Meeting Book 2013 rev8.indd 20 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Dysregulated Neural Response to Social Evaluation In Bullied Adolescents: A Potential Mechanism that Promotes Risk for Social Anxiety Disorder Monday, Poster #48 (continued)

Johanna M . Jarcho Virtual School. They generate a cartoon avatar and personal profile they believe will be shown to a purported group of “Other Students .” Participants learn the Other Students have a reputation for being ‘Nice,’ ‘Unpredictable,’ or ‘Mean .’ Reputation comprehension is assessed prior to completing the Virtual School paradigm in the fMRI scanner .During the task, participants enter classrooms populated by Other Students . For each trial, participants are cued to anticipate social evaluation when “Typing . . ” appears above one of the Other Students . Because Other Students have an established reputation, participants anticipate different types of social evaluation from each peer . Unpredictable peers then provide 50% positive and negative feedback, while Nice and Mean peers provide 100% positive or 100% negative feedback (respectively) . Participants then make a positive, negative, sarcastic, or avoidant response to peer social evaluation . Results: Replicating prior behavioral findings (Jarcho et al., 2013), adolescents learned Other Student reputations, made responses during the task that varied by peer reputation and feedback, and believed they were interacting with real peers (100% deception) . As hypothesized, brain activity during anticipated social evaluation varied based on participant exposure to peer victimization and Other Student reputation (p < .005; cluster extent > 70 voxels). Specifically, while anticipating unpredictable, relative to predictable positive or negative social evaluation, victimized adolescents exhibited heightened activity in frontostriatal-amygdala circuits compared with non-victimized adolescents . Discussion: Exposure to peer victimization is associated with differential engagement of a brain network implicated in self-reflection, reward, and threat processing . This engagement varies depending on the type of social evaluation (i .e ., uncertain vs . certain) victimized adolescents anticipate . These data suggest one mechanism by which exposure to bullying may lead to SAD is through disruptions in neural circuits engaged by unpredictable social evaluation . Longitudinal studies are needed to more fully test this hypothesis .

ACNP Annual Meeting Book 2013 rev8.indd 21 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Buspirone Blocks Dopamine D3 Receptors in the Non-Human Primate Brain When Administered Orally

Monday, Poster #139

Sung Won Kim, Joanna Fowler, Phil Skolnick, Yeona Kang, Dohyun Kim, Nora D . Volkow National Institute on Drug Abuse

Background: Converging lines of evidence indicate that dopamine D3 receptor

(D3R) antagonists may be effective as treatments/medications for substance use

disorders (SUDs) in animal and human . However, no selective D 3R antagonists are clinically available for testing this hypothesis . Buspirone (Buspar®) originally

characterized as a selective 5-HT1A partial agonist, has been used as an anxiolytic

for more than 25 years . However, buspirone also binds to D3R and D4R with

high affinity as an antagonist and with lower affinity to2 D R in vitro . Recently, this azapirone has been shown to interfere with cocaine reward in non-human

primates . Here we evaluate buspirone’s ability to block D3R in the non-human

primate brain and compared it to D2R and D1R blockade in pharmacologically- relevant and safe dose ranges . 11 Methods: In six female baboons, we used PET with [ C]PHNO (D3R-preferring 11 11 radioligand), [ C]raclopride (D2R/D3R radioligand) and [ C]NNC-112 (D1R radioligand) to measure occupancy of oral versus parenteral (IM) buspirone at multiple time points after drug administration . One of major metabolites, 6’-OH buspirone (IM, 1 mg/Kg) was also administered at 3 hrs before [11C]PHNO scan . Results: Intramuscular administration of buspirone (0 .19 and 0 .5 mg/Kg) showed high occupancy (50-85%) at 15 min and then rapid wash-out by 2 hrs in a dose dependent manner for both [11C]PHNO and [11C]raclopride PET studies . Interestingly, oral buspirone (3 mg/Kg) significantly blocked 11[ C]PHNO binding in globus pallidus and substantia nigra (55-74% after 3 hours), while blockade of [11C]raclopride was minimal (10%) in striatum . One of buspirone’s metabolites, 11 6’-OH buspirone (D3R antagonist) significantly also blocked (89%) [ C]PHNO binding in substantia nigra . No blockade was observed for [11C]NNC-112 by both oral and parental administration of buspirone .

ACNP Annual Meeting Book 2013 rev8.indd 22 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Buspirone Blocks Dopamine D3 Receptors in the Non-Human Primate Brain When Administered Orally

Monday, Poster #139 (continued)

Nora D . Volkow

11 Discussion: Since [ C]PHNO binding has been known to reflect D3R binding 11 predominantly and little blockade was observed in [ C]raclopride (D2R/D3R radioligand) binding after oral buspirone, we conclude that oral buspirone/its

metabolites blocked D3R significantly and would merit testing for therapeutic efficacy in SUDs in human.

ACNP Annual Meeting Book 2013 rev8.indd 23 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Naloxone-Reversible Modulation of Pain Circuitry by Left Prefrontal Repetitive Transcranial Magnetic Stimulation

Monday, Poster #61

Joseph J . Taylor, Jeffrey J . Borckardt, Melanie Canterberry, Xingbao Li, Colleen A . Hanlon, Truman Brown, Mark S . George Medical University of South Carolina

Background: A 20-minute session of 10 Hz repetitive transcranial magnetic stimulation (rTMS) of Brodmann Area (BA) 9 of the left dorsolateral prefrontal cortex (DLPFC) can produce analgesic effects on postoperative and laboratory- induced pain. This analgesia is blocked by pretreatment with naloxone, a μ-opioid antagonist . The purpose of this sham controlled, double blind, crossover study was to identify the neural circuitry that underlies the analgesic effects of left DLPFC rTMS and to examine how the function of this circuit, including midbrain and medulla, changes during opioid blockade . Methods: Fourteen healthy volunteers were randomized to receive intravenous saline or naloxone immediately prior to sham and real left DLPFC rTMS on the same experimental visit . One week later, each participant received the novel pretreatment but the same stimulation paradigm . Using short sessions of heat on capsaicin-sensitized skin, hot allodynia was assessed during 3T functional magnetic resonance imaging (fMRI) scanning at baseline, post-sham rTMS, and post-real rTMS . Data were analyzed using whole-brain voxel-based analysis as well as time series extractions from anatomically defined regions of interest representing midbrain and medulla . Results: Consistent with previous findings, real rTMS significantly reduced hot allodynia ratings . This analgesia was associated with elevated BOLD signal in DLPFC and diminished BOLD signal in the anterior cingulate, thalamus, midbrain and medulla during pain . Naloxone pretreatment largely abolished rTMS-induced analgesia as well as rTMS-induced attenuation of BOLD signal response to painful stimuli throughout pain processing regions, including midbrain and medulla . Discussion: These preliminary results suggest that left DLPFC rTMS drives top- down opioidergic analgesia .

ACNP Annual Meeting Book 2013 rev8.indd 24 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

DREADDs in Drosophila: Pharmacogenetic Control of Neurons and Behavior in the Fly

Monday, Poster #180

Charles D . Nichols, Jaime Becnel, Oralee Johnson, Zana Majeed, Vi Tran, Bangning Yu, Bryan L . Roth, Robin L . Cooper, Edmund K . Kerut Louisiana State University Health Sciences Center

Background: Drosophila melanogaster is an important genetic model system that has provided much information on the molecular basis of behaviors conserved with mammalian systems and psychiatric disorders . These include sleep, aggression, social interaction, learning and memory, and response to drugs of abuse that are all mediated by similar and fundamentally shared mechanisms involving neurotransmitters like serotonin, dopamine, glutamate, and GABA . One of the advantages of the fly is the extensive toolkit of genetic methods to manipulate gene expression in the fly. In combination with the ability to precisely control temporal and spatial expression in the fly, there are several methods used to conditionally control neuronal activity that include temperature sensitive blockade of synaptic vesicle recycling withshibirets, constitutive activation/inactivation with NaChBac/Kir channels, temperature regulated activation/inactivation with TrpA/TrpM channels, and light regulated channelrhodopsins . A disadvantage to these methods is that they each are all essentially switches, and either turn the neuron all on or all off, and have little to no dose responsive control . We have now adapted Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology to the fruit fly to provide true dose responsive control of neuronal function and behavior through manipulation of GPCR receptors and downstream effector pathways . Unlike these other methods, additional equipment like dedicated temperature incubators or blue light sources and fiber optics are not required, activating drug is simply fed to the fly. Furthermore, conditional control of activity is reversible .Due to the ubiquitous nature of GPCRs, this system will also be useful in the examination of the role of signal transduction pathway effectors in almost every tissue of the fly, and is not limited to study of only neurons and behaviors . Methods: UAS-DREADD constructs were created for each of the three primary mammalian muscarinic DREADDs (hM4Di, a silencing receptor coupled to

ACNP Annual Meeting Book 2013 rev8.indd 25 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

DREADDs in Drosophila: Pharmacogenetic Control of Neurons and Behavior in the Fly

Monday, Poster #180 (continued)

Charles D . Nichols Gi; hM1Dq, an activating receptor coupled to Gq; rM3DBs, coupled to Gs and increases in cAMP levels), and transgenic fly strains created for each. DREADDs were expressed in discreet neuronal circuits and tissues using various GAL4 drivers and the ability of activation of the DREADDs to control behaviors was examined in a panel of behaviors that included sensory perception, learning and memory, circadian, and courtship . Effector pathway responses were measured in tissue culture . Neuronal activity was measured by real-time live cell calcium imaging in larval brain ventral ganglia neurons using GcAMP and confocal microscopy . Heart rate control was measured using larval heart preparations and light microscopy . The activating ligand clozapine-N-oxide (CNO) was administered by feeding to flies in the food, or application in media. Results: DREADD activation was found to dose responsively and reversible control behaviors, neuronal activity, and physiological processes by simple feeding or application of activating ligand, CNO . Discussion: We have successfully translated DREADD technology from mammalian systems to Drosophila . DREADD activation confers dose responsive and reversible control over not only signal transduction and effector pathways, but also neuronal activity, behaviors, and physiological processes . DREADDs provide an additional level of more fine control of neurons and circuits than the current switch-based all on or all off approaches . This control to only partially activate or inactivate a neuron acutely or chronically allows us to study more subtle behaviors that may be masked by more aggressive methods . In our previous work, we generated several genetic tools for examination of the Drosophila serotonin system, and defined a role for serotonin in many behaviors relevant to neuropsychiatric disorders like social interaction and learning and memory . We are now incorporating DREADD technology into our study of serotonin neuropharmacology in the fly to enhance our discovery of conserved mechanisms underlying behaviors that will ultimately enhance our understanding of human psychiatric diseases .

ACNP Annual Meeting Book 2013 rev8.indd 26 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Striatal Activation Induced by mGluR2 Positive Allosteric Modulation Correlates with Negative Symptom Reduction in Schizophrenia

Monday, Poster #52

Daniel Wolf, Kosha Ruparel, Bruce Turetsky, Christian Kohler, Theodore D . Satterthwaite, Mark Elliott, Mary March, Alan Cross, Mark Smith, Stephen R . Zukin, Ruben C . Gur, Raquel E . Gur University of Pennsylvania Department of Psychiatry

Background: Cognitive deficits and negative symptoms contribute strongly to disability in schizophrenia, and are resistant to existing medications, creating a critical need for novel therapeutic targets and agents . Inspired by the glutamate hypothesis, recent drug development efforts have focused on ameliorating putative deficits in NMDA signaling. In animal models, mGluR2/3 agonists and mGluR2 positive allosteric modulators (PAMs) have reversed the physiologic and behavioral effects of NMDA receptor antagonists . However the clinical utility of such agents remains uncertain, and their impact on neural circuit function in humans remains unknown. Progress in this area will benefit from studying novel agents targeting cognition and negative symptoms using integrative paradigms that incorporate clinical, neurocognitive performance and neurophysiological measures in order to evaluate early signals of efficacy. We therefore performed this fMRI study as part of a Phase 1 pilot study (NCT00986531) evaluating the mgluR2 PAM AZD8529 as an adjunctive treatment for cognitive deficits and negative symptoms . We hypothesized the drug would improve cognition and symptoms, and that clinical improvements would correlate with changes in fMRI activation . Methods: Subjects with complete fMRI data were 26 patients (10 female) with DSMIV schizophrenia, stably treated with antipsychotics . 3T MRI scanning was performed following three days treatment with AZD8529 (80mg once-daily) or placebo . The study design was double blind, placebo-controlled, counterbalanced within-subject crossover, with a 14-day washout between drug and placebo phases . During fMRI scanning, subjects performed a fractal n-back task (0, 1, 2, and 3-back block design), as well as a continuous performance task and an emotion

ACNP Annual Meeting Book 2013 rev8.indd 27 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Striatal Activation Induced by mGluR2 Positive Allosteric Modulation Correlates with Negative Symptom Reduction in Schizophrenia

Monday, Poster #52 (continued)

Daniel Wolf

identification task. We focus here on the n-back task; the other two tasks did not show signficant drug effects. fMRI analysis focused on task-activated regions of interest including anterior cingulate (ACC) and dorsolateral prefrontal cortex (DLPFC) . Exploratory whole-brain voxelwise analyses were also conducted to test for drug effects outside of the a priori ROIs . Results: No significant effects of drug were found on average clinical symptoms or on behavioral performance during in-scanner or out-of-scanner tasks . BOLD activation in DLPFC and ACC showed expected increases with working memory load . Relative to placebo, drug increased activation in ACC (p= .031) . Although activation trended higher on drug in left and right DLPFC there was no significant main effect of drug in these regions. An exploratory whole brain analysis demonstrated the most robust drug effects in basal ganglia; we therefore also conducted region of interest analyses in in right and left caudate, putamen, and pallidum. The main effect of drug was significant in all these regions due to increased activation by drug compared to placebo (L Caudate, p<0 .001; R Caudate p<0 .001; L Putamen p=0 .0014; R Putamen p<0 .001; L Pallidum p=0 .017; R Pallidum p<0.001). No regions showed significant interaction effects of drug with working memory load level . Subjects who showed greater caudate activation by the drug also showed greater reductions in PANSS negative symptom scores (correlation of drug-placebo difference scores, r=-0 .47, p=0 .02) . A similar trend was seen in the putamen (r=-0 .37, p=0 .06), but not in other drug-activated regions, suggesting the symptom-activation correlation was specific to striatum. Discussion: The mGluR2 PAM was generally well-tolerated . In this pilot study the drug did not significantly improve cognitive performance, nor did it reduce clinical symptoms on average . However, the drug did increase fMRI activity in the anterior cingulate and basal ganglia during a working memory task, and the extent of drug-induced striatal activation correlated with reductions in negative

ACNP Annual Meeting Book 2013 rev8.indd 28 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Striatal Activation Induced by mGluR2 Positive Allosteric Modulation Correlates with Negative Symptom Reduction in Schizophrenia

Monday, Poster #52 (continued)

Daniel Wolf

symptom severity . These results encourage further investigation of this mgluR2 PAM and related agents, including studies focused on the potential role of striatal mechanisms impacting emotion and motivation . Our results also support the use of fMRI for sensitive detection of drug effects . Imaging biomarkers may reveal therapeutic mechanisms, and help tailor drug development and treatment towards specific patient populations and symptom domains.

ACNP Annual Meeting Book 2013 rev8.indd 29 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Prenatal Exposure to Maternal Infection Alters Neonatal Brain Structure

Monday, Poster #49

John H . Gilmore, Mark Connelly, Philip Nielsen, Sandra Woolson, Robert Hamer, Rebecca Knickmeyer, Sarah Short, Xiujuan Geng University of North Carolina at Chapel Hill

Background: Prenatal exposure to maternal infection is a risk factor for neuropsychiatric disorder . Studies in animal models suggest that prenatal exposure to infection causes significant alterations in structural brain development, though studies in humans are lacking . Methods: Prospective, longitudinal follow-up study of a cohort of 445 infants, both singleton and twins, born to women assessed for infection during pregnancy by prospective interviews and medical records review . At 2 weeks after birth infants underwent 3T MRI scans . Global and cortical tissue volumes were determined Results: Neonates exposed to maternal infection had a significant reduction in cortical gray matter (1.9%; p = 0.04) and non-significant reductions in intracranial volume (ICV; 1 .5%; p = 0 .11) and total gray matter (1 .65%; p = 0 .07) compared to infants with no exposure. Infants with first exposure to infection in the third trimester had significant reductions in ICV (3.5%; p = 0.02), total gray matter (4 .1%; p = 0 .004), unmyelinated white matter (3 .6%, p = 0 .03), as well as cortical gray (4 .9%; p = 0 .0008) and cortical white matter volumes (3 .5%; p = 0 .03) . Discussion: Prenatal exposure in maternal infection results in cortical gray matter volume reductions, especially for first exposure to infection in the rd3 trimester . This study indicates that prenatal exposure to infection can significantly alter prenatal brain development in humans, providing a plausible mechanistic basis for the relationship between prenatal exposure to infection and increased risk for neuropsychiatric disorders .

ACNP Annual Meeting Book 2013 rev8.indd 30 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Application of Sequencing, Fatty Acid Profiling, and Metabolomics Investigations to Explore Pathogenesis and Treatment Strategy for Anorexia Nervosa

Wednesday, Poster #68

Pei-an Betty Shih, Jun Yang, Christophe Morisseau, Ashley Van Zeeland, Toni- Kim Clarke, Andrew W . Bergen, Pierre Magistretti, Katherine Ann Halmi, Wade Berrettini, Nicholas Schork, Walter H . Kaye, Bruce D . Hammock University of California, San Diego

Background: Individuals with Anorexia Nervosa (AN) restrict eating and become emaciated . They tend to have an aversion to foods rich in fat . We have identified a novel AN susceptibility gene, Epoxide Hydrolase 2(EPHX2), through a series of complementary genetic study designs (GWAS, exon-based sequencing, single-locus association and replication studies) in 1205 AN and 1948 controls (p=0 .0004 to 0 .00000016)(Molecular Psychiatry, 2013). To assess the mechanisms by which EPHX2 influences AN risk, here we applied a multi- disciplinary approach using lipidomics, metabolomics, and ex vivo techniques to evaluate the biological functions of EPHX2 . Methods: EPHX2 codes for soluble epoxide hydrolase (sEH) which binds to specific epoxides and converts them to the corresponding diols; thereby it plays a major role in the metabolism of endogenous lipid epoxides, such as the epoxyeicosatrienoic acids (EETs), a derivative of arachidonic acid (ARA) . We measured polyunsaturated fatty acids (PUFAs) and eicosanoids (bioactive lipid mediators that are derived from the metabolism of PUFAs) in 20 female AN cases and 17 age-, gender- and race-matched controls using the GC/MS and LC/MS/MS systems . EET-to-DHETs ratios were calculated as proxy markers of in vivo sEH activity, whereas ex vivo sEH activity was directly measured in 36 controls . Results: Omega 6 PUFAs (DGLA, ARA, and Osbond acids) and omega 3 PUFAs (ALA, SDA, EPA, and DHA) were significantly elevated in ANs compared to controls (p=0 .0003 to 0 .00004) . Controlling for effects of age and BMI, the 8.9.EpETrE of ARA and 8.9.EET-to-Diol ratio were significantly higher in ANs compared to controls (p<0 .0001) whereas the eicosanoids markers of LA, another PUFA substrate of sEH, were not significantly different. The ex vivo sEH activity

ACNP Annual Meeting Book 2013 rev8.indd 31 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Application of Sequencing, Fatty Acid Profiling, and Metabolomics Investigations to Explore Pathogenesis and Treatment Strategy for Anorexia Nervosa

Wednesday, Poster #68 (continued)

Pei-an Betty Shih

measured in 13 controls showed marginal association with 8 .9 .EET-to- Diol ratio (p=0 .07), suggesting 8 .9 .EpETrE of ARA may be a sensitive activity target of sEH . Variant allele carriers of an AN-associated EPHX2 SNP in the 3’-UTR region showed significant association with 11,12- EET-to-Diol ratio (p=0.02) after controlling for the effects of age, BMI, and disease status, further providing evidence for EPHX2 variation’s influence on sEH activity and the subsequent effects on PUFA metabolism and eicosanoid activity . Discussion: This study suggests that EPHX2 influences AN risk through biological interaction with the PUFA pathway, specifically the ARA. It demonstrates that an application of multiple genetic designs interrogating common and rare variation is an effective approach to identify otherwise unsuspected risk genes in AN; that joint investigations of genetic mechanisms with their biological non-genetic partners (e .g .: diet, stress) may lead to improved understanding of pathophysiology, and new treatment strategies for AN .

ACNP Annual Meeting Book 2013 rev8.indd 32 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Retinoid-Related Orphan Receptor Alpha: A Novel Candidate Gene for Psychiatric Disease

Monday, Poster #236

Joseph I . Friedman, Sander Markx, Terry Vrijenhoek, Ronald Kim, Joris A . Veltman , Arthur Mikhno, James R . Moeller, Mala Ananth, David K . Leung, Han G . Brunner, Vincent Giguere, Panayotis K . Thanos Icahn School of Medicine At Mount Sinai

Background: Several recent association studies have identified the retinoid- related orphan receptor alpha (RORα) gene as a significant risk locus for posttraumatic stress disorder, bipolar disorder, and autism . Indeed, the naturally occurring staggerer RORα mutant and genetically engineered RORα null mice demonstrate brain changes including: cerebellar atrophy, Purkinje cell atrophy and loss, degeneration of granule cells, and limted data showing structural changes in the olfactory bulb, in association with severe ataxia and other cerebellar dysunction . This restricted pattern of changes to the cerebellum in the RORa mutant leaves major gaps in any model trying to explain RORa gene-related susceptibility to this diversity of psychiatric disease . Therefore, in order to bridge this translation gap we conducted an investigation of the neuropsychological and neuroimaging intermediate phenotypes in a multiply affected family with a non- functional duplication of the RORa gene, and in RORa-deficient mice models. Methods: Clinical, neuropsychological and genetic data were collected from six members of a single pedigree with three members harboring a rare duplication of isoform 1 of the RORα gene, presumably resulting in a frameshift leading to an early stop-codon and thus a non-functional protein . In addition, magnetic resonance imaging (MRI) was conducted on these same subjects, and fluorodeoxyglucose-positron emission tomography (FDG-PET) brain scans to quantify regional glucose metabolism were obtained from all family members and from 14 unrelated, normal age-matched controls (NC) . FDG-PET data processing was carried out via voxel-based, canonical variates analysis and Scaled Subprofile Model of Principal Components analysis . In a parallel experiment, laboratory generated homozygous (KO) (N=13) and heterozygous (HT) (N=12) RORα-deficient mice were compared to wild type

ACNP Annual Meeting Book 2013 rev8.indd 33 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Retinoid-Related Orphan Receptor Alpha: A Novel Candidate Gene for Psychiatric Disease

Monday, Poster #236 (continued)

Joseph I . Friedman

(WT) (N=11) mice on performance on tests modeling cognitive deficits including novel object recognition and T-maze testing, and tests of locomotor activity and coordination including open field and rotarod tests. In addition, brain glucoe metabolism (BGluM) was assessed in these mice using [18F] FDG micro-PET . Results: The three family members harboring the RORα duplication carried diagnoses of schizophrenia, schizoaffective disorder and major depression . Moreover, the three affected family members demonstrated significant neuropsychological dysfunction, whereas none of the three family members without the RORα duplication demonstrated any neuropsychological impairments . T1-weighted MRI images demonstrated all three individuals harboring the duplication to have peri-sylvian fissure and pre-pontine atrophy in addition to ventricular enlargement . None of the three family members without the duplication showed any anatomical abnormalities on MRI . FDG-PET data robustly differentiated the three family members with the RORα duplication from the family members without the RORα duplication and all NC subjects (p < 0 .05) . A unique pattern of white matter (WM) hyper-metabolism observed in the corpus callosum, internal capsule, in the vicinity of the medial prefrontal cortex, temporal cortex, and sensorimortor cortex and hypo-metabolism observed in the vicinity of the sensorimotor cortex, occipital cortex, and inferior parietal cortex was unique to the three family members affected with the RORα duplication compared to family members without the RORα duplication and all NC subjects .Neuropsychological test performance of the mice demonstrated KO mice had a significantly decreased ability to recognize novel objects compared to both WT and HT mice. Moreover, KO mice had a significantly lower percentage of correct trials on the T-maze compared to both WT and HT mice. Micro-PET data demonstrated significant hypo-activation in KO animals compared to WT animals in the rhinal cortex, cerebellum, paraflocculuc, thalamic nucleus, primary somatosensory cortex, lateral orbital tract, and piriform cortex .

ACNP Annual Meeting Book 2013 rev8.indd 34 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Retinoid-Related Orphan Receptor Alpha: A Novel Candidate Gene for Psychiatric Disease

Monday, Poster #236 (continued)

Joseph I . Friedman

Contrastingly, KO animals showed significant hyper-activation compared to WT animals in the periaqueductal gray, colliculi, olfactory bulb, cerebellar nuclei, and striatum. Moreover, KO mice showed a significant negative correlation between activation at both the cerebellum (r = -0 .839, p < .05) and the periaqueductal gray (r = -0 .829, p < .05) and the percentage of correct trials during T Maze testing . Discussion: These data provide the first evidence that disruption of the RORα gene has negative structural and functional brain consequences outside the cerebellum . Indeed, the unique patterns of both abnormal hypo- and hyperactivation associated with RORα disruptions in the human and animal subjects, and its correlation with impaired spatial memory, suggests abnormalities in the synchrony of interconnected neural networks possibly contributing to the susceptibility to a diverse array of psychiatric disease . Further investigation is warranted .

ACNP Annual Meeting Book 2013 rev8.indd 35 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Automated Analysis of Disorganized Communication Predicts Transition to Psychosis Among Clinical High Risk Patients

Tuesday, Poster #4

Gillinder Bedi, Facundo Carillo, Guillermo Cecchi, Diego Fernandez Slezak, Mariano Sigman, Jordan E . DeVylder, Felix M . Muchomba, Cheryl M . Corcoran Columbia University Medical Center

Background: Subthreshold thought disorder has been identified as predictive of psychosis onset among patients at clinical high risk (CHR) for psychosis (Bearden et al ., 2011) . Assessment of thought disorder is achieved through clinical ratings of speech production . Analyzing speech with automated methods may present a direct, objective measure to complement existing methods, potentially offering a unique ‘window into the mind’ . We evaluated the trajectory of disorganized communication leading to psychosis using clinical rating scales in a large cohort of clinical high risk (CHR) patients . We also assessed whether a novel, automated method of speech analysis could differentiate those who went on to transition to psychosis from those who did not over a 2 .5 year period . Methods: 100 patients at CHR for psychosis were ascertained and followed quarterly for up to 2 .5 years, or until time of dropout or transition to psychosis . Disorganized communication was assessed for predictive value for psychosis both at baseline and as a latent trajectory over time . A subcohort of 35 CHR patients had transcribed interviews, which were analyzed for semantic and syntactic coherence using a novel automated speech analysis approach . We employed machine learning with leave-one out cross validation to assess whether the semantic and syntactic indices identified predicted conversion to psychosis over the period of follow up . To further validate the method, we applied the classification algorithms developed to two separate cohorts of schizophrenia patients and healthy controls . Results: Psychosis transition in the overall sample was 26% . Both baseline disorganized communication and a trajectory of high persistent disorganized communication were predictive of psychosis, with similar sensitivity and specificity ~0.6. Automated speech-based analyses of speech from a single time

ACNP Annual Meeting Book 2013 rev8.indd 36 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Automated Analysis of Disorganized Communication Predicts Transition to Psychosis Among Clinical High Risk Patients

Tuesday, Poster #4 (continued)

Cheryl M . Corcoran

point predicted transition to psychosis with a sensitivity of 0.8 and specificity of 0 .93 . The algorithms developed also accurately discriminated between schizophrenia patients and healthy controls in two separate cohorts . Discussion: Persistent disorganized communication predicts psychosis onset; importantly this feature of psychosis risk can be accurately identified using automated speech analyses. These findings are consistent with neural and electrophysiological studies of psychosis risk, and have important implications for treatment strategies and prognosis assessment in CHR individuals .

ACNP Annual Meeting Book 2013 rev8.indd 37 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Dissecting Nucleus Accumbens Dynorphin Neurons in Aversion and Reward

Wednesday, Poster #196

Ream Al-Hasani, Jordan G . McCall, Nicole Capik, Blessan Sebastian, Daniel Hong, Audra Foshage, Michael Krashes, Bradford Lowell, Thomas Kash, Michael R . Bruchas Washington University, St . Louis

Background: The adverse effects of stress are well documented, yet many of the underlying mechanisms remain unclear and controversial . The dynorphin/kappa opioid system is implicated in the mediation of stress and resultant vulnerability to drug abuse . It is thought that stress causes dynorphin release activating kappa- opioid receptors (KOR) within both dopaminergic and serotonergic nuclei as well as their striatal targets . Consequently, much attention has focused on these systems in the modulation of KOR-mediated responses . Despite our current knowledge of central dynorphinergic cell body populations, a clear description of the axonal projections of these neurons is unknown . Methods: We crossed the Cre-dependent tdTomato (Ai9) reporter mouse to a mouse expressing Cre recombinase under the same promoter as dynorphin (Dyn-Cre) so only dynorphinergic cells express tdTomato . This allows complete visualization of dynorphinergic circuitry throughout the brain .We also virally targeted channelrhodopsin-2 to striatal dynorphinergic neurons and optogenetically activated neuronal populations in both the dorsal and ventral NAc shell to measure aversion and reward behaviors using place preference, aversion, and operant conditioning . Results: Using our dynorphin-cre-tDtomato cross we show robust dynorphin expression in cell bodies throughout the brainstem and forebrain . Clear visualization of intact projections throughout the brain and dynorphinergic projections can be seen from and within the cortex, striatum, amygdala, and numerous monoaminergic nuclei .Dynorphinergic neurons within the striatum are particularly interesting for the study of stress and drug abuse . Prior studies have shown that KOR agonists inhibit dopamine and serotonin release in the nucleus accumbens (NAc), which regulates aversive behaviors . Therefore, we investigated

ACNP Annual Meeting Book 2013 rev8.indd 38 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Dissecting Nucleus Accumbens Dynorphin Neurons in Aversion and Reward

Wednesday, Poster #196 (continued)

Michael R . Bruchas

whether specific modulation of dynorphinergic neuronal firing in the NAcis sufficient to induce aversive behaviors. This activation significantly increased c-Fos immunoreactivity in dynorphinergic neurons and inhibited electrically- evoked EPSCs which was reversed by norBNI application . Furthermore, activation of ventral NAc shell induced conditioned and real-time aversive behavior, while dorsal NAc shell stimulation resulted in a place preference which was also shown to be positively reinforcing in an operant task paradigm . Discussion: The results presented here for the first time show a discrete subregion of dynorphin-containing cells in the ventral shell of the accumbens are required for aversion mediated by KOR activation . Furthermore, dorsal accumbens dynorphin cell activity is consistent with reward, perhaps via a classical dopamine D1-mechanism, but this requires further study . Understanding the mechanisms by which the dynorphin/kappa opioid system regulates negative affective behaviors will provide valuable insight into potential treatments for stress disorders and drug abuse .

ACNP Annual Meeting Book 2013 rev8.indd 39 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Mismatch Negativity Predicts Psychosis Onset and is Associated with Plasma Markers of Inflammation in Youth at Clinical High Risk for Psychosis

Wednesday, Poster #47

Daniel H . Mathalon, Diana Perkins, Kristin Cadenhead, Gregory A . Light, Peter Bachman, Jason Johannesen, Aysenil Belger, Margaret Niznikiewicz, Erica Duncan, Ricardo Carrion , Jean Addington, Tyrone Cannon, Barbara A . Cornblatt, Larry J . Seidman, Elaine Walker, Scott Woods University of California, San Francisco

Background: The mismatch negativity (MMN), an event-related brain potential (ERP) component elicited pre-attentively by deviant auditory stimuli imbedded in a stream of standard stimuli, has been repeatedly shown to be reduced in amplitude in schizophrenia . Prior studies from several groups have shown MMN to be reduced in patients at clinical high risk (CHR) for psychosis, particularly in those who subsequently develop a psychotic disorder, principally schizophrenia . MMN is thought to depend on neurotransmission at the N-methyl-d-aspartate (NMDA) sub-class of glutamate receptors based on human and non-human primate studies showing NMDA receptor antagonists to disrupt MMN . Recent interpretations of the MMN have emphasized its reflection of both short-term (seconds) and longer term (minutes to hours) synaptic plasticity in the service of auditory sensory/perceptual learning, since the amplitude of the MMN to a deviant stimulus increases as a function of the number of repetitions of the preceding standard stimulus and also as a function of the emergence of more enduring memory traces for complex sounds through repeated exposures to these sounds. A plethora of basic neuroscience data indicates that neuroinflammation and inflammatory cytokines compromise mechanisms of synaptic plasticity such as long-term potentiation . Moreover, prior studies have shown schizophrenia and other psychiatric disorders to be associated with elevations in peripheral markers of inflammation. Using data collected as part of the North American Prodromal Longitudinal Study (NAPLS), we examined whether MMN was reduced in CHR patients, particularly those who went on to convert to a psychotic disorder, and further, whether blood plasma markers of inflammation were associated with reductions in MMN amplitude in CHR patients .

ACNP Annual Meeting Book 2013 rev8.indd 40 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Mismatch Negativity Predicts Psychosis Onset and is Associated with Plasma Markers of Inflammation in Youth at Clinical High Risk for Psychosis

Wednesday, Poster #47 (continued)

Daniel H . Mathalon

Methods: As part of the ongoing multi-site NAPLS study, 212 CHR youth meeting criteria for a psychosis prodrome syndrome (SIPS interview) and 152 age-matched healthy controls (HC) underwent electroencephalographic (EEG) recording during a 3-deviant (pitch, duration, pitch+duration) MMN paradigm administered while subjects performed a visual distractor task . In addition, 27 CHR individuals who subsequently converted to psychosis were compared with 75 CHR individuals who had not converted by the 24-month follow-up assessment . MMN was measured at electrodes Fz and Cz, using linked mastoids as reference . Blood plasma samples were drawn from a sub-group of subjects including 32 CHR-converters, 40 CHR non-converters, and 35 healthy controls, and were subject to analysis on a Luminex® multiplex platform . Analytes of inflammatory markers that distinguished CHR converters from non-converters were identified (n=30) and aggregated (z-transformed) to form an “inflammatory threshold index” . For each subject, this index was the calculated as the number of analytes that exceeded a z-threshold set to flag deviant analyte values. Results: Results showed that CHR patients had reduced MMN amplitudes at baseline relative to healthy controls for duration deviant MMN (p< .05), but not for pitch or combination deviant MMNs (Group x Deviant Type interaction p= .011) . Moreover, baseline MMN amplitude, irrespective of deviant type, was significantly reduced in the CHR converters relative to the CHR non-converters (Group main effect p= .024) . As expected based on the method used to derive it, the inflammatory threshold index was significantly elevated in CHR converters relative to CHR non-converters (p< .00001) . Of note, both the CHR converters (p<.00001) and the CHR non-converters (p<.005) showed significant elevations of the inflammatory index relative to healthy controls. Reduced pitch-deviant MMN amplitudes were significantly associated with elevated scores on the inflammatory threshold index in CHR patients (r= .38, p= .002, n=66) , but not in healthy controls

ACNP Annual Meeting Book 2013 rev8.indd 41 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Mismatch Negativity Predicts Psychosis Onset and is Associated with Plasma Markers of Inflammation in Youth at Clinical High Risk for Psychosis

Wednesday, Poster #47 (continued)

Daniel H . Mathalon

(r=.11, p=.57, n=35). Furthermore, while this MMN-inflammation relationship was strongly evident in the CHR converters (r= .57, p= .007, n=21), it was not evident in the CHR non-converters (r= .16, p= .34, n=39) . Discussion: Results to date replicate previous findings showing MMN amplitude to be reduced in CHR patients, particularly those who go on to convert to a psychotic disorder . Accordingly, disruption of NMDA-dependent synaptic plasticity, as reflected by the MMN, appears to precede psychosis onset and predicts the likelihood of conversion to a psychotic illness . In addition, the identification of a number of plasma analyte markers of inflammation that are elevated in CHR converters suggests that an active inflammatory process precedes psychosis onset in CHR patients who develop psychosis . Moreover, consistent with literature showing neuroinflammation to compromise mechanisms of synaptic plasticity, baseline elevations in plasma markers of inflammation were significantly associated with MMN amplitude reductions in the subgroup of CHR patients who subsequently converted to a psychotic disorder .

ACNP Annual Meeting Book 2013 rev8.indd 42 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Age-related Sperm DNA Methylation Changes are Transmitted to Offspring and Associated with Abnormal Behavior and Dysregulated Gene Expression

Tuesday, Poster #43

Maria H . Milekic, Yurong Xin, Anne O’Donnell, Victoria Fatemeh . Haghighi, Jay A . Gingrich, John Edwards, Timothy Bestor Columbia University

Background: Accumulating evidence support that advanced paternal age (APA) poses an increased risk in children for psychiatric disorders such as schizophrenia (SZ), bipolar and autism spectrum disorders (ASD) . There is clear evidence that de novo single nucleotide and copy number variations contribute to SZ and ASD, and that APA is associated with an increased rate of these types of mutations . Likewise, aging is associated with altered DNA methylation in both mammalian somatic and germ cells, and epigenetic abnormalities have been observed in the psychiatric disorders associated with APA . Accordingly, we hypothesized that DNA methylation abnormalities arising in the sperm of older fathers are inherited by the offspring and result in altered gene expression and behavior . Methods: Old (12mo) and young (3mo) male 129SvEv mice were bred with two female (3mo) 129SvEv mice to generate old (OFO) and young (YFO) father offspring . The males were removed after 2 weeks to prevent direct contact with the offspring and the females were separated to control for maternal and litter effects . At 3mo the offspring were tested on a behavioral battery, including tasks such as open field, startle activity and prepulse inhibition. We determined DNA methylation using a whole genome sequencing approach called Methylation Mapping Analysis by Paired-end Sequencing (Methyl-MAPS) (Edwards et al . Genomic Res. 2010) . Epididymal sperm from old and young male mice (n=4/group) was collected after the breeding . The brains of OFO and YFO were harvested at the end of behavioral testing . Methyl-MAPS libraries were prepared for both the fathers’ sperm (n=4/group), as well as from one hemisphere from OFO and YFO (n=4/group) . Mate-pair libraries were prepared for sequencing on the ABI SOLiD platform according to methods described by Edwards et al . (Genomic Res. 2010) . Data was processed and analyzed as described by Xin et

ACNP Annual Meeting Book 2013 rev8.indd 43 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Age-related Sperm DNA Methylation Changes are Transmitted to Offspring and Associated with Abnormal Behavior and Dysregulated Gene Expression

Tuesday, Poster #43 (continued)

Maria H . Milekic

al . (Epigenetics, 2011) .Transcriptome RNA-seq was performed on the remaining hemisphere from the same OFO and YFO samples used for Methyl-MAPS . Library construction and sequencing were performed by the Columbia Genome Center on an Illumina HiSeq2000 . Off-Line Basecaller (OLB-1 .9 .4) was used for base calling and the pass filter reads were mapped to the mouse genome (NCBI37/ mm9) using Tophat . We estimated the relative abundance (aka expression level) of genes and splice isoforms using cufflinks with default settings. Results: To determine whether aging alters sperm DNA methylation patterns, we performed genome-wide methylation profiling of epididymal sperm DNA pooled from young or old male mice using Methyl-MAPS . Mapping the methylation difference between the two groups across the regions up- and downstream of the transcription start site (TSS) and the first, internal and last exons of 20,496 RefSeq genes, we found that old mice had a significant loss of methylation at the regions flanking the TSS compared to young males. Comparing CpG island (CGI) and non-CGI promoters, the methylation difference was more profound at the regions up- and downstream of CGI promoter, so called CGI shores . Behavioral testing of the offspring of these old and young males revealed that OFO have significantly reduced exploratory, startle amplitude and prepulse inhibition compared to YFO . Performing Methyl-MAPS on brain DNA from OFO and YFO we found that, similar to the old fathers, OFO have significantly reduced DNA methylation at the regions flanking the TSS. This difference was specific to promoter CGI shores . Because DNA methylation patterns were altered in regions known to regulate transcription, we performed transcriptome RNA-seq on the remaining hemisphere of OFO and YFO . Differential gene expression analysis revealed a significant change in the expression of genes previously implicated in ASD and mental retardation (En2 and CA8), as well as genes regulating neural development (NeuroD1), synaptogenesis (Cbln1 and Cbln3) and cell signaling (Gabra6) .

ACNP Annual Meeting Book 2013 rev8.indd 44 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Age-related Sperm DNA Methylation Changes are Transmitted to Offspring and Associated with Abnormal Behavior and Dysregulated Gene Expression

Tuesday, Poster #43 (continued)

Maria H . Milekic

Discussion: Similar to the epidemiological findings in humans, increased paternal age in mice is associated with behavioral alterations in the offspring . This seems to be mediated, in part, by germ line transmission of DNA methylation abnormalities arising in the sperm of older fathers . Our whole genome methylation experiments on sperm DNA from old and young mice, revealed that there is a loss of methylation at promoter CGI shores with aging and that this specific signature is also present in the OFO . These CGI shores have been shown to contain cell-, tissue- and species specific DNA methylation differences (Irizarry, Nat. Genet, 2009), which are associated with gene expression . RNA-seq on brains from OFO and YFO revealed significant changes in genes implicated in ASD, and known to regulated neural development and synaptic functions. These findings indicate novel pathways and mechanisms that may contribute to ASD and SZ and which may eventually lead to the development of new and more effective therapeutic interventions .

ACNP Annual Meeting Book 2013 rev8.indd 45 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Prospective Examination Of Prepulse Inhibition In OIF/OEF Marines Suggests Reduced Sensorimotor Gating Is A Pre- existing Factor In Those That Develop PTSD After Combat Deployment

Wednesday, Poster #13

Victoria Risbrough, Dean Acheson, Dewleen G . Baker, Caroline Nievergelt, Kate Yurgil, Mark A . Geyer University of California San Diego

Background: Development of combat-related posttraumatic stress disorder (PTSD) is one of the major health concerns arising following the wars in Iraq and Afghanistan (Smith et al ., 2008; Polusny et al ., 2011) . To develop more effective treatment and prevention efforts, a greater understanding of theneurobiological processes involved in the etiology and course of PTSD is needed (Baker et al ., 2012) . To understand PTSD etiology, it is critical to differentiate components of PTSD-related phenotypes that are pre-existing factors from those that emerge specifically after trauma. This distinction can only be addressed by prospective studies . Here we tested the hypothesis that sensorimotor gating is a pre-existing factor in development of PTSD . Prepulse Inhibition (PPI) is a cross-species operational measure of sensorimotor gating and putative measureof pre-attentional information processing (Geyer & Braff, 1987) . Presentation of a neutral acoustic “prepulse” 30-300 ms before a more intense, startling stimulus reduces startle magnitude, possibly via direction of attentional resources toward the prepulse creating a “gate” for the subsequent startle stimulus (Swerdlow et al ., 1999) . PPI has a well defined neural circuit and is modulated by both subcortical and cortical circuits such as the prefrontal cortex. PPI has been found to be deficient in a number of psychiatric disorders (Swerdlow et al ., 2006; Castellanos et al ., 1996; Perry et al ., 2001; Ahmari etal ., 2012; Ludewig et al ., 2002), however its role in PTSD is currently unclear (Kohl et al ., 2013) . Methods: These data are collected as part of the Marine Resiliency Study (MRS), a prospective study of psychological and biological markers in a sample of Marines deployed to either Iraq or Afghanistan from 2008-2011 . Marines completed the PPI test as well as a clinician administered PTSD symptom scale (CAPS) prior

ACNP Annual Meeting Book 2013 rev8.indd 46 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Prospective Examination Of Prepulse Inhibition In OIF/OEF Marines Suggests Reduced Sensorimotor Gating Is A Pre- existing Factor In Those That Develop PTSD After Combat Deployment

Wednesday, Poster #13 (continued)

Dean Acheson

to deployment, 3 months post-deployment, and 6 months post-deployment . PPI was assessed as previously described (Acheson et al . 2012) . In brief the session used 114 dB acoustic startle pulses, amd 86-dB prepulses (16 dB above the 70 dB background noise) that preceded the startle pulse by 30, 60 or 120 msec (i .e . interstimulus intervals) . Results: Of the 1229 Marines that did not have PTSD before deployment and had complete EMG and CAPS data at the 6-month time point, 46 (4%) developed PTSD after deployment (CAPS score >65) . A linear mixed effects model found that Marines who tested positive for PTSD 6-months after return from combat deployment displayed significantly lower PPI performance across all pre- and post-deployment assessment periods relative to Marines who did not test positive at 6 months . There were no main effects of time point . PPI reductions in the PTSD group were greatest at 30 and 60 ms interstimulus intervals. No significant differences in either general startle magnitude or startle habituation emerged at any assessment period, although there was a trend for the PTSD group to show higher baseline startle at the pre-deployment time point . Effect of group remained when covarying for cohort, traumatic brain injury, and hearing loss . Further, post-deployment PPI performance did not correlate with Marine self-report of combat experience, suggesting that PPI performance is a stable trait unaffected by trauma experience itself . Discussion: This study represents the first longitudinal test of PPI performance in relation to risk for later development of PTSD following combat experience . These results suggest that deficient PPI performance may represent a pre-existing risk factor for development of PTSD in response to traumatic experience . Ongoing studies are now in progress to determine if environmental or genetic perturbations mediate the role of PPI as a risk factor for PTSD .

ACNP Annual Meeting Book 2013 rev8.indd 47 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Disrupting AMPA Receptor Endocytosis Restores the Ability to Form New, and Enables the Recovery of Old, Memories in Mice Genetically Designed to Mimic Alzheimer’s Disease

Tuesday, Poster #92

Sheena Josselyn, Adelaide Yiu, Valentina Mercaldo, Derya Sargin, Paul Frankland Hospital for Sick Children/University of Toronto

Background: The clinical hallmark of Alzheimer’s disease (AD) is a progressive decline in cognitive function . The sequence of this decline often follows a stereotyped course; patients first show difficulty forming new memories, then deficits in retrieving older memories followed by deficits in other cognitive domains, and a loss of overall bodily functions . The ultimate outcome of AD is death . B-amyloid (A-beta) is widely implicated in the neuropathology underlying AD and chronically high levels of A-beta may induce cell death . This neurodegeneration readily accounts for the memory and cognitive impairment observed in the later stages of AD . In the early stages of AD, however, patients show deficits in forming new memories and high levels of A-beta but no detectable cell death . This suggests that high levels of A-beta may directly interfere with the synaptic plasticity required for normal memory formation . How A-beta impairs memory is unknown . In vitro, high levels of A-beta have been shown to decrease synaptic strength by promoting the internalization of postsynaptic AMPA-type glutamate receptors (AMPARs), suggesting the some of the memory deficits in AD may be due to excessive AMPAR internalization . Here we investigated the role of AMPAR internalization in the memory deficits observed in several types of mice genetically designed to recapitulate important aspects of AD . Methods: We examined the effects of acutely or chronically increasing A-beta levels on the ability of mice to form stable long-term spatial and contextual fear memories . To transiently increase A-beta levels in wild-type (WT) mice we used replication-defective herpes simplex viral (HSV) vectors expressing human amyloid precursor protein (APP) containing both the Swedish and Indiana familial AD mutations . To chronically increase A-beta levels we used TgCRND8 mice, transgenic mice that chronically express the same mutated APP construct .

ACNP Annual Meeting Book 2013 rev8.indd 48 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Disrupting AMPA Receptor Endocytosis Restores the Ability to Form New, and Enables the Recovery of Old, Memories in Mice Genetically Designed to Mimic Alzheimer’s Disease

Tuesday, Poster #92 (continued)

Sheena Josselyn

We used several methods to interfere with AMPAR internalization . First we used viral vectors to express a peptide designed to specifically interfere with GluA2-containing AMPAR endocytosis (GluA2-3Y peptide) . Second, we use TAT (Trans-Activator of Transcription) proteins to systemically deliver this small interfering GluA2-3Y peptide . Importantly, the use of this non-toxic method of delivering this peptide via systemic administration may facilitate the translation of our results to the clinic . As a third method to disrupt GluA2-containing AMPAR endocytosis, we targeted Arf6 (ADP-ribosylation factor 6) expression, which is thought to be critical for this form of clathrin-mediated endocytosis . Results: We observed that either acute or chronic increases in A-beta levels impaired the ability of mice to form stable long-term spatial or a contextual fear memory without inducing cell death. These memory consolidation deficits were accompanied by a decrease in the surface levels of GluA2-containing AMPAR, suggesting that the loss of GluA2-containing AMPAR may be responsible for the memory deficits. Consistent with this interpretation, we observed a strikingly similar phenotype when we used viral vectors to express a constitutively active from of Arf6 (Arf6-Q67L) to induce endocytosis of GluA2-containing AMPAR only in the hippocampus of WT mice. Moreover, the memory deficits induced by increasing A-beta levels were occluded by directly activating Arf6, suggesting that A-beta was acting through this pathway to produce the memory deficits. These results are consistent with the interpretation that high levels of A-beta produce memory deficits by facilitating GluA2-containing AMPAR endocytosis. To examine this more directly, we tested whether it was possible to reverse the memory deficits produced by high levels of A-beta by disrupting AMPAR trafficking. Importantly, transiently interfering with AMPAR internalization (by either a specific interfering peptide or interfering with Arf6 function) was sufficient to reverse the memory deficits produced by either acute or chronic overexpression

ACNP Annual Meeting Book 2013 rev8.indd 49 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Disrupting AMPA Receptor Endocytosis Restores the Ability to Form New, and Enables the Recovery of Old, Memories in Mice Genetically Designed to Mimic Alzheimer’s Disease

Tuesday, Poster #92 (continued)

Sheena Josselyn

of A-beta . Together, these data are consistent with the interpretation that high levels of A-beta impair memory by inducing the loss of surface GluA2-containing AMPAR . It is now well-appreciated that memories, even after consolidation, are modifiable. The process of remembering is thought to reactivate memory representations in the brain . The reactivated memory is re-stored in a second wave of consolidation referred to as reconsolidation . Strikingly, similarly disrupting AMPAR endocytosis during a memory reminder enabled the recovery of an otherwise inaccessible memory in mice with chronically high A-beta levels . This result suggests that memory reactivation and subsequent reconsolidation may open a “window of plasticity” in which otherwise “lost” memories may be successfully reconsolidated (and consequently “recovered”) by disrupting AMPAR internalization at the time of the reminder. Our findings raise the possibility that targeting AMPAR trafficking could restore both the ability to form new memories as well as enable recovery of lost past memories in AD patients . Discussion: The results from these studies may not only lead to a better understanding of how A-beta disrupts memory but may help identify a novel therapeutic strategy to allow AD patients to form new memories as well as recover “lost” memories .

ACNP Annual Meeting Book 2013 rev8.indd 50 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Selective Effects of the 5-HT2C Receptor Agonist Meta- chlorophenylpiperazine (mCPP) on Intake of a Palatable Snack Food in Healthy Female Volunteers: Correlation with Regional Brain Activations Measured by BOPLD fMRI

Wednesday, Poster #107

Colin T . Dourish, Jason M . Thomas, Suzanne Higgs P1vital

Background: The 5-HT2C receptoragonist meta-chlorophenylpiperazine (mCPP) has been reported to decrease food intake in lean and obese volunteers although the behavioural selectivity of these effects and the brain mechanisms involved are unclear . In a recent study using a universal eating monitor to measure meal microstructure we showed that mCPP caused a dose related decrease in appetite ratings and enhanced the satiation quotient (change in hunger ratings divided by caloric intake) in lean females . However, despite these changes in rating derived measures the effects of mCPP on total food intake were not statistically significant. Therefore, in the present study, we investigated for the first time the potential influence of palatability on the response to mCPP by comparing the effects of the drug on the consumption of a pasta meal and a palatable snack in lean females . In addition, to investigate the brain mechanisms involved we used functional magnetic resonance imaging (fMRI) to determine the effects of a dose of mCPP that decreases appetite on blood oxygen level dependent (BOLD) signals . Methods: The study used a within-subject double blind placebo controlled design and 24 healthy female volunteers received placebo and 30mg mCPP in a counterbalanced order one week apart . Participants were scanned using BOLD fMRI pre and post oral dosing and after the second scan were provided with a pasta meal and allowed to eat to satiety . Food intake and meal microstructure were recorded using a Sussex Ingestion Pattern Monitor (SIPM) . The SIPM comprises a concealed weighing system and computer software to enable detailed collection and analysis of human eating behaviour and continuously monitors food intake in parallel with measures of appetite and satiety. When participants had finished their pasta meal they were offered a palatable snack (chocolate chip cookies) and

ACNP Annual Meeting Book 2013 rev8.indd 51 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Wednesday, Poster #107 (continued)

Colin T . Dourish

were again allowed to eat to satiety . Cookie intake and snack microstructure were recorded using the SIPM . Results: mCPP significantly reduced hunger and the desire to eat but did not reduce the amount of pasta consumed during the meal. However, the drug significantly reduced pasta eating rate and increased pause length between mouthfuls of pasta. In contrast, mCPP significantly reduced the amount of cookies consumed. In addition, the drug reduced the size of cookie mouthfuls, the total number of cookie portions eaten and the cookie eating rate and increased the pause duration between mouthfuls of cookies . mCPP also decreased pleasantness ratings of both the pasta meal and the cookie snack but the temporal patterns of these responses were significantly different. Thus, the effect of mCPP on pleasantness ratings of pasta had a slow onset and increased throughout the meal whereas the effect of the drug on pleasantness ratings of cookies was immediately apparent and was maintained at the same level throughout the snack intake . Analysis of the BOLD fMRI results showed that mCPP attenuated activity in the hypothalamus, insula, brainstem, anterior cingulate cortex and dorsolateral prefrontal cortex . In addition, correlational analyses revealed that mCPP-induced BOLD changes in the hippocampus, anterior cingulate cortex, midbrain and orbitofrontal cortex were significantly and negatively correlated with cookie eating rate. These correlations were not apparent with pasta eating rate . Discussion: These results show for the first time that mCPP decreases the consumption of a highly palatable snack food in humans . Furthermore, this was a selective effect as the drug had no effect on the consumption of a pasta meal suggesting that the effects of mCPP on eating may be determined by the hedonic properties of food . This interpretation is consistent with the contrasting time courses of the effects of mCPP on pleasantness ratings of the pasta and cookies

ACNP Annual Meeting Book 2013 rev8.indd 52 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Wednesday, Poster #107 (continued)

Colin T . Dourish

during the meal . The fMRI results show that mCPP attenuated BOLD signals in key areas involved in the processing of appetitive, rewarding and motivational stimuli . Furthermore, changes in hippocampus, anterior cingulate cortex, midbrain and orbitofrontal cortex were negatively correlated with cookie eating rate but not pasta eating rate suggesting that these brain regions which are known to be involved in reward and memory processing could mediate the selective

hedonic effects observed . Finally, as a selective 5-HT2C receptor agonist has recently been approved by the FDA for the treatment of obesity these findings could have important implications for drug therapy in obese patients where the over consumption of highly palatable foods may be an important contributory factor to the development and maintenance of the disease .

ACNP Annual Meeting Book 2013 rev8.indd 53 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Locus Specific Epigenetic Reprogramming: Bidirectional Regulation of the FosB Gene Using Synthetic Transcription Factors In Vivo

Tuesday, Poster #81

Elizabeth Heller, Hannah Cates, Haosheng Sun, Catherine Pena, Deveroux Ferguson, Scott Knight, H . Steve Zhang, Eric Nestler Icahn School of Medicine at Mount Sinai, Department of Neuroscience

Background: Transcriptional regulation underlies sensitivity to psychostimulant exposure and is associated with altered expression of several chromatin-modifying enzymes in key brain reward regions . Genome-wide assessments of histone posttranslational modifications (HPTMs) have identified drug and stress regulation at numerous target genes implicated in the associated behavioral abnormalities . However, it has not previously been possible to manipulate the epigenome in order to causally link the chromatin state of a single locus with behavioral and molecular responses to psychostimulant exposure . Engineered transcription factors, such as zinc finger proteins (ZFPs) and transcription activator-like effectors (TALEs), can direct enzymatic moieties to specific genomic loci. We are interested in epigenetic regulation of the immediate early gene, FosB, which is both necessary and sufficient for many of the downstream molecular changes mediating stress and reward response . Previous work has demonstrated that chronic cocaine exposure in both humans and rodents leads to a reduction in the levels of the histone methyltransferase, G9a, and the repressive epigenetic mark, histone H3 lysine 9 dimethylation (H3K9me2), at the FosB locus . This may be the mechanism by which FosB and its stable splice variant, DFosB, accumulate in reward regions of the brain in order to mediate drug responsiveness . Furthermore, DFosB expression is reduced in the brain reward regions of chronically stressed rodents and depressed human patients; we have recently found an increase in H3K9me2 at the FosB promoter in depressed human Nucleus accumbens (NAc) relative to healthy controls . Despite the robustness of these correlations, it has not yet been possibly to directly link a particular HPTM at the FosB gene to behavioral response, due to the use of experimental paradigms that affect the entire genome (e .g . overexpression of G9a, HPTM ChIP-chip, cocaine or stress

ACNP Annual Meeting Book 2013 rev8.indd 54 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Locus Specific Epigenetic Reprogramming: Bidirectional Regulation of the FosB Gene Using Synthetic Transcription Factors In Vivo

Tuesday, Poster #81 (continued)

Elizabeth Heller

exposure) . Thus, we have pioneered the use of engineered transcription factors to direct a single epigenetic modification to a single gene of interest, within a single brain region . Methods: A suite of 65 6-finger cys2/his2 ZFPs were designed in silico to recognize 18bp motifs within -200 to +1000 bp of the FosB promoter relative to the transcription start site . These ZFPs were tethered to the transcriptional activation domain, p65, and screened in vitro for activation of FosB mRNA expression by qRT-PCR . From this screen several ZFPs were selected for fusion to alternative enzymatic domains, such as the preSET/SET domains of G9a and the viral activation domain, VP64 . In addition, three TALE-VP64 constructs were designed to target similar sequences. To confirm specificity of the binding of the ZFP across the genome, ZFP-NFD (no functional domain) constructs were fused to 3xFLAG affinity tag, expressed in vitro and subject to chromatin immmunopurification (ChIP)-Sequencing. For in vivo analysis, mouse NAc neurons were infected with herpes simplex virus (HSV) expressing each of the constructs, and qRT-PCR and immunohistochemistry was used to determine activation or repression of FosB expression . We relied on qChIP using a variety of anti-HPTM antibodies to analyze the chromatin modifications induced by the ZFP-G9a and ZFP-p65 constructs . To determine the role of epigenetic remodeling on behavioral responses to psychotimulant exposure, mice were subject to either cocaine locomotor sensitization or acute social stress following HSV NAc infection with the ZFP constructs . Results: We have found that FosB-ZFP-p65 and -TALE-VP64 constructs efficiently and robustly activate FosB/DFosB expression in NAc neurons, while FosB-ZFP-G9a represses expression . In addition, immunohistochemistry with an anti-FosB/DFosB antibody demonstrates that FosB-ZFP-G9a blocks cocaine induction of FosB/DFosB in NAc, while basal levels of protein are unchanged .

ACNP Annual Meeting Book 2013 rev8.indd 55 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Locus Specific Epigenetic Reprogramming: Bidirectional Regulation of the FosB Gene Using Synthetic Transcription Factors In Vivo

Tuesday, Poster #81 (continued)

Elizabeth Heller

Using qChIP, we have found that the mechanism of this repression is HSV-G9a deposition of H3K9me2 specifically at the FosB gene in vivo, while FosB- ZFP-p65 activates FosB via H3K9/14 acetylation. In addition, this gene-specific epigenetic remodeling is associated with changes in FosB promoter binding by additional HPTMs and the transcription factor, pCREB, which is a known regulator of activity dependent activation of FosB. Engineered transcription factors are also able to modulate behavior, as FosB-ZFP-p65 expression in the NAc enhances cocaine locomotor sensitization, while FosB-ZFP-G9a expression blocks the cocaine effect on locomotor as well as sensitizes animals to stress . Discussion: Engineered transcription factors are effective tools to probe the behavioral and molecular consequences of chromatin remodeling at a single locus in vivo. Using this approach, we have identified a direct molecular mechanism for cocaine-mediated activation of theFosB gene, and have efficiently manipulated behavioral responses to drugs of abuse and stress. This work opens the field for a more mechanistic and causal analysis of the role of epigenetics in regulating the neurobiological mechanisms that underlie reward pathology .

ACNP Annual Meeting Book 2013 rev8.indd 56 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Suicidal Ideation in Depressed New Mothers: Relationship with Childhood Trauma and Sleep Disturbance

Wednesday, Poster #223

Dorothy Sit, James Luther, Jesse Dills, Heather Eng, Dan Buysse, Michele Okun, Stephen Wisniewski, Katherine L . Wisner University of Pittsburgh, School of Medicine, Department of Psychiatry

Background: Of new mothers with a positive depression screening (Edinburgh Postnatal Depression Scale - EPDS>10) 19 .3 percent (n=1396) had thoughts of self-harm (Wisner et al, JAMA Psychiatry 2013) . The high rate of suicidal ideation (SI) in new mothers is a major concern . Without proper treatment, mothers with SI are at increased risk for suicide. From the 1997-1999 UK Confidential Enquiries into Maternal Death suicide was the leading cause of maternal death from 42 days to 1 year postpartum; 28 percent of maternal deaths (n=242) resulted from suicide (Oates 2003) . In this cross-sectional study, the objective was to characterize potential risk factors for postpartum women with SI who were enrolled in the primary study to screen for postpartum depression (PPD)(Wisner et al, 2013) . The aims were to examine the relationship between SI and childhood or adult history of trauma (physical abuse or sexual abuse) and sleep disturbances in new mothers within 4-6 weeks after delivery . The hypothesis was childhood trauma, current sleep disturbance and the interaction between childhood trauma and current sleep disturbance were associated with SI . Methods: Eligible subjects included new mothers who received an EPDS depression screen within 4-6 weeks after delivery and a completed home visit evaluation. The primary psychiatric diagnosis was confirmed by the Structured Clinical Interview for DSM-IV (SCID) . Patients with Bipolar Disorders, primary psychotic disorders, alcohol or substance use disorders were excluded . We compared the groups with an EPDS item 10 (“The thought of harming myself has occurred to me”) = 0 (“never”), 1 (“hardly ever”), 2 or 3 (“sometimes” or “quite often”) . We recorded baseline demographic characteristics including age, race, educational level, marital status, health insurance and parity . We examined comorbid disorders, adult and childhood abuse history, onset of the current depressive episode, total depression scores on the Structured Interview Guide for

ACNP Annual Meeting Book 2013 rev8.indd 57 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Suicidal Ideation in Depressed New Mothers: Relationship with Childhood Trauma and Sleep Disturbance

Wednesday, Poster #223 (continued)

Dorothy Sit

the Hamilton Depression Rating Scale, Atypical Depression Symptoms Version (SIGH-ADS) - a 29-item instrument that incorporates the Hamilton Rating Scale for Depression and a set of questions to assess atypical neuro-vegetative symptoms and the global assessment of function . For sleep disturbance we examined the SIGH-ADS sleep symptoms (insomnia – items H6, H7, H8 and wake time after sleep onset-WASO greater than 20 minutes) . Results: Of 648 eligible mothers, 496 (77%) reported that they “never” had thoughts of self-harm; 98 (15%) had SI “hardly ever”, and 34 (5%) had SI “sometimes or quite often” . Younger mothers, African Americans and mothers with public health insurance were significantly more likely to have SI. Mothers with the onset of depressive episodes before pregnancy or in the post-partum, a history of physical abuse in childhood, and lowered global functioning were significantly more likely to have SI. Cumulative logistic regression models suggested a main effect for history of childhood physical abuse (odds ratio- OR=1.681, 95% confidence interval-CI=1.045, 2.704, p=0.032) and a marginally significant interaction of childhood physical abuse with WASO > 20 minutes (OR=1 .576, 95%CI 0 .950, 2 .614, p=0 .078) . Discussion: A high percentage of maternal deaths are from suicide (Oates, 2003) . Our data suggested that among mothers with a positive depression screening, having a past history of childhood trauma and possibly having recent sleep disturbance contributed to increased risk for thoughts of suicide .Altered stress responses in patients with early life abuse could increase their susceptibility to suicide (Lupien et al 2009) . Patients with childhood abuse who completed suicide expressed reduced levels of glucocorticoid receptor-GR whereas non-abused patients who completed suicide did not express altered GR (McGowan,Meaney et al 2009) . New research is imperative to extend our knowledge of the relationship between abnormal responses to stress and the cognitive processes involved with making decisions and experience of reward (Dombrovski et al, 2013) which could underlie suicidal thoughts and precede suicide in postpartum mothers .

ACNP Annual Meeting Book 2013 rev8.indd 58 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

The Contribution of Adult Hippocampal Neurogenesis to Fear Memory Generalization

Tuesday, Poster #25

Mazen A . Kheirbek, Liam J . Drew, Elizabeth Balough, Christine A . Denny, Rene Hen New York State Psychiatric Institute/RFMH

Background: Maladaptive fearfulness is a hallmark of a number of anxiety disorders . In particular, in disorders such as post-traumatic stress disorder, it is frequently observed that fear becomes expressed in safe situations that are similar to the original trauma . That is to say, fear is overgeneralized to neutral situations . The dentate gyrus (DG) subregion of the hippocampus functions in pattern separation, a process by which representations of similar experiences or events are transformed into non-overlapping representations so as to facilitate their storage as discrete units . We hypothesize that impairments in pattern separation contribute to the overgeneralization of fear seen in certain anxiety disorders . Recently, adult-born granule cells (GCs) in the DG have been implicated in pattern separation . However, it remains unclear how these young neurons facilitate this process, or whether their functional contribution differs from that of mature GCs . Here, we have probed the mechanism by which immature GCs of the DG may act to prevent the generalization of a contextual fear memory . To address the online role of immature GCs in contextual encoding, generalization and anxiety, we used optogenetic techniques to selectively and bidirectionally modulate the activity of immature and mature GCs in a region-specific manner. Methods: To target opsins selectively to immature GCs, a Nestin-CreERT2 line was crossed to either a conditional archaerhodopsin-3 (Arch) or a channelrhodopsin-2 (ChR2) line . Tamoxifen injection in adult mice induced recombination in neural stem cells and transit-amplifying progenitors to generate opsin-expressing adult- born GCs . For targeting mature GCs, we crossed the conditional opsin lines with an Arc-CreERT2 line, which directs recombination to cells expressing the immediate early gene Arc . Injection of Tamoxifen paired with exploration of a novel environment induced recombination and expression of opsins in a sparse population of mature GCs (but not immature GCs that don’t express significant levels of Arc) . Six weeks after TMX, mice were tested for behavioral effects

ACNP Annual Meeting Book 2013 rev8.indd 59 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

The Contribution of Adult Hippocampal Neurogenesis to Fear Memory Generalization

Tuesday, Poster #25 (continued)

Mazen A . Kheirbek

of light-induced inhibition or excitation in the dorsal or ventral DG . As this manipulation allows for epoch selective modulation of activity in adult-generated neurons and their mature counterparts, we tested whether these cells play a context-specific role in a pattern separation task that requires mice to discriminate between a shock-paired context and a similar, safe context . Activity in adult-born GCs or a similar number of mature GCs in the dorsal DG was suppressed during exposure to either the conditioning context or the similar, safe context . Results: Histological analysis showed that Nestin-ChR2 and Nestin-Arch lines expressed opsins in nearly all immature adult-born, GCs, that Arc-ChR2 and Arc-Arch lines expressed opsins almost exclusively in mature GCs and that similar numbers of opsin-expressing neurons were generated in the Nestin-opsin and the Arc-opsin lines . Optical modulation in vivo, demonstrated that while none of the manipulations impacted baseline anxiety state, excitation of either cohort of cells impaired context acquisition . Optical inhibition of adult-generated GCs, but not of an equal number of mature GCs in the dorsal DG disrupted the rapid encoding of contextual fear memories, indicating a selective contribution of adult-generated neurons to rapid encoding of contexts . In a contextual fear discrimination experiment, we found that inhibition of young GCs during exposure to the similar, safe context, but not the conditioning context, impaired discrimination . Surprisingly, inhibition of a population of mature GCs in the similar context improved the animals’ ability to discriminate between contexts . Discussion: This study reveals differential contributions of mature and immature neurons of the DG to contextual fear encoding and discrimination. Specifically, we show that while young GCs are not needed for the maintenance of an already learned contextual memory, they are necessary for the disambiguation of similar information from already learned information . In contrast, inhibiting the activity of mature neurons improves discrimination, indicating opposite functions for these two populations of cells within the DG . Immature neurons in the dorsal

ACNP Annual Meeting Book 2013 rev8.indd 60 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

The Contribution of Adult Hippocampal Neurogenesis to Fear Memory Generalization

Tuesday, Poster #25 (continued)

Mazen A . Kheirbek

DG are required for the rapid encoding of novel contextual information and to disambiguate novel representations from already learned ones, which is consistent with their proposed role in pattern separation . In contrast mature GCs appear to be involved in generalization . We hypothesize therefore that strategies aimed at stimulating neurogenesis or modulating the activity of mature GCs may restrain overgeneralization and may be effective for the treatment of anxiety disorders .

ACNP Annual Meeting Book 2013 rev8.indd 61 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Intranasal Ketamine in Treatment-Resistant Depression

Tuesday, Poster #139

Kyle A . Lapidus, Cara F . Levitch, Laili Soleimani, Andrew M . Perez, Jess W . Brallier, Michael K . Parides, Dan V . Iosifescu, Dennis S . Charney, James W . Murrough Mount Sinai Medical Center

Background: Current treatments for depression are only partially effective and exhibit delays in onset of therapeutic efficacy. Several studies have reported a rapid onset of antidepressant action for intravenous (IV) ketamine – and NMDA receptor antagonist – in patients with treatment resistant depression (TRD) . Despite potential efficacy, the requirement for IV administration imposes potential limitations to therapeutic delivery . In contrast, ketamine delivery via an intranasal (IN) route may provide a more feasible treatment approach . Herein we report the first placebo-controlled study of IN ketamine in TRD. Methods: Twenty subjects with TRD in a current major depressive episode were randomized to receive IN ketamine hydrochloride (50 mg) or 0 .9% saline solution, in a crossover design with one of two treatment orders: either ketamine-placebo (KET-PBO) or placebo-ketamine (PBO-KET); KET or PBO were administered 1-2 weeks apart . 18 subjects received both treatments under randomized, double blind conditions . Before administration, subjects were admitted to a clinical research unit and study drug was administed by an anesthesiologist . Continuous vital signs monitoring was employed during and for 4 hours following treatment. The primary efficacy outcome measure was change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) score at 24 hours following KET, compared to PBO . Response and remission rates at 24 hours represented secondary outcomes. Clinical response was defined as MADRS decrease ≥ 50% from baseline and remission was defined as a MADRS score of ≤ 9. To assess hemodynamic side effects, vital signs were monitored and clinically significant changes were defined as systolic or diastolic blood pressure (BP) >180/100 or >20% increase above baseline level or tachycardia with heart rate >110 beats/minute . Management by medication interventions and treatment discontinuation was to be provided for significant hemodynamic changes. Other secondary outcomes included general adverse events, acute psychotomimetic

ACNP Annual Meeting Book 2013 rev8.indd 62 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Intranasal Ketamine in Treatment-Resistant Depression

Tuesday, Poster #139 (continued)

Kyle A . Lapidus

effects, and dissociative effects, measured with the Systematic Assessment for Treatment Emergent Effects (SAFTEE), Brief Psychiatric Rating Scale (BPRS), and Clinician-Administered Dissociative States Scale (CADSS) respectively . Results: Subjects evidenced significant improvement in depressive symptoms within 24 hours after ketamine compared to placebo (t=4 .4, p<0 .001) . Following KET, 8 of 19 subjects responded (42%), compared to 2 of 19 (11%) following PBO . Among study completers (those who received both treatment conditions), 8 (44%) met the response criterion . Of these 8, 1 (6%) also responded to placebo, while no completer met response criteria only for placebo (p=0 .0325 based on McNemar’s test) . Intranasal ketamine was well tolerated with few side effects. Specifically, following ketamine, the mean increase in BPRS was 0.3, and in CADSS was 1.37. No patient exhibited clinically significant changes in hemodynamics . Discussion: In this study, we demonstrated a rapid antidepressant effect of IN ketamine in patients with TRD . IN KET was well tolerated with almost no psychotmimetic or dissociative side effects and with no significant hemodynamic effects including blood pressure and heart rate changes . No interventions by anesthesiology were needed . Future studies are indicated to identify strategies for maintaining antidepressant response in patients who respond to intranasal ketamine .

ACNP Annual Meeting Book 2013 rev8.indd 63 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Specific Elevation of βCaMKII in the Lateral Habenula Lead to Core Symptoms of Depression

Monday, Poster #13

Hailan Hu, Fritz Henn, Kun Li, Tai Zhou, Zhongfei Yang, Lujian Liao, Catherine Wong, Roberto Malinow, John R . Yates III Mount Sinai School of Medicine

Background: The congenital lines of leartned helpless rats (cLH) have been useful in identifying the anatomical circuit which appears to mediate depression in humans as well as helplessness in animals, and these studies point to a critical role of the lateral habenula . The cLH lines show increased activation of the l . habenula and this has been seen in patients undergoing tryptophan depletion with return of depressive symprotoms . Responders to both ketamine and scopolamine have been shown to have decreased habenular activity . Methods: The current study was a proteomic investigation of protein differences in disected l . habenula tissue between cLH animals and control animals animals using 15N enrichment for mass spectometry to look for protein differences . A mouse model was created which could express the increase in βCaMKII found was made and tested for depressive features Down regulation or inhibition of βCaMKII was used to determine if this reversed the depressive phenotype. Results: The proteomic screen revealed an almost doubling in βCaMKII in the helpless animals which was resrticted to the l . habenula, the levels in the hippocampus were actuaslly decreased by about 40% reflecting the loss of neuronal tissue in the model . Histological examination of the habenula showed uniform increase in neuronal levles of the enzyme in the lateral habenula and no increase in the medial habenula. This was verified using western blots. Overexpression of the protein in mouse models resulted in a doubling of the immobility time in the forced swim test and resulted in increased synaptic activity in the lateral habenula restrcted to neurons showing overexpression of the protein . A knockdown of the βCaMKII resuced the depressive phenotype and reduced synaptic activity. Increasing αCaMKII in mouse models had no effect on synaptic efficacy or behavioral measures of depression. Blocking the target of βCaMKII, GluR1 reversed the depressive sympotomolgy .

ACNP Annual Meeting Book 2013 rev8.indd 64 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2:30 p.m. – 6:30 p.m. Hot Topics Regency Ballroom 1 & 2 PL

Specific Elevation of βCaMKII in the Lateral Habenula Lead to Core Symptoms of Depression

Monday, Poster #13 (continued)

Fritz Henn

Discussion: These data suggest that the central role of the l . habenula in depression suggested by both animal studies and human imaging studies is due to a specific change in protein levels of βCaMKII, which increases synaptic firing leadingndirectly to the downstream regulation of the 5HT and DA systems. This data provides a toally new and clearly defined target for antidepressant development .

ACNP Annual Meeting Book 2013 rev8.indd 65 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

ACNP Annual Meeting Book 2013 rev8.indd 66 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

President’s Plenary

Welcoming Remarks and Moment of Silence PL David Lewis President

Presentation of Honorific Awards John Krystal Chair, Honorific Awards Committee

Neural Circuitry Structure and Plasticity: Substrate for Brain Disorders and Novel Therapeutics

8:30 a .m . Homeostatic Plasticity: Keeping Your Brain in Balance Gina Turrigiano

9:15 a .m . Genetic Dissection of Cortical Circuit Organization and Assembly: Chandeliers Light Up the Path Z. Josh Huang

10:00 a .m . Surprise at the Synapse: MHC Class I, Pruning and Plasticity Carla Shatz

10:45 a .m . Dynamic Modulation of Dorsolateral Prefrontal Cortex Microcircuits: Focus of Vulnerability in Mental Disease Amy Arnsten

ACNP Annual Meeting Book 2013 rev8.indd 67 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Homeostatic Plasticity: Keeping Your Brain in Balance

PL Gina Turrigiano Brandeis University

The positive-feedback nature of Hebbian synaptic plasticity can destabilize the properties of neuronal networks . Recent work from my lab and others has suggested that this destabilizing influence is counteracted by homeostatic plasticity mechanisms that stabilize neuronal activity . One such mechanism, homeostatic synaptic scaling, is a form of synaptic plasticity that adjusts the strength of all of a neuron’s excitatory synapses up or down to stabilize firing. Here I will discuss our recent work showing synaptic scaling is a cell-autonomous process in which neurons detect changes in their own firing rates through a set of calcium-dependent sensors that then regulate receptor trafficking to increase or decrease the accumulation of glutamate receptors at synaptic sites . I will discuss the signaling pathways that underlie this process, the biophysical changes at synapses that allow synaptic strength to be scaled up or down, and the role this plasticity plays in keeping neocortical activity stable .

Gina Turrigiano received her BA from Reed College in 1984 and her PhD from University of California San Diego in 1990 . She then trained as a postdoc with Eve Marder at Brandeis University before joining the faculty in 1994 . She is now a full professor in the Dept . of Biology, the Volen Center for Complex Systems, and the Center for Behavioral Genomics at Brandeis . She has received numerous awards for her research including an NIH career development award, a Sloan Foundation fellowship, a MacArthur foundation fellowship, McKnight Foundation Technological Innovation and Neurobiology of Disease awards, an NIH director’s pioneer award, the HFSP Nakasone Award, election to the American Academy of Arts and Sciences (2012) and election to the National Academy of Sciences (2013). Her scientific interests include mechanisms of synaptic and intrinsic plasticity and the experience-dependent refinement of neocortical microcircuitry .

ACNP Annual Meeting Book 2013 rev8.indd 68 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Genetic Dissection of Cortical Circuit Organization and Assembly: Chandeliers Light Up the Path PL Z . Josh Huang Cold Spring Harbor Laboratory

Despite their immense complexity and sophisticated operations that underlie mental functioning, the fundamental plan for the cellular organization of cerebral cortex is encoded in the genome, which directs cascades of developmental programs in each fetus . Therefore, genetic approaches that engage intrinsic biological mechanisms have the potential to penetrate cortical complexity and achieve appropriate cellular and molecular specificity, and analyses of circuits assembly will facilitate deciphering their functional organization . I suggest that, similar to “genetic screens” that so powerfully identified genes and principles underlying embryonic patterning, systematic genetic targeting of cell types and their progenitors, basic units of circuit organization and construction, will not only provide experimental entry points but also establish a paradigm that coherently link molecular, developmental, and systems studies of cortical circuits . I will summarize our progress on the genetic targeting of GABAergic interneurons and glutamatergic projection neuron, an effort that has facilitated reliable identification and manipulation of cell types and enabled comprehensive analysis from cell specification, connectivity, to their functional role in networks. The chandelier cell (ChC) is arguably the most distinctive class of interneurons that may shape cortical ensembles by exerting decisive control over pyramidal cell firing. I will present results on the stringent genetic mechanisms that specify ChC identity and their laminar deployment, evidence of a massive postnatal pruning process that likely shapes their circuit integration, and on-going studies on their local and long-range synaptic connectivity . With increasing experimental access to cellular build blocks of the cortex, we are poised to explore how stereotyped circuit motifs are assembled and organized, how they are molded by neural activity, and how their developmental trajectory might be altered in models of mental disorders .

Dr . Z . Josh Huang is currently Charles and Marie Robertson Professor of Neuroscience at the Cold Spring Harbor Laboratory in Long Island, New York . He received his PhD in Cell and Molecular Biology at Brandeis University

ACNP Annual Meeting Book 2013 rev8.indd 69 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Genetic Dissection of Cortical Circuit Organization and Assembly: Chandeliers Light Up the Path PL Z . Josh Huang (continued)

and his postdoctoral training at Massachusetts Institute of Technology . His long term research goal aims to understand the basic mechanisms underlying the developmental assembly and function organization of neural circuits in the cerebral cortex . His laboratory has pioneered the use of mouse engineering toward a genetic dissection of GABAergic inhibitory circuitry by systematically targeting distinct cell types . This approach establishes concrete entry points for studying cortical circuits, builds a solid middle ground that coherently link systems neuroscience and molecular-development neuroscience, and provides a paradigm to examine the development mental trajectory of circuit pathogenesis in models of neuropsychiatric disorders . He is the recipient of Pew Scholar Award in Biomedical Science, McKnight Scholar Award in Neuroscience, Distinguished Investigator of NARSAD-Brain and Behavior Research Foundation, and Simon’s Investigator of Simons Foundation Autism Research Initiative

ACNP Annual Meeting Book 2013 rev8.indd 70 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Surprise at the Synapse: MHC Class I, Pruning and Plasticity

Carla Shatz PL Stanford School of Medicine

Connections in adult brain are highly precise, but they do not start out that way . Precision emerges during development as synaptic connections remodel in a process requiring neural activity (action potentials and synaptic transmission) . Activity also regulates neuronal gene expression . In an unbiased screen, Major Histocompatibility Class I (MHCI) genes were unexpectedly discovered to be in neurons, at synapses and regulated by activity and visual experience (Corriveau et al, 1998) . To assess requirements for MHCI in CNS, mutant mice lacking stable surface expression of all MHCI, or of specific MHCI genes Kb and Db, were examined . Synapse pruning in developing visual system fails, and ocular dominance (OD) plasticity in visual cortex is greater than in WT (Huh et al, 2000; Datwani et al, 2009) . In a search for receptors that could interact with neuronal MHCI, PirB, an innate immune receptor, was found expressed in neurons throughout mouse CNS . In mutant mice lacking PirB, OD plasticity is enhanced(Syken et al ., 2006), LTP and LTD are altered, and spine density on L Pyramidal neurons is increased . Thus, PirB, like MHCI, appears to act to “brake” synaptic plasticity . The commonality of phenotypes present in these mice suggests a model (Shatz, 2009) in which PirB may bind and transduce signals from MHCI ligands in neurons . Together, results imply that this family of molecules, thought previously to function only in immunity, may also act at neuronal synapses to limit how much- or how quickly- synapse strength changes in response to new experience . These molecules may be crucial for controlling circuit excitability and stability in developing as well as adult brain . Changes in their function could contribute to developmental disorders such as Autism and Schizophrenia .

Dr . Carla Shatz is Sapp Family Provostial Professor of Biology and Neurobiology and Director of Bio-X, Stanford University’s pioneering interdisciplinary biosciences program that brings together faculty from across the entire university- Clinicians, Biologists, Engineers, Physicists, Computer Scientists- to unlock the secrets of the human body . She received her B .A . in Chemistry from Radcliffe College in 1969, an M .Phil . in Physiology in 1971 from University College London as a Marshall Scholar, and a Ph .D . in Neurobiology from Harvard Medical

ACNP Annual Meeting Book 2013 rev8.indd 71 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Surprise at the Synapse: MHC Class I, Pruning and Plasticity

PL Carla Shatz (continued)

School in 1976 . Dr . Shatz is a neuroscientist who has devoted her research career to understanding the dynamic interplay between genes and environment that shapes brain circuits - the very essence of our being . Her research on cellular and molecular mechanisms of how the early developing brain is transformed into adult circuitry during critical periods of development has relevance not only for treating disorders such as autism and schizophrenia, but also for understanding how the nervous and immune systems interact . Dr . Shatz is past president of the 40,000 member Society for Neuroscience; prior to Stanford, she was Chairwoman of the Department of Neurobiology at Harvard Medical School . She has received many awards and honors including election to the the National Academy of Sciences, the American Philosophical Society, the Institute of Medicine . In 2011 she was elected as a Foreign Member of the Royal Society of London . Most recently (2013), she received the Sackler Prize for Distinguished Achievement in Developmental Psychobiology and she shared the Robert J . and Claire Pasarow Foundation Award in Neuropsychiatry Research with Karl Deisseroth and Helen Mayberg .

ACNP Annual Meeting Book 2013 rev8.indd 72 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 11:30 a.m. President’s Plenary Grand Ballroom

Dynamic Modulation of Dorsolateral Prefrontal Cortex Microcircuits: Focus of Vulnerability in Mental Disease PL Amy Arnsten Yale University School of Medicine

Working memory relies on layer III pyramidal cell circuits in the dorsolateral prefrontal cortex (dlPFC), the circuits most afflicted in patients with schizophrenia. These neurons excite each other through NMDA-NR2B receptor synapses on spines to keep information “in mind” in the absence of sensory stimulation . The strength of these synaptic connections is dynamically gated by the arousal systems . Cholinergic stimulation of nicotinic alpha7 receptors permits NMDA actions, while catecholamines sculpt or strengthen inputs through regulation of feedforward cAMP-Ca2+-K+ channel signaling . For example, exposure to an uncontrollable stressor causes a rapid loss of dlPFC neuronal firing via cAMP- PKA opening of HCN and KCNQ channels near the synapse, while DISC1 anchors PDE4A to regulate this process . Many of the proteins regulating layer III dlPFC network strength are genetically altered in patients with schizophrenia, suggesting that this is a key site for vulnerabilities in mental illness . Dysregulation of cAMP-Ca2+-K+ channel signaling with advancing age also contributes to age-related cognitive decline, and may increase susceptibility for Alzheimer’s Disease . In contrast, agents that inhibit Ca2+-cAMP signaling in PFC, such as the alpha2A-AR agonist guanfacine, are an effective new strategy for treating PFC cognitive deficits.

Dr . Amy F .T . Arnsten is Professor of Neurobiology at Yale Medical School . She received her BA from Brown University, and her Ph .D . in Neuroscience from UCSD, followed by post-doctoral fellowships with Dr . Susan Iversen at Cambridge, and Dr . Patricia Goldman-Rakic at Yale . Dr . Arnsten studies the molecular regulation of the primate cortex, with the goal of discovering informed strategies for the treatment of cognitive disorders .

ACNP Annual Meeting Book 2013 rev8.indd 73 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:00 p.m. Women’s Luncheon Great Hall 5 & 6

Women’s Luncheon

PL “ACNP Women Presidents Panel: Past, Present, and Future Challenges”

Presented by the Women’s Task Force

Co-Chairs: Karen F . Berman and Linda S . Brady

Panelists:

Huda Akil

Raquel Gur

Judith Rapaport

Carol Tamminga

ACNP Annual Meeting Book 2013 rev8.indd 74 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

1:30 p.m. – 3:00 p.m. Distinguished Lecture Grand Ballroom

Distinguished Lecture

The Story of Rett Syndrome and the Insight it Provides into PL Neuropsychiatric Disorders

Presented by: Huda Zoghbi

ACNP Annual Meeting Book 2013 rev8.indd 75 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

1:30 p.m. – 3:00 p.m. Distinguished Lecture Grand Ballroom

The Story of Rett Syndrome and the Insight it Provides into Neuropsychiatric Disorders PL Huda Zoghbi Baylor College of Medicine Rett Syndrome, a postnatal neurological disorder that causes a broad range of severe neurological and behavioral disabilities, is fascinating in that its symptoms appear after a period of normal development and point to disturbances in most brain cells and regions . The quest for the gene revealed that the disease is caused by mutations in the X-linked MECP2. Interestingly, some patients with either hypomorphic mutations in MECP2 or favorable patterns of X chromsome inactivation present with mild intellectual disabilities and psychiatric phenotypes . The path from gene discovery to therapy, however, is not a straightforward one and requires deep understanding of pathogenic mechanisms and key molecular and anatomical determinants of various symptoms and pathologies . We have used genetic, behavioral, physiological and molecular approaches to interrogate the pathogenesis of Rett and MECP2 disorders . Recent discoveries suggest that MeCP2 is critical for many neuronal functions, especially for the ability of neurons to respond to change. Moreover, the findings reveal functions of the protein that were not suspected previously . Huda Zoghbi is Professor of Pediatrics, Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine and serves as an Investigator with the Howard Hughes Medical Institute . She is also the Director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital . Zoghbi’s interest is in using the tools of modern genetics to understand the proper development of the brain as well as what goes awry in specific neurodevelopmental and neurodegenerative conditions . She has published seminal work regarding the molecular basis of Rett syndrome and of late-onset neurodegenerative diseases . Dr . Zoghbi is a member of several professional organizations including the McKnight Foundation Neuroscience Board and is a senior editor for the newly founded journal eLife . In 2000 she was elected to the Institute of Medicine, and in 2004 she was elected to the National Academy of Sciences . Among Dr . Zoghbi’s honors are, the IPSEN prize in neuronal plasticity, the Bristol Myers-Squibb Neuroscience Distinguished Achievement Award, the Vilcek Prize, the Gruber prize in Neuroscience, and the Dickson prize in Medicine .

ACNP Annual Meeting Book 2013 rev8.indd 76 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 4:15 p.m. Mini-Panel Diplomat Ballroom 1 & 2

Neuronal Immaturity in Schizophrenia Chair: Mickey Matsumoto

3:00 p .m . GABA Signaling in Postmortem Human Brain and Schizophrenia: A Question of Immaturity? Joel E. Kleinman

3:25 p .m . Immature Neurons in Schizophrenia? Support from MP Investigations on Proteoglycan Expression Sabina Berretta

3:50 p .m . Immature Dentate Gyrus as a Candidate Endophenotype of Neuropsychiatric Disorders Tsuyoshi Miyakawa

4:15 p.m. – 5:30 p.m. Mini-Panel Diplomat Ballroom 1 & 2

Social Processes Initiative in Neurobiology of the Schizophrenia(s) Chair: Anil Malhotra

4:15 p .m . The Neural Circuitry of Social Impairments in Schizophrenia Spectrum Disorders Robert W. Buchanan

4:40 p.m. Altered Structural and Functional Network Topology in Deficit Schizophrenia Philip R. Szeszko

5:05 p.m. Network Topology in Deficit Schizophrenia, Nondeficit Schizophrenia, and Bipolar Sisorder: From Circuits to Functional Outcome Aristotle Voineskos

ACNP Annual Meeting Book 2013 rev8.indd 77 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 2

Autism Spectrum Disorders: From Rare Chromosomal Abnormalities to Common Molecular Targets

Chair: Ted Abel Co-Chair: Noboru Hiroi

PA 3:00 p .m . Role of Copy Number Variants in Autism Spectrum Disorders Santhosh Girirajan

3:30 p .m . Comprehensive Phenotyping of Mouse Autism Models Ted Abel

4:00 p .m . Tbx1 and Sept5 Contribute to Behavioral and Neuronal Phenotypes in MouseModels of 22q11 .2-Associated ASD Noboru Hiroi

4:30 p .m . The Translation of Translational Control in Autism Spectrum Disorders Eric Klann

5:00 p .m . Discussant: Alice Luo Clayton

ACNP Annual Meeting Book 2013 rev8.indd 78 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 2

Can Biology Inform Treatment Prediction and Selection in Depression?

Chair: Amit Etkin Co-Chair: Madhukar Trivedi

PA 3:00 p .m . Large-scale Pre-treatment Prediction of Remission with Antidepressants for Individual Patients Based on Cognitive and Emotional Test Performance, as Well as Its Neuroimaging Correlates Amit Etkin

3:30 p .m . Initial Results of the NIMH-funded EMBARC Study Madhukar Trivedi

4:00 p.m. Inflammatory Biomarkers Predict Differential Outcome of Depression Treatment with Escitalorpam and Nortriptyline in the GENDEP Project Rudolf Uher

4:30 p .m . Brain Serotonin 1A Receptor Binding as a Predictor of Treatment Outcome in Major Depressive Disorder Ramin V. Parsey

5:00 p .m . Discussant: Thomas R. Insel

ACNP Annual Meeting Book 2013 rev8.indd 79 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 3

Circuitry Underlying Obsessive-compulsive Disorder: Lessons from Deep Brain Stimulation and Ablative Surgery

Chair: Suzanne Haber Co-Chair: Gregory J . Quirk

PA 3:00 p .m . Ablative Limbic System Surgery for the Treatment of OCD Emad N. Eskandar

3:30 p .m . The Circuitry of Deep Brain Stimulation and Cingulatomy: Monkey Tracing vs . Human Tracking Suzanne Haber

4:00 p .m . DBS of Ventral Striatum in Rodents Modulates Fear Extinction via Prefrontal and Orbitofrontal Projections Gregory J. Quirk

4:30 p .m . Deep Brain Stimulation for Intractable OCD: Population and Outcomes Benjamin Greenberg

5:00 p .m . Discussant: Scott Rauch

ACNP Annual Meeting Book 2013 rev8.indd 80 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 1

Kicking Over the Traces - Noncatecholic Biogenic Amines and Their Receptors

Chair: David K . Grandy Co-Chair: Gregory M . Miller

PA 3:00 p .m . Evidence from Molecular Modeling, Site-Directed Mutagenesis and Behavioral Testing Indicate Trace Amine-Associated Receptor 1 is a Methamphetamine Receptor David K. Grandy

3:30 p .m . Selective TAAR1 Ligands and Transgenic Animal Models Reveal a Role of TAAR1 in Cognitive, Neurologic and Psychiatric Disorders Raul R. Gainetdinov

4:00 p .m . Trace Amine Associated Receptor 1 Modulation of the Rewarding and Immunological Effects of Drugs of Abuse Supports its Relevance as a Therapeutic Target Gregory M. Miller

4:30 p .m . The Activation of Intracellular Signaling Systems by Amphetamines: A Potential Role for Trace Amine Receptors Susan G. Amara

5:00 p .m . Discussant: David Shurtleff

ACNP Annual Meeting Book 2013 rev8.indd 81 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 3

Structural and Functional Brain Changes in Young People at Risk for Severe Mental Illness

Chair: Martin Alda Co-Chair: Nitin Gogtay

PA 3:00 p .m . Clinical Stages and Developmental Trajectories of Bipolar Disorder: Family-based Analysis Martin Alda

3:30 p .m . Population Neuroscience and Psychiatric Genetics: A Two-way Street Tomas Paus

4:00 p .m . Vulnerability or Resilience? Brain Developmental Studies in Non Psychotic Siblings of Childhood Onset Schizophrenia Patients Nitin Gogtay

4:30 p .m . Neuroanatomical Changes in Bipolar Disorders – Causes Versus Consequences of the Illness Tomas Hajek

5:00 p .m . Discussant: Mary L. Phillips

ACNP Annual Meeting Book 2013 rev8.indd 82 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 1

The Role of Inflammation in the Pathophysiology of Mood, Aggressive and Medical Disorders: A Deadly Combination

Chair: Emil F . Coccaro

3:00 p.m. Plasma Markers of Inflammation are Elevated in Subjects with PA Intermittent Explosive Disorder and Correlate Directly with Aggression in Human Subjects Emil F. Coccaro

3:30 p.m. Stress, Trauma, and Inflammation in Non-Psychiatric Subjects Janice Kiecolt-Glaser

4:00 p.m. Inflammation and Depression: Sleep Disturbance Moderates Induction of Depressed Mood by an Inflammatory Challenge Michael R. Irwin

4:30 p .m . Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with Treatment- Resistant Depression Jennifer C. Felger

5:00 p .m . Discussant: Charles B. Nemeroff

ACNP Annual Meeting Book 2013 rev8.indd 83 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

7:30 p.m. – 9:00 p.m. Study Group Atlantic Ballroom 2

Medical and Non-medical Use of Stimulant Drugs for Cognitive Enhancement Chair: James Swanson Co-Chair: Wilson M . Compton

Participants: William Pelham Trevor W . Robbins Barbara J . Sahakian James T . McCracken SG Susanna N . Visser Ruben Baler Kathleen Ries . Merikangas Raul Gonzalez James G . Waxmonsky Tim Wigal Marc Lerner

ACNP Annual Meeting Book 2013 rev8.indd 84 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

7:30 p.m. – 9:00 p.m. Study Group Regency Ballroom 2

Mental Illness, Violence and the Gun Control Debate: Evidence, Policy, Privacy and Stigma - on Behalf of the ACNP Ethics Committee Chair: David Pickar Co-Chair: Jerrold Rosenbaum Participants: David Pickar Jerrold Rosenbaum Emil F . Coccaro Kenneth L . Davis SG Paul S . Appelbaum Brian Frosh J . Dee Higley

7:30 p.m. – 9:00 p.m. Study Group Regency Ballroom 3

New Models of Open Innovation to Rejuvenate the Biopharmaceutical Ecosystem, A Proposal by the ACNP Liaison Committee Chair: Dean F . Wong Co-Chair: Lisa Gold

Participants: Dean F . Wong Robert Innis Lawrence M . Sung Steven Paul Phillip Phan Steven Grant Husseini Manji

ACNP Annual Meeting Book 2013 rev8.indd 85 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

7:30 p.m. – 9:00 p.m. Study Group Atlantic Ballroom 1

The Assessment Of Suicidal Ideation, Behavior & Risk: At Baseline; As a Measure of Clinical Outcome, and/or as a Treatment Emergent SAE

Co-Chair: Eric Youngstrom Chair: Roger E . Meyer

Participants: Roger E . Meyer Ahmad Hameed John Greist SG Phillip Chappell J . John Mann David V . Sheehan Cheryl McCullumsmith Larry Alphs Richard C . Shelton Paula J . Clayton Kelly Posner

ACNP Annual Meeting Book 2013 rev8.indd 86 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

7:30 p.m. – 9:00 p.m. Study Group Regency Ballroom 1

The Challenges of Designing and Interpreting Clinical Trials with Depot Antipsychotics

Chair: W . Wolfgang Fleischhacker

Participants: Raymond Sanchez Srihari Gopal Maxine X . Patel Stephan Heres Keith H . Nuechterlein Hiroyuki Uchida SG

ACNP Annual Meeting Book 2013 rev8.indd 87 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

ACNP Annual Meeting Book 2013 rev8.indd 88 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 9:45 a.m. Mini-Panel Diplomat Ballroom 1 & 2

After the Trauma: Developmental Trajectories from Childhood to Adult Psychiatric Disorders

Chair: Michael D . De Bellis

8:30 a .m . The Neurobiology of PTSD Symptoms in Maltreated Children and Adolescents Michael D. De Bellis

8:55 a.m. Sex-specific Effects of Childhood Emotional Abuse on Affective Processing in Bipolar Disorder Patients Katherine E. Burdick

9:20 a .m . The Long-Term Consequences of Childhood Maltreatment: Effects on Brain Structure and Subclinical Psychopathology in Healthy Adults MP Pamela DeRosse

ACNP Annual Meeting Book 2013 rev8.indd 89 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

9:45 a.m. – 11:00 a.m. Mini-Panel Diplomat Ballroom 1 & 2

Biochemical and Behavioral Pharmacology of Synthetic Cathinone Derivatives Found in Psychoactive Bath Salts Products

Chair: Richard B . Rothman Co-Chair: Michael H . Baumann

9:45 a .m . Effects of Newly-emerging Synthetic Cathinone Derivatives on Monoamine Transporter Function in Rats Michael H. Baumann

10:10 a .m . Intravenous Self-administration of 3,4-Methylenedioxypyrovalerone (MDPV) and 4-Methylmethcathinone (4-MMC, Mephedrone) in Rats Michael A. Taffe MP 10:35 a .m . Abuse-related and Abuse-limiting Effects of Synthetic Cathinone “Bath Salt” Derivatives on Intracranial Self-Stimulation in Rats Matthew L. Banks

ACNP Annual Meeting Book 2013 rev8.indd 90 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 2

At the Crossroads of Physics, Physiology, and Psychiatry: Rational Design of Noninvasive Neuromodulation Therapies

Chair: Sarah Lisanby

8:30 a .m . Targeting of Transcranial Direct Current Stimulation: Insights from Cellular and Computational Models Marom Bikson

9:00 a .m . Optimizing Stimulus Pulse Characteristics for Transcranial Magnetic Stimulation and Electroconvulsive Therapy Via Device Development, Computational Modeling, and Biophysically- motivated Dosing Paradigms Angel V. Peterchev

9:30 a .m . Mechanisms of Targeting Cortical State Dynamics with PA Neuromodulation Flavio Frohlich

10:00 a .m . Enhancement of Working Memory in Sleep Deprived Young Adults and in Elderly Adults using rTMS Informed by Covariance-modeled fMRI Bruce Luber

10:30 a .m . Discussant: Zafiris J. Daskalakis

ACNP Annual Meeting Book 2013 rev8.indd 91 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 3

Augmentation of Antidepressant Response by Autoreceptor-Mediated Mechanisms: Clinical Experience and Mechanisms of Action

Chair: Salomon Z . Langer Co-Chair: Torgny H . Svensson

8:30 a .m . Autoreceptor-mediated Regulation of Neurotransmission: Pharmacological Targets and Potential for Improved Treatment of Major Psychiatric Disorders Salomon Z. Langer

9:00 a .m . Rapid Augmentation of Antidepressant Effect in Treatment- resistant MDD by Add-on Low Dose Aripiprazole PA Daniel E. Casey

9:30 a .m . Low Doses of Atypical Antipsychotic Drugs Added to Selective Serotonin Inhibitors Produce a Ketamine-like Facilitation of Prefrontal Glutamatergic Neurotransmission Torgny H. Svensson

10:00 a .m . Emerging Role of Atypical Antipsychotics as Add-on Therapy in Major Depression Siegfried Kasper

10:30 a .m . Discussant: Dennis S. Charney

ACNP Annual Meeting Book 2013 rev8.indd 92 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 2

Neuroactive Steroids and Oxysterols as Endogenous Modulators of GABA and Glutamate Receptors: Basic Mechanisms and Therapeutic Implications

Chair: Steven Paul Co-Chair: Charles Zorumski

8:30 a .m . GABAergic Neurosteroids as Novel Targets for Therapeutic Drug Development in Psychiatry Charles Zorumski

9:00 a .m . Natural and Synthetic Neuroactive Steroids and Oxysterols as Potent NMDA Receptor Allosteric Modulators: Therapeutic Considerations Steven Paul PA 9:30 a .m . Neuroactive Steroids Ganaxolone and Allopregnanolone in the Treatment of Epilepsy, Traumatic Brain Injury, and Neurobehavioral Disorders Michael A. Rogawski

10:00 a .m . Neurosteroids as Novel Therapeutics and Biomarker Candidates in Schizophrenia and PTSD Christine E. Marx

10:30 a .m . Discussant: Bruce S. McEwen

ACNP Annual Meeting Book 2013 rev8.indd 93 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 3

Nutrition, Neurodevelopment, and Risk for Schizophrenia and Autism: From Epidemiology to Epigenetics

Chair: Joshua L . Roffman Co-Chair: Donald Goff

8:30 a .m . Periconceptional Folic Acid and Neurodevelopmental Disorders: Historical Context and Current Research Ezra Susser

9:00 a .m . Effects of Periconceptional Folate on Language Delay and Autism Spectrum Disorders: The Norwegian Mother and Child Cohort Study Camilla Stoltenberg

PA 9:30 a .m . Longitudinal Effects of In Utero Folate Exposure on Cortical Thickness: Implications for Neurodevelopmental Disorders Joshua L. Roffman

10:00 a .m . The Placental and Neuronal Methylomes at the Interface of Genetic and Environmental Risk and Protective Factors in Autism Janine LaSalle

10:30 a .m . Discussant: Donald Goff

ACNP Annual Meeting Book 2013 rev8.indd 94 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 1

Peripheral Immune and Endocrine Pathways as Markers of PTSD Risk and Symptom Development: Evidence from Prospective Studies

Chair: Victoria Risbrough

8:30 a .m . Longitudinal Plasma Testosterone Trajectory and its Relation to Combat, Temperament and PTSD Eric Vermetten

9:00 a .m . Evidence for Plasma C-Reactive Protein Concentration as Biomarker of PTSD Risk Dewleen G. Baker

9:30 a .m . Blood-Based Gene-expression Predictors of PTSD Risk and Resilience Among Deployed Marines: A Pilot Study PA Stephen J. Glatt

10:00 a .m . Exaggerated Threat Sensitivity and Avoidance as Contributors to Elevated Inflammation in Posttraumatic Stress Disorder: Data from the Mind Your Heart Study Aoife O’Donovan

10:30 a .m . Discussant: Thomas Neylan

ACNP Annual Meeting Book 2013 rev8.indd 95 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 1

The Future of Translational Research in Addiction

Chair: Harriet de Wit

8:30 a .m . Cross-species Behavioral Tests for Investigations of Addictive and Psychiatric Disorders Mark A. Geyer

9:00 a .m . Neurocircuitries for Social Stress and Drug Abuse: Novel Targets for Intervention Klaus A. Miczek

9:30 a .m . Towards Consilience in Animal and Human Behavioral Models in Addiction David Stephens PA 10:00 a .m . Identifying the Molecular Determinants of Inhibitory Control Problems in Addictions J. David Jentsch

10:30 a .m . Discussant: Harriet de Wit

ACNP Annual Meeting Book 2013 rev8.indd 96 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. - 1:30 p.m. Data Blitz Session Regency Ballroom 2

Data Blitz Session

Chair: William Carlezon

This session is comprised of rigorously timed 5 minute presentations by 12 young investigators .

11:30 a .m . Can Serotonin Put Your Mind at Rest? Julia Sacher

11:40 a .m . Effects of Pharmacogenetic Manipulation of the Nucleus Ac+H3cumbens on Neuronal Activity and Alcohol-Related Behaviors Angela Ozburn

11:50 a .m . Feedforward and Feedback Control Abnormalities During Precision Grasping Implicate Cerebellar Dysfunction in Autism Spectrum Disorder Matthew Mosconi

12:00 p .m . Frequency and Characteristics of Isolated Psychiatric Episodes in PL Anti-NMDA Receptor Encephalitis Matthew Kayser

12:10 p .m . Genetic Background Regulates the Effect of Antidepressant Treatment on Behavioral Despair and Hippocampal Neurogenesis in Mice Brooke Miller

12:20 p .m . High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish David Kokel

12:30 p .m . Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders Joshua Kantrowitz

ACNP Annual Meeting Book 2013 rev8.indd 97 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. - 1:30 p.m. Data Blitz Session Regency Ballroom 2

Data Blitz Session

Chair: William Carlezon

12:40 p .m . Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants Josh Woolley

12:50 p .m . Poverty and the Past: The Relation between Hippocampus Function and Memory Performance is linked to Childhood Poverty Elizabeth Duval

1:00 p .m . Rare Genetic Variants in VMAT1 (SLC18A1) Are Functional in Vitro and Associated with Bipolar Disorder Falk Lohoff

1:10 p .m . Real-time Functional MRI Feedback, Compared to Sham, Reduces Cue-Induced Nicotine Craving in Smokers: Results from the First Clinical Trial PL Colleen Hanlon

1:20 p .m . Substrate-selective COX-2 Inhibition Decreases Anxiety via Endocannabinoid Activation Sachin Patel

ACNP Annual Meeting Book 2013 rev8.indd 98 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Can Serotonin Put Your Mind at Rest?

Tuesday, Poster #192

Alexander Schäfer, Inga Burmann, Ralf Regenthal, Katrin Arelin, Andre Pampel, Arno Villringer, Daniel Margulies, Julia Sacher Max Planck Institute for Human Cognitive and Brain Sciences

Background: The serotonin transporter (5-HTT) is essential to maintaining adequate brain serotonin homeostasis, and alteration of its function has been linked to heightened susceptibility for depression and anxiety (Holmes et al . 2003) . Differences in the 5-HTT genotype have also been recently related to variation in intrinsic functional brain organization (Li et al ., 2012) . While preliminary evidence supports a connection between the serotonergic system and intrinsic brain activity, the precise role of serotonin in modulating its functional organization is not known . Here we demonstrate that a single dose of a selective serotonin reuptake inhibitor (SSRI) dramatically alters intrinsic functional connectivity throughout the human brain . Methods: Degree centrality (DC) mapping of resting-state functional magnetic resonance imaging (rs-fMRI) data was applied to twenty-one individual datasets of healthy, anti-depressant naïve participants following a single oral dose of PL the selective serotonin reuptake inhibitor (SSRI) escitalopram in a randomized placebo-controlled design . Degree centrality measures connectivity by counting the number of connections of each specific node. This number is then assigned as a centrality value to the given node (a node is defined by each separate voxel in gray matter resulting in a network of ~ 63000 voxels). rs-fMRI data was acquired on a Siemens Verio 3 tesla scanner equipped with a 32-channel head coil (410 volumes, TR=2000ms) . Standard image preprocessing was performed using FSL and AFNI (Biswal et al ., 2010) . Results: DC-analysis revealed a widespread decrease in connectivity in most cortical and subcortical areas (p=0 .01, cluster corrected) following the oral intake of a single dose of 20 mg escitalopram . While the majority of functional connectivity decreased, localized increases were observed in cerebellar and thalamic regions . These connectivity changes could not be explained by alterations in the local signal properties, such as the amplitude of the resting state signal, and appeared to be specific to the correlation between regions which points towards

ACNP Annual Meeting Book 2013 rev8.indd 99 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Can Serotonin Put Your Mind at Rest?

Tuesday, Poster #192 (continued)

Julia Sacher

an alteration in long range synchronization . It is noteworthy that these neural changes were also reflected in behavioral findings of significantly increased Visual Analogue Scores (VAS)-scores for concentration, alertness, attention and coordination (p<0 .001, post-hoc Bonferroni corrected) . Discussion: The increase in connectivity found in the thalamus and cerebellum may be of particular relevance for the excitability of the many serotonergic projection neurons that terminate in the thalamus . By cerebellar modulation these neurons can turn from burst into tonic mode, a mechanism hypothesized to alert cortical networks . This conceptional framework is further supported by the reported increases in concentration, alertness, attention and coordination . Our findings are the first to directly link a single dose of an SSRI to such a substantial mechanism of modulating intrinsic functional connectivity in the human brain . The evidence we present for an acute and global change in connectivity following a single dose of escitalopram is a first step towards identifying noninvasive PL neural biomarkers for individual responsivity of the human brain to serotonergic modulation .

100

ACNP Annual Meeting Book 2013 rev8.indd 100 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Effects of Pharmacogenetic Manipulation of the Nucleus Accumbens on Neuronal Activity and Alcohol-Related Behaviors

Tuesday, Poster #53

Angela Ozburn, Ryan Logan, Puja Parekh, Jake Bosin, Colleen A . McClung University of Pittsburgh Medical Center

Background: Chronic alcohol intake leads to long lasting changes in reward- and stress-related neuronal circuitry . The nucleus accumbens (NAc) is an integral component of this circuitry . Promising clinical trials have shown that deep brain stimulation of the NAc decreases alcohol craving and relapse in alcohol dependent subjects . Here, we used a cutting edge pharmacogenetic approach to induce activity in the NAc to reduce alcohol-related behaviors in mice . We used the mutagenized muscarinic G protein-coupled receptors hM3Dq and hM4Di that are selectively activated by the pharmacologically inert and orally bioavailable drug, clozapine-N-oxide (CNO) . We tested the ability of these channels to change NAc activity and assessed the effects of altered NAc activity to alter binge-like alcohol drinking, tastant intake, and reward . Methods: Mice were stereotaxically injected with AAV2 hSyn-HA hM3Dq, PL -hM4Di, or -eGFP bilaterally into NAc . Experiments were carried out to verify CNO induced changes in NAc activity (via ex-vivo whole cell electrophysiological recordings) . We tested the effect of altering NAc activity on binge ethanol intake (or intake of sucrose, quinine, and water) using the drinking in the dark paradigm (n=9-10/group) . We also evaluated the effects of altering NAc activity on the rewarding properties of ethanol using conditioned place preference (n=7- 10/group) . Results: CNO increased NAc firing in hM3Dq positive cells and decreased firing in hM4Di cells, confirming the ability of these channels to spatially and temporally alter neuronal activity. Increasing NAc activity significantly decreased binge drinking (p<0 .05) without altering intake for other tastants . Increasing NAc activity is not rewarding and altering NAc activity does not change the rewarding properties of ethanol . Discussion: These experiments demonstrate that neuronal activity can be controlled in a spatial and temporal manner using pharmacogenetics. We find that

101

ACNP Annual Meeting Book 2013 rev8.indd 101 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Effects of Pharmacogenetic Manipulation of the Nucleus Accumbens on Neuronal Activity and Alcohol-Related Behaviors

Tuesday, Poster #53 (continued)

Angela Ozburn

increasing NAc activity decreases binge drinking without altering the rewarding properties of ethanol . Ongoing experiments aim to identify the the effects of altering NAc activity on the aversive properties of ethanol, and identifying transcriptional changes induced by this pharmacogenetic manipulation .These findings could have promising implications for treatment.

102

ACNP Annual Meeting Book 2013 rev8.indd 102 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Feedforward and Feedback Control Abnormalities During Precision Grasping Implicate Cerebellar Dysfunction in Autism Spectrum Disorder

Tuesday, Poster #182

Matthew W . Mosconi, Suman Mohanty, Rachel K . Greene, Lauren Schmitt, David E . Vaillancourt, John A . Sweeney University of Texas Southwestern

Background: Sensorimotor impairments are present in the majority of individuals with autism spectrum disorder (ASD). Yet, these deficits and their neurophysiological mechanisms have not been systematically assessed . In the present study, we examined visually guided fine motor control in individuals with ASD. The relative influence of the quality of sensory input on movement abnormalities in ASD was examined by varying the precision of visual feedback . Methods: Twenty-eight individuals with ASD and 29 healthy controls matched on age (range: 6-35 years), IQ and handedness performed precision grip force tasks in which they viewed a white FORCE bar on a screen that moved upwards with increased manual force toward a fixed green TARGET bar. In the first PL experiment, subjects were instructed to reach a target force level as fast as they could, and to sustain the target force level for the duration of the trial (15 sec) . Target force levels were varied between 5-85% of each individual’s maximum force across trials . To assess the integrity of feedforward control mechanisms, we examined the accuracy and force dynamics of initial, rapid force generation . To assess feedback control mechanisms, force accuracy and variability were measured during sustained force generation . The regularity of each subject’s sustained force time series also was examined to determine the degree to which individuals made online adjustments to refine their performance. A second experiment was performed to assess the relative impact of changes in sensory input on sustained precision force generation . During this task, the vertical distance the FORCE bar moved per Newton of force was varied between .12-145 mm . Thus, in experiment 2, visual feedback precision was increased by moving the FORCE bar a greater distance for every Newton of force generated . Results: Primary responses generated by feedforward mechanisms were

103

ACNP Annual Meeting Book 2013 rev8.indd 103 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Feedforward and Feedback Control Abnormalities During Precision Grasping Implicate Cerebellar Dysfunction in Autism Spectrum Disorder

Tuesday, Poster #182 (continued)

Matthew W . Mosconi

hypermetric for individuals with ASD compared to controls . Individuals with ASD also showed increased rates of force increase during their primary movements that were associated with the degree to which they overshot target force levels . During sustained force generation in which subjects attempted to maintain alignment of the force and target bars, individuals with ASD demonstrated increased force error and variability. These deficits implicating feedback control alterations were more severe at larger force levels, and at the most and the least precise visual feedback conditions. Spectral analyses showed that sustained force deficits in individuals with ASD were associated with reduced power in the 0-1 Hz frequency range and increased power at higher frequencies (1-3 Hz) . Across all force levels and all levels of visual feedback precision, the force time series of subjects with ASD PL was less complex, or more regular . Discussion: These studies identified three distinct sensorimotor deficits in individuals with ASD . First, individuals with ASD show reduced accuracy and alterations in their force dynamics during primary motor responses suggesting that forward control mechanisms are disrupted in this disorder . Second, reduced accuracy of sustained motor responses indicates that feedback control systems also are impaired in ASD. The severity of feedback control deficits covaried with changes in both the motor execution and sensory processing demands, implicating abnormalities in both input and output processes . Third, increased force variability and increased regularity in the time-dependent structure of sustained precision force suggest that individuals with ASD utilize fewer degrees of freedom to correct their force precision during goal-directed actions . Taken together, these behavioral findings are consistent with the hypothesis that dysfunctions within cerebellar circuitry in ASD lead to both hypermetric feedforward motor processes and more variable sensory feedback control of motor commands .

104

ACNP Annual Meeting Book 2013 rev8.indd 104 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-NMDA Receptor Encephalitis

Tuesday, Poster #190

Matthew Kayser, Maarten Titulaer, Nuria Gresa-Arribas, Josep Dalmau Perelman School of Medicine at the University of Pennsylvania

Background: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an autoimmune disorder in which IgG antibodies are directed against the NR1 subunit of the NMDA receptor (NMDAR) . The disorder includes a range of psychotic symptoms early in the course of the disease followed by neurologic involvement, and ultimately protracted cognitive and behavioral symptoms .The occurrence of severe behavioral changes reminiscent of a schizophrenia-like illness has fueled speculation that this disorder might define a subset of patients misdiagnosed with a primary psychiatric disease . Hoewever, the frequency and type of isolated psychiatric episodes (pure psychiatric symptoms without neurological involvement) either as initial presentation of the disease or as relapse are unknown . This work aims to determine the frequency, symptoms, and outcome of isolated psychiatric episodes in a large cohort of patients with anti- PL NMDAR encephalitis . Methods: This was an observational cohort of patients diagnosed over a 5 year period (median follow-up 2 years) .571 patients with IgG antibodies against the NR1 subunit of the NMDAR were included in the study . Antibody studies were performed at the Universities of Pennsylvania and Barcelona, and clinical information was obtained by the authors or referring physicians . We measured frequency, type of symptoms, and outcome of patients with anti-NMDAR encephalitis and isolated psychiatric manifestations .All patients had a detailed work up to rule out other disorders, including brain MRI, and blood and CSF studies. Isolated psychiatric presentations were defined as episodes (either initial presentation or relapse) that occurred in association with NMDAR antibodies in serum or CSF without neurological involvement. Relapse was defined by the new onset or worsening of symptoms at least two months after improvement or stabilization, without any other etiology involved, and persistent detection of NMDAR antibodies .

105

ACNP Annual Meeting Book 2013 rev8.indd 105 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-NMDA Receptor Encephalitis

Tuesday, Poster #190 (continued)

Matthew Kayser

Results: 23/571 patients (4%) developed isolated psychiatric episodes, 5 at disease onset and 18 during relapses . For all 23 patients, age (median 20 years), gender (91% female), and tumor association (43%, ovarian teratoma) were similar to the population at large . Predominant symptoms included, delusional thinking (74%), mood disturbances (70%, usually manic), and aggression (57%) . Brain MRI was abnormal in 10/22 (45%) and CSF showed pleocytosis in 17/22 (77%) . Eighty three percent of the patients had full/substantial recovery after immunotherapy and tumor resection when appropriate . After relapse, 17/18 (94%) patients returned to a similar or better pre-relapse functional level . Discussion: We report 23 patients with anti-NMDAR encephalitis who developed isolated psychiatric symptoms either as initial episode of the disease (5 patients) or as relapse of encephalitis (18 patients) . Predominant symptoms included delusional thinking, auditory or visual hallucinations, and manic and aggressive PL behavior . The fact that 5 patients had initial psychiatric presentations without neurologic symptoms or past history of encephalitis suggests that some cases of anti-NMDAR encephalitis can be mistaken for a primary psychiatric disorder . Therefore, isolated psychiatric episodes are rare but can occur as initial onset or relapse of anti-NMDAR encephalitis . Recognition of these episodes is important because they respond to immunotherapy . In patients with new onset psychosis, history of encephalitis, subtle neurological symptoms, and/or abnormal ancillary tests should prompt screening for NMDAR antibodies .

106

ACNP Annual Meeting Book 2013 rev8.indd 106 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Genetic Background Regulates the Effect of Antidepressant Treatment on Behavioral Despair and Hippocampal Neurogenesis in Mice Tuesday, Poster #90

Brooke H . Miller, Thomas A . Lanz, Zane Zeier, Miguel Lopez-Teledono, Robin Kleiman, Mathew Pletcher, Claes Wahlestedt University of Florida College of Medicine Background: There is strong evidence that chronic treatment with antidepressants such as fluoxetine induces an increase in adult hippocampal cell proliferation and neuronal differentiation, and that this effect may be associated with the behavioral response to antidepressants . Methods: In order to test the association between antidepressant efficacy and hippocampal neurogenesis, we treated mice from 30 inbred strains with chronic oral fluoxetine and measured the effect of drug treatment on behavioral despair and hippocampal gene expression. The effect of fluoxetine on neurogenesis (BrdU labeling) was measured in a subset of the 30 strains . Results: We found that approximately 60% of the strains showed a positive behavioral response to fluoxetine treatment, similar to the percent response PL observed in human cohorts. Gene expression analysis identified a set of approximately 100 genes, many of which have been associated with neurogenesis, that clustered based on the strain-specific behavioral response to fluoxetine. This gene set was found to reliably predict the effect of fluoxetine on cell proliferation (as measured by BrdU labeling) in the dentate gyrus of a subset of the inbred strains. Subsequent genome-wide association mapping (GWAS) identified several genetic loci associated with both the behavioral and neurogenic response to fluoxetine. Discussion: These results suggest that the behavioral response to fluoxetine is under genetic regulation and associated with hippocampal neurogenesis: strains that show a positive behavioral response to fluoxetine also show an increase in hippocampal neurogenesis, whereas no change in neurogenesis is observed in strains that do not show a behavioral response . Additional genetic and genomic analysis was used to identify gene networks and genomic loci that may regulate antidepressant efficacy.

107

ACNP Annual Meeting Book 2013 rev8.indd 107 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish

Tuesday, Poster #20

David Kokel Massachusetts General Hospital

Background: Behavioral phenotyping is an effective way to discover novel neuroactive drugs. However, it has been difficult to develop efficient behavioral phenotyping assays for large-scale chemical screens . New technologies and behavioral phenotyping assays in the zebrafish are opening new opportunities to understand the central nervous system (CNS) and discover neuroactive drugs . These technologies are ushering in a new phase of discovery-based research in behavioral pharmacology . Neuroactive compounds with new structures, targets, mechanisms, and functions are being discovered . Given the fundamental differences between the human and zebrafish nervous systems it will be difficult to translate zebrafish discoveries to clinical medicine. However, given the molecular genetic similarities between humans and zebrafish, it is likely that some of the compounds being identified in the zebrafish will find translational PL utility in humans . The greatest new successes in CNS drug discovery will likely leverage the advantages of many model systems, including in vitro, cellular and rodent models, in addition to zebrafish. Methods: To determine how small molecules affect zebrafish behavior, we have built a fully automated phenotyping system capable of tracking and quantifying zebrafish behaviors in HT, 96-well format. The platform is a high content imaging system that combines robotic stimulus presentation with high-quality digital video capture and image processing algorithms . Results: Preliminary screening of 30,000 compounds in one behavioral assay has identified 44 ‘hit’ compounds and zero false positives among 5,155 DMSO-treated negative control wells . Of these 44 hits, 9 are known bioactive compounds . All 9 of the known hits are annotated as GABA receptor agonists . These data suggest that some of the 35 other novel hit compounds from this screen may also target GABAergic and other anxiety-related pathways .

108

ACNP Annual Meeting Book 2013 rev8.indd 108 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish

Tuesday, Poster #20 (continued)

David Kokel

Discussion: The compounds identified in this screen may have utility beyond anxiety-related research. It is difficult to predict exactly how behavior-modifying compounds will work, or what their translational utility will be . However, history suggests that psychiatric medicines are often discovered based on phenotypic observations. Given the efficacy of behavior-based neuroactive drug discovery, and the historical lack of high-throughput phenotyping technologies, it is likely that new large-scale behavior-based screening efforts in the zebrafish will successfully identify new neuroactive compounds .

109

ACNP Annual Meeting Book 2013 rev8.indd 109 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders

Tuesday, Poster #156

Joshua T . Kantrowitz, Michael Epstein, Odeta Beggel, Nayla Scaramello, Gail Silipo, Elisa Dias, Stephanie Rohrig, Batsheva Halberstam, Marlene Carlson, Daniel C . Javitt Columbia University

Background: Over the past 20 years, attention has turned increasingly to dysfunction of the N-methyl-D-aspartate (NMDAR)-type glutamate receptors as a fundamental deficit underlying pathophysiology in major psychiatric disorders such as schizophrenia and affective illnesses . In schizophrenia, a major focus has been on development of compounds to enhance NMDAR function . Proof-of- principle trials have been conducted with glycine-site agonists including glycine and D-serine, and with high affinity glycine transport inhibitors. Although significant improvement has been observed on negative and total symptoms in some, but not all, studies, effects of these compounds on cognition remain relatively understudied . Furthermore, relatively low doses of D-serine have been PL used because of concerns regarding nephrotoxicity . Two studies have been done to assess potential effects of D-serine on cognitive function. The first investigated effects of high dose (60 mg/kg/d) D-serine X 6 weeks on neurocognition as assessed both with neurophysiological and neurocognitive measures . A second piloted effects of acute D-serine treatment in the enhancement of cognitive plasticity during an auditory learning task . In affective disorders, NMDAR antagonists represent a potential treatment modality for treatment resistant major depression and bipolar depressive disorders . Acute treatment with intravenous ketamine induces near-immediate relief for treatment resistant depressive symptoms that last for up to 2 weeks . However, practical approaches to prolong this acute benefit are still being developed. D-Cycloserine (DCS) is an antibiotic hat cross reacts with the glycine site of the NMDAR, and, at high dose, acts as a net NMDAR antagonist. Antidepressant effects of DCS were first described in the 1950’s and have recently been confirmed in a double blind RCT of treatment resistant MDD . The present study investigates utility of acute ketamine challenge,

110

ACNP Annual Meeting Book 2013 rev8.indd 110 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders

Tuesday, Poster #156 (continued)

Joshua T . Kantrowitz

added to ongoing treatment, to induce improvement followed by high-dose DCS to maintain improvement, as a potential near-term, practical approach for MDD treatment . A concern with use of NMDAR antagonists is a risk of treatment emergent psychosis . In this study, DCS is added to ongoing treatment with antipsychotics (Seroquel, fluoxetine/olanzapine, lurasidone) also approved for treatment of bipolar depression . Methods: We will present data from three NMDAR modulator studies, as follows: 1 . ERP biomarker: In this study, neurophysiological and neurocognitive data were collected during a double blind, crossover study of high dose (60 mg/ kg/d) D-serine vs . placebo added to existing antipsychotic medication (n=16) . These neurophysiological data were combined with previously unpublished measures obtained as part of a previously reported open label dose finding study (Kantrowitz 2010) (n=19) . Primary outcome measures for neurophysiology PL included amplitude of the mismatch negativity (MMN) and visual P1 potentials, analyzed as described previously (Friedman 2012) . The primary neurocognitive outcome measure was composite score on the MATRICS neuropsychological battery . Clinical symptoms were assessed using the PANSS . 2 . D-serine + cognitive remediation: In this study, MMN was measured before and after subjects completed an auditory training program (coinciding with peak d-serine levels) and post intervention ERP (NCT01474395) . Cognitive remediation consisted of an auditory frequency discrimination task shown to promote learning in healthy controls (Ahissar 2006) . Outcome measures included tone matching accuracy and MMN . 3 .DCS in bipolar depression: DCS has been reported to be effective in treatment of refractory MDD . This study evaluates effectiveness of DCS as maintenance treatment for bipolar depression after acute ketamine administration . DCS (1000 mg) was added to standard treatment for 8 weeks in an open label tolerability investigation .

111

ACNP Annual Meeting Book 2013 rev8.indd 111 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders

Tuesday, Poster #156 (continued)

Joshua T . Kantrowitz

Results:ERP biomarker:33 subjects with a mean age of 42 .7±9 .9 and a mean chlorpromazine equivalent dose of 749±545 completed . 14 completed double- blind, while 19 additional subjects received open label D-serine . There were no significant between design (open label vs. double-blind D-serine) differences across ERP, and results were combined across design . Comparisons between the D-serine and placebo groups found significant, moderate/large effect size difference in MMN to frequency deviants and a non-significant, but moderate effect size improvement in Visual P1 . For cognitive outcomes, across all subjects, a moderate effect size, significant drug effect was seen for the MCCB composite and Visual learning domains. D-serine also induced a significant, moderate effect-size reduction in PANSS total symptoms. While no significant drug effect was seen across any individual factors, moderate effect size differences were seen for the negative and depressive factors that favored D-serine vs . PL placebo . NMDA+cognitive remediation ERP analysis is ongoing . 13 patients have completed, and after controlling for baseline pitch processing, significant drug by order effect was seen. A trend towards significance was seen for a drug effect for within visit improvement (p=0 .063), primarily in subjects receiving d-serineon day 1 . NMDA-Bipolar Enrollment is ongoing . 3 patients have received open label ketamine followed by NMDAR antagonist dose (1000 mg/ day) DCS. All three patients remitted with ketamine no significant side effects. As of this writing, remission was maintained in all subjects (3 to 6 weeks), with no significant treatment emergent side effects. Discussion: The development of treatments targeted at the glutamatergic system remains novel. These findings represent the first double-blind data with 60 mg/ kg D-serine in schizophrenia, and the first data on DCS in bipolar depression. No significant treatment-related side effects were observed, supporting viability of the NMDAR treatment approach in schizophrenia and affective illnesses .

112

ACNP Annual Meeting Book 2013 rev8.indd 112 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants

Tuesday, Poster #233

Josh Woolley, Chris Fussell, Wanda Lai, Olivia Lam, Brandon Chuang, Bruno Biagianti, Dan Fulford, Daniel H . Mathalon, Sophia Vinogradov UCSF

Background: Restricted expression of affect, including both reduced frequency and intensity of facial emotional expression, is a common negative symptom of schizophrenia that is correlated with worse functional outcomes and quality of life. Furthermore, there are currently no available treatments for these deficits. The neuropeptide oxytocin (OT) has multiple prosocial effects when administered intranasally in humans and offers a potential remedy for these expressivity deficits. OT has been implicated in bonding and has shown promise in enhancing social cognition in schizophrenia . However, the effects of oxytocin administration on facial expressivity have not been investigated in any healthy or patient population . Therefore, we investigated the effects of oxytocin on emotional expression in patients with schizophrenia and age-matched healthy controls while they observed PL emotionally provocative photos . Methods: Twenty-five male individuals with SCID-confirmed schizophrenia and twenty-seven male, age-matched, healthy participants participated in the study . Testing was performed in a randomized, double-blind, cross-over, placebo- controlled, within-subject design, with the two testing days separated by one week . On each test day, 40 IU of oxytocin or placebo (PCB) was self-administered intranasally . Participants were video recorded while they performed a facial trustworthiness assessment task . During this task, participants were shown 49 faces, and 49 positive (e .g ., sports), 49 negative (e .g ., snakes), and 49 neutral (e .g ., household objects) affective photos from the International Affective Picture System (IAPS) . Positive, neutral, and negative photos were chosen from the IAPS based on published ratings of arousal and valence . Effectiveness of the photos to produce pleasant and unpleasant feelings in patients with schizophrenia was validated in a previous study . Participants’ facial expressions were coded from the videos independently by two raters, who were blind to condition, using

113

ACNP Annual Meeting Book 2013 rev8.indd 113 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants

Tuesday, Poster #233 (continued)

Josh Woolley

the Facial Expression Coding System (FACES) . FACES is a behavioral coding system validated for use in patients with schizophrenia based on a dimensional model of emotion, in which each expression is coded for valence (positive/ negative) and intensity (weak/strong) . FACES ratings converge with ratings made using Ekman’s Facial Action Coding System and with data from facial muscle activity, psychophysiology, and subjective report . Inter-rater agreement was excellent (correlation coefficients: 0.94 to 0.96). Given the preponderance of zeroes in the data (particularly for the schizophrenia group; i .e ., lack of facial affect), we conducted non-parametric tests where possible . Results: Healthy controls (HC) and individuals with schizophrenia (SZ) were well matched on age (Mean (SD) SZ: 43 .2 (11), HC: 42 (13 .7) p = 0 .5) . Mann- Whitney U tests revealed that, on the PCB day, individuals with SZ showed significantly lower number (SZ: 1.1 (2.4) vs. HC: 5.8 (7.6)) and intensity of facial PL expressions (SZ: 0 .5 (0 .9) vs . HC: 1 .0 (0 .7)) than HCs (all p’s < 0 .01) consistent with previous studies . To test the effects of intranasal OT administration on facial expressivity we performed a repeated-measures ANOVA with one within-subject factor, Drug (OT and PCB), and one between-subject factor, Group(SZ and HC), for number and intensity of facial expressions . For number of expressions, we found a significant Drug effect (SZ: PCB: 1.1 (2.4) vs. OT: 2.7 (6.5); HC: PCB: 5 .8 (7 .6) vs . OT: 8 .4 (9 .8); F(1) = 6 .6, p = .01) but no significant Drug X Group interaction (F(1) = 0 .4, p = 0 .5) . Looking separately at positive and negative expressions revealed a significant Drug effect for negative (SZ: PCB: 0.4 (1.4) vs . OT: 1 .7 (4 .9); HC: PCB: 3 .0 (3 .9) vs . OT 4 .6 (5 .6); (F(1) = 6 .7, p = 0 .01) but not positive (SZ: PCB: 0 .7 (1 .6) vs . OT: 1 .0 (2 .6); HC: PCB: 2 .8 (5 .1) vs . OT: 3 .8 (7 .9); (F(1) = 1 .4, p = 0.2) expressions. We found no significant Drug or Drug X Group effects for intensity of facial affect (p’s > 0 .05) . Looking separately by group, related samples Wilcoxon Signed Rank tests revealed that OT increased the total number of facial expressions significantly in SZ (p = 0 .01); and

114

ACNP Annual Meeting Book 2013 rev8.indd 114 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants

Tuesday, Poster #233 (continued)

Josh Woolley

non-significantly in HC (p = 0 .1) but had no effect on the intensity of facial expressions in either group . Discussion: Our results suggest that administration of a single dose of oxytocin increases facial expressivity in SZ and HC during viewing of emotionally provocative photos . While OT appeared to selectively increase negative expressions this was likely due to our stimuli being more effective at inducing negative expressions . The mechanism of OT’s effect on facial expressivity is unknown . OT may increase facial expressivity by increasing participants’ psychological or physiological response to the emotional cues . Alternatively, facial expressivity is modulated by parasympathetic tone and OT is known to affect parasympathetic tone in humans and rodents . Therefore, OT administration may increase facial expressivity by directly altering parasympathetic regulation to facial musculature without affecting other responses to the emotional cues . PL Further research is necessary to explore these various hypotheses . In sum, the present study provides support for using OT as a pharmacological agent to remediate the facial expressivity deficits in SZ. Larger studies focused on patients with schizophrenia who have significant baseline negative symptoms are needed to confirm and extend our findings.

115

ACNP Annual Meeting Book 2013 rev8.indd 115 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Poverty and the Past: The Relation Between Hippocampus Function and Memory Performance is Linked to Childhood Poverty

Tuesday, Poster #193

Elizabeth R . Duval, Sarah N. Garfinkel, Chandra S . Sripada, James E . Swain, Gary W . Evans, Israel Liberzon University of Michigan Health System

Background: Childhood poverty is a risk factor for poorer cognitive performance both among children and possibly in adulthood, although most of the adult studies rely on retrospective estimates of childhood SES . While connections between poverty and cognitive deficits have been accumulating, the underlying neural mechanisms are undetermined . In order to investigate the neurobiological link between childhood poverty and memory deficits, we examined neural activity and working memory in a prospective design among young adults with and without childhood history of poverty . We predicted that memory recall would differ between the two groups, and that these differences would be related to PL differences in hippocampal activation during encoding . Methods: Fifty four right handed healthy adults between the ages of 20 and 27 were divided into two groups based on family income to need ratio at age nine . Twenty-eight came from middle income families, and 26 were from households falling below the poverty line . Within the context of a larger study, participants underwent fMRI scanning while encoding line drawings of common objects and animals, followed by a memory recall task . Signal detection (d-prime) was the measure of performance . D-prime was entered as a regressor into fMRI analyses, to examine brain activations during encoding that predicted memory recall performance . The effects of childhood poverty were also examined with respect to memory related activations . Results: Adults who grew up in middle income families performed significantly better than the poverty group (t(52) = 2 .21, p < 0 .05) . A d-prime regressor in fMRI analysis demonstrated a significant positive relationship between activation in left hippocampal regions during encoding and memory recall performance (p < .005, >10 contiguous voxels) . This relationship remained even after controlling

116

ACNP Annual Meeting Book 2013 rev8.indd 116 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Poverty and the Past: The Relation Between Hippocampus Function and Memory Performance is Linked to Childhood Poverty

Tuesday, Poster #193 (continued)

Elizabeth R . Duval

for current income to need ratios . The relationship between left hippocampal activation during encoding was significant in the middle income group (Pearson’s r = .48, p < .01) but not in the poverty group (Pearson’s r = .29, p > .05) . Discussion: Our prospective results confirm previous retrospective studies that childhood poverty is associated with poorer memory performance during adulthood. Our findings indicate left hippocampal activation during encoding is related to performance on a subsequent recall task. More specifically, the degree of left hippocampal activation during encoding was associated with better memory recall, but these relationships were demonstrated in the middle income group only . Future studies should continue to investigate mediators and moderators of these relations, including chronic stress, parenting, and other factors related to poverty . PL

117

ACNP Annual Meeting Book 2013 rev8.indd 117 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Rare Genetic Variants in VMAT1 (SLC18A1) Are Functional in Vitro and Associated with Bipolar Disorder

Tuesday, Poster #191

Falk W . Lohoff, Rachel Hodge, Sneha Narasimhan, Glenn Doyle University of Pennsylvania

Background: The gene encoding the vesicular monoamine transporter 1 (VMAT1) has recently emerged as a candidate gene for bipolar disorder (BPD), schizophrenia and emotional behavior . We have shown that the common amino acid substitution polymorphism Thr136Ile leads to increased monoamine transport in vitro and affects negative emotion processing in vivo . In this study we conducted deep sequencing of patients with BPD in order to detect rare VMAT1 variants and to determine their function in vitro . Methods: Sanger sequencing of all VMAT1 exons was carried out in 196 BPD individuals and 196 Caucasian controls . Novel rare variants that are likely to change protein function were tested for functional relevance using monoamine reuptake assays in CV-1 cells . Missense SNPs that were functional in vitro were then genotyped in a large cohort of BPD (n=4023) and normal controls (n=3305) PL of European descent from the NIMH Genetic Initiative using standard ABI TaqMan genotyping protocols . Results: Sequencing of BPD patients identified several novel and rare variants. Comparison of sequencing results of rare variants in BPD individuals with normal controls from the 1000 Genome project shows that the global burden of rare variants was increased in the BPD group . Interestingly, several novel variants were only detected in the BPD group but were absent in the controls .Monoamine uptake in vitro was carried out for Gln10Arg, Phe84Ser, Ala101Pro, Arg138Leu and Leu392Val . Phe84Ser robustly increased monoamine uptake in particular for DA (p<0 .001) and the three variants, Ala101Pro, Arg138Leu and Leu392Val decreased uptake, with Arg138Leu showing the largest effect for DA (P<0 .001), although similar results were also obtained for 5-HT and NE .Because of the robust functional effects of Phe84Ser and Arg138Leu, we genotyped these rare variants in a large sample of BPD cases and controls . The Ser84 allele was absent in controls but present in seven BPD individuals, including one homozygote

118

ACNP Annual Meeting Book 2013 rev8.indd 118 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Rare Genetic Variants in VMAT1 (SLC18A1) Are Functional in Vitro and Associated with Bipolar Disorder

Tuesday, Poster #191 (continued)

Falk W . Lohoff

and six heterozygotes (Fisher exact test, P=0 .009) . The Leu138 frequency did not differ statistically between cases and controls . Haplotype analysis of the individuals with the rare variant Phe84Ser showed that all subjects had almost exclusively the same halplotype Thr–Ser–Thr, indicative of a common origin and founder population effect . Discussion: Sequencing detected several rare and novel missense variants in BPD patients .In vitro results show that rare variants lead to “hyper or hypo” transport of monoamines . Association analyses of the rare variants Phe84Ser and Arg138Leu show that the Ser84 allele was only present in BPD but not controls . Given that the common Thr136Ile was previously shown to increased monoamine transport and has an effect on interindividual responses to medial PFC activation of negative words and threat-related amygdala reactivity, the rare Phe84Ser variant may have similar effect on these brain circuits and may contribute to the pathophysiology of PL BPD . Future studies are needed to comprehensively investigate common and rare SNP-dosage effects on transporter function in vivo and risk for BPD .

119

ACNP Annual Meeting Book 2013 rev8.indd 119 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Real-time Functional MRI Feedback, Compared to Sham, Reduces Cue-Induced Nicotine Craving in Smokers: Results from the First Clinical Trial

Tuesday, Poster #216

Colleen A . Hanlon, Karen Hartwell, Jeffrey J . Borckardt, James J . Prisciandaro, Melanie Canterberry, Xingbao Li, Max Owens, Todd LeMatty, Michael Saladin, Megan Moran-Santa Maria, Mark S . George, Kathleen T . Brady Hanlon Lab

Background: Realtime functional MRI feedback (rtfMRI) is an emerging and innovative technique which allows an individual to receive ongoing feedback about their own neural activity while they perform a given task . Here we present data from the first single-blind, sham controlled clinical trial for rtfMRI asa means of lowering cue-induced craving among smokers . Methods: Forty nicotine dependent smokers, who stated that they were motivated to quit, were enrolled in the rtfMRI protocol which consisted of 3 rtfMRI sessions (1 hour duration, 1 week apart), and 2 follow up visits (1 week, 1 month) . Patients PL were randomized to either the real or sham feedback group . At each visit, a patient-tailored feedback region (craving ROI) was established through a “crave” run in which the participants were instructed to crave when viewing smoking related cues . This ROI, in the region of the anterior cingulate or medial prefrontal cortex, was then ‘fed back’ to the individuals on 3 subsequent “reduce” craving runs . During the reduce craving scans they were exposed to similar smoking and neutral cues while receiving visual feedback (a thermometer) of BOLD signal activity from the ROI . They were instructed to reduce their craving and the activity in the ROI . Smoking-cue reactivity was measured through psychophysiologic assessments and self-reported metrics before, during, and after each fMRI visit . The primary endpoint was a change in smoking cue-reactivity as measured by heart rate, skin conductance, and self-reported craving metrics . Results: Individuals were unable to reliably identify if they were in the real or sham group, confirming that the integrity of the blind. The real and sham group did not differ in demographic or drug use variables (e .g . age, gender, smoking history, baseline carbon monoxide, FTND score). There was a significant effect

120

ACNP Annual Meeting Book 2013 rev8.indd 120 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Real-time Functional MRI Feedback, Compared to Sham, Reduces Cue-Induced Nicotine Craving in Smokers: Results from the First Clinical Trial

Tuesday, Poster #216 (continued)

Colleen A . Hanlon

of group for both psychophysiologic parameters (heart rate: F=14 .13, p=0 .0002; skin conductance:F=9 .67, p=0 .0019), with the “real feedback” group having a lower physiologic response to cues . There was also a prominent difference among the self-reported craving metrics (Questionnaire of Smoking Urges Factor 1: F=4 .52, p=0 .041, peak craving: F=4 .00, p=0 .053) with the “real feedback” group having a lower urge to smoke or peak craving than the sham group . Finally, there was a significant main effect ofpercent BOLD signal change in the craving ROI . That is, the real feedback group over time had a lower BOLD response in this region than did the sham feedback group . Discussion: These data demonstrate that smokers who are motivated to quit can modulate their cue-induced craving and regional brain activity by using three sessions of realtime feedback training from a patient-tailored ROI . Interestingly, PL these effects translate into a reduction of psychophysiologic arousal by the cues an hour after the scan as well as a lower self-reported craving during the scans . Further work is needed to determine if these exciting findings can be translated into some form of therapy for treatment seeking smokers, or those with other addictions .

121

ACNP Annual Meeting Book 2013 rev8.indd 121 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

11:30 a.m. – 1:30 p.m. Data Blitz Session Regency Ballroom 2

Substrate-selective COX-2 Inhibition Decreases Anxiety via Endocannabinoid Activation

Tuesday, Poster #232

Daniel Hermanson, Nolan Hartley, Joyonna Gamble-George, Lawrence Marnett, Sachin Patel Vanderbilt University School of Medicine

Background: Augmentation of endogenous cannabinoid (eCB) signaling represents an emerging approach to the treatment of affective disorders . Cyclooxygenase-2 (COX-2) oxygenates arachidonic acid to form prostaglandins, but also inactivates eCBs in vitro . However, the viability of COX-2 as a therapeutic target for in vivo eCB augmentation has not been explored . Methods: Here we utilized medicinal chemistry and in vivo analytical and behavioral pharmacological approaches to demonstrate a key role for COX-2 in the regulation of endocannabinoid (eCB) levels in vivo. A novel pharmacological strategy involving “substrate-selective” inhibition of COX-2 was developed used to augment eCB signaling without affecting related non-eCB lipids or prostaglandin synthesis . PL Results: Administration of the substrate-selective inhibitor LM-4131 increased brain and peripheral anandamide levels without affecting prostaglandin levels or levels or other related non-endocannabinoid lipids . Behaviorally, LM-4131 reduced anxiety-like behaviors in a variety of pre-clinical models . These effects were mediated via activation of CB1 type cannabinoid receptors . LM-4131 also reduced stress-indcued anxiety states in animals . Discussion: These data indicate that substrate-selective COX-2 inhibition represents a viable approach to enhance eCB signaling for the treatment of affective disorders . These data also highlight a key role for COX-2 in the regulation of central eCB signaling and validate COX-2 as a new molecular target for psychiatric drug discovery .

122

ACNP Annual Meeting Book 2013 rev8.indd 122 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 4:15 p.m. Mini-Panel Diplomat Ballroom 1 & 2

Emerging Role of the Primary Cilium in Neuropsychiatric Disorders

Chair: Bernard Lerer

3:00 p .m . The Role of AHI1 in Regulating Primary Cilia Signaling Russell J. Ferland

3:25 p.m. Functional Significance of Primary Cilia to GPCR Signaling and Relationship to Neuropsychiatric Disease Mark Von Zastrow

3:50 p .m . Abnormal Response to Stress in Heterozygous AHI1 Knockout Mice: A Consequence of Primary Ciliary Dysfunction? Bernard Lerer

4:15 p.m. – 5:30 p.m. Mini-Panel Diplomat Ballroom 1 & 2

Adolescent Brain Development and Affective Disorders: The Role of Reward and Threat Circuitry

Chair: Erika E . Forbes MP

4:15 p .m . Adolescent VTA Neurons Exhibit Latent Neuronal Correlate of Reward Opportunity Bita Moghaddam

4:40 p .m . Adolescents’ Neural Response to Personally Relevant Social Reward Is Associated with Severity of Mania and Depression Erika E. Forbes

5:05 p .m . Neural Mechanisms of Frustration in Chronically Irritable Youth Ellen Leibenluft

123

ACNP Annual Meeting Book 2013 rev8.indd 123 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 3

An Update from the Clinic on mGluR2/3 Approaches for Treating Schizophrenia – Understanding Human Circuit Engagement through to Recent Clinical Trials

Chair: Nicholas Brandon

3:00 p .m . The Development of Pomaglumetad Methionil as an Innovative Glutamate-based Pharmacotherapy for Schizophrenia Bruce J. Kinon

3:30 p .m . Discovery and Early Clinical Development of Novel mGlu2 Receptor Pams Hilde Lavreysen

4:00 p .m . AZD8529 - An mglur2 Positive Allosteric Modulator for the Treatment of Schizophrenia Alan Cross

4:30 p.m. Efficacy of an mGluR2 Agonist (LY354740) and an mGluR2 Positive Allosteric Modulator (AZD8529) in Attenuating Ketamine Effects in Humans John H. Krystal

5:00 p .m . Discussant: Daniel R. Weinberger PA

124

ACNP Annual Meeting Book 2013 rev8.indd 124 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 3

Anxiety and the Striatum, an Unusual Suspect

Chair: Monique Ernst

3:00 p .m . Neural Response in Striatum Varies by Reward Magnitude, Decision Making, and Anxiety Diagnosis in Adolescents Amanda E. Guyer

3:30 p .m . Cortico-amygdala Pathways form Hierarchical Networks that Predict Output to the Striatum Julie L. Fudge

4:00 p .m . The Impact of Induced Anxiety on Ventral Striatal Response to Aversive and Appetitive Prediction Error Signals Oliver J. Robinson

4:30 p .m . Endocannabinoids in the Dopaminergic Control of Punishment and its Avoidance Joseph Cheer

5:00 p .m . Discussant: Mauricio Delgado

125

ACNP Annual Meeting Book 2013 rev8.indd 125 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 2

Biotypes of Psychosis

Chair: Carol A . Tamminga Co-Chair: Godfrey D . Pearlson

3:00 p .m . Phenotypic Characterization of the Schizophrenia- bipolar Disorder Continuum Matcheri Keshavan

3:30 p.m. Identification of Distinct Psychosis Biotypes with Multivariate Taxometric Analyses of Neuro-pathologically Relevant Biomarkers Brett A. Clementz

4:00 p .m . Validating Psychosis Biotypes Carol A. Tamminga

4:30 p .m . Multivariate Fusion Methods Identify Gene Components Associated with Heritable Resting State fMRI Abnomalities in BSNIP Probands and Relatives Godfrey D. Pearlson

5:00 p .m . Discussant: Steven E. Hyman

126

ACNP Annual Meeting Book 2013 rev8.indd 126 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 1

Pathophysiology and Treatment of Obesity and Glucose Dysregulation in Schizophrenia

Chair: Lars Fredrik Jarskog Co-Chair: Scott Stroup

3:00 p .m . Effect of Metformin on Weight in Patients with Schizophrenia with Impaired Fasting Glucose Scott Stroup

3:30 p .m . Dopamine, Clean Up Your “AKT”! Restoring Insulin Signaling in Brain Aurelio Galli

4:00 p .m . Dysglycemic Signals in Antipsychotic-Treated Children and Adolescents with Schizophrenia-Spectrum Disorders: Trajectories, and Moderating and Mediating Factors Christoph Correll

4:30 p .m . No Effect of Adjunctive, Repeated Dose Intranasal Insulin Treatment on Body Metabolism in Patients with Schizophrenia Xiaoduo Fan

5:00 p .m . Discussant: Robert W. Buchanan PA

127

ACNP Annual Meeting Book 2013 rev8.indd 127 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 2

Posttraumatic Stress Disorder: From Markers to Mechanisms

Chair: Murray B . Stein

3:00 p.m. Identification of Novel Gene Regulatory Networks Associated with PTSD: Evidence from Whole Genome Studies Examining DNA Methylation Douglas E. Williamson

3:30 p.m. Allele Specific Epigenetic Modifications - A Molecular Mediator of Gene-environment Interactions in Stress Related Psychiatric Disorders? Torsten Klengel

4:00 p .m . Opioid Receptor-Like 1 (OPRL1) is Involved in Amygdala- dependent Fear in Mice and Humans with PTSD Kerry J. Ressler

4:30 p.m. Contextual Processing Deficits in PTSD: Translational Studies Israel Liberzon

5:00 p .m . Discussant: Charles R. Marmar

128

ACNP Annual Meeting Book 2013 rev8.indd 128 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 1

Treating Addiction: Should We Aim High or Low?

Chair: Marina E . Wolf

3:00 p .m . Rapid LTP in Accumbens Is a Common Feature of Relapse to Multiple Classes of Addictive Drug Peter W. Kalivas

3:30 p .m . Synaptic Depression via Positive Allosteric Modulation of mGluR1 Suppresses Cue-induced Cocaine Craving Marina E. Wolf

4:00 p .m . Silent Synapse-based Circuitry Reorganization in Cocaine Craving Yan Dong

4:30 p .m . Withdrawal from Acute Amphetamine Potently Down-Regulates VTA Dopamine Neuron Activity: Reversal by Ketamine Anthony A. Grace

5:00 p .m . Discussant: Anissa Abi-Dargham

129

ACNP Annual Meeting Book 2013 rev8.indd 129 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

130

ACNP Annual Meeting Book 2013 rev8.indd 130 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 9:45 a.m. Mini-Panel Diplomat Ballroom 1-2

Are the Putative Therapeutic Effects of Kappa-opioid Antagonists Explained by Anti-stress Actions? Chair: William Carlezon 8:30 a .m . Disruption of Kappa-opioid Receptor Actions Reduces Stress Effects on Cognitive Function and Anxiety-like Behavior Ashlee Van’t Veer 8:55 a .m . Dynorphin-kappa Systems in Compulsive-like Responding with Extended Access to Elicit Drugs George F. Koob 9:20 a .m . The Dissociable Effects of Kappa-opioid Receptor Activation on Intolerance to Delay and Response Inhibition Brendan Walker

9:45 a.m. – 11:00 a.m. Mini-Panel Diplomat Ballroom 1-2

Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS, CNTRaCs and NEWMEDS Chair: Cameron S . Carter 9:45 a .m . New Neuroscience Based Cognitive Paradigms for Biomarker Research in Schizophrenia Deanna M. Barch 10:10 a .m . Developing Imaging Biomarkers for Treatment Development: MP Beyond CNTRICS, CNTRaCs and NEWMEDS Angus W. MacDonald 10:35 a .m . Imaging Biomarkers for Psychiatric Disorders: The NEWMEDS Experience Andreas Meyer-Lindenberg

131

ACNP Annual Meeting Book 2013 rev8.indd 131 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 3

Alterations of the Glutamate Cycle in Severe Mental Illness

Chair: Adrienne C . Lahti Co-Chair: Robert E . McCullumsmith

8:30 a .m . Glutamatergic Abnormalities in Medicated and Unmedicated Patients with Schizophrenia Adrienne C. Lahti

9:00 a .m . Abnormalities of Glutamate Transporter Expression in Schizophrenia: Evidence for Increased Glutamate Reuptake and Altered Subcellular Partitioning of EAAT2 Interacting Proteins Robert E. McCullumsmith

9:30 a .m . Psychosis and Cognition Related to Different Brain Glutamate Pools in Schizophrenia Juan Bustillo

10:00 a .m . Functional Implications of Altered In Vivo Glutamate and GABA Systems in Schizophrenia Laura M. Rowland

10:30 a .m . Discussant: Kelvin O. Lim

132

ACNP Annual Meeting Book 2013 rev8.indd 132 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 1

Epigenetic Mechanisms in Neuropsychiatric Disorders

Chair: Paul Kenny Co-Chair: Claes Wahlestedt

8:30 a .m . MicroRNAs and Drug Addiction Paul Kenny

9:00 a .m . Global Transcriptome Analysis of Human Cerebrospinal Fluid Claes Wahlestedt

9:30 a .m . Insights into the Roles of the Methyl-DNA Binding Protein MeCP2 in Addictive-like Behaviors Anne E. West

10:00 a .m . MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy and Intact Serotonergic Activity Alon Chen

10:30 a .m . Discussant: Eric Nestler

133

ACNP Annual Meeting Book 2013 rev8.indd 133 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 3

α4β2-Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics

Chair: A . Eden Evins Co-Chair: Irina Esterlis

8:30 a.m. In Vivo Evidence for β2*-nAChR Upregulation in Smokers as Compared to Nonsmokers with Schizophrenia Irina Esterlis

9:00 a .m . Nicotinic CHRNA4 Exon 5 Genotype Predicts Clinical Outcome in Schizophrenia and Neuroleptic Drug Treatment-response Georg Winterer

9:30 a.m. Examining the α4β2 Nicotinic Partial Agnoist Varenicline on the Tobacco Abstinence Syndrome in Schizophrenia Versus Control Smokers Victoria C. Wing

10:00 a .m . Extended Duration Pharmacotherapy with Varenicline Prevents Relapse to Smoking in Adult Smokers with Schizophrenia A. Eden Evins

10:30 a .m . Discussant: Tony P. George

134

ACNP Annual Meeting Book 2013 rev8.indd 134 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Atlantic Ballroom 2

Manipulating BDNF-TrkB Signaling in Brain Disorders: Complex Regulation and Cellular & Systems Level Interactions as Novel Substrates for Translational Medicine

Chair: Keri Martinowich Co-Chair: Francis Lee

8:30 a .m . Differential Contribution of Individual BDNF Splice Variants to Brain and Behavioral Functions Keri Martinowich

9:00 a .m . Role of Slitrk5 in Regulating BDNF Dependent Signaling Francis Lee

9:30 a .m . Convergence of BDNF and Glucocorticoid Receptor Signaling Moses V. Chao

10:00 a .m . Synaptic Repair: Translating BDNF Biology into New Medicines for Psychiatric Diseases Bai Lu

10:30 a .m . Discussant: Ronald S. Duman

135

ACNP Annual Meeting Book 2013 rev8.indd 135 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 2

New Directions for Optogenetics: Investigating Plasticity Mechanisms Underlying Psychiatric Disorders

Chair: Helen Blair Simpson Co-Chair: Susanne E . Ahmari

8:30 a .m . Brief Repeated Cortico-striatal Stimulation Leads to Persistent OCD-relevant Behaviors Susanne E. Ahmari

9:00 a .m . Cortical Control of Brainstem Neuromodulatory Systems in Motivated Behavior Melissa R. Warden

9:30 a .m . Different Patterns of Stimulation in Projections from VTA to PFC Exert Distinct Effects on Behavioral Flexibility Vikaas S. Sohal

10:00 a .m . Molecular and Circuit Basis of Impaired Hippocampal-prefrontal Synchrony in a Mouse Model of Schizophrenia Predisposition Joshua A. Gordon

10:30 a .m . Discussant: Karl Deisseroth

136

ACNP Annual Meeting Book 2013 rev8.indd 136 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:30 a.m. – 11:00 a.m. Panel Regency Ballroom 1

The Ventromedial Prefrontal Cortex in Conditioning and Extinction in Chronically Relapsing Disorders

Chair: Rita Goldstein Co-Chair: Karen K . Szumlinski

8:30 a .m . Factors that Impact the Functional Reactivity of the Fear Extinction Network Across Disorders Mohammed R. Milad

9:00 a .m . Retention of Extinction Learning for Monetary Reward in Cocaine Addiction: Role of the Amygdala and VMPFC Rita Goldstein

9:30 a.m. Deficits in Ventromedial Prefrontal Cortex Group1 Metabotropic Glutamate Receptors Underpin Cognitive Dysfunction during Protracted Cocaine Withdrawal Karen K. Szumlinski

10:00 a .m . Role of Ventral Medial Prefrontal Cortex (Mpfc) and Its Projections to Accumbens Shell on Context-induced Reinstatement of Heroin Seeking in Rats Jennifer M. Bossert

10:30 a .m . Discussant: Gregory J. Quirk

137

ACNP Annual Meeting Book 2013 rev8.indd 137 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 4:15 p.m. Mini-Panel Diplomat Ballroom 1-2

Human Brain Evolution and Comparative Epigenomics Chair: Schahram Akbarian 3:00 p .m . Decoding the Molecular Evolution of Cognition Genevieve Konopka 3:25 p .m . Divergent Whole Genome Methylation Maps of Human and Chimpanzee Brains Reveal Epigenetic Basis of Human Regulatory Evolution and Disease Susceptibility Soojin V. Yi 3:50 p .m . Neuronal Epigenome Mapping in Human and Non-human Primate Prefrontal Cortex Jogender Singh Tushir

4:15 p.m. – 5:30 p.m. Mini-Panel Diplomat Ballroom 1 & 2

Intergenerational Transmission of Trauma – From Animal Models to Humans Chair: Kerry J . Ressler Co-Chair: Jacek Debiec 4:15 p .m . Behavioral and Neural Mechanisms of the Intergenerational Transmission of Trauma Jacek Debiec

MP 4:40 p .m . Epigenetic Markers in the GR and FKBP5 Genes in Children of Holocaust Survivors Rachel Yehuda 5:05 p .m . Transgenerational Imprints on Structure and Function in the Mammalian Nervous System Brian Dias

138

ACNP Annual Meeting Book 2013 rev8.indd 138 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 2

Legal Damages: New Insights into Chronic Marijuana Effects on Human Brain Structure and Function

Chair: Steven Grant Co-Chair: James M . Bjork

3:00 p .m . Impact of Chronic Marijuana Use on Reward and Control Brain Networks Francesca M. Filbey

3:30 p .m . Effect of Long-term Cannabis Use on Axonal Fiber Connectivity Andrew Zalesky

4:00 p .m . Unmotivated? Signatures of Blunted Dopaminergic Responsiveness in Chronic Marihuana Abuse Nora D. Volkow

4:30 p .m . Multimodal MR Imaging in Adolescent MJ Users Deborah Yurgelun-Todd

5:00 p .m . Discussant: Linda Porrino

139

ACNP Annual Meeting Book 2013 rev8.indd 139 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 3

Early Stress and Emotion Dysregulation

Chair: Christian Schmahl Co-Chair: Larry Siever

3:00 p .m . Weakening Fear Memories as a Potential Treatment for Posttraumatic Stress Disorder Karim Nader

3:30 p .m . Effect of Direct Eye Contact in PTSD Related to Interpersonal Trauma: An fMRI Study of Activation of an Innate Alarm System Ruth Lanius

4:00 p .m . Examining the Genetic Underpinnings of the Amygdala Habituation Deficit in Borderline Personality Disorder M. Mercedes Perez-Rodriguez

4:30 p.m. Influence of Dissociation on Emotional Distraction in Borderline Personality Disorder Annegret Krause-Utz

5:00 p .m . Discussant: Andreas Meyer-Lindenberg

140

ACNP Annual Meeting Book 2013 rev8.indd 140 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 3

Glutamate-dopamine Interactions in Nicotine and Cocaine Dependence: Biomarkers and Therapy Opportunities

Chair: Dean F . Wong Co-Chair: Gerhard Gründer

3:00 p .m . In Vivo Imaging of Human mGluR5 and nAch Receptors with PET: Dynamic Duo for Abuse Studies and Drug Occupancy? Dean F. Wong

3:30 p .m . Dopamine Activity and Reward Processing in Smokers Before and After Smoking Cessation: Combined [18F]FDOPA/fMRI Studies Gerhard Gründer

4:00 p .m . Reduced mGluR5 Receptor Binding in Smokers and Ex-smokers Determined by [11C]ABP688 Positron Emission Tomography: Clinical and Scientific Relevance Gregor Hasler

4:30 p .m . Understanding Glutamate, Acetylcholine and Dopamine Interactions in Nicotine Dependence Using Animal Models Manoranjan S. D’Souza

5:00 p .m . Discussant: Athina Markou

141

ACNP Annual Meeting Book 2013 rev8.indd 141 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 2

Multidimensional Data Integration and Causality: A Systems Approach for Unraveling the Molecular Architecture of Mental Disorders

Chair: Thomas Lehner

3:00 p .m . Elucidating the Complexity of Psychiatric Disorders via the Integration of High-dimensional, Multiscale Data Eric E. Schadt

3:30 p .m . Cis and Trans Data Integration to Find Mechanisms Causing Psychiatric Disorders Edwin van den Oord

4:00 p .m . The ENIGMA Consortium: Meta-analyzing Neuroimaging and Genetic Data from 125 Institutions Paul Thompson

4:30 p .m . Computational Analysis of Complex Human Disorders Andrey Rzhetsky

5:00 p .m . Discussant: Steven E. Hyman

142

ACNP Annual Meeting Book 2013 rev8.indd 142 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Atlantic Ballroom 1

Neurobiological Regulation of Palatable Food Binging and Seeking

Chair: Jacqueline F . McGinty

3:00 p .m . Extended Amygdala-hypothalamic Inhibitory Circuits Regulate Feeding Garret D. Stuber

3:30 p .m . Cholinergic Control of Food Intake: Mechanisms Highjacked by Nicotine Marina Picciotto

4:00 p .m . Serotonin Control in the Proclivity for High Impulsive Action and Binge Eating Kathryn Cunningham

4:30 p .m . Neural Correlates of Craving, Cognitive Control and Reward Processing in Obesity and Binge-eating Disorder Marc N. Potenza

5:00 p .m . Discussant: Jacqueline F. McGinty

143

ACNP Annual Meeting Book 2013 rev8.indd 143 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

3:00 p.m. – 5:30 p.m. Panel Regency Ballroom 1

Public-private Repositioning Partnerships: A New Path to Achieve Target Validation and Proof of Concept for Novel CNS Indications

Chair: Linda S . Brady Co-Chair: Jeffrey S . Nye

3:00 p .m . Drug Repositioning Through Open Innovation - An Industry Perspective Donald Frail

3:30 p .m . The MRC/AstraZeneca Mechanisms of Disease Compound Sharing Initiative Christopher Watkins

4:00 p .m . NCATS/NIH-Industry Pilot Program on Drug Repositioning Christine Colvis

4:30 p .m . Open Innovation and Mobile Health Technology to Improve and Accelerate Clinical Development Tomasz Sablinski

5:00 p .m . Discussant: Jeffrey J. Nye

144

ACNP Annual Meeting Book 2013 rev8.indd 144 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

145

ACNP Annual Meeting Book 2013 rev8.indd 145 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

146

ACNP Annual Meeting Book 2013 rev8.indd 146 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Atlantic Ballroom 1

Brain on Fire: Inflammation in Neurological and Psychiatric Illness

Chair: Scott Russo Co-Chair: Danielle L . Graham

8:00 a .m . Pruning Developing CNS Synapses: An Active Role for Glia and Immune Molecules Beth Stevens

8:30 a.m. Monitoring Neuroinflammation and Demyelination Using Magnetic Resonance Imaging in a Preclinical Setting Danielle L. Graham

9:00 a .m . Role of the Peripheral Immune System in Stress-induced Depressive Behavior Georgia E. Hodes

9:30 a .m . Testing the Cytokine Hypothesis of Depression: Trials and Tribulations Andrew H. Miller

10:00 a .m . Discussant: Christopher McDougle

147

ACNP Annual Meeting Book 2013 rev8.indd 147 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Regency Ballroom 2

Broadening the Trajectories of Risk: Specific and Non-specific Markers of Risk of Psychopathology

Chair: Kathleen Ries Merikangas

8:00 a .m . Comorbidity of Medical and Psychiatric Disorders in the Neurodevelopmental Genomics Cohort Study Kathleen Ries Merikangas

8:30 a .m . The Study of Developmental Trajectories in Autism Spectrum Disorders; Lessons Learned Peter Szatmari

9:00 a .m . Clinical, Neurobiological and Circadian Correlates of the Onset and Course of Major Mood Disorders: From Childhood Risk to Adolescent-onset and Persistence into Adulthood Ian Hickie

9:30 a .m . Brain-behavior Measures in Psychosis Spectrum Youths of the Philadelphia Neurodevelopmental Cohort Raquel E. Gur

10:00 a .m . Discussant: Patrick McLzorry

148

ACNP Annual Meeting Book 2013 rev8.indd 148 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Atlantic Ballroom 3

Building a More Predictive Mouse: Humanized Mouse Models for Neuropsychiatric Disorders

Chair: Mark A . Geyer

8:00 a .m . The Tryptophan Hydroxylase Arg439His Knockin (Tph2KI) Mouse: A Naturalistic Model of 5-HT Deficiency Jacob Jacobsen

8:30 a .m . Modeling the Contributions of Dopamine to ADHD via a Novel, Knock-in Mouse Model Maureen K. Hahn

9:00 a .m . Development and Characterization of Mice Humanzied for the COMTval158met Polymorphism Victoria Risbrough

9:30 a .m . DISC1-Boymaw Fusion Gene May Contribute to Major Psychiatric Disorders in the Scottish Schizophrenia Family Xianjin Zhou

10:00 a .m . Discussant: John Talpos

149

ACNP Annual Meeting Book 2013 rev8.indd 149 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Atlantic Ballroom 2

Melatonin and Its Receptors: Important Players in Major Depressive Disorder

Chair: Pierre Blier

8:00 a .m . Melatonin-mediated Potentiation of Physical Activity-induced Neurogenesis in the Dentate Gyrus of the C3H/HeN Mouse . Margarita L. Dubocovich

8:30 a .m . Interactions between Melatonin and 5-HT Receptors to Enhance Monoaminergic Transmission in the Rat Brain Pierre Blier

9:00 a .m . Impact of Hippocampal Neurogenesis on Cognition and Mood Rene Hen

9:30 a .m . A Pilot, Placebo-controlled Study of Buspirone Plus Melatonin in Major Depressive Disorder Maurizio Fava

10:00 a .m . Discussant: Gabriella Gobbi

150

ACNP Annual Meeting Book 2013 rev8.indd 150 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Diplomat Ballroom 1-2

Molecular Regulation and Clinical Applications of Phosphodiesterase 4, the Major Enzyme for Degrading cAMP

Chair: Robert Innis Co-Chair: Akira Sawa

8:00 a .m . PDE4 in Huntington’s Disease: Pathology of Cross-seeding of Huntingtin and Amyloidogenic DISC1 Koko Ishizuka

8:30 a .m . Control of Mood by Selective Potentiation of cAMP Signaling in Ventral Striatum James A. Bibb

9:00 a .m . Structural and Pharmacological Studies of PDE4 Subtype Selective Allosteric Inhibitors Mark Gurney

9:30 a .m . Binding of 11C-(R)-rolipram to Phosphodiesterase 4 is Downregulated in Major Depressive Disorder and Normalized with Antidepressant Treatment Robert Innis

10:00 a .m . Discussant: Carlos Zarate, Jr.

151

ACNP Annual Meeting Book 2013 rev8.indd 151 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Regency Ballroom 1

Naltrexone Revisited: New Findings Beyond Mu, Beyond Dopamine and Beyond Addiction

Chair: Robert M . Swift

8:00 a .m . Naltrexone Effects on GABAergic Neuroactive Steroids: Associations to Subjective Responses and Pharmacogenetics Lara Ray

8:30 a .m . Neurocognitive Effects of Naltrexone Charlotte A. Boettiger

9:00 a .m . Naltrexone Pharmacotherapy for Adverse Metabolic Outcomes of Second Generation Antipsychotic Agents Igor Elman

9:30 a .m . Microglial Activation Alters Reward Circuitry in Chronic Pain States Catherine Cahill

10:00 a .m . Discussant: Stephanie O’Malley

152

ACNP Annual Meeting Book 2013 rev8.indd 152 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

8:00 a.m. – 10:30 a.m. Panel Regency Ballroom 3

Understanding Neurodevelopmental Risk Factors Leading to Anxiety and Depression to Inform Novel Early Interventions in Vulnerable Children

Chair: Ned H . Kalin

8:00 a .m . Neurobiology of Trauma and Infant Attachment: Short-term Benefits and Long-term Costs Regina M. Sullivan

8:30 a .m . Primate Anxious Temperament and Amygdala Metabolism are Environmentally Sensitive and Associated with Amygdalar Gene Expression Andrew S. Fox

9:00 a .m . Glucocorticoid Receptor Activation Induced Epigenetic Changes and Their Moderation by Genetic Variants as Potential Mediators of Risk and Resilience to Early Trauma-associated Psychiatric Disorders Elisabeth B. Binder

9:30 a .m . The Pervasive and Persistent Neurobiological Consequences of Child Abuse and Neglect; Clinical Implications Charles B. Nemeroff

10:00 a .m . Discussant: Bruce McEwen

153

ACNP Annual Meeting Book 2013 rev8.indd 153 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Atlantic Ballroom 3

Applying Animal and Human Models of Risk Avoidance and Impulsivity to Understanding Eating Disorders

Chair: Walter Kaye Co-Chair: Barry Setlow

12:00 p .m . A Translational Assessment of Reward-based Learning in Adolescents with Bulimia Nervosa Rachel Marsh

12:30 p .m . Harm Avoidant Behaviors and Altered Limbic and Executive Neural Function in Anorexia Nervosa Walter Kaye

1:00 p .m . Striatal Dopamine D2 Receptor Modulation of Risky Decision Making Barry Setlow

1:30 p .m . D1- and D2-like Dopamine Receptors, Impulsive Temperament and Corticostriatal Function as Related to Risky Decision- making: Multimodal Imaging in Healthy Research Participants Edythe D. London

2:00 p .m . Discussant: Trevor Robbins

154

ACNP Annual Meeting Book 2013 rev8.indd 154 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Atlantic Ballroom 2

Behavioral, Endocrine, and Neural Plasticity Changes Reflecting Stress Associated with Mouse and Monkey Models of Heavy Alcohol Drinking

Chair: Howard C . Becker Co-Chair: Kathleen A . Grant

12:00 p .m . Behavioral and Neural Adaptations Linked to Stress Associated with a Mouse Model of Ethanol Dependence and Relapse Drinking Howard C. Becker

12:30 p .m . Behavioral and Endocrine Adaptations in a Monkey Model of Heavy Alcohol Drinking Kathleen A. Grant

1:00 p .m . Chronic Ethanol Exposure Increases Output from the Sensorimotor Striatum in Mouse and Monkey Models via Changes in Neuronal Excitability and Synaptic Transmission David Lovinger

1:30 p .m . Similar Dopamine System Adaptations in Mouse and Monkey Models of Excessive Alcohol Exposure Sara R. Jones

2:00 p .m . Discussant: Antonio Noronha

155

ACNP Annual Meeting Book 2013 rev8.indd 155 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Regency Ballroom 1

Cognition, Biomarkers, and Longitudinal Outcomes in Geriatric Mood Disorders

Chair: Helen Lavretsky Co-Chair: Charles Reynolds

12:00 p .m . Longitudnial BDNF Levels in Both an Elderly Cohort and an Inflammatory Cytokine-exposed Cohort: Risk for Cognitive Deficits Francis E. Lotrich

12:30 p .m . Late-life Depression May Increase Risk of Dementia but Does Not Increase Risk of Developing Mild Cognitive Impairment Meryl Butters

1:00 p .m . Cognitive Control Network: Motivational Disturbances and Treatment Response of Late Life Depression George S. Alexopoulos

1:30 p .m . Combination of Methylpehnidate with Citalopram is Superior to Either Drug Alone in Improving Clinical and Cognitive Outcomes in Geriatric Depression Helen Lavretsky

2:00 p .m . Discussant: Wesley Thompson

156

ACNP Annual Meeting Book 2013 rev8.indd 156 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Regency Ballroom 2

Experimental Therapeutics and Drug Development Targeting Inflammation in Developmental Disorders

Chair: Eric Hollander Co-Chair: Carlos A . Pardo

12:00 p .m . Gastrointestinal Symptoms in a Mouse Model of an Environmental Risk Factor for Autism and Schizophrenia Paul H. Patterson

12:30 p .m . Immune System as a Target for Therapeutic Intervention in Neurodevelopmental Disorders: Lessons from the Rett Syndrome Jonathan Kipnis

1:00 p .m . PET Imaging of Microglial Activation in Young Adults with Autism Spectrum Disorder Kazuhiko Nakamura

1:30 p.m. Translational Experimental Therapeutics of Inflammation and Fever in Autism Spectrum Disorder : Hot Tubs, Locus Coeruleus Modulation and Helminth Therapy Eric Hollander

2:00 p .m . Discussant: Carlos Pardo

157

ACNP Annual Meeting Book 2013 rev8.indd 157 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Diplomat Ballroom 1-2

Novel Molecules and Mechanisms in Vulnerability and Resilience Throughout Life

Chair: Marcelo A . Wood Co-Chair: Tallie Z . Baram

12:00 p .m . miRNA Programming in Neurodevelopment: Epigenetic Targets in a Dynamic Landscape Tracy Bale

12:30 p .m . Epigenetic Pathways during Early Postnatal Life: How Does a Neuron “Know” to Modulate Its Epigenetic Machinery in Response to Early-life Experience? Tallie Z. Baram

1:00 p .m . How Neocortical Tet-mediated DNA Hydroxymethylation Regulates Memory Timothy W. Bredy

1:30 p.m. Neuron-specific Nucleosome Remodeling: A Missing Link in Our Understanding of Epigenetic Mechanisms Underlying Intellectual Disability Disorders Marcelo A. Wood

2:00 p .m . Discussant: Farah Lubin

158

ACNP Annual Meeting Book 2013 rev8.indd 158 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Atlantic Ballroom 1

Strategies for the Development of Novel Therapies for Schizophrenia: From Clinic to Laboratory (And Back Again)

Chair: Joel E . Kleinman

12:00 p .m . Psychiatric GWAS Consortium Triples Schizophrenia GWAS Sample-size to 31,000 Cases and 37,000 Controls Stephan Ripke

12:30 p .m . Integrating the Genome, Epigenome, and Transcriptome in the Human Brain: Accounting for Biological and Technical Heterogeneity Andrew Jaffe

1:00 p .m . Understanding ZNF804A: Allelic Variation, Alternative Transcripts, Brain Development and Schizophrenia Thomas M. Hyde

1:30 p .m . Applying Lessons from DISC1 to Convert Gene Discoveries into Drug Discoveries Nicholas Brandon

2:00 p .m . Discussant: Paul Harrison

159

ACNP Annual Meeting Book 2013 rev8.indd 159 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

12:00 p.m. – 2:30 p.m. Panel Regency Ballroom 3

The Insula Salience Network: Alterations in Its Connectivity in Developmental, Anxiety, Mood and Personality Disorders

Chair: Harold W . Koenigsberg

12:00 p .m . Insula – Conceptualizing Its Architecture, Function and Connectivity, with Applications to Understanding Large-scale Brain Networks in Psychopathology and Autism Vinod Menon

12:30 p .m . Insula-amygdala Function and Connectivity in Trauma-related Disorders: Relationship to Childhood Maltreatment Murray B. Stein

1:00 p .m . Borderline Personality Disorder Patients Show Reduced Insula- amygdala Functional Connectivity and Fail to Habituate When Viewing Repeated Negative Emotional Pictures Harold W. Koenigsberg

1:30 p .m . Elevated Posterior Insula–ventral Striatal Connectivity to Reward in Youth with Bipolar Spectrum Disorders Relative to Youth with Other Behavioral and Emotional Dyregulation Disorders: A Potential Neural Marker of Heightened Reward-related Perceptual Salience in Bipolar Youth Mary L. Phillips

2:00 p .m . Discussant: Kevin Ochsner

160

ACNP Annual Meeting Book 2013 rev8.indd 160 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

161

ACNP Annual Meeting Book 2013 rev8.indd 161 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

162

ACNP Annual Meeting Book 2013 rev8.indd 162 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I – Monday, December 9, 2013

Advocacy Affiliate – Cure Alliance for Mental Illness Research Parity for Mental Illness Robin Cunningham and Hakon Heimer

M1 . 2013 Report of the Membership Advisory Task Force Linda Carpenter, Lisa Monteggia, Margaret Haney, Katherine Burdick, Jennifer Bartz, Elisabeth Binder, Paul Holtzheimer, Amit Etkin, Erica Forbes, Marlene Freeman, Thomas Schulze, Christina Barr, Gregory Light, Vaishali Bakshi, Raymond Cho, Cynthia Crawford, Philip Szeszko

M2 . Elevations of Brain Kynurenic Acid in Prenatal Rats Result in Long- lasting Impairments in Cortical Development and Cognitive Flexibility: Implications for Schizophrenia John P . Bruno, Sarah Vunck, Michelle Pershing, Ana Pocivavsek, Dave Bortz, Christinna Jorgensen, Peter Fredericks, Benedetta Leuner, Robert Schwarcz

M3 . Evidence for Both an Alpha7 Nicotinic and a Glycine B Receptor Mediation of Working Memory in the Rat Sarah Vunck, Michelle Pershing, Dave Bortz, Christinna Jorgensen, Robert Schwarcz, John P . Bruno

M4 . Attenuation of Metabolic Consequences from Atypical Antipsychotic Use in Schizophrenia: Folate Supplementation and the Role of Pharmacogenomics Vicki Ellingrod, Tyler Grove, Stephan F . Taylor, Kyle Burghardt

M5 . Weight Gain Independent, Centrally-mediated Effects of Olanzapine on Glucose Metabolism Margaret Hahn, Araba Chintoh, Gary Remington, Celine Teo, Steve W . Mann, Paul Fletcher, Jose Nobrega, Adria Giacca

163

ACNP Annual Meeting Book 2013 rev8.indd 163 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M6 . Disturbances of Tryptophan Metabolism and Risk of Depression in Hcv Patients Treated with Ifn-alpha Gregory F . Oxenkrug, Waldemar Turski, Wojciech Zgrajka, Joel Weinstock, Paul Summergrad

M7 . Sensitive Biomarkers of Metabolic Risk in Children Treated with Antipsychotics Ginger E . Nicol, Michael D . Yingling, Julia A . Schweiger, John W . Newcomer

M8 . Increased Rate of Chiari I Malformation in Children of Depressed Mothers Treated with Selective Serotonin Reuptake Inhibitors during Pregnancy Rebecca Knickmeyer, Samantha Meltzer-Brody, Sandra Woolson, Robert M . Hamer, Keith Smith, Kenneth Lury, John Gilmore

M9 . Olanzapine and Diet Affect CNS and Peripheral Metabolic Outcomes in a Non-human Primate Cynthia L . Bethea, Oleg Varlamov, Paul Kievit, Arubala P . Reddy, Charles T . Roberts

M10 . The Risk of Switch to Mania in Patients with Bipolar Disorder during Treatment with Antidepressants Alone and in Combination with a Mood Stabilizer Mikael Landén, Michael E . Thase

M11. Do α2-containing Nicotinic Acetylcholine Receptors Play a Role in Baseline and Nicotine-modulated Behaviors in Mice? Shahrdad Lotfipour, Janet Byun, Prescott Leach, Christie D . Fowler, Niall Murphy, Paul Kenny, Thomas J . Gould, Jim Boulter

M12 . Intraaccumbal Administration of Zeta Inhibitory Peptide (ZIP) Erases Drug Memory and Prevents Cocaine Reinstatement Lisa A . Briand, Chris Pierce

164

ACNP Annual Meeting Book 2013 rev8.indd 164 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M13. Cocaine Sensitivity Is Regulated by Striatal α5-containing Nicotinic Acetylcholine Receptors Christie D . Fowler, Brian Lee, Paul Kenny

M14 . Exome Sequencing in Rhesus Macaques Exhibiting Individual Differences in Aggression Carlos Driscoll, Kevin Blackistone, Jessica Clemente, Stephen Lindell, Stephen Suomi, Christina Barr

M15 . Conditional Elimination of the Interleukin-1 Receptor for the Study of the Impact of Inflammatory Cytokines on Brain and Behavior Matthew J . Robson, Chong-Bin Zhu, Kathryn M . Lindler, Nicole Baganz, Jane Wright, William Hewlett, Randy D . Blakely

M16 . Genes Harboring Addiction-related Variants Alter Dose-response Relationships for Stimulant Reward George Uhl, Frank S . Hall, Barbara Ranscht, Noriko Uetani, Jana Drgonova

M17 . Mother’s 5-HTTLPR Genotype X Infant’s Genotype Interact to Affect Mother-infant Interactions and Developmental Outcomes: Aggression, Anxiety, and Social Behavior Patrick O’Connell, Jenna Jackson, Stephen Lindell, Andrea Sorenson, Courtney Lindell, Melanie L . Schwandt, Stephen J . Suomi, Christina Barr, J . Dee Higley

M18 . Genome-wide Mapping of Complex Psychiatric Traits in Commercially Available Outbred Mice Clarissa C . Parker, Natalia M . Gonzales, Abraham A . Palmer

M19 . A Cross-species Investigation into the Role of Lhx6 in Cortical Inhibitory Circuitry Disturbances in Schizophrenia David W . Volk, Jessica R . Edelson, David A . Lewis

165

ACNP Annual Meeting Book 2013 rev8.indd 165 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M20 . DNA Methylation Network Dysregulation Expressed in Lymphocytes of Schizophrenic Patients Robert C . Smith, James Auta, Henry Sershen, Abel Lajtha, Sylvia Boules, Patricia L . Gerbarg, , Richard Brown , John M . Davis, Alessandro Guidotti

M21. Region-specific Alteration of Wnt Signaling in Bipolar Disorders Ghanshyam N . Pandey, Xinguo Ren, Hooriyah S . Rizavi, Yogesh Dwivedi

M22 . An Integrated-omics Approach to Understanding Psychoneuroimmunology Crosstalk Anil G . Jegga, Gayle Wittenberg, Xiang Yao, Lynn Yieh, Guang Chen, Vaibhav Narayan

M23 . Key Role of Decreased Vesicular Uptake in the Profound Myocardial Norepinephrine Depletion in Parkinson’s Disease Irwin J . Kopin, Patti Sullivan, David S . Goldstein

M24 . Chondroitin Sulfate Proteoglycan Abnormalities in Schizophrenic and Bipolar Disorder Subjects Harry Pantazopoulos, Florian Jaquet, Doel Ghosh, Anna Wallin, Bruce Caterson, Sabina Berretta

M25 . CSF and Plasma Interleukin-6 and Personality Traits in Suicide Attempters Jussi Jokinen, Josef Isung, Shahin Aeinehband, Fariborz Mobarrez, Peter Nordström, Bo Runeson, Fredrik Piehl, Marie Åsberg

M26 . Body Mass Index Affects Brain Dopaminergic Signaling After Glucose Ingestion Gene-Jack Wang, Nora D . Volkow, Dardo Tomasi, Antonio Convit, Christopher Wong, Elena Shumay, Joanna Fowler

166

ACNP Annual Meeting Book 2013 rev8.indd 166 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M27 . Abnormal Bioenergetics in Schizophrenia and Bipolar Disorders Studied by Dynamic 31P-MRS Fei Du, Cagri Yuksel, Scott Lukas, Bruce Cohen, Dost Ongur

M28 . Expression of CHRNA7 and the Chimeric Gene CHRFAM7A are Altered in the Postmortem Dorsolateral Prefrontal Cortex in Major Psychiatric Disorders Yasuto Kunii, Thomas M . Hyde, Amy Deep-Soboslay, Daniel R . Weinberger, Joel E . Kleinman, Barbara Lipska

M29 . Neural Correlates of Response Inhibition and Concentration of Glutamate/GABA in the Anterior Cingulate Cortex in Borderline Personality Disorder Annegret Krause-Utz, Julia van Eijk, Sylvia Cackowski, Traute Demirakca, Christian Schmahl, Gabriele Ende

M30 . Measuring the Effects of Acute Alcohol Infusion on Human Brain Metabolites: An MR Spectroscopy Study Claire Mann, Caitlin Durkee, Erica N . Grodin, Vijay A . Ramchandani, Reza Momenan

M31 . Morphological Alterations in Layer 3 Pyramidal Cells of the Dorsolateral Prefrontal Cortex in Schizophrenia: Role of Actin Cytoskeleton Dibyadeep Datta, Dominique Arion, David A . Lewis

M32 . Impact of DOPA Decarboxylase Genetic Variation on Its In Vivo Enzymatic Activity in Humans Daniel P . Eisenberg, Joseph C . Masdeu, Philip Kohn, Bhaskar S . Kolachana, Daniel R . Weinberger, Karen F . Berman

M33 . Synaptophysin, vGlut1, Mitofusin2 and Calcineurin Protein Levels in the Anterior Cingulate Cortex in Schizophrenia: Relation to Treatment and Treatment Response Rosalinda C . Roberts, Keri A . Barksdale, Adrienne C . Lahti

167

ACNP Annual Meeting Book 2013 rev8.indd 167 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M34 . Neurochemistry of First-hospitalization Manic Youth Marguerite R . Schneider, Tessa Benanzer, Wade Weber, Luis R . Patino Duran, Jeffrey Strawn, Jeffrey Welge, Caleb Adler, Strakowski Stephen, Melissa DelBello

M35 . Cortical Thickness in Individuals with Subclinical and Clinical Psychotic Symptoms Iris Sommer, Marieke Begemann, Remko van Lutterveld

M36 . Brain Activation to Natural Cues and Drug Cues and Dopamine Receptors in Cocaine Addicts Dardo Tomasi, Gene-Jack Wang, Elisabeth Caparelli, Nora D . Volkow

M37. Brain-derived Neurotrophic Factor and Deficient Amygdala Habituation in Borderline Personality Disorder: A Research Domain Criteria Imaging Genetics Study M . Mercedes Perez-Rodriguez, Antonia S . New, Kim Goldstein, Qiaoping Yuan, Zhifeng Zhou, Colin A . Hodgkinson, David Goldman, Larry Siever, Erin Hazlett

M38 . The Spatiotempotal Organization of Subcortical Anatomy in Human Development Armin Raznahan, Shaw Phillip, Clasen Liv, Deanna Greenstein, Jason Lerch, Mallar Chakravarty, Jay Giedd

M39 . Parametric Modulation of Neural Activity during Face Emotion Processing in Unaffected Youth at Familial Risk for Bipolar Disorder Melissa A . Brotman, Christen M . Deveney, Laura A . Thomas, Kendra Hinton, Jennifer Yi, Daniel S . Pine, Ellen Leibenluft

168

ACNP Annual Meeting Book 2013 rev8.indd 168 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M40 . Non-smoking Chronic Alcoholics Following Withdrawal Show Increased Cerebral Blood Flow and Altered Brain Docosahexaenoic (DHA) Metabolism on Partial Volume Error-corrected PET John C . Umhau, Weiyin Zhou, Shantalaxmi Thada, Peter Herscovitch, Norman Salem Jr,, Joseph R . Hibbeln, Jussi Hirvonen, Stanley Rapoport

M41 . Developmental Differences in Resting-state Network Connectivity in Autism Spectrum Disorder Dienke Bos, Tamar van Raalten, Anouk Smits, Janna van Belle, Serge Rombouts, Sarah Durston

M42 . Abnormal Functional Brain Network Organization for Visual Processing of Non-appearance Stimuli in Body Dysmorphic Disorder Teena Moody, Jesse Brown, Alex D . Leow, Liang Zhan, Jamie Feusner

M43 . Reward-based Spatial Learning in Unmedicated Adults with Obsessive- compulsive Disorder Rachel Marsh, Yuankai Huo, Ge Lui, Mark J . Packard, Gregory Z . Tau, XueJun Hao, Bradley S . Peterson, Zhishun Wang, Helen Blair . Simpson

M44 . Alterations of Cortical Thickness Related to Clinical Severity, but Not the Untreated Disease Duration in Schizophrenia Su Lui, Yuan Xiao, Li Yao, Yong He, Qiyong Gong

M45 . Differential Effects of Estrogen Hormone Therapy on CA1 Hippocampal Subfield Volume Change Over a 2-Year Observation Period in Postmenopausal Women at Risk for Alzheimer’s Disease: Conjugated Equine Estrogen Versus Estradiol Heather Kenna, Kristen Sheau, Tonita Wroolie, Ryan G . Kelley, Katherine Williams, Allan Reiss, Natalie Rasgon

169

ACNP Annual Meeting Book 2013 rev8.indd 169 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M46 . Effects of Serotonin Depletion on Punishment Processing in the Orbito Frontal and Anterior Cingulate Cortices in Healthy Women Katrin Helmbold, Michael Zvyagintsev, Brigitte Dahmen, Sarah Bubenzer, Tilman J . Gaber, Molly Crockett, Martin Klasen, Cristina L . Sanchez, Albert Eisert, Kerstin Konrad, Ute Habel, Beate Herpertz-Dahlmann, Florian Daniel . Zepf

M47 . Serotonin and Affect Regulation in Humans: A Combined 5-HT1A [11C] CUMI-101 PET and FMRI Study Sudhakar Selvaraj, Elias Mouchlianitis, Paul Faulkner, Federico Turkheimer, Philip Cowen, Jonathan Roiser, Oliver Howes

M48 . Dysregulated Neural Response to Social Evaluation in Bullied Adolescents: A Potential Mechanism that Promotes Risk for Social Anxiety Disorder Johanna M . Jarcho, Megan Davis, Ellen Leibenluft, Nathan Fox, Tomer Shechner, Daniel S . Pine, Eric Nelson

M49 . Prenatal Exposure to Maternal Infection Alters Neonatal Brain Structure John H . Gilmore, Mark Connelly, Philip Nielsen, Sandra Woolson, Robert Hamer, Rebecca Knickmeyer, Sarah Short, Xiujuan Geng

M50 . Memory Retrieval of Addiction-related Images Induce Greater Insular Activation as Revealed by an fMRI Based Delayed Matching to Sample Task Amy Janes, Robert Ross, Stacey Farmer, Blaise Frederick, Lisa Nickerson, Scott Lukas, Chantal Stern

M51 . Nicotinic Acetylcholine Receptor Density as a Predictor of Quitting Smoking with Treatment Arthur Brody, Alexey Mukhin, Michael Mamoun, Trinh Luu, Meaghan Neary, Lidia Liang, Jennifer Shieh, Catherine A . Sugar, Jed Rose, Mark Mandelkern

170

ACNP Annual Meeting Book 2013 rev8.indd 170 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M52 . Striatal Activation Induced by mGluR2 Positive Allosteric Modulation Correlates with Negative Symptom Reduction in Schizophrenia Daniel Wolf, Kosha Ruparel, Bruce Turetsky, Christian Kohler, Theodore D . Satterthwaite, Mark Elliott, Mary March, Alan Cross, Mark Smith, Stephen R . Zukin, Ruben C . Gur, Raquel E . Gur

M53 . Olfactory Functional Magnetic Resonance Imaging (fMRI) in Combat Veterans: Brain Reactivity to Trauma-related Odor Cues Bernadette M . Cortese, Qing X . Yang, Ron Acierno, Kimberly Leslie, Thomas W . Uhde

M54. Methylphenidate and Brain Activity in a Reward/Conflict Paradigm Iliyian Ivanov, Xun Liu, Suzanne Clerkin, Kurt Schulz, Jin Fan, Jeffrey Newcorn

M55 . Being Liked Increases Social Motivation, but Not in Depressed Individuals: A µ-Opioid Positron Emission Tomography (PET) Study of the Ventral Striatum David T . Hsu, Benjamin J . Sanford, Kortni Meyers, Kathleen E . Hazlett, Tiffany Love, Brian J . Mickey, Scott Langenecker, Jon-Kar Zubieta

M56 . Prediction Error Reactivity and Its Relation to Reward Expectancy Are Altered in Major Depressive Disorder: Preliminary Findings from the EMBARC Study Tsafrir Greenberg, Henry Chase, Jorge Almeida, Richelle Stiffler, Carlos R . Zevallos, Haris Aslam, Thilo Deckersbach, Sarah Weyandt, Crystal Cooper, Benji T . Kurian, Patrick J . McGrath, Maurizio Fava, Myrna M . Weissman, Ramin V . Parsey, Madhukar Trivedi, Mary L . Phillips

171

ACNP Annual Meeting Book 2013 rev8.indd 171 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M57 . In Vivo Neurochemical Effects of Ketamine in OCD: A Pilot Proton Magnetic Resonance Spectroscopy Time-course Study of Cortical Glutamate-glutamine and GABA Carolyn I . Rodriguez, Lawrence S . Kegeles, Amanda Levinson, Todd Ogden, Xiangling Mao, Matthew Milak, Dikoma Shungu, Helen Blair . Simpson

M58 . Subcortical Biophysical Abnormalities in Patients with Mood Disorders Anand Kumar, Shaolin Yang, Olusola Ajilore, Minjie Wu, Rebecca Charlton, Jamie Cohen, Melissa Lamar

M59 . Accounting for Dynamic Fluctuations across Time When Examining Test-retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study Henry Chase, Jay Fournier, Tsafrir Greenberg, Jorge Almeida, Richelle Stiffler, Crystal Cooper, Thilo Deckersbach, Sarah Weyandt, Philips Adams, Maurizio Fava, Patrick J . McGrath, Myrna M . Weissman, Ramin V . Parsey, Benji T . Kurian, Madhukar Trivedi, Mary L . Phillips

M60 . Increased Serotonin Transporter Binding Is Associated with Depression Development during Interferon-alpha Exposure in Humans Francis E . Lotrich, Rajesh Narendran

M61 . Naloxone-reversible Modulation of Pain Circuitry by Left Prefrontal Repetitive Transcranial Magnetic Stimulation Joseph J . Taylor, Jeffrey J . Borckardt, Melanie Canterberry, Xingbao Li, Colleen A . Hanlon, Truman Brown, Mark S . George

M62 . Abnormalities of Two Distributed Brain Networks in Major Depression Alexander Petti, Daniel Kessler, Mary Heitzeg, Scott Langenecker, Tiffany Love, Kenneth Silk, Jon-Kar Zubieta, Chandra Sripada, Brian J . Mickey

172

ACNP Annual Meeting Book 2013 rev8.indd 172 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M63 . Contrasting Gray Matter Volume Biomarkers by Diagnosis and Biotype Across Schizophrenia - Bipolar Disorder Psychosis Dimension Elena I . Ivleva, Anup S . Bidesi , Brett A . Clementz, Matcheri S . Keshavan, Shashwath A . Meda, Godfrey D . Pearlson, John A . Sweeney, Gunvant K . Thaker, Carol A . Tamminga

M64 . Neuroimaging Abnormalities in Borderline Personality Disorder: MRI, MRS, fMRI and DTI Findings Courtney McKenzie, Henry Nasrallah

M65 . Cerebral Blood Flow Differences in Major Depressive Disorder Using Arterial Spin Labeling: Preliminary Results from the EMBARC Study Crystal Cooper, Hanzhang Lu, Jorge Almeida, Henry Chase, Thomas Carmody, Maurizio Fava, Tony Jin, Benji T . Kurian, Patrick J . McGrath, Melvin McInnis, Maria Oquendo, Ramin V . Parsey, Myrna M . Weissman, Sarah Weyandt, Mary L . Phillips, Madhukar Trivedi

M66 . Exposure to Regional Anesthesia during Labor and Delivery and Its Effect on Neonatal Brain Morphology Marisa N . Spann, Ravi Bansal, Tove Rosen, Bradley S . Peterson

M67 . Abnormal Deactivation of Ventrolateral Prefrontal Cortex during Emotion Processing in Youth with Bipolar Disorder: Effects of Medication and Mood State Danella Hafeman, Genna Bebko, Michele A . Bertocci, Lisa Bonar, Susan Perlman, Vaibhav Diwadkar, Robert Kowatch, Boris Birmaher, Sarah Horwitz, Eugene Arnold, Mary Fristad, Eric Youngstrom, Robert Findling, Thomas Frazier, Wayne Drevets, Mary L . Phillips

M68 . Kappa Opioid Receptor Systems and Threat, Loss, and Reward Responsiveness Robert Pietrzak, Yiyun Huang, Mika Naganawa, Stefani Corsi- Travali, Richard E . Carson, Alexander Neumeister

173

ACNP Annual Meeting Book 2013 rev8.indd 173 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M69 . Pallidial Resting State Connectivity in Bipolar Disorder: Implications for Differences between Manic and Depressive States Amit Anand, Harish Karne

M70 . Hippocampus NAA as Biological Marker of Anhedonia in PTSD and Trauma-exposed Adults: Preliminary 1H-MRS Findings Isabelle I . Rosso, David I . Crowley, Lily I . Preer, Marisa Silveri, J . Eric Jensen

M71 . Equal HIV Risk Reduction with Buprenorphine-naloxone or Methadone George E . Woody, Douglas Bruce, P . Todd Korthuis, Sumedha Chhatre, Maureen Hillhouse, James L . Sorensen, Andrew J . Saxon, Petra Jacobs, David S . Metzger, Sabrina Poole, Walter Ling

M72 . Excellent Test-retest Reliability of Cerebral Blood Flow in Healthy Individuals Measured with Arterial Spin Labeling: EMBARC Study Preliminary Results Jorge Almeida, Hanzhang Lu, Henry Chase, Jay Fournier, Crystal Cooper, Thilo Deckersbach, Mohammad Zia, Maurizio Fava, Benji T . Kurian, Patrick J . McGrath, Maria Oquendo, Melvin McInnis, Ramin V . Parsey, Myrna M . Weissman, Madhukar Trivedi, Mary L . Phillips

M73 . Cortico-striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-high Risk for Psychosis Investigated with 1H MRS Camilo de la Fuente, Pablo León-Ortiz, Xiangling Mao, Francisco Reyes-Madrigal, Oscar Rodríguez-Mayoral, Patricia Alvarado- Alanis, Rodolfo Solis-Vivanco, Rafael Favila, Ariel Graff, Dikoma Shungu

M74 . Cortical Thickness as a Contributor to Abnormal Oscillations in Schizophrenia? José Cañive, Yu-Han Chen, Breannan Howell, Cassandra Wootton, Michael Hunter, Mingxiong Huang , Gregory A . Miller, J Christopher Edgar

174

ACNP Annual Meeting Book 2013 rev8.indd 174 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M75 . Lithium and Brain Glucose Metabolism in Patients with Bipolar-I Disorder Abesh Bhattacharjee, Monte S . Buchsbaum, Michael J . McCarthy, Anna DeModena, John Kelsoe

M76 . FDG-PET Scans in Patients with Good and Poor Prognosis Schizophrenia Monte S . Buchsbaum, Marie-Cecile Bralet, Serge Mitelman

M77 . Tau PET Imaging of Neurocognitive Disorders Using Newly Developed Tau Ligand [11C]PBB3 Tetsuya Suhara, Hitoshi Shimada, Masahiro Maruyama, Hitoshi Shinotoh, Bin Ji, Jun Maeda, Harumasa Takano, Naruhiko Sahara, Ming-Rong Zhang, Hiroshi Ito, Makoto Higuchi

M78 . Food Reward Circuitry Hyperactivation, Acylated Ghrelin, and Hedonic Capacity in Women with Remitted Major Depressive Disorder Laura M . Holsen, Kara Christensen, Priyanka Moondra, Anne A . Klibanski, Jill M . Goldstein

M79 . Brain Injury in Battered Women and Its Relationship to Microstructural White Matter Alterations: A Diffusion Tensor Imaging Study Eve Valera, Alan Francis, Nikos Makris, Zhi Li, Ezra Wegbreit, Margaret O’Connor

M80 . Examining Fronto-striatal Circuit Structure and Function in Treatment- naïve Children and Adolescents with Obsessive Compulsive Disorder Stephanie Ameis, Colleen Dockstader, Don Mabbott, Sandra Mendlowitz, Reva Schachter, Clara Tam, Fang Liu, Elysa Widjaja, Russell Schachar, Paul D . Arnold

175

ACNP Annual Meeting Book 2013 rev8.indd 175 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M81 . Multimodal Brain Connectivity Analysis Using Functional-by-Structural Hierarchical Mapping Olusola Ajilore, Liang Zhan, Johnson Jonaris, Gad Elkarim, Aifeng Zhang, Jamie Feusner, Shaolin Yang, Paul Thompson, Anand Kumar, Alex D . Leow

M82 . Modulation of Resting Brain Cerebral Blood Flow by the GABA B Agonist, Baclofen: A Longitudinal Perfusion fMRI Study in Marijuana Dependent Treatment Seeking Individuals Kanchana Jagannathan, Reagan R . Wetherill, Julian Bender, Barbara Johnson, Joel Mumma, Kyle Kampman, Charles P . O’Brien, Anna Rose Childress, Teresa R . Franklin, Kimberly A . Young, Jesse J . Suh

M83. Chemokine-specific Relationships to AD Biomarkers in CSF in Healthy Older Adults Nunzio Pomara, Davide Bruno, Chelsea Reichert, Jay Nierenberg, John J . Sidtis, Frank T . Martiniuk, Henrik Zetterberg, Kaj Blennow

M84 . Varenicline Effects on Neural Reward Processing among Non-treatment- seeking Alcohol Dependent Individuals Joseph P . Schacht, Raymond F . Anton, Patrick Randall, Xingbao Li, Scott Henderson, Hugh Myrick

M85 . PACAP Receptor (ADCYAP1R1) Genotype Associates with Fear Responses in the Amygdala and Hippocampus in Highly-traumatized Civilians Kerry J . Ressler, Jennifer Stevens, Lynn Almli, Negar Fani, David Gutman, Bekh Bradley, Seth D . Norrholm, Ebony Glover, Tanja Jovanovic

M86 . Association Between Primary Insomnia and Major Depression: Distinct Entities or Spectrum Disorders? Ruth Benca, Brady Riedner, Michael Goldstein, Lihong Cui, Anja Schmitz, Jihui Zhang, Kathleen Merikangas

176

ACNP Annual Meeting Book 2013 rev8.indd 176 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M87 . Neuroprotective Kynurenine Pathway Metabolites Are Associated with Larger Hippocampal and Amygdalar Volumes in Patients with Major Depressive Disorder Jonathan Savitz, Wayne C . Drevets, Teresa Victor, Jerzy Bodurka, Kent Teague, Robert Dantzer

M88 . Evaluating the Impact of Early Life Stress on DLPFC Functional Connectivity in Healthy Adults: Informing Future Studies of Transcranial Magnetic Stimulation Noah S . Philip, Thomas R . Valentine, Audrey R . Tyrka, Lawrence H . Price, Lawrence H . Sweet, Linda L . Carpenter

M89 . Persistent Cannabis Use During Adolescence Is Linked to Thinner Hippocampal Cortex in Late Life After Decades of Abstinence Alison Burggren, Brian Renner, Edythe D . London

M90 . Maternal Depression Affects Brain Responses to Baby Cry James E . Swain, S Ho, Katherine Rosenblum, Maria Muzik

M91 . Socially Rewarding Stimuli and Anhedonia Severity Among Depressed Adolescents Vilma Gabbay, Sarah E . Henderson, Ana Vallejo, Rachel G . Klein

M92 . Sleep Duration Contributes to Cortico-limbic Functional Connectivity, Emotional Functioning, & Psychological Health William Killgore

M93 . A Longitudinal MR Spectroscopy Study of the Anterior Cingulate Cortex and Hippocampus Before and After Antipsychotic Treatment in Patients with Schizophrenia Meredith A . Reid, Nina V . Kraguljac, David M . White, Jan A . den Hollander, Adrienne C . Lahti

177

ACNP Annual Meeting Book 2013 rev8.indd 177 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M94 . Glutamate Levels Determined with Magnetic Resonance Spectroscopy (MRS) in the Medial Prefrontal Cortex of Patients with Psychosis as Compared to Healthy Volunteers Stefano Marenco, Yan Zhang, Anna Slagle, Susie Kuo, Christian Meyer, Adhiraaj Sethi, Alan S . Barnett, Jun Shen, Daniel R . Weinberger, Karen F . Berman

M95 . Longitudinal Effects of Antipsychotic Treatment on Functional Connectivity of the Striatum in Patients with First-episode Psychosis Deepak Sarpal, Delbert G . Robinson, Todd Lencz, Toshikazu Ikuta, Miklos Argyelan, Katherine H . Karlsgodt, Juan A . Gallego, John Kane, Philip R . Szeszko, Anil Malhotra

M96 . Multimodal Analysis of Brain Networks Structural and Functional Connectivity Changes in Non-medicated Late-life Depression Reza Tadayon-Nejad, Shaolin Yang, Anand Kumar, Olusola Ajilore

M97 . Neural Response during Indirect and Direct Processing of Emotional Faces Predicts Improvement Following Cognitive Behavioral Therapy in Generalized Social Anxiety Disorder Heide Klumpp, Daniel Fitzgerald, David Post, K . Luan Phan

M98 . The Effect of Electroconvulsive Therapy on Emotional Processing in Major Depressive Disorder: A Neuroimaging Study Miklos Argyelan, Styliani Kaliora, Harlington Hanna, Toshikazu Ikuta, Peter B . Kingsley, Deepak Sarpal, Philip R . Szeszko, Anil Malhotra, Georgios Petrides

M99 . Categories and Dimensions of Anxiety and Depression in the Resting fMRI Signal Desmond Oathes, Alan F . Schatzberg, Amit Etkin

M100 . Changes in Cortical Thickness in Children of Parents with Bipolar Disorder Roberto Sassi, Lindsay Hanford, Luciano Minuzzi, Geoffrey Hall

178

ACNP Annual Meeting Book 2013 rev8.indd 178 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M101 . Myelin and Axon Abnormalities in Schizophrenia and Bipolar Disorder Measured with Magnetization Transfer Ratio and Diffusion Tensor Spectroscopy Ann K . Shinn, Fei Du, Thida Thida, Bruce M . Cohen, Dost Ongur, Kathryn E . Lewandowski

M102. Brain White Matter Development Is Associated with a Human-specific Haplotype Increasing the Synthesis of Long Chain Fatty Acids Bart D . Peters, Aristotle N . Voineskos, Philip R . Szeszko, Tristram Lett, Pamela DeRosse, Saurav Guha, Toshikazu Ikuta, Daniel Felsky, Majnu John, James L . Kennedy, Anil Malhotra

M103 . Ketamine Reduces Left Nucleus Accumbens Volume within 24 Hours of Treatment of Major Depressive Disorder Patients Chadi Abdallah, Andrea Jackowski, Ramiro Salas, Swapnil Gupta, João R Sato, Lee C . Chang, Xiangling Mao, Jeremy Coplan, Dikoma Shungu, Sanjay J . Mathew

M104 . Visual Hallucinations in Patients with Schizophrenia Are Associated with Visual Cortex Hyperconnectivity to Amygdala and Hippocampus Judith M . Ford, Vanessa Palzes, Brian J . Roach, Steven Potkin, Theo Van Erp, Jessica Turner, James Voyvodic, Bryon Mueller, Vincent Calhoun, Ayse Belger, Jatin Vaidya, Adrian Preda, FBIRN, Daniel H . Mathalon

M105 . Baclofen Reduces Resting Blood Flow, and Correlations with Limbic Cue Reactivity, in the Ventral Striatum of Cocaine-dependent Men Kimberly A . Young, Teresa R . Franklin, Yin Li, Kanchana Jagannathan, Reagan R . Wetherill, Jesse J . Suh, Zachary D . Singer, Samuel E . Davidson, Zachary A . Monge, Charles P . O’Brien, Anna R . Childress

179

ACNP Annual Meeting Book 2013 rev8.indd 179 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M106 . “Trouble Waiting to Happen?” Heightened Striatal Resting Perfusion in Cocaine Patients Predicts Limbic Vulnerability to Drug Cues Anna R . Childress, Kimberly A . Young, Teresa R . Franklin, Kanchana Jagannathan, Yin Li, Jesse J . Suh, Ronald Ehrman, Ze Wang, Zachary D . Singer, Zachary A . Monge, Daniel D . Langleben, Charles P . O’Brien

M107 . Test-retest Reliability in Extinction Recall: A Neuroimaging Study of Healthy Adults Jennifer Britton, Carolyn Spiro, Tomer Shechner, Gang Chen, Daniel S . Pine

M108 . Hippocampal and Amigdala Volume Increase in Lithium-treated Bipolar I Patients Compared with Unmedicated Patients and Healthy Subjects Carlos Lopez-Jaramillo, Cristian David . Vargas Upegui, Juan Palacio, Gabriel Castrillon, Eduard Vieta, Carrie Bearden, Scott C . Fears, Nelson Freimer, Javier I . Escobar

M109 . Greater Translocator Protein (TSPO) Distribution Volume During Major Depressive Episodes of Major Depressive Disorder Jeffrey H . Meyer, Elaine Setiawan, Romina Mizrahi, Pablo Rusjan, Alan A . Wilson, Sylvain Houle

M110 . Distinct Patterns of Functional Connectivity in Patients with Childhood- onset Schizophrenia, Their Unaffected Siblings, and Healthy Controls Rebecca A . Berman, Harrison McAdams, Deanna Greenstein, Nitin Gogtay, Judith L . Rapoport

M111 . Alterations in Amygdala Functional Circuitry as a Neural Marker of Emotion Dysregulation in Young Children Amy K . Roy, Rachel G . Klein, Clare Kelly, Francisco Xavier Castellanos

180

ACNP Annual Meeting Book 2013 rev8.indd 180 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M112 . Fear-potentiated Startle during Extinction Is Associated with Alterations in White Matter Connectivity Negar Fani, Tricia King, Amita Srivastava, Ryan Brewster, Seth D . Norrholm, Kerry J . Ressler, Tanja Jovanovic

M113 . Diffuse Tensor Imaging-based Brain Signatures Accurately Discriminate a Functional Pain from Health: Examining Central Mechanisms in Visceral Pain Jennifer Labus, John D . Van Horn, Carinna Torgerson, Cody Ashe- McNalley, Andrei Irimia, Micah C . Chambers, Arpana Gupta, Kirsten Tillisch, Emeran A . Mayer

M114 . Clinical and Neuropsychological Correlates of DTI-derived Connectome Structure in Euthymic Bipolar I Disorder Alex D . Leow, Olusola Ajilore, Johnson Gadelkarim, Jamie Feusner, Teena Moody, Anand Kumar, Lori Altshuler

M115 . Intrinsic Hippocampal Activity as a Biomarker for Cognition and Symptoms in Schizophrenia Jason Tregellas, Jason Smucny, Josette Harris, Ann Olincy, Robert Freedman

M116 . Morphometric and Volumetric Subcortical Differences in Alcoholics with and without Comorbid Drug Use Disorders Erica N . Grodin, Reza Momenan

M117 . A Preliminary Comparison of Methodologies for Quantifying Brain Gamma-aminobutyric-acid Concentrations In Vivo Using Proton Magnetic Resonance Spectroscopy James J . Prisciandaro, Andrew Prescot, Joseph P . Schacht, Raymond F . Anton, Perry F . Renshaw, Truman Brown

M118 . Prefrontal Cortex Activation during Safety Signal Processing in Generalized Anxiety Disorder as a Correlate of Overgeneralization Katja Beesdo-Baum, Kevin Hilbert, Ulrike Lueken

181

ACNP Annual Meeting Book 2013 rev8.indd 181 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M119 . Longitudinal Change in Amyloid Deposition, Measured by PET and 11-C-PiB, in Older Adults Susan M . Resnick, Murat Bilgel, Yang An, Madhav Thambisetty, Michael Kraut, Yun Zhou, Dean F . Wong

M120. Global Resting-state fMRI Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-compulsive Disorder Alan Anticevic, Sien Hu, Sheng Zhang, Patricia Gruner, Aleksandar Savic, Eileen Billingslea, Suzanne Wasylink, Grega Repovs, Michael Cole, Sarah Bednarski, John H . Krystal, Michael H . Bloch, Chiang- shan Ray Li, Christopher Pittenger

M121 . Examining Domains of Borderline Personality Disorder Using MRI S . Charles Schulz, Kathryn R . Cullen, Bryon Mueller, Alaa Houri, Lizz Coykendall, Kelvin O . Lim

M122 . The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue Yu-Shin Ding, Janice Hwang, Catherine Yeckel, Jean-Dominique Gallezot, Renata Belfort-Deaguiar, Devrim Ersahin, Richard Carson, Robert Sherwin

M123 . Measuring Smoking-induced Extrastriatal Dopamine Release: A [11C] FLB-457 PET Study Victoria C . Wing, Doris E . Payer, Tony P . George, Isabelle Boileau

M124 . A Longitudinal Mentoring and Training Program for Psychiatric Scientists David J . Kupfer, Alan F . Schatzberg, Leslie Dunn, Melissa DeRosier, Helena Kraemer, Andrea Schneider

M125 . EEG and fMRI Findings of Reduced Neural Synchronization during Visual Integration in Schizophrenia Jonathan K . Wynn, Junghee Lee, William Horan, Brian J . Roach, Alexander S . Korb, Judith M . Ford, Michael F . Green

182

ACNP Annual Meeting Book 2013 rev8.indd 182 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M126 . Translating Functional Neuroimaging into Clinical Care by Modeling Normative Variance in Cognition and Neural Function: Insights from the Cognitive Connectome George A . James, Jennifer S . Fausett, Jennifer L . Gess, Tonisha Kearney-Ramos, Clinton D . Kilts

M127 . Low Fractional Anisotropy of the Right Ventral Anterior Cingulate Related to Depressive Symptoms in Atherosclerotic Vascular Disease Kelly Rowe Bijanki, Joy Matsui, Helen S . Mayberg, Vincent A . Magnotta, Stephan Arndt, Hans Johnson, Peggy C . Nopoulos, Sergio Paradiso, Laurie M . McCormick, Jess Fiedorowicz, Eric Epping, David J . Moser

M128 . Moderate and Heavy Marijuana Use: Differences in Whole-brain Functional Network Structure that Underlie Iowa Gambling Task Performance Malaak N . Moussa, Linda Porrino

M129 . Executive Control Network Dysfunction in Major Depressive Disorder Patients with Early Life Stress: Preliminary Findings from the International Study to Predict Optimized Treatment in Depression Shefali Miller, Lisa McTeague, Anett Gyurak, Brian Patenaude, Leanne Williams, Amit Etkin

M130 . Striatal Dopamine Transporter Availability in Obsessive-compulsive Disorder: A Randomized Clinical Trial Using [Tc99m]-TRODAT-1 SPECT Marcelo Q . Hoexter, Darin Dougherty, Roseli G . Shavitt, Juliana Belo . Diniz, Thilo Deckersbach, Ming Chi, João R Sato, Geraldo Busatto, Euripedes C Miguel, Rodrigo Bressan

M131 . Cortico-amygdala Coupling as a Marker of Early Relapse Risk in Cocaine-addicted Individuals Meredith J . McHugh, Demers Catherine, Braud Jacquelyn, Betty J . Salmeron, Michael D . Devous, Richard W . Briggs, N . Robrina Walker, Bryon Adinoff, Elliot A . Stein

183

ACNP Annual Meeting Book 2013 rev8.indd 183 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M132 . Distinct Types of Sensory Prediction-error Signals in Schizophrenia with Active Psychosis Guillermo Horga, Anissa Abi-Dargham, Bradley S . Peterson

M133 . Poor Amygdalofrontal Connectivity Predicts Symptomatic Deterioration in At-risk Youth Daphne J . Holt, Emily A . Boeke, Avram J . Holmes, Garth Coombs, Amy Farabaugh, Maren Nyer, Maeve Ward, Susanna Crowell, Clair Cassiello, Angela Pisoni, Paola Pedrelli, Randy L . Buckner, Maurizio Fava

M134 . Ketamine-induced Changes in [11C]ABP688 Binding in Healthy Human Subjects Irina Esterlis, Nicole Dellagioia, Gerard Sanacora, Michael H . Bloch, Wendol Williams, Nabeel B . Nabulsi, John H . Krystal, Ramin V . Parsey, Richard E . Carson, Christine DeLorenzo

M135. Modafinil-induced Enhancement of Learning and Related fMRI Activation in Humans Reflects Individual Differences in Striatal Dopamine D2/D3 Receptor Availability Dara Ghahremani, Chelsea Roberson, Kenji Ishibashi, Golnaz Tabibnia, John Monterosso, Mark Mandelkern, Russell Poldrack, Edythe D . London

M136 . Social Impairment Is Related to Frontolimbic Structural Connectivity and Functional Activity in Autism Spectrum Disorders Kimberly A . Stigler, Tom A . Hummer, Yang Wang, Brenna C . McDonald, Andrew J . Saykin

M137 . Watching Cerebral Blood Flow Using fMRI Yunjie Tong, Blaise Frederick

184

ACNP Annual Meeting Book 2013 rev8.indd 184 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M138 . Early Life Stress and Intra- and Extra-amygdaloid Effective Connectivity Merida Grant, Kimberly Wood, Muriah Wheelock, Karthik R . Sreenivasan , Richard C . Shelton, David C . Knight, Gopikrishna Deshpande, Joshua R . Shuman

M139 . Buspirone Blocks Dopamine D3 Receptors in the Non-human Primate Brain when Administered Orally Sung Won Kim, Joanna Fowler, Phil Skolnick, Yeona Kang, Dohyun Kim, Nora D . Volkow

M140 . A Novel fMRI Task to Evaluate Social Reward and Social Threat Hypersensitivity in Depressed Mothers of Psychiatrically Ill Children Holly A . Swartz, Jill M . Cyranowski, Jennifer Silk, Marlissa Amole, Marigrace Ambrosia, Susan Murphy, Stacy Martin, Judith Morgan, Samuel Musselman, Erika E . Forbes

M141 . Disrupted Resting State Functional Connectivity in Unmedicated Patients with Schizophrenia Nina V . Kraguljac, David M . White, Jennifer Hadley, Adrienne C . Lahti

M142. Connectivity Deficits in Chronic Stress and Depression: Resilience, Reversibility, and Clinical Implications Andrew T . Drysdale, Benjamin Zebley, Ashley C . Chen, Amit Etkin, Marc J . Dubin, Conor Liston

M143 . Reduced Functional Connectivity in Executive Networks Associated with Cigarette and Alcohol Use Barbara Weiland, Amithrupa Sabbineni, Vincent Calhoun, Robert Welsh, Angela Bryan, Kent Hutchison

185

ACNP Annual Meeting Book 2013 rev8.indd 185 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M144 . Functional Connectivity of the Intraparietal Sulcus Is Affected by Both Copy Number and Sequence Variation of the Williams Syndrome Gene LIMK1 Michael D . Gregory, J . Shane . Kippenhan, Carolyn Mervis, Melanie Sottile, Jasmin Czarapata, Katherine Roe, Ena Xiao, Yunxia Tong, Bhaskar S . Kolachana, Daniel R . Weinberger, Venkata S . Mattay, Karen F . Berman

M145 . In Anorexia Nervosa, Anxious Rumination Is Grounded in the Activation of Abnormal Interoceptive Insular Cortex William K . Simmons, Kara Kerr, Scott Moseman, Jason Avery, Jennifer Dobson, Kaiping Burrows, Nancy Zucker

M146 . First HDAC PET Radiotracer Ready for Human Translation Changning Wang, Frederick A . Schroeder, Edward Holson, Stephen J . Haggarty, Jacob M . Hooker

M147 . Cannabis Use Is Associated with Nucleus Accumbens and Amygdala Abnormalities in Young Adult Recreational Users Jodi M . Gilman, John Kuster, Sang Lee, Myung Joo Lee, Byoung Woo Kim, Nikos Makris, Andre van der Kouwe, Anne Blood, Hans C . Breiter

M148. Predictive Classification of Pediatric Bipolar Disorder Morphometric Features of the Amygdala Benson Mwangi, Danielle Spiker, Giovana B . Zunta-Soares, Jair C . Soares

M149. Suicide Risk and Mood Regulation Deficits: Emotional Reactivity as an Exploratory Pathway Rebecca Bernert, Melanie Hom, Madeleine Goodkind, Kathy Peng, Desmond Oathes, Michelle Primeau, Amit Etkin

186

ACNP Annual Meeting Book 2013 rev8.indd 186 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M150 . Relation of Diet, Exercise, and Body Mass Index to a Brain Imaging Biomarker of Plaques and Tangles in Non-demented Middle-aged and Older Adults David A . Merrill, Prabha Siddarth, Cyrus A . Raji, Gary Small

M151 . A Twin Study Identifying the Origin of Abnormal Automatic Responses to Threat Related Stimuli in PTSD F . Caroline Davis, Michael B . VanElzakker, Lindsay K . Staples, Natasha B . Lasko, Scott Orr, Roger K . Pitman, Lisa M . Shin

M152 . Brain Morphology in Adolescents and Young Adults at High and Low Risk for Alcohol Dependence: Separating Cause and Consequence Shirley Y . Hill, Wang Shuhui, Howard Carter, Robert Terwillinger

M153. Unsupervised Identification of Population Patterns in High-dimensional Multimodal Neuroimaging Scans: A Data-driven Machine Learning Approach Benson Mwangi, Khader M . Hasan, Jair C . Soares

M154 . Electrophysiological and Anatomical Evidence for Two Distinct but Interacting Neural Circuit Abnormalities in the Auditory Cortex in Schizophrenia Yoji Hirano, Naoya Oribe, Shigenobu Kanba, Toshiaki Onitsuka, Taiga Hosokawa, Martha Shenton, Robert W . McCarley, Kevin M . Spencer

M155 . Dopaminergic Activity and Altered Insula Response to Sweet Taste Processing in Anorexia Nervosa Ursula F . Bailer, Julie L . Fudge, Julie C . Price, Carolyn C . Meltzer, Angela Wagner, Chester A . Mathis, Walter Kaye

M156 . Reduced Prefrontal Gamma Band Power in Patients with Schizophrenia Studied with MEG during Working Memory Dani Rubinstein, Daniel P . Eisenberg, Frederick W . Carver, Daniel R . Weinberger, Richard Coppola, Karen F . Berman

187

ACNP Annual Meeting Book 2013 rev8.indd 187 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M157 . Resting State Functional Connectivity of the Habenula as a Biomarker of Depression and Treatment Response Philip Baldwin, Humsini Viswanath, Kenia Velasquez, Sanjay J . Mathew, Ramiro Salas

M158 . Lower Limbic System mGluR5 Availability in Cocaine Dependent Subjects: A High-resolution PET [11C]ABP688 Study Michele Milella, Laura Marengo, Kevin Larcher, Aryandokht Fotros, Alain Dagher, Pedro Rosa-Neto, Chawki Benkelfat, Marco Leyton

M159 . Prefrontal Response to Visual Drug Cues Predicts Adherence to Extended-release Injectable Naltrexone in Heroin-dependent Individuals An-Li Wang, Kanchana Jagannathan, Igor Elman, George E . Woody, Shira J . Blady, Emily D . Dowd, James W . Cornish, Anna R . Childress, Charles P . O’Brien, Daniel D . Langleben

M160 . Amygdala Activation to Emotion Stimuli as a Predictor of Treatment Outcomes in Major Depressive Disorder: The International Study to Predict Optimized Treatment in Depression (iSPOT-D) Leanne Williams, Mayuresh Korgaonkar, Stuart Grieve, Amit Etkin

M161 . Relationship between Central Mu-opioid System Response and Affect to Feeding Is Altered by the Pathophysiology of Obesity Paul Burghardt, Amy Rothberg, Kate Dykhuis, Charles Burant, Jon- Kar Zubieta

M162 . Development of Cingulum Bundle White Matter in Pediatric Obsessive Compulsive Disorder Kate D . Fitzgerald, Elyse Reamer, Yanni Liu, Robert C . Welsh, Stephan Taylor

M163 . Prenatal Vigabatrin Exposure Attenuates Naloxone-induced Withdrawal Behaviors in Neonates Jakub Kaczmarzyk, Giovanni Santoro, Sandy Scherrer, Stergiani Agorastos, Jonathan D . Brodie, Joseph Carrion, Krishna Patel, Rebecca Silverman, Michelle Choi, Christina Veith, Danielle Mullin, Stephen L . Dewey 188

ACNP Annual Meeting Book 2013 rev8.indd 188 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M164 . Group ICA Analysis of Smokers and Controls Philip Baldwin, Ramiro Salas

M165 . Resting State Functional Connectivity of the Dorsal Attention, Frontoparietal, Cingulo-opercular, and Default Mode Networks in Children with a History of Depression and/or an Anxiety Disorder Chad Sylvester, Deanna M . Barch, Jonathan Power, Michael Gaffrey, Bradley Schlaggar, Joan Luby

M166 . Longitudinal fMRI Study of Quetiapine in Bipolar Mania Caleb Adler, Andrew Davis, Melissa DelBello, Wade Weber, James Eliassen, Thomas Blom, Jeffrey Welge, David Fleck, Strakowski Stephen

M167 . Increased Glutamate in the Dorsal Anterior Cingulate Cortex Is Associated with Anxiety Symptom Domain in MDD with High Inflammation Ebrahim Haroon, Bobbi Woolwine, Xiangchuan Chen, Xiaoping Hu, Andrew H . Miller

M168 . Intravenous Morphine Self-administration Reduces In Vivo Regional Glucose Utilization (18FDG-PET) and Accelerates Fear Extinction Behavior in Rats Thien Le, Reed Selwyn, Robert Ursano, Kwang Choi

M169 . Brain Diffusion Tensor Imaging and 31P Spectroscopy of In Vivo Tau P301L Toxicity Mechanisms Naruhiko Sahara, Pablo Perez, Yan Ren, Huadong Zeng, Jada Lewis, Marcelo Febo

M170 . In Vivo Diffusion Tensor Imaging Evidence for Reversible White Matter Microstructural Integrity Disruption with Binge but Not Chronic Ethanol Exposure Natalie M . Zahr, Edith V . Sullivan, Adolf Pfefferbaum

189

ACNP Annual Meeting Book 2013 rev8.indd 189 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M171 . Differentiating Neural Networks Underlying Risk for Depression in Youth Manpreet K . Singh, Ryan G . Kelley, Meghan Howe, Ian Gotlib, Kiki Chang

M172 . Pre-symptomatic Functional Brain Changes in PS1 E280A Mutation Carriers Compared to Other Biomarkers: Pilot Data from the Alzheimer’s Prevention Initiative Biomarker Project Pierre Tariot, Adam S . Fleisher, Kewei Chen, Jessica Langbaum, Auttawut Roontiva, Pradeep Thiyyagura, Ji Luo, Napatkamon Ayutyanont, Stephanie A . Parks, Francisco Lopera, Eric Reiman, Xiaofen Liu, Wendy Lee

M173 . Multiscale Computer Modeling of Antipsychotic Targets: ER Parameters Modulate Calcium Wave Propagation Mohamed A . Sherif, Robert McDougal, Samuel Neymotin, Michael Hines, William Lytton

M174 . Association of Clinical Variables and Calf Arterial Compliance in Veterans with Psychiatric Diagnoses Maju Koola, John Sorkin, William Brown, Bruce Cuthbert, Jeffrey Hollis, Ngoc-Anh Le, Jeffrey Raines, Erica Duncan

M175 . High Variability and Lack of Change on the ADAS-Cog: Placebo Analyses of the CODR Database Danielle Popp, Lori M . Garzio, Peter Boehm, Christopher Randolph

M176 . Comparative Trials of Long-acting Injectable vs . Daily Oral Antipsychotic Treatment in Schizophrenia: Do Pragmatic vs . Explanatory Study Designs Matter? Cynthia A . Bossie, Larry Alphs

190

ACNP Annual Meeting Book 2013 rev8.indd 190 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M177 . Mapping of the Brain-wide of the Glymphatic Waste Removal Pathway by MRI and PET Imaging Helene Benveniste, Joanna Fowler, Paul Vaska, Maiken Nedergaard, Hedok Lee, Gene-Jack Wang, Nora D . Volkow

M178 . Developing a Smart Phone App to Monitor Mood, Social Rhythms, Sleep and Social Activity: Technology to Support Effective Management of Bipolar Disorder Ellen Frank, Mark Matthews, Tanzeem Choudhury, Stephen Voida, Saeed Abdullah

M179 . Cognitive-affective Remediation Training Intervention in Anxiety and Depression Anett Gyurak, James Gross, Larry Chan, Amit Etkin

M180 . DREADDs in Drosophila: Pharmacogenetic Control of Neurons and Behavior in the Fly Charles D . Nichols, Jaime Becnel, Oralee Johnson, Zana Majeed, Vi Tran, Bangning Yu, Bryan L . Roth, Robin L . Cooper, Edmund K . Kerut

M181 . Forecasting Non-remitting PTSD Symptom Trajectory by Advanced Modeling Methods Isaac Galatzer-Levy, Karen-Inge Karstoft, Sara Freedman, Yael Ankri, Moran Gilad, Alexander Statnikov, Arieh Y . Shalev

M182 . Withdrawn

M183. Olfactory Identification Deficits Predict Response to Cholinesterase Inhibitors in Patients with Mild Cognitive Impairment Davangere P . Devanand, Gregory Pelton, Howard Andrews, Bruce Levin

191

ACNP Annual Meeting Book 2013 rev8.indd 191 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M184 . ALKS 5461, a Novel Opioid Modulator, Produces Remission and Decreases Core Depressive Symptoms and Anhedonia as an Adjunctive Treatment: A Sequential Parallel Comparison Design Trial in Inadequate Responders to Antidepressants Marlene P . Freeman, Randall Marshall, Asli Memisoglu, Richard Leigh-Pemberton, Elliot W . Ehrich, Michael E . Thase, Madhukar Trivedi, J . Alexander Bodkin, Maurizio Fava

M185 . MicroRNA Dysregulation in Cerebrospinal Fluid in Patients with Schizophrenia Juan A . Gallego, Todd Lencz, Brian Cantley, Anil Malhotra

M186 . Pharmacometabolomics of Atypical Antipsychotics in Bipolar Disorder: An Untargeted Approach Kyle Burghardt, Vicki Ellingrod

M187 . Meta-analysis of the Discriminative Validity of Caregiver, Teacher, and Youth Checklists for Assessing Pediatric Bipolar Disorder Eric Youngstrom, Jacquelynne Genzlinger, Ericka McKinney, Greg Egerton, Anna Van Meter

M188 . Development of a Lab-on-a-Chip Biosensor for Clozapine Monitoring Deanna L . Kelly, Hadar Ben-Yoav, Veronika Stock, Thomas Winkler, Gregory Payne, Sheryl Chocron, Eunkyoung Kim, Gopal Vyas, Raymond Love, Heidi J . Wehring, Kelli M . Sullivan, Stephanie Feldman, Fang Liu, Robert P . McMahon, Reza Ghodssi

M189 . Print ‘Close the Use of a Novel Urine Drug Monitoring Test to Help Assess How Well Clinicians Predict Antipsychotic Medication Non- adherence Matthew Keats, Harry Leider, Kathryn Bronstein , Mary Anne Lang

M190 . Functional Capacity Assessment in Older Adults Sara J . Czaja, Philip D . Harvey, David Loewenstein

192

ACNP Annual Meeting Book 2013 rev8.indd 192 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M191 . Estimating Endogenous Dopamine Levels at D2 and D3 Receptors in Humans Using the Agonist Radiotracer [11C]-(+)-PHNO Ariel Graff, Fernando Caravaggio, Shinichiro Nakajima, Philip Gerretsen, David Mamo, Gary Remington, Alan A . Wilson

M192 . Central 5-HT4 Receptor Binding as Biomarker of Serotonergic Tonus in Humans: A [11C]SB207145 PET Study Mette Haahr, Patrick Fisher, Christian Gaden, Vibe Frokjaer, Brenda McMahon, Karine Madsen, Wim Baaré, Szabolz Lehel, Anne Norremolle, Eugenii Alfredovich . Rabiner, Gitte M . Knudsen

M193 . A Mixture Model Estimate of Time to Antidepressant Drug-effect in Association with Covariates Using the STAR*D Sample Yin Yao, Mengyuan Xu, Eleanor Murphy, Harold Wang, Francis J . McMahon

M194 . Responses to Blocked Goal Attainment in Preschoolers at Risk for Bipolar Disorder Wan-Ling Tseng, Christen M . Deveney, Amanda E . Guyer, Jennifer Yi, Kimberly Espy, Lauren Wakschlag, Kenneth Towbin, Ellen Leibenluft, Melissa A . Brotman

M195 . Assessing Effort-based Decision-making in Schizophrenia with Two Novel Behavioral Paradigms Felice Reddy, William Horan, Jonathan K . Wynn, Patricia Corey- Lisle, Gregory Maglinte, Deanna M . Barch, Robert W . Buchanan, James Gold, Jared Young, Michael F . Green

M196 . MCI and Everyday Task Performance Samir Sabbag, Sara J . Czaja, Philip Harvey

M197 . Differential Prefrontal Control of Brainstem Neuromodulatory Systems in Depression-related Behavior Melissa R . Warden, Emily Ferenczi, Karl Deisseroth

193

ACNP Annual Meeting Book 2013 rev8.indd 193 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M198 . Addiction-related Genes in Gambling Disorders: New Insights from Parallel Human and Pre-clinical Models Daniela S . S . Lobo, Lily Aleksandrova, Jo Knight, David Casey, Nady el-Guebaly, Jose Nobrega, James L . Kennedy

M199 . Effects of Combined Adrenoreceptor Antagonist Treatment with Prazosin and Propranolol on Alcohol Drinking in Humans and Rodents Murray A . Raskind, Janice C . Froehlich, Elaine R . Peskind, Dennis D . Rasmussen

M200 . Postural Sway Abnormalities in Chronic Schizophrenia Brent G . Nelson, Kelvin O . Lim

M201 . Enhancement of rTMS Neuromodulatory Effects with Novel Waveforms Demonstrated via Controllable Pulse Parameter TMS (cTMS) Stefan M . Goetz, Bruce Luber, Sarah Lisanby, Cassie I . Kozyrkov, Warren M . Grill, Angel V . Peterchev

M202 . Computerized Cognitive Remediation for Geriatric Depression Sarah Shizuko Morimoto, Bruce E . Wexler, Willie Hu, George S . Alexopoulos

M203 . The Effect of Real Time fMRI Neurofeedback on Food and Cigarette Craving Luke Stoeckel

M204 . Orion Bionetworks: Causal Modeling Using Network Ensemble Simulations of Clinical, Imaging and Genetic Data to Predict Multiple Sclerosis Magali Haas, Iya Khalil, Phil De Jager

M205. Specific Elevation of βCaMKII in the Lateral Habenula Lead to Core Symptoms of Depression Hailan Hu, Henn Fritz, Kun Li, Tai Zhou, Zhongfei Yang, Lujian Liao, Roberto Malinow, John R . Yates III

194

ACNP Annual Meeting Book 2013 rev8.indd 194 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M206 . Mechanisms of Ventral Pallidal Enkephalin Regulation in Cocaine Addiction Yonatan M . Kupchik, Peter W . Kalivas

M207 . Abnormalities in Striato-pallidal-thalamic Surface Morphology as an Endophenotype for Obsessive-compulsive Disorder Shaw Phillip, Wendy Sharp, Judith L . Rapoport

M208 . High Blood Cytokine Levels Are Linked to Decreased Verbal Fluency and Broca’s Area Volume Reduction in Schizophrenia Thomas W . Weickert, Stu Fillman, Rhoshel Lenroot, Jason Bruggemann, Maryann O’Donnell, Stanley V . Catts, Cynthia S . Weickert

M209 . 5-HT3 Receptors Are Involved in the Mechanism of Action of the New Antidepressant Drug Vortioxetine Francesc Artigas, Maurizio Riga, Pau Celada, Connie Sanchez

M210 . Implications of the Human Mu Opioid Receptor (OPRM1 A118G) Polymorphism in the Neurobiology of Stress and Placebo Responses Marta Pecina, Tiffany Love, Colin A . Hodgkinson, David Goldman, Christian Stohler, Jon-Kar Zubieta

M211. Pattern Classification Accuracy to Taste Stimulation in Eating Disorders Guido K .W . Frank, Carrie Keffler, Megan Shott

M212 . Whole-brain Dynamics Are Shifted in Animals with Learned Helplessness Martine Mirrione, Bo Li, Stephen Shea, Henn Fritz

M213 . Sleep Misperception in Bipolar Disorder: Are Our Patients Getting 7 Hours of Sleep? Erika F .H . Saunders, Scott Seaman , Julio Fernandez-Mendoza, Andrew Jacobs, Alan J . Gelenberg

195

ACNP Annual Meeting Book 2013 rev8.indd 195 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M214 . The Clinical Relevance of Neural Network Dynamics for Bipolar Disorder Sophia Frangou, Danai Dima

M215 . Early Adverse Life Events: Interaction with Glucocorticoid [NR3C1] and Proinflammatory Cytokine [IL-1 β] Polymorphisms to Influence Gray Matter Variations in Females with and without Chronic Abdominal Pain Arpana Gupta, Emeran A . Mayer, Mariam Bonyadi, Jennifer Labus, Cody Ashe-McNalley, Nuwanthi Heendeniya, Lin Chang, Lisa Kilpatrick

M216 . Amygdalar Projections to Basilar Dendrites of mPFC Pyramidal Neurons Mediate CRF-induced EPSCs that Are Enhanced by Ketamine Rong-Jian Liu, Kristie Ota, Ronald S . Duman, George Aghajanian

M217. Identification of Signaling Cascades Regulating the Extinction and Reconsolidation of Cocaine-associated Memories Using Phosphoproteomics Jane R . Taylor, Thomas Abbott, Erol E . Gulcicek, Kathryn Stone, Lisa Chung, Christopher Colangelo, Mary M . Torregrossa

M218 . Role of a Beta-2 Adrenergic Receptor-regulated CRF-releasing Pathway from the BNST to the VTA in Stress-induced Relapse of Cocaine Use John R . Mantsch, Oliver Vranjkovic, Jordan M . Blacktop

M219 . Brain Glucose Metabolism Predicts Fear Extinction Recall and Global Functioning in Trauma-exposed Populations with and without PTSD Marie-France Marin, Huijin Song, Lindsay K . Staples, Michael B . VanElzakker, Natasha B . Lasko, Roger K . Pitman, Lisa M . Shin, Mohammed R . Milad

196

ACNP Annual Meeting Book 2013 rev8.indd 196 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M220 . Imaging Amino Acid Neurotransmitter Responses to a Single Subanesthetic Dose of Ketamine in Major Depressive Disorder Using Proton Magnetic Resonance Spectroscopy Matthew Milak, Stephanie Mulhern, Caitlin Proper , Amy Parter, Lawrence S . Kegeles, Todd Ogden, Xiangling Mao, Carolyn Rodriguez, Maria Oquendo, Raymond Suckow, Thomas Cooper, Dikoma Shungu, J . John Mann

M221 . The Central Nucleus of the Amygdala Is Required for Habitual Cocaine Seeking through Functional Connectivity with the Dorsolateral Striatum Jennifer E . Murray, David Belin, Barry J . Everitt

M222 . Dopamine DREADDs: Chemicogenetic Control of VTA Dopamine Activity during Reinstatement of Cocaine Seeking Stephen V . Mahler, Brittney M . Cox, Gary Aston-Jones

M223 . Dorsal and Ventral Prefrontal Neuronal Activity and Cocaine Seeking: More Complex than Thought David Moorman, Gary Aston-Jones

M224. Cytokine and Chemokine Profiling of Plasma and CSF Identifies the MCP-4/MCP-1 Ratio as a Novel Candidate Plasma Biomarker for Chronic Post-traumatic Stress Disorder Harvey B . Pollard, Clifton L . Dalgard, Catherine Jozwik, Meera Srivastava, Ofer Eidelman, Robert Ursano, David Jacobowitz, Omer Bonne

M225 . Biomarkers Differentiating Major Depressive Disorder Subtypes Husseini K . Manji, Lynn Yieh, Jieping Ye, Yashu Liu, Tao Yang, Michael Farnum, Xiang Yao, Willem Talloen, Thomas Steckler, Pim Drinkenberg, Pieter J . Peeters, Vaibhav Narayan, Gayle Wittenberg

M226 . Contribution of a Mesocorticolimbic Subcircuit to Drug Context- induced Reinstatement of Cocaine-seeking Behavior in Rats Rita A . Fuchs, Heather C . Lasseter, Xiaohu Xie, Amy A . Arguello, Audrey M . Wells, Matthew A . Hodges

197

ACNP Annual Meeting Book 2013 rev8.indd 197 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M227 . The Involvement of the Serotonergic System in the Nucleus Accumbens Shell on EtOH-seeking: Role of 5HT7 Receptors and Response to Conditioned Cues Gerald A . Deehan, Sheketha R . Hauser, Eric A . Engleman, Jessica A . Wilden, William Truitt, William J . McBride, Zachary A . Rodd

M228 . Maltreated Preschoolers: The Association of Stress Exposure with Adrenocortical and Behavioral Outcomes Audrey R . Tyrka, Stephanie H . Parade, Nicole M . Eslinger, Brittney Shillan, Ashley Clement, Rebecca Berger, Susan Dickstein, Ronald Seifer

M229 . Contributions of Ventral Dopamine Target Neurons to Risk-seeking Decisions in a Macaque Model of Compulsive Gambling Brianna Sleezer, Benjamin Hayden

M230 . Frontal and Subcortical Pathways Provide a Basis for Segmenting the Cingulum Bundle: Implications for Understanding the Default Mode Network, Diffusion Imaging, and Surgical Targets for Psychiatric Disorders Sarah R . Heilbronner, Suzanne Haber

M231 . Rules Prefrontal Pathways Use in the Anterior Limb of the Internal Capsule: Implications for Neuroimaging and Deep Brain Stimulation Ziad Safadi, Suzanne Haber

M232 . Exploring Side Effects Similarity as a Novel Approach for Inferring Shared Mechanisms and Targets among Antidepressant and Anti- inflammatory Drugs Vaibhav Narayan, Yu Sun, Gayle Wittenberg, Michael Farnum

M233 . Functional Network Connectivity Dynamics in Schizophrenia and Bipolar Disorder Vincent Calhoun, Barnaly Rashid, Eswar Damaraju, Godfrey Pearlson

198

ACNP Annual Meeting Book 2013 rev8.indd 198 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session I—Monday M234 . Withdrawn

M235 . Treatment of Dopaminergic Dysfunction in Schizophrenia Using Non- dopaminergic Mechanisms: A Computational Modeling Approach Peter J . Siekmeier, David vanMaanen

M236 . Retinoid-related Orphan Receptor Alpha: A Novel Candidate Gene for Psychiatric Disease Joseph I . Friedman, Sander Markx, Terry Vrijenhoek, Ronald Kim, Joris A . Veltman, Arthur Mikhno, James R . Moeller, Mala Ananth, David K . Leung, Han G . Brunner, Vincent Giguere, Panayotis K . Thanos

M237 . Early Adverse Life Events: Interactions with Corticotropin Releasing Hormone Receptor 1 and Progestoerone Receptor Polymorphisms Healthy Controls and Patients with Chronic Abdominal Pain Lisa Kilpatrick, Arpana Gupta, Nuwanthi Heendeniya, Jennifer Labus, Emeran A . Mayer

M238 . Vocational Outcome in Patients with Psychotic and Affective Disorders: A Nation-wide, Historical-prospective Study Mark Weiser, Ori Kapara, Nomi Werbeloff, Rinat Yoffe, Michael Davidson

199

ACNP Annual Meeting Book 2013 rev8.indd 199 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

200

ACNP Annual Meeting Book 2013 rev8.indd 200 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II – Tuesday, December 10, 2013

Advocacy Affiliate – Cure Alliance for Mental Illness Research Parity for Mental Illness Robin Cunningham, Hakon Heimer

T1 . 2013 Report of the Membership Advisory Task Force Linda Carpenter, Lisa Monteggia, Margaret Haney, Katherine Burdick, Jennifer Bartz, Elisabeth Binder, Paul Holtzheimer, Amit Etkin, Erica Forbes, Marlene Freeman, Thomas Schulze, Christina Barr, Gregory Light, Vaishali Bakshi, Raymond Cho, Cynthia Crawford, Philip Szeszko

T2. Effects of CFA-induced Chronic Inflammatory Pain on Opioid Self- administration and Accumbal Dopamine Release in Heroin Dependent Rats Jose Moron-Concepcion, Lucia Hipolito-Cubedo

T3 . Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine Relapse Cassandra Gipson, Yonatan M . Kupchik, Neringa Stankeviciute, Peter W . Kalivas

T4 . Behavioral and Molecular Consequences of GAD1 Downregulation in Cannabinoid Receptor 1 Expressing Interneurons Jacquelyn Brown, Szatmar Horvath, Krassimira Garbett, Monica Everheart, Karoly Mirnics

T5. Modeling Fall Propensity in Parkinson’s Disease: Deficits in the Attentional Control of Complex Movements in Rats with Cortical- cholinergic and Striatal-dopaminergic Deafferentation Martin Sarter, Aaron Kucinski

T6 . Different Adolescent Traumatic Stress Pre-exposures Differentially Modify Adulthood Predator Stress Responses in Rats Nicole L .T . Moore, Daniel E . Altman, Sangeeta Gauchan, Raymond F . Genovese

201

ACNP Annual Meeting Book 2013 rev8.indd 201 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T7. Genetic Interaction between Integrin β3 (Itgb3) and Serotonin Transporter (Slc6a4) Modifies Depressive-like Behaviors in the Mouse Seth Varney, Alonzo Whyte, Tammy Jessen, Ana Carneiro

T8 . Dopamine-independent Motor Control and Hyperactivity Involving Acetylcholine Systems Kazutaka Ikeda, Yoko Hagino, Shinya Kasai

T9 . A New Model for Studying Effects of Witnessing Traumatic Events in Rats Samina Salim, Gaurav Patki, Naimesh Solanki, Farida Allam, Amber Ansari

T10. Identification of Early Risk for Substance Use: fMRI Responses to Cocaine-associated Cues in Juvenile Rats Steven Lowen, Michael Rohan, Britta S . Thompson, Kai Sonntag, Susan L . Andersen

T11 . Interaction between BDNF and Social Environment in Brain Physiology and Behavior Robert Schloesser, Dennisse Jimenez, Julia Hill, Keri Martinowich

T12 . Early Life FGF2 Treatment Alters Vasopressin and Oxytocin Gene Expression in Animals that Differ in Their Response to Novelty Cortney Turner, Pamela Maras, Yoav Litvin, Stanley J . Watson, Bruce S . McEwen, Huda Akil

T13 . Attitudes of Children and Adolescents and Their Caregivers Towards Long-acting Injectable Antipsychotics in a Cohort of Youth Initiating Oral Antipsychotic Treatment Christoph U . Correll, Owen Muir, Aseel Al-Jadiri, Sandeep Kapoor, Morgan Carella, Eva Sheridan, Lisa David, John Kane

202

ACNP Annual Meeting Book 2013 rev8.indd 202 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T14 . Comorbidity of PTSD and Alcoholism: A Rat Model of PTSD Leads to Escalated Ethanol Consumption Jenica Tapocik, Jesse R . Schank, Cheryl Mayo, Courtney King, Jim Koenig, Markus Heilig, Greg I . Elmer

T15 . Mouse Model of Chromosome 15q13 .3 Microdeletion Syndrome Demonstrates Features of Autism Spectrum Disorder Jeffrey Kogan, Adam Gross, Rick Shin, Qian Chen, Noah Walton, Carrie Heusner, Amy Lin, Sosuke Miyoshi, Shintaro Nishimura, Shinichi Miyake, Katsunori Tajinda, Kouichi Tamura, Mickey Matsumoto

T16 . Distinct Roles of PKC Signaling at Direct and Indirect Pathway Medium Spiny Neurons during Reinstatement of Cocaine-seeking Pavel I . Ortinski, Lisa A . Briand, R . Christopher Pierce, Heath D . Schmidt

T17 . Amygdala-ventral Pallidum Pathway Decreases Dopamine Activity Following Chronic Mild Stress in Rats Chun-hui Chang, Anthony A . Grace

T18 . Roles of Glucocorticoids in a Trajectory from Adolescent Social Stress to Adult Behavior Minae Niwa, Akira Sawa

T19 . High Traumatic Stress Reactivity Alters Behavior and Corticotropin- releasing Factor-1 (CRF1Rs) in Prefrontal Cortex-amygdala Circuitry Nicholas W . Gilpin

T20 . High-throughput Behavior-based Neuroactive Drug Discovery in Zebrafish David Kokel

203

ACNP Annual Meeting Book 2013 rev8.indd 203 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T21 . Cortical Synaptic Alterations and Pharmacologic Rescue of Behavioral Changes in a Mouse Model of Bipolar Disorder with Conditional Forebrain Knockout of Ankyrin-G Shanshan Zhu, Solange P . Brown, Vann Bennett, Mikhail V . Pletnikov, Christopher A . Ross

T22 . Activity-based Anorexia in the Rat Induces Reward-related Alterations in Enkephalin Gene Expression and Dopamine Release in the Nucleus Accumbens Nicole M . Avena, Susan Murray, Nicole Barbarich-Marstellar, Pedro Rada

T23 . Repeated Ketamine Exposure during Adolescence Produces Long Lasting Stress Resistance in Adulthood Eric M . Parise, Lyonna F . Alcantara, Brandon L . Warren, Carlos A . Bolanos-Guzman

T24 . Susceptibility to Chronic Social Defeat Stress Increases Morphine Reward Megan Kechner, Michelle Mazei-Robison

T25 . The Contribution of Adult Hippocampal Neurogenesis to Fear Memory Generalization Mazen A . Kheirbek, Liam J . Drew, Elizabeth Balough, Christine A . Denny, Rene Hen

T26 . Individual Differences in Instrumental Performance in Naïve Rats Predict Distinctive Responses to Chronic Stress Shigenobu Toda, Yoshio Iguchi, Yoshio Minabe

T27 . Pay Attention: Modelling the Inattentive and Impulsive Subtypes of Adult ADHD in the Rat - Using the 5-Choice Continuous Performance Task (5C-CPT) Anneka Tomlinson, Joanna Neill

204

ACNP Annual Meeting Book 2013 rev8.indd 204 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T28 . Lesions of the Basolateral Amygdala Induce Elevated Risk-taking in Rats Caitlin Orsini, Barry Setlow

T29 . Loss Estrogen-related Receptor Alpha Activity Affects Behaviors Related to Eating Disorders in Mice Huxing Cui, Michael L . Lutter

T30 . Chronic Phenytoin Administration Prevents Single Prolonged Stress Induced Extinction Retention Deficits and Glucocorticoid Upregulation Sophie A . George, Dayan K . Knox, Mariana Rodriguez, John Riley, Israel Liberzon

T31 . Independent Effects of Lps and Social Isolation on Forced Swim Behavior in Female Mice Cristina L . Sanchez, Nicole L . Schramm-Sapyta, Cynthia M . Kuhn, Florian Daniel . Zepf

T32 . Hippocampal-prefrontal BDNF Circuits in Fear Extinction Luis E . Rosas-Vidal, Fabricio H . Do Monte, Gregory J . Quirk

T33 . Adolescent Cannabinoid Treatment Leads to Persistent Increase in Frontostriatal CB1 Expression Associated with Upregulation of Class I HDACs Subroto Ghose, Hersh Trivedi, Kelly Gleason, Marcus Shanks, Shari Birnbaum

T34 . Determinants of Conditioned Reinforcing Effectiveness: Implications for Relapse to Cocaine-seeking Gregory T . Collins, Charles P . France

T35 . Ketamine Alters Socially-evoked Activity in the Amygdala Takuma Mihara, Rosanna Sobota, Robert Lin, Robert Featherstone, Steven J . Siegel

205

ACNP Annual Meeting Book 2013 rev8.indd 205 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T36 . Modulation of Fear-related Behaviours by Prefrontal Cortical Gabaergic Transmission and Its Relevance to Schizophrenia Stan B . Floresco, Patrick B . Piantadosi

T37 . Central CRTH2/GPR44, a Second Prostaglandin D2 Receptor, Mediates Emotional Impairment in the Lipopolysaccharide and Tumor-induced Sickness Behavior Model Hitoshi Hashimoto, Ryota Haba, Norihito Shintani, Yusuke Onaka, Hiroyuki Hirai, Kin-ya Nagata, Masataka Nakamura, Akemichi Baba

T38 . Timing May Matter: Vulnerability and Resilience to Acute Trauma Vary According to the Circadian Phase at Which Exposure Occurs Hagit Cohen, Shlomi Cohen, Aleksander Mathé, Joseph Zohar

T39 . Variations in a Stress Paradigm on Top of Early Interference with the Expression of Multiple Genes Leads to Disparate Behavioral Responses in Rats - A Possible Role for Essential Amino Acids Eyal Asor, Avi Avital, Ehud Klein, Dorit Ben-Shachar

T40 . Neural Disconnectivity and Loss of Connections Symmetry in Brains of Mice Knockout for the Neurodevelopmental Gene Ahi1 Amit Lotan, Tzuri Lifschytz, Omer Lory, Gadi Goelman, Bernard Lerer

T41 . Epigenetic Regulation of Dopamine D2 Receptor in the Core of the Nucleus Accumbens Contributes to Addiction Liability Shelly B . Flagel, Sraboni Chaudhury, Maria Waselus, Stanley J . Watson, Huda Akil

T42 . Positive Allosteric Modulation of mGluR5 Reverses the Akt Signaling Deficits in Serine Racemase Knockout Mice, a Genetic Model of Schizophrenia Due to NMDA Receptor Hypofunction Darrick T . Balu, Shunsuke Takagi, Thomas Steckler, Jose Manuel Bartolome, Carrie K . Jones, Jeffrey Conn, Joseph T . Coyle

206

ACNP Annual Meeting Book 2013 rev8.indd 206 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T43 . Age-related Sperm DNA Methylation Changes Are Transmitted to Offspring and Associated with Abnormal Behavior and Dysregulated Gene Expression Maria H . Milekic, Yurong Xin, Anne O’Donnell, Victoria Fatemeh . Haghighi, Jay A . Gingrich, John Edwards, Timothy Bestor

T44 . Single Prolonged Stress Decreases Sign-tracking Conditioned Responses and Attenuates Cue-induced Reinstatement of Cocaine-seeking Behavior Christopher Fitzpatrick, Terry E . Robinson, Jonathan D . Morrow

T45 . Empathic Fear Responses in Mice Are Triggered by Recognition of a Shared Experience Jeff Sanders, Mark Mayford, Dilip V . Jeste

T46 . Selective Removal of Parvalbumin Interneurons from Striatal Networks to Model the Pathophysiology of Tourette Syndrome Meiyu Xu, Vladimir Pogorelov, Lina Li, Christopher Pittenger

T47 . Effects of Prenatal and Postnatal Hypoxia on Brain Derived Neurotrophic Factor Signaling in Mice Anilkumar Pillai, Kristy R . Howell, Sarah Mehta

T48 . Cocaine-induced Adaptations in Alpha2delta-1 Calcium Channel Subunit in Nucleus Accumbens Contribute to Cocaine-induced Drug Seeking Sade Spencer, Robyn M . Brown, Gabriel Quintero, Yonatan M . Kupchik, Kathryn Reissner, Peter W . Kalivas

T49 . Chronic Prenatal Kynurenine Elevation in Rats: A Naturalistic Model of Schizophrenia with Biochemical Abnormalities and Deficits in Hippocampal-mediated Learning and Memory Robert Schwarcz, Ana Pocivavsek, Greg I . Elmer, John Bruno

207

ACNP Annual Meeting Book 2013 rev8.indd 207 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T50 . Evidence for a Novel Role of Acid Sensing Ion Channel, Asic1a in the Molecular Biology of Mood and Anxiety James R . Shoblock, Natalie Welty, Yi Liu, Changlu Liu, Timothy Lovenberg, Guang Chen

T51 . Repeated Administration of an Acetylcholinesterase Inhibitor Attenuates Nicotine Taking in Rats Adrian Arreola, Blake Kimmey, Laura Rupprecht, Alycia Lee, Matthew Hayes, Heath D . Schmidt

T52 . Withdrawn

T53 . Effects of Pharmacogenetic Manipulation of the Nucleus Accumbens on Neuronal Activity and Alcohol-related Behaviors Angela Ozburn, Ryan Logan, Puja Parekh, Jake Bosin, Colleen A . McClung

T54 . Re-exposure to Nicotine After Chronic Nicotine Exposure and Withdrawal Potentiates Reward Responsiveness in Rats: Implications for Relapse Andre Der-Avakian, Manoranjan S . D’Souza, Diego A . Pizzagalli, Athina Markou

T55 . Effects of Maternal Separation on Depressive- and Anxiety- Like Behaviors and Cardiovascular Function in Stress-susceptible Rats Ilan A . Kerman, Samir Rana, Nateka Jackson, Phyllis C . Pugh

T56 . Spontaneous Nicotine Withdrawal Enhanced Anxiety-like Behavior in the Fear-potentiated Startle Procedure in Rats Xia Li, Athina Markou, Victoria Risbrough

T57 . Long-term Modulation of Memory and Emotion after a Systemic Inflammatory Event Natalie Tronson, Ian Speirs

208

ACNP Annual Meeting Book 2013 rev8.indd 208 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T58 . Selective Enhancement of Cue-induced Motivation in Obesity Prone vs . Resistant Rats Is Accompanied by Sensitization to Cocaine and Increased Striatal AMPA Receptor Expression Carrie R . Ferrario, Cameron Nobile, Michael J .F . Robinson, Kent Berridge

T59 . Withdrawn

T60 . Ultra-high Magnetic Field (9 .4 Tesla) Magnetic Resonance Imaging Reveals Neuroanatomical and Neurochemical Homologies between Schizophrenia and the Serine Racemase Knockout Mouse Matthew D . Puhl, Dionyssios Mintzopoulos, J . Eric Jensen, Timothy E . Gillis, Marc J . Kaufman, Joseph T . Coyle

T61 . Loss of GFAP-positive Astrocytes in the Nucleus Accumbens Following Cocaine Self-administration and Extinction Is Associated with Increased IL-6 Expression Phuong K . Tran, Heather A . Boger, Sade Spencer, Michael D . Scofield, Peter W . Kalivas, Kathryn J . Reissner

T62 . Evaluation of an Electronic Information System to Enhance Practice at a Medication-assisted Opioid Treatment Program Lawrence Brown, Steven Kritz, Melissa Lin, Ben Louie, Roberto Zavala, Charles Madray

T63 . Effects of Social Defeat Stress on Anhedonia in the Intracranial Self- stimulation Test Rachel Donahue, John Muschamp, Sam Golden, Scott Russo, Eric Nestler, William Carlezon Jr .

T64 . Toward a Bidirectional Model Animal of Bipolar Disorder: Genetic Susceptibility to Conditions that Induce Cycling between Mania and Depression in Mice Jared W . Young, Davide Dulcis, Jordy van Enkhuizen, Nicholas Spitzer, Andrea Grim, Mark A . Geyer

209

ACNP Annual Meeting Book 2013 rev8.indd 209 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T65 . Adolescent Cannabis Exposure Interacts with a Glial Genetic Risk Factor to Produce Cognitive Deficits in Adulthood Bagrat Abazyan, Sofya Abazyan, Michael Ballinger, Atsushi Kamiya, Mikhail V . Pletnikov

T66 . The Interplay of Cannabinoid Signaling and DISC1 during Adolescence: Effects on Prefrontal Cortex Function in Adulthood Michael Ballinger, Bagrat Abazyan, Yu Taniguchi, Atsushi Saito, Koki Ito, Mikhail Pletnikov, Atsushi Kamiya

T67. A Zebrafish Model for the Functional Analysis of Genes in Autism Ellen J . Hoffman, Joseph M . Fernandez, Antonio J . Giraldez, Matthew State

T68 . Reduced Motivation to Consume Alcohol After an Extended Access Eric Augier, Ruslan Damadzic, Erick Singley, Alexandra Pincus, Markus Heilig

T69 . Effects of Perinatal and Adolescent Oxidative Stress “Double Hit” on GABAergic Interneurons and Behavior in Mice Susan B . Powell, Loek deJong, Mary E . Kamenski, Jacinta Lucero, Jared W . Young, M . Margarita Behrens

T70 . Hyperactivity and Cortical Disinhibition in Mice with Restricted Expression of Mutant Huntingtin to Parvalbumin-positive Cells Sarah E . Dougherty, John J . Hollimon, Laura J . McMeekin, Andrew S . Bohannon, Andrew B . West, Mathieu Lesort, John J . Hablitz, Rita M . Cowell

T71 . Overexpression of CRF in the Central Nucleus of the Amygdala Diminishes the Dysphoric-like State Associated with Nicotine Withdrawal in Rats Xiaoli Qi, Zhiying Shan, Yue Ji, Valerie Guerra, Jon C . Alexander, Brandi Ormerod, Adrie Bruijnzeel

210

ACNP Annual Meeting Book 2013 rev8.indd 210 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T72 . G-protein-dependent Signaling in Corticostriatal Afferents Regulates Locomotor Sensitization, Drug-taking and Drug-seeking Behaviors Kerry Kerstetter, Amanda Wunsch, Tess Donckels, John F . Neumaier, Susan Ferguson

T73 . Christianson Syndrome Protein NHE6 Regulates Intra-endosomal pH, BDNF Signaling and Circuit Development Eric M . Morrow, Julie Kauer, Qing Ouyang, Sofia Lizarraga

T74 . Memory Enhancement by Targeting Cdk5 Regulation of the NMDA Receptor Subunit NR2B Florian Plattner, Adan Hernandez, Karine Pozo, Gabriel Mettlach, Tanvir Singh, Deena Sajitharan, Chunfeng Tan, James A . Bibb

T75 . Reduced Somatostatin and Vasoactive Intestinal Peptide mRNAs in the Frontal Cortex of Subjects with Schizophrenia and Bipolar Disorder Samantha J . Fung, Cynthia S . Weickert

T76 . Dopamine D1-D2 Receptor Heteromer Activation Induces Place Aversion and Abolishes Cocaine Reward via a Cyclin-dependent Kinase 5 Mechanism Melissa L . Perreault, Ahmed Hasbi, Maurice Shen, Brian F . O’Dowd, Susan R . George

T77 . Schizophrenia-associated Alterations of Microtubule-associated Protein 2 in Human Auditory Cortex Micah Shelton, Jason Newman, Kenneth Fish, Matthew L . MacDonald, Peter Penzes, David A . Lewis, Robert A . Sweet

T78 . Novel Replacement Strategy for Dissecting NMDA Receptor Regulation John Gray, Roger Nicoll

T79. Gene Expression Profiling of Stress-induced Changes in CA3 Neurons Using Translating Ribosome Affinity Purification (TRAP) Jason Gray, Todd Rubin, Bruce S . McEwen

211

ACNP Annual Meeting Book 2013 rev8.indd 211 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T80 . Glutamatergic Neurons in the Ventral Tegmental Area: Properties & Physiological Role Thomas S . Hnasko, Ji Hoon Yoo, Gregory Hjelmstad, Howard Fields, Robert Edwards

T81. Locus Specific Epigenetic Reprogramming: Bidirectional Regulation of the FosB Gene Using Synthetic Transcription Factors In Vivo Elizabeth Heller, Hannah Cates, Haosheng Sun, Catherine Pena, Deveroux Ferguson, Scott Knight, H . Steve Zhang, Eric Nestler

T82 . Revealing Lithium’s Molecular Mechanisms in Bipolar Disorder: Using the Circadian Clock Michael J . McCarthy, Hongbing Wei, Stephen Beesley, Bruce M . Cohen, Donna L . McPhie, David Welsh

T83 . A Cross-sectional Examination of Telomere Length and Telomerase in a Well-characterized Sample of Individuals with Major Depressive Disorder Compared to Controls Naomi M . Simon, Zandra Walton, Jennifer Prescott, Elizabeth Hoge, Aparna Keshaviah, T .H . Eric Bui, Noah Schwarz, Taylor Dryman, Rebecca A . Ojserkis, David Mischoulon, John Worthington, Immaculata DeVivo, Maurizio Fava, Kwok-Kin Wong

T84 . Effects of Early Life Stress on Adulthood Stress Reactivity and Its Mechanisms Li Li

T85. Brain Region-specific Changes in Extracellular Signal-regulated Kinase (ERK)-5 Signaling in Suicide Subjects Yogesh Dwivedi, Ghanshyam Pandey, Hui Zhang

T86 . The Genome in Three Dimensions: A New Frontier in Human Brain Research Amanda Mitchell, Rahul Bharadwaj, Catheryne Whittle, Karoly Mirnics, Yasmin Hurd, Schahram Akbarian

212

ACNP Annual Meeting Book 2013 rev8.indd 212 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T87 . Acute but Not Chronic Psychosocial Stress Alters the Density and Immune-phenotype of Microglia in Mouse Stress-responsive Brain Regions Michael Lehmann, Miles Herkenham

T88. The Neuron-specific Chromatin Regulatory Subunit BAF53b is Necessary for Epigenetic Regulation of Synaptic Plasticity and Memory Annie Vogel-Ciernia, Dina Matheos, Ruth Barrett, Marcelo A . Wood

T89 . Nucleus Accumbens Medium Spiny Neuron Subtypes Differentially Mediate Susceptibility and Resilience to Social Defeat Stress T . Chase Francis, Ramesh Chandra, Julie Brooks, Genesis Dayrit, Eric Finkel, Jeffrey D . Lenz, Sergio Iñiguez, Patricio O’Donnell, Mary Kay Lobo

T90 . Genetic Background Regulates the Effect of Antidepressant Treatment on Behavioral Despair and Hippocampal Neurogenesis in Mice Brooke H . Miller, Thomas A . Lanz, Zane Zeier, Miguel Lopez- Teledono, Robin Kleiman, Mathew Pletcher, Claes Wahlestedt

T91 . Genetic Modulation of Neuronal Competition Homeostasis in the Adult Dentate Gyrus to Enhance Hippocampal Functions Amar Sahay, Kathleen McAvoy, Kimberly Scobie, Stefan Berger, Nannan Guo, Sreyan Choudhry, Sam Miake-Lye, Rene Hen, Mark Nelson

T92 . Disrupting AMPA Receptor Endocytosis Restores the Ability to Form New, and Enables the Recovery of Old, Memories in Mice Genetically Designed to Mimic Alzheimer’s Disease Sheena Josselyn, Adelaide Yiu, Valentina Mercaldo, Derya Sargin, Paul Frankland

T93 . Fragile X Mental Retardation Protein (FMRP) –Metabotropic Glutamate Receptor 5 (mGluR5) Signaling in Schizophrenia and Autism S . Hossein Fatemi, Timothy Folsom

213

ACNP Annual Meeting Book 2013 rev8.indd 213 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T94 . Orbitofrontal Cortical Dendritic Spines: Markers of Adolescent (Stressor) Experience and Determinants of Habit Formation Elizabeth A . Hinton, Andrew M . Swanson, Shannon L . Gourley

T95 . The Methyltransferase PRDM2 Regulates Escalated Alcohol Consumption Estelle Barbier, Jenica Tapocik, Andrea L . Johnstone, Jesse Schank, Zhifeng Zhou, Qiaoping Yuan, David Goldman, Claes Wahlestedt, Markus Heilig

T96 . Alterations in Telencephalic Neuronal Fate, Neuronal Calcium Signaling and Neurotransmitter Release in iPSC Models of Bipolar Disorder Melvin McInnis, Monica Bame, Haiming Chen, Cynthia J . DeLong, Todd J . Herron, Omar Mabrouk, Robert Kennedy, K Sue O’Shea

T97 . Modulation of Dopamine Transporter by DISC1 Assemblies: A Novel Pharmacological Target Verian Bader, Svenja Trossbach, Ingrid Prikulis, Sandra Schäble, Angelica de Souza, Zoe A . Hughes, Nicholas Brandon, Joseph Huston, Carsten Korth

T98. Role of Hippocampal ΔFosB in Associations of Cocaine with Environment Andrew Eagle, Paula Gajewski, Pamela Kennedy, Alfred Jay Robison

T99 . Overexpression of the Steroidogenic Enzyme Cytochrome P450 Side Chain Cleavage in the Ventral Tegmental Area Increases 3α,5α-THP and Reduces Long-term Operant Ethanol Self-administration in Alcohol Preferring Rats A . Leslie Morrow, Jason B . Cook, David F Werner, Antoniette M . Maldonado-Devincci, Maggie N . Leonard, Kristen R Fisher, Todd K . O’Buckley, Patrizia Porcu, Thomas J . McCown, Clyde Hodge, Joyce Besheer

214

ACNP Annual Meeting Book 2013 rev8.indd 214 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T100 . Increased Rage, TLRs, and HMGB1 Expression in the Human Alcoholic Orbitofrontal Cortex Is Linked to Adolescent Drinking Ryan P . Vetreno, Liya Qin, Fulton T . Crews

T101. The Extent of the Incorporation of the G Protein, Gsα, in Lipid Raft Membrane Fractions from Erythrocyte Membranes May Provide a Biomarker for Major Depressive Disorder Mark M . Rasenick, Robert Donati, Cynthia Fu, Sergi Costafreda, Peng Liu, Lauren Marangell

T102 . Epigenetic Enzyme Expression Changes Associated with Alcohol Dependence Andrea L . Johnstone, Christopher A . Rienas, Estelle Barbier, Jenica Tapocik, Markus Meinhardt, Shaun P . Brothers, Wolfgang H . Sommer, Markus Heilig, Claes Wahlestedt

T103. Mechanisms of Focal Thalamic Degeneration in Thiamine Deficiency Induced Wernicke’s Encephalopathy-korsakoff Syndrome (WE-KS) Fulton T . Crews, Liya Qin

T104 . Expression of VEGF Receptor Is Higher with SSRI Treatment in Depressed Individuals and Correlates with Number of Cells, Capillaries and Dendrite Length in the Hippocampal Neurogenic Niche Adrienne N . Santiago, Yan Liu, Mihran J . Bakalian, Andrew J . Dwork, Gorazd B . Rosoklija, René Hen, Victoria Arango, J . John Mann, Maura Boldrini

T105 . Stress-context Detecting Function of the Mesolimbic Reward Circuit: The Role of CRF in Gating BDNF Signaling Jessica Walsh, Allyson Friedman, Haosheng Sun, Stacy Ku, Elizabeth Heller, Barbara Juarez, Veronica Burnham, Michelle Mazei-Robison, Deveroux Ferguson, Sam Golden, Ja Wook Koo, Dipesh Chaudhury, Daniel J . Christoffel, Scott Russo, Eric Nestler, Ming-Hu Han

215

ACNP Annual Meeting Book 2013 rev8.indd 215 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T106 . Altered Synaptic Protein Expression and Co-expression Network Topology Linked to Spine Loss in the Auditory Cortex of Schizophrenia Matthew L . MacDonald, Ying Ding, Jason Newman, Nathan Yates, David A . Lewis, Robert A . Sweet

T107 . Neurotrophin Receptor TrkB Expression in Dentate Gyrus and Hilus of Treated and Untreated Subjects with Major Depression Correlates with Number of Neural Progenitor Cells and Neurons Giulia Bracci, Mihran J . Bakalian, Andrew J . Dwork, René Hen, Gorazd B . Rosoklija, Victoria Arango, J . John Mann, Maura Boldrini

T108 . DNA Methylation and Dysregulation of the GABAergic Phenotype in Post-mortem Human Hippocampus in Schizophrenia and Bipolar Disorder W . Brad Ruzicka, Francine M . Benes

T109 . Using the Olfactory Epithelium as a Surrogate Tissue to Explore Dynamic Molecular Signatures for Brain Diseases Soumya Narayan, Koko Ishizuka, Narayan Rai, Charlee McLean, Pearl K . Kim, Maria Hipolito, Youjin Chung, Sandra Lin, John Nurnberger, Nicola Cascella, Akira Sawa, Evaristus Nwulia

T110. Neurobiological Basis of Augmentation Strategy of Serotonin Specific Reuptake Inhibitor by Compounds Able to Limit High Affinity Nicotinic Acetylcholine Receptors Yann S . Mineur, Emily Einstein, Mattis Wigenstrand, Sam Blakeman, Gianna Fote, Marina Picciotto

T111 . Actin Cytoskeleton Dysregulation in Schizophrenia and Bipolar Disorder: Relevance to Dendritic Spine Pathology Glenn Konopaske, Sivan Subburaju, Joseph T . Coyle, Francine M . Benes

216

ACNP Annual Meeting Book 2013 rev8.indd 216 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T112 . Depression Decreases CD4 and Chemokine Receptor Expression in T-lymphocytes and Macrophages Tami D . Benton, Kevin Lynch, Steven D . Douglas, Benoit Dubé, David Gettes, Nancy Tustin, David S . Metzger, Sergei Spitsin, Dwight L . Evans

T113. Nicotinic Modulators in Subtype-specific Cortical GABAergic Neurons: Implication for Critical Period Development Michael Demars, Noreen Bukhari, Poromendro Burman, Ayan Hussein, Hirofumi Morishita

T114 . Regulation of Primary Cilia Morphology in Striatum by 5 HT6 Receptor Signaling John F . Neumaier, Matthew Brodsky, Jane Sullivan

T115 . PET/CT versus PET/MR for the Clinical Evaluation of Patients with Dementia Yu-Shin Ding, Timothy Shepherd, Fernando Boada, Kent Friedman

T116 . Neuroimaging Predictors of Clinical Response and Potential Markers of Treatment with Duloxetine in Major Depressive Disorder Cynthia Fu, Sergi Costafreda, Mark M . Rasenick, Robert Donati, Peng Liu, Lauren Marangell

T117 . Whole Genome DNA Cytosine Methylation in a Rat Model of Fetal Alcohol Syndrome Kornel Schuebel, Kevin Blackistone, Isioma Mordi, Qiaoping Yuan, Jennifer Thomas, David Goldman

T118 . Activity-dependent Phosphorylation of MeCP2 Regulates Interaction with NCoR Daniel Ebert, Michael E . Greenberg

217

ACNP Annual Meeting Book 2013 rev8.indd 217 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T119 . Epigenetic and Behavioral Correlates of Adolescent Intermittent Ethanol Exposure at Adulthood Subhash C . Pandey, Amul J . Sakharkar, Lei Tang, Tara Teppen, Huaibo Zhang

T120 . Group I Metabotrobic Glutamate Receptor Activation Negatively Regulates Glua2-lacking Ampa Receptors in Cultured Nucleus Accumbens Neurons Jessica A . Loweth, Jeremy M . Reimers, Kuei Y . Tseng, Marina E . Wolf

T121 . CSF from HD Subjects Can Seed Aggregation of Mutant Huntingtin Steven Potkin, Zhiqun Tan, Leslie Thompson, Charles Glabe

T122 . Telomere Length in Schizophrenia as a Function of Age and Illness Duration Owen M . Wolkowitz, Barton W . Palmer, Danielle Glorioso, Wesley Thompson, Elissa S . Epel, Jue Lin, Elizabeth Blackburn, Dilip V . Jeste

T123. Cognitive Dysfunction and Higher Levels of Autofluorescence (AF) in Schizophrenia (SZ) Patient-derived Cells and Animal Models Tsuyoshi Tsujimura, Chi Ying . Lin, Juan A . Gallego, Xela Indurkhya, Nao Gamo, Minori Koga, Tess Maseda, Tom Sedlak, Anil Malhotra, Carsten Korth, Koko Ishizuka , Akira Sawa

T124 . Functional Analysis of the Schizophrenia-associated Gene, TCF4 Matthew D . Rannals, Andrew Jaffe, Ran Tao, Thomas M . Hyde, Joel E . Kleinman, Daniel Weinberger, Brady J . Maher

T125 . Regulation of Tyrosine Hydroxylase by CLOCK: Potential Mechanisms Underlying the Circadian Control of Dopamine and Reward Wilbur Williams , Angela Ozburn, Colleen A . McClung

218

ACNP Annual Meeting Book 2013 rev8.indd 218 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T126. Rats Prone to Obesity Show ‘Addiction-like’ Deficits in Behavior and Synaptic Plasticity Robyn M . Brown, Yonatan M . Kupchik, Sade Spencer, Constanza Garcia-Keller, Danielle Schwartz, Kelsey Jordan, Thomas C . Jhou, Peter W . Kalivas

T127 . Analysis of the Pain Transcriptome Using RNA-Seq Samridhi Goswami, Santosh Mishra, Mark Hoon, Andrew Mannes, Michael Iadarola

T128 . Actigraphy Measured Sleep Disruption as a Predictor of Survival among Women with Advanced Breast Cancer David Spiegel, Oxana Palesh, Arianna Aldridge-Gerry, Jamie Zeitzer, Cheryl Koopman, Janine Giese-Davis, Booil Jo, Helena Kraemer, Eric Neri, Bita Nouriani

T129. Inflammation, Depression and N-3 Fatty Acids: A Case of Personalized Medicine Mark Hyman . Rapaport, Pamela Schettler, Thaddeus W . Pace, Becky Kinkead, Andrew A . Nierenberg, David Mischoulon

T130 . The Opiate Antagonist, Naltrexone, in the Treatment of Trichotillomania: Results of a Double-blind, Placebo-controlled Study Jon E . Grant, Brian Odlaug, Suck Won Kim

T131 . Perinatal Choline Supplementation Is Associated with Earlier Maturation of P50 Sensory Gating and May Improve Preschool Attentional Function Randal Ross, Sharon Hunter, Lizbeth McCarthy, Amanda Hutchison, Brandie Wagner, Sherry Leonard, Karen Stevens, Robert Freedman

T132. An International Study of the GRID-HAMD: Has It Fulfilled Its Promise? Janet B .W . Williams, Matej Ondrus, Melanie Kitzinger, Jennie Persson, Marlene Popescu, Risto Valjakka

219

ACNP Annual Meeting Book 2013 rev8.indd 219 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T133 . Methadone and Suboxone for Subutex Injectors: Primary Outcomes of Pilot RCT George E . Woody, David Otiashvili, Gvantsa Piralishvili, Zura Sikharulidze, George Kamkamidze, Sabrina Poole

T134 . Treatment-related Improvement in Neuropsychological Functioning in Depressed Patients at High Risk for Suicidal Behavior: Paroxetine vs . Bupropion Marianne Gorlyn, John Keilp, Ainsley Burke, Maria Oquendo, J . John Mann, Michael Grunebaum

T135 . How Far Are Duplicate Subjects Willing to Go? Changing Indications and Identifiers in Order to Participate in Studies at Distant Sites Lilit Gevorgyan, Zoe Shiovitz, Marlene Zarrow, Thomas Shiovitz

T136 . Corticostriatothalamic Circuit Dysfunction in Major Depressive Disorder Olusola Ajilore, Melissa Lamar, Jamie Cohen, Anand Kumar

T137 . Aripiprazole Lauroxil (ALKS 9070), a Novel Once-monthly Prodrug of Aripiprazole, Achieves Therapeutically Relevant Levels and Is Well-tolerated in Adult Patients with Schizophrenia Following Deltoid Administration Ryan Turncliff, Marjie Hard, David Brown, Mark Lerman, Adam Lowy, Morteza Marandi, Yangchun Du, Robert Risinger, Elliot W . Ehrich

T138. Clinical Assessment of Lurasidone Benefit and Risk in the Treatment of Bipolar I Depression Using Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed Leslie Citrome, Terence A . Ketter, Josephine Cucchiaro, Antony Loebel

220

ACNP Annual Meeting Book 2013 rev8.indd 220 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T139 . Intranasal Ketamine in Treatment-resistant Depression Kyle A . Lapidus, Cara F . Levitch, Laili Soleimani, Andrew M . Perez, Jess W . Brallier, Michael K . Parides, Dan V . Iosifescu, Dennis S . Charney, James W . Murrough

T140 . Do Structured, Taped and Reviewed Rating Interviews Improve Outcomes in Antidepressant Trials? Arif Khan, James Faucett, Walter A . Brown

T141 . Patient-reported Outcome of Antipsychotic Treatment - Relationships to Psychopathology, Compliance and Remission Dieter Naber

T142. The Efficacy of Vortioxetine versus Placebo in the Treatment of Adults with Major Depressive Disorder: Patient Level Data from 10 Short-term Studies and a Meta-analysis Michael E . Thase, Atul Mahableshwarkar, Marianne Dragheim

T143 . Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia Robert C . Smith, Revital Amiaz, Si .Tian Mei, Lawrence Maayan, Hua Jin, Sylvia Boules, Henry Sershen, Chunbo Li, Juanjuan Ren, Liu Yanhong, Harshita Ravishankar, Abel Lajtha, Alessandro Guidotti, Mark Weiser, John M . Davis

T144. Citalopram Decreases Acute CSF Aβ Production in Young Healthy Subjects Yvette Sheline, Tim West, Kevin Yarasheski, Robert A . Swarm, John Cirrito, Jin-Moo Lee, Mateusz S . Jasielec, Christine Frederiksen, Robert Chott, John C . Morris, Mark A . Mintun

T145. The Differential Effect of Early and Efficient Interventions for Acute PTSD Declines with Time Arieh Y . Shalev, Yael Ankri, Moran Gilad, Yossi Israeli-Shalev, Meng Qian, Isaac Galatzer-Levy, Sara Freedman

221

ACNP Annual Meeting Book 2013 rev8.indd 221 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T146 . Reduced p11 in Blood Cells Predicts Antidepressant Response to Citalopram Per Svenningsson, Louise Berg, Daniel Matthews, Alan Malinger, Marisa Toups, Madhukar Trivedi, Carlos A . Zarate, Paul Greengard

T147 . Effects of Acute and Sustained Administration of the Antidepressant Vilazodone on Monoaminergic Systems: In Vivo Electrophysiological Studies Pierre Blier, Agnes Crnic, Mostafa El Mansari

T148. The Efficacy of Levomilnacipran ER in Patients with Prominent Fatigue Symptoms: Post Hoc Pooled Analyses of Double-blind Placebo- controlled Trials Carl Gommoll, Adam Ruth, Changzheng Chen, William M . Greenberg, Maurizio Fava

T149. Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-resistant Depression: A Double-blind, Double-randomization, Placebo-controlled Phase 2a Study Jaskaran Singh, Margaret Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand , Husseini K . Manji, Wayne Drevets, Luc Van Nueten

T150 . The Triple Reuptake Inhibitor Antidepressant Effects (TRIADE) Trial: Amitifadine for the Treatment of Major Depressive Disorder Marlene P . Freeman, Anthony McKinney, Mark Bradshaw, Pierre Tran, Timothy Hsu, Maurizio Fava

T151 . Reliability of Behavioral Phenotyping Predictors of Treatment Response in the EMBARC Study Diego A . Pizzagalli, Daniel Dillon, Pia Pechtel, Phillip Adams, Thomas Carmody, Crystal Cooper, Patricia J . Deldin, Maurizio Fava, Benji T . Kurian, Patrick J . McGrath, Melvin McInnis, David W . Morris, Ramin V . Parsey, Madhukar Trivedi, Myrna M . Weissman, Gerard Bruder

222

ACNP Annual Meeting Book 2013 rev8.indd 222 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T152 . Can Oxytocin Enhance Learning during Social Cognitive Skills Training in Schizophrenia? Michael C . Davis, Michael F . Green, Junghee Lee, William Horan, Jonathan K . Wynn, Stephen R . Marder

T153 . Examining for Potential Duplicate Patients in Clinical Trials: CATIE Analysis Jonathan Rabinowitz, Yaacov Z . Rabinowitz

T154 . A Double-blind Placebo-controlled Study of Long-chain Omega-3 Fatty Acid Supplementation for Depression in Youth at Ultra-high Risk for Bipolar Disorder Melissa DelBello, Jeffrey Welge, Jeffrey Strawn, Luis R . Patino Duran, Lauren Stahl, Thomas Blom, Stephen Strakowski, Robert McNamara

T155 . Reliability of Electrophysiological Predictors of Treatment Response in the EMBARC Study Diego A . Pizzagalli, Craig E . Tenke, Jürgen Kayser, Pia Pechtel, Daniel Dillon, Crystal Cooper, Patricia J . Deldin, Maurizio Fava, Benji T . Kurian, Patrick J . McGrath, Ramin V . Parsey, Eva Petkova, Madhukar Trivedi, Myrna M . Weissman, Sarah Weyandt, Gerard Bruder

T156 . Modulation of N-methyl-D-aspartate (NMDAR)-type Glutamate Receptors in Psychiatric Disorders Joshua T . Kantrowitz, Michael Epstein, Odeta Beggel, Nayla Scaramello, Gail Silipo, Elisa Dias, Stephanie Rohrig, Batsheva Halberstam, Marlene Carlson, Daniel C . Javitt

T157 . Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Tissue-specific Insulin Sensitivity in Healthy Volunteers John W . Newcomer, Karen Flavin, Michael D . Yingling, Julia A . Schweiger, Angie Stevens, Ginger E . Nicol

223

ACNP Annual Meeting Book 2013 rev8.indd 223 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T158. Efficacy and Safety of Vilazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Trial Nunzio Pomara, Carl Gommoll, Dalei Chen, Rene Nunez, Maju Mathews, Harry A . Croft

T159. Efficacy of Cariprazine Across Schizophrenia Symptoms: A Post Hoc Analysis of PANSS Data from a Phase III, Double-blind, Placebo- and Active-controlled Trial Stephen R . Zukin, Jeffrey A . Lieberman, Andrew J . Cutler, Kaifeng Lu, Raffaele Migliore, István Laszlovszky, György Németh, Suresh Durgam

T160. Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Vortioxetine on Cognitive Dysfunction in Adult Patients with Major Depressive Disorder (MDD) Roger S . McIntyre, Soren Lophaven, Christina K . Olsen

T161. Cognitive Remediation in Bipolar Disorder: Efficacy and Neural Correlates of Treatment Kathryn E . Lewandowski, Matcheri Keshavan, Bruce M . Cohen, Sarah H . Sperry, Dost Ongur

T162 . Automated Analysis of Disorganized Communication Predicts Transition to Psychosis among Clinical High Risk Patients Gillinder Bedi, Facundo Carillo, Guillermo Cecchi, Diego Fernandez Slezak, Mariano Sigman, Jordan E . DeVylder, Felix M . Muchomba, Cheryl M . Corcoran

T163 . Protocol Complexity and Enrollment Eligibility Exclusivity: Are Today’s Depression Study Volunteers Truly Representative? Charles S . Wilcox, Judy L . Morrissey, Nader Oskooilar, Mellissa M . Henry, Daniel E . Grosz, My-Linh Tong, Don F . De Francisco

224

ACNP Annual Meeting Book 2013 rev8.indd 224 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T164 . Auditory Steady State Evoked Potential Abnormalities in Schizophrenia Are Normalized by an mGluR2 Positive Allosteric Modulator Bruce Turetsky, Daniel Wolf, Christian Kohler, Mary March, Alan Cross, Mark Smith, Stephen R . Zukin, Raquel E . Gur

T165 . Effects of Neurokinin 1 Receptor Antagonism on Brain Response to Emotional Visual Stimuli in Co-morbid Alcohol Dependence and Posttraumatic Stress Disorder Primavera Spagnolo, Laura Kwako, Reza Momenan, Melanie L . Schwandt, Vijay A . Ramchandani, Daniel W . Hommer, David T . George, Markus Heilig

T166 . Baseline Characteristics that Result in Higher Placebo on the MCCB Using Regression Analysis George Haig, Earle Bain

T167 . Long-term Follow-up of Gamma Capsulotomy for Intractable OCD Steven Rasmussen, Benjamin Greenberg

T168 . N-Acetylcysteine for the Treatment of Non-suicidal Self-injurious Behavior in Adolescents: A Preliminary Study Kathryn R . Cullen, Bonnie Klimes-Dougan, Lori LaRiviere, Alaa Houri, Melinda Westlund, Bernard Lim, Ana Bortnova, Katharine Nelson, Michael J . Miller, S . Charles Schulz, Bryon Mueller, Lynn Eberly, Kelvin O . Lim

T169 . Phase 2 Evaluation of ITI-007, a Novel Approach to the Treatment of Schizophrenia Kimberly E . Vanover, Sharon Mates, Paul Greengard, Robert E . Davis

T170. Modafinil for the Treatment of Cocaine Dependence Kyle M . Kampman, Jennifer G . Plebani, Kevin G . Lynch, Helen M . Pettinati, Elizabeth Mahoney, Mary Slome, Margo Hendrickson, Charles P . O’Brien

225

ACNP Annual Meeting Book 2013 rev8.indd 225 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T171 . Personality Predicts Dropout and Placebo Response Risk in Patients with Bipolar Depression Gary S . Sachs, Cynthia Siu, Josephine Cucchiaro, Robert Silva, Fred Grossman, Jay Hsu, Amir Kalali, Antony Loebel

T172 . Sleep Architecture Abnormalities as a Risk Factor for Elevated Suicidal Ideation: A Polysomnographic Investigation of Sleep in Treatment Resistant Unipolar and Bipolar Depression Rebecca Bernert, David Luckenbaugh, Wallace C . Duncan, Carlos A . Zarate

T173 . Benzoate, a D-amino Acid Oxidase Inhibitor, for Treatment of Early- phase Alzheimer’s Disease: A Randomized, Double-blind, Placebo- controlled Trial Guochuan Emil Tsai

T174 . Early Changes in Apathy Predicts Response to Adjunctive Oral Methylphenidate in Depressed Patients Sidney Kennedy, Sakina Rizvi, Joseph Geraci, Arun Ravindran

T175 . CONSORT-NP: Guidelines for Reporting of Neuropsyhological Test Results in Clinical Trials Robert M . Bilder

T176 . Effects of Antidepressant Medication on Emotion Regulation in Major Depressive Disorder: An iSPOT-D Report Leanne Williams, Kateri McRae, William Rekshan, James Gross

T177. Trichuris Suis Ova (TSO) as an Immune-inflammatory Treatment for Repetitive Behaviors in ASD Eric Hollander, Casara J . Ferretti, Bonnie P . Taylor, Rachel Noone, Jonathan Kirsch, Emma Racine

226

ACNP Annual Meeting Book 2013 rev8.indd 226 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T178. Safety and Efficacy of Short-term Treatment with the Acetylcholinesterase Inhibitors Rivastigmine and Huperzine a to Reduce the Subjective and Reinforcing Effects Produced by Acute Cocaine Exposure Christopher D . Verrico, James J . Mahoney, Kimberly N . Cooper, Tabish Iqbal, Thomas F . Newton, Richard De La Garza

T179 . The Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) Study: Rationale, Design and Progress Madhukar Trivedi, Patrick J . McGrath, Maurizio Fava, Ramin V . Parsey, Marisa Toups, Benji T . Kurian, Mary L . Phillips, Maria Oquendo, Gerard Bruder, Diego A . Pizzagalli, Sarah Weyandt, Randy Buckner, Philips Adams, Thomas Carmody, Eva Petkova, Myrna M . Weissman

T180 . Safety and Effectiveness of Aripiprazole Once-monthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials (246 and 247) W . Wolfgang Fleischhacker, Raymond Sanchez, Tsai Lan-Feng, Timothy Peters-Strickland, Ross A . Baker, Anna Eramo, Dusan Kostic, John Kane

T181 . Neural Response in Visual Cortex to Emotional Stimuli Predicts Clinical Outcome across Rapid Antidepressant Agents Maura L . Furey, Joanna Szczepanik, Allison C . Nugent, Nancy Brutsche, David Luckenbaugh, Carlos A . Zarate

T182 . Feedforward and Feedback Control Abnormalities during Precision Grasping Implicate Cerebellar Dysfunction in Autism Spectrum Disorder Matthew W . Mosconi, Suman Mohanty, Rachel K . Greene, Lauren Schmitt, David E . Vaillancourt, John A . Sweeney

227

ACNP Annual Meeting Book 2013 rev8.indd 227 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T183 . Elevated Maternal C-reactive Protein and Schizophrenia in a National Birth Cohort Alan Brown, Sarah E . Canetta, Helja-Marja Surcel, Susanna Hinkka- Yli-Salomäki, Andre Sourander

T184 . Childhood Maltreatment and the Structure of the Incidence of Psychiatric Disorders: A National Study Carlos Blanco, Melanie Wall, Chelsea Jin

T185 . Factors Impacting Functional Disability and PTSD Symptoms in OEF/ OIF/OND Veterans with PTSD F . Andrew Kozel, Jeffrey Spence, Christina Bass, Cassie Rae . Morgan, Penelope Jones, Caitlin D . Schraufnagel , Mary B . Turner, John Hart

T186 . Early-onset and Very-early-onset Bipolar Disorder: Distinct or Similar Clinical Conditions? Lukas Propper, Claire O’Donovan, Martina Ruzickova, Cynthia Calkin, Tomas Hajek, Abigail Ortiz, Claire Slaney, Julie Garnham, Martin Alda

T187 . Obsessive-compulsive Symptom Dimensions in School Age Children and Their First Degree Relatives: Results from a Large Community- based Study Pedro de Alvarenga, Raony Cassab Cezar, Tais Moriyama, Marcelo Hoexter, Gisele Manfro, James Leckman, Euripedes Constantino . Miguel, Maria Conceicao Rosario

T188 . Premorbid Impairments in Childhood-onset Schizophrenia David I . Driver, Deanna Greenstein, Madison Farmer, Judith L . Rapoport, Nitin Gogtay

228

ACNP Annual Meeting Book 2013 rev8.indd 228 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T189. Replication and Refinement of the Predictive Value of Cognitive Markers in ADNI: Four Year Follow-up Data Jesus J . Gomar, Concepcion Conejero-Goldberg, Peter Davies, Terry E . Goldberg

T190 . Frequency and Characteristics of Isolated Psychiatric Episodes in Anti- NMDA Receptor Encephalitis Matthew Kayser, Maarten Titulaer, Nuria Gresa-Arribas, Josep Dalmau

T191 . Rare Genetic Variants in VMAT1 (SLC18A1) Are Functional In Vitro and Associated with Bipolar Disorder Falk W . Lohoff, Rachel Hodge, Sneha Narasimhan, Glenn Doyle

T192 . Can Serotonin Put Your Mind at Rest? Alexander Schäfer, Inga Burmann, Ralf Regenthal, Katrin Arelin, Andre Pampel, Arno Villringer, Daniel Margulies, Julia Sacher

T193 . Poverty and the Past: The Relation between Hippocampus Function and Memory Performance Is Linked to Childhood Poverty Elizabeth R . Duval, Sarah N . Garfinkel, Chandra S . Sripada, James E . Swain, Gary W . Evans, Israel Liberzon

T194. Therapeutic Benefits of Dutasteride, a 5 Alpha-reductase Type I Inhibitor, in PMDD: Results of a Pilot Study Pedro Martinez, Lynnette K . Nieman, Leslie Morrow, Dahima Cintron, Karla Thompson, David Rubinow, Peter Schmidt

T195 . The Hypothalamic-pituitary-adrenal Axis, Reproductive Aging, and Depression: Results of Cortisol and ACTH Response to Dex/CRH Testing in Women with and without Perimenopause-related Depression Gioia Guerrieri, Rivka Ben Dor, Leslie Smith, Karla Thompson, Pedro Martinez, David Rubinow, Peter Schmidt

229

ACNP Annual Meeting Book 2013 rev8.indd 229 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T196 . Impaired Glycemic Control in Urban African Americans with Type 2 Diabetes: Depression and Deficits in Functional Capacity Dominique L . Musselman, David Ziemer, Julia Seay, Marcia McNutt, Erica Royster, Bridget Larsen, Terrika Barham, Angelo Brown, Octavia Vogel, Lawrence Phillips, Philip Harvey

T197 . Mu Opioid Receptor A118G Polymorphism Alters Venous Plasma Cortisol Prolactin and Heart Rate during Stress Edward F . Domino, Keeley Erhardt, Mika Fujita-Hirasawa

T198. Inflammation Is Heightened in Iraq and Afghanistan Veterans with Posttraumatic Stress Disorder Aoife O’Donovan, Beth Cohen, Karen Seal, Daniel Bertenthal, Shira Maguen, Mark Pacult, Thomas Neylan

T199 . Reduced Function of Cacna1c Encoded Cav1 .2 during a Hormone Sensitive Period in Brain Development Leads to Sex-dependent Resilience to Despair in Adulthood Michal Arad, Margaret M . McCarthy, Todd D . Gould

T200 . Fasting-induced Increase in Plasma Ghrelin Is Blunted by Intravenous Alcohol Administration: A Within-subject Placebo-controlled Study Lorenzo Leggio, Melanie L . Schwandt, Emily N . Oot, Alexandra A . Dias, Vijay A . Ramchandani

T201 . Early Life Adversity Increases Risk of New Onset Depression during the Menopause Transition C . Neill Epperson, Mary Sammel, Stephanie Scalice, Sarah Conlin, Ellen Freeman

T202 . Cortisol Response to Psychosocial Stress during Depression and Remission Uma Rao, Matthew C . Morris

230

ACNP Annual Meeting Book 2013 rev8.indd 230 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T203 . Salivary Cortisol Response to Trier Social Stress Test in Healthy Third Trimester Pregnant Women and Third Trimester Pregnant Women at Elevated Risk of Developing Postpartum Depression Kristina M . Deligiannidis, Aimee R . Kroll-Desrosiers, Bruce A . Barton, Anthony J . Rothschild

T204 . Direct Comparison of the Psychometric Properties of Multiple Interview and Patient-rated Assessments of Suicidal Ideation and Behavior in a Large Inpatient Sample Eric Youngstrom, Ahmad Hameed, Michael Mitchell, Andrew Freeman, Anna Van Meter, Guillermo Perez Algorta, Alan J . Gelenberg, Roger Meyer

T205 . Methylation of the Leukocyte Glucocorticoid Receptor: Early Adversity and HPA Axis Function Audrey R . Tyrka, Lawrence H . Price, Carmen J . Marsit, Noah S . Philip, Linda L . Carpenter

T206 . Third Trimester Free Thyroxine and Thyroid Binding Globulin Predict Subsequent Perinatal Depression and Anxiety Symptoms as Well as Syndromal Depression Cort Pedersen, Jacqueline Johnson, Nacire Garcia, Melissa Stansbury, Jane Leserman

T207 . Dexamethasone Attenuates Impaired Fear Inhibition in PTSD in a Double-blind Placebo-controlled Study Tanja Jovanovic, Seth D . Norrholm, Jennifer Stevens, Karin M . Nylocks, Kimberly Kerley, Bekh Bradley, Kerry J . Ressler

T208 . Next-generation Psychiatric Drugs: Acetyl-L-carnitine Carla Nasca, Danielle Zelli, Per Svenningsson, Aleksander Mathé, Bruce S . McEwen

231

ACNP Annual Meeting Book 2013 rev8.indd 231 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T209 . Sex Steroid Receptor Gene Expression Correlates with the Expression of Neurodevelopmental Genes and Modulates Gray Matter Volume in the Human Brain Tuong-Vi Nguyen, Peter Schmidt, J . Shane . Kippenhan, Melanie Sottile, Victor Ekuta, Bhaskar S . Kolachana, Beth A . Verchinski, Venkata S . Mattay, Joel E . Kleinman, Barbara Lipska, Daniel R . Weinberger, Karen F . Berman

T210 . Disruption of Early Maternal Care Results in Epigenetic Regulation of the Oxytocin Receptor (OXTR) Gene in Rhesus Macaques Maggie B . Baker, Stephen Lindell, Qiaoping Yuan, Zhifeng Zhou, J . Dee Higley, Stephen Suomi, Christina Barr

T211 . Consumption of a High-fructose Diet during Adolescence Alters HPA Axis Function, Increases Anxiety-like and Depressive-like Behaviors, and Remodels Hypothalamic Gene Expression Gretchen Neigh, Zachary Johnson, Constance Harrell

T212 . Use of Gonadotropin-releasing Hormone Agonist Experimental Model to Isolate Predictors of Depressive Symptoms in Menopause: Role of Nocturnal Hot Flashes and Sleep Disturbance Hadine Joffe, Semmie Kim, Sybil Crawford, Marlene P . Freeman, Nicole Economou, David White, Lee S . Cohen, Janet E . Hall

T213. Menopause and Metabolic Function: Interactive Influences on Depression Symptoms and Emotional Regulation Alison Berent-Spillson, Courtney Marsh, Carol Persad, Jon-Kar Zubieta, Yolanda Smith

T214 . Effects of Intranasal CRF on Brain Response to Threat in Humans Royce J . Lee, Jayant Pinto, Eryka Nosal, Vernon Towle

232

ACNP Annual Meeting Book 2013 rev8.indd 232 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T215 . Vasopressin and CRF Regulation of Hypothalamic-pituitary-adrenal Axis Responsivity in Healthy Volunteers and Drug Free Former Cocaine Dependent Participants Brian Reed, Elizabeth Ducat, Brenda Ray, Molly Deutsch-Feldman, Mary Jeanne Kreek

T216 . Real-time Functional MRI Feedback, Compared to Sham, Reduces Cue- induced Nicotine Craving in Smokers: Results from the First Clinical Trial Colleen A . Hanlon, Karen Hartwell, Jeffrey J . Borckardt, James J . Prisciandaro, Melanie Canterberry, Xingbao Li, Max Owens, Todd LeMatty, Michael Saladin, Megan Moran-Santa Maria, Mark S . George, Kathleen T . Brady

T217. Selective Suppression of α-synuclein in Monoaminergic Neurons of Mice by Intranasal Delivery of Targeted Small Interfering RNA or Antisense Oligonucleotides: Potential Therapy for Parkinson’s Disease Ariadna Recasens, Mireia Galofré, Iria Carballo-Carbajal, A . Ferrés- Coy, Jordi Bové, Celine Perier, María del Carmen Carmona, M . I . Santos, S . Baena, M Rosario Chica, Andrés P . Montefeltro, R . Revilla, Analia Bortolozzi

T218 . Autonomic Responses to Intraoperative Subcallosal Cingulate DBS Patricio Riva Posse, Cory Inman, Stephan Hamann, Steven Garlow, Robert Gross, Helen S . Mayberg

T219 . A Two-site Pilot Study Suggests that Three Days (9 Sessions) of High Dose Left Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) Is Feasible, Safe, and Reduces Suicidal Thinking in Suicidal Inpatients Mark S . George, Rema Raman, Sonia Jain, David M . Benedek, Christopher G . Pelic, Geoffrey G . Grammer, Karen Stokes, Matthew Schmidt, Chad Spiegel, Nancy DeAlmeida, Kathryn Beaver, Jeffrey J . Borckardt, Xiaoying Sun, Murray B . Stein

233

ACNP Annual Meeting Book 2013 rev8.indd 233 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T220 . Anxiety Moderates Response to Psychosocial Treatment for Depression in Bipolar Disorder: Results from Systematic Treatment Enhancement Program for Bipolar Disorder Thilo Deckersbach, Amy Peters, Navneet Kaur, Andrew K . Corse, Amanda R . Arulpragasam, Louisa Sylvia, Pedro Vieira da Silva, Michael Otto, Ellen Frank, David Miklowitz, Michael Berk, Darin Dougherty, Andrew A . Nierenberg

T221 . Addition of a Comprehensive, Individualized, Person Centered Management Program, to Memantine Alone Produces a 900% Increment in a Pivotal Trial Global Measure over Medication Treatment Alone in Advanced Alzheimer’s Disease Barry Reisberg, Sunnie Kenowsky, Sloane Heller, Istvan Boksay, James Golomb, Santosh Ghimire, Carol Torossian, Iryna Lobach

T222 . Neuropeptide-S Microinfusion into Basolateral Amygdala Rescues Behavior in a Rat Model of Posttraumatic Stress Disorder by Increasing Expression of BDNF and Neuropeptide Y-Y1 Receptor Aleksander Mathé, Joseph Zohar, Hagit Cohen

T223 . Monitoring Depression Severity Using the Patient Health Questionnaire during a Treatment Course of Transcranial Magnetic Stimulation Umut Ozbek, Jonathan Cohen, Rebecca Gordon, Marc J . Dubin

T224 . Electroconvulsive Therapy Pre-treatment with Low Dose Propofol: Comparison with Unmodified Treatment Adarsh Tripathi, Nathan Winek, Kapil Goel, Douglas D’Agati, Jesus Gallegos, Geetha Jayaram, Thai Nguyen, Punit Vaidya, Peter Zandi, Jitendra Trivedi, Irving M . Reti

T225 . The Effects of an Index Course of Magnetic Seizure Therapy and Electroconvulsive Therapy on Verbal Learning and Memory Shawn M . McClintock, Mustafa Husain, C . Munro Cullum, Angel V . Peterchev, Ira Bernstein, Louis Stool, Bruce Luber, Paul Croarkin, Elisabeth Bernhardt, Kenneth Trevino, Sarah Lisanby

234

ACNP Annual Meeting Book 2013 rev8.indd 234 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T226 . Rapid Reduction in Suicide Risk in Depressed Elderly Treated with Electroconvulsive Therapy (ECT): Data from Phase I of the PRIDE Study Charles Kellner, Georgios Petrides, Rebecca Knapp, W Vaughn McCall, Mustafa Husain, Robert Young, Sarah Lisanby

T227 . Transcendental Meditation for the Treatment of PTSD in Veterans Kelvin O . Lim, Amy Moran, Michael Kuskowski, Gregory Lamberty

T228. Modifiable Risk Factors and Reports of Depression in Young, Middle- aged, and Older Adults Prabha Siddarth, Aaron Kaufman, David A . Merrill, Cyrus A . Raji, Fernando Torres-Gil, Gary W . Small

T229 . Electroconvulsive Therapy Response and Resting State Functional Connectivity in Older Patients with Major Depressive Disorder Chris Abbott, Thomas Jones, Nicholas T . Lemke, Shruti Gopal

T230 . Clinical Experience of Seven DBS for OCD Patients at an Academic Medical Center Laurie M . McCormick, James Beeghly, Jeremy Greenlee

T231 . Hyperthermia and the Improvement of ASD Symptoms Casara J . Ferretti, Bonnie P . Taylor, Rachel Noone, Emma Racine, Jonathan Kirsch, Eric Hollander

T232 . Substrate-selective COX-2 Inhibition Decreases Anxiety via Endocannabinoid Activation Daniel Hermanson, Nolan Hartley, Joyonna Gamble-George, Lawrence Marnett, Sachin Patel

235

ACNP Annual Meeting Book 2013 rev8.indd 235 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session II—Tuesday T233 . Oxytocin and Facial Expressivity in Patients with Schizophrenia and Healthy Participants Josh Woolley, Chris Fussell, Wanda Lai, Olivia Lam, Brandon Chuang, Bruno Biagianti, Dan Fulford, Daniel H . Mathalon, Sophia Vinogradov

T234 . Withdrawn

T235 . Endothelial Function in Schizophrenia Bernard A . Fischer, William R . Keller, Robert P . McMahon, Walter Meyer, Michael Miller, Robert W . Buchanan

T236 . New Insight into How Ventral Tegmental Area Neurons Encode Action Sequence and Outcome Associations Jesse Wood, Nicholas Simon, Frederick S . Koerner, Robert E . Kass, Bita Moghaddam

T237 . Adolescent Ventral Tegmental Area Neurons Maintain Cue Evoked Responding After Extinction: A Mechanism for Adolescent Behavioral Flexibility? Nicholas Simon, Yunbok Kim, Jesse Wood, Bita Moghaddam

236

ACNP Annual Meeting Book 2013 rev8.indd 236 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

237

ACNP Annual Meeting Book 2013 rev8.indd 237 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

238

ACNP Annual Meeting Book 2013 rev8.indd 238 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III – Wednesday, December 11, 2013

Advocacy Affiliate – Cure Alliance for Mental Illness Research Parity for Mental Illness Robin Cunningham, Hakon Heimer

W1 . 2013 Report of the Membership Advisory Task Force Linda Carpenter, Lisa Monteggia, Margaret Haney, Katherine Burdick, Jennifer Bartz, Elisabeth Binder, Paul Holtzheimer, Amit Etkin, Erica Forbes, Marlene Freeman, Thomas Schulze, Christina Barr, Gregory Light, Vaishali Bakshi, Raymond Cho, Cynthia Crawford, Philip Szeszko

W2 . Interoceptive Awareness in Meditators during Cardiorespiratory Deviations in Body Arousal Sahib Khalsa, David Rudrauf, Richard Davidson, Daniel Tranel

W3 . Neural Mechanisms of Extinction Learning for Monetary Reward in Health and Cocaine Addiction Anna Konova, Muhammad Parvaz, Nelly Alia-Klein, Rita Goldstein

W4 . Withdrawn

W5 . BDNF, Synaptic Function and Cognitive Decline in Healthy Subjects and Pre-clinical Alzheimer’s Disease Pradeep J . Nathan

W6 . Prolonged Temporal Interaction for Peripheral Visual Processing in Schizophrenia: Evidence from a Three-flash Illusion Yue Chen, Daniel Norton, Charles Stromeyer

239

ACNP Annual Meeting Book 2013 rev8.indd 239 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W7 . Social Isolation Stress Markedly Reduces the Response of Cortical Dopaminergic Neurons to Pleasurable Stimuli . Giovanni Biggio, Laura Dazzi

W8 . Impaired Neural Functioning Following Internally Focused Cognition in Obsessive-compulsive Disorder Emily R . Stern, Alexandra F . Muratore, Stephan F . Taylor, James L . Abelson, Patrick R . Hof, Wayne K . Goodman

W9 . Hyperconnectivity of Default Mode and Emotion-salience Neural Networks in Late-adolescent, Remitted Depression Rachel Jacobs, Laura Gabriel, Kelly Ryan, Sara Weisenbach, Amanda M . Baker, Amy T . Peters, Rachel Ringrose, Gloria Harrington, Jon-Kar Zubieta, K . Luan Phan, Scott Langenecker, Robert Welsh

W10 . Altered GABAergic Signaling in Prefrontal Cortex Contributes to Impaired Working Memory in Aged F344 Rats Jennifer Bizon, Cristina Banuelos, Sofia Beas, Joseph McQuail, Ryan Gilbert, Barry Setlow

W11 . Negative Symptoms in the Early Course of Schizophrenia: Their Longitudinal Stability and Relationship to Early Cognitive Processes Joseph Ventura, Kenneth Subotnik, Michael J . Gitlin, Denise Gretchen-Doorly, Gerhard S . Hellemann, Kathleen F . Villa, Keith H . Nuechterlein

W12 . Error Monitoring in Autism: Correlates to Symptom Severity Melisa Carrasco, Gregory L . Hanna, Catherine Lord, William J . Gehring

240

ACNP Annual Meeting Book 2013 rev8.indd 240 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W13 . Prospective Examination of Prepulse Inhibition in OIF/OEF Marines Suggests Reduced Sensorimotor Gating Is a Pre-existing Factor in Those that Develop PTSD after Combat Deployment Victoria Risbrough, Dean Acheson, Dewleen G . Baker, Caroline Nievergelt, Kate Yurgil, Mark A . Geyer

W14 . Relationship between Peritraumatic Distress and Attentional Avoidance of Trauma-relevant Threat in the Prediction of Posttraumatic Stress Disorder: Preliminary Results from a Prospective Study Charmaine Thomas, Christopher Sears, Etienne Very, Juliette Salles, T .H . Eric Bui

W15 . Reduced Impairment, Yet Increased Reliability of Cognitive Control Measurements in Remitted MDD Scott Langenecker, Rachel Jacobs, Natania Crane, Kelly Ryan, Sara Weisenbach, Olusola Ajilore, Michelle Kassel, Laura B . Gabriel, Jon-Kar Zubieta

W16. Neural Substrates of Spatial Working Memory Deficits in Patients with Neurofibromatosis 1 (NF1) Amira Ibrahim, Caroline A . Montojo, Tena Rosser, Nicole Enrique, Katherine H . Karlsgodt, Alcino Silva, Carrie Bearden

W17 . Positive and Negative Symptom Correlates of Second-generation Antipsychotic Adherence in Recent-onset Schizophrenia Kenneth Subotnik, Joseph Ventura, Denise Gretchen-Doorly, Gerhard S . Hellemann, Elisha R . Agee, Laurie R . Casaus, John S . Luo, Kathleen F . Villa, Keith H . Nuechterlein

W18 . Early Changes in Neural Responses to Emotional Information Predict Clinical Response to SSRI Treatment in Depression Beata Godlewska, Ray Norbury, Philip Cowen, Catherine J . Harmer

241

ACNP Annual Meeting Book 2013 rev8.indd 241 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W19 . Differential Alterations of Internally-generated Behavioral Responses and Dose-dependent Treatment Effects in Antipsychotic Naïve First Episode Schizophrenia and Psychotic Mood Disorder Patients Sarah Keedy, James Reilly, Jeffrey R . Bishop, Margret Harris, Peter J . Weiden, John A . Sweeney

W20 . Progressive Reduction of Visual P300 Amplitude in Patients with First Episode Schizophrenia Robert McCarley, Naoya Oribe, Yoji Hirano, Shigenobu Kanba, Elisabetta del Re, Larry J . Seidman, Raquelle Mesholam-Gately, Martha Shenton, Jill M . Goldstein, Kevin M . Spencer, Margaret Niznikiewicz

W21 . Adolescents’ Neural Response to Personally Relevant Social Reward: A Novel Paradigm with Relevance to Affective Symptoms and Sensation Seeking Erika E . Forbes, Lisa Sheeber, Nicholas Allen, Jennifer Silk, Marigrace Ambrosia

W22 . Startle Latency and Magnitude Predict Clinical Outcome in the Psychosis Prodrome: Findings from the North American Prodromal Longitudinal Study (NAPLS) Kristin Cadenhead, Jean Addington, Carrie Bearden, Tyrone Cannon, Barbara A . Cornblatt, Daniel H . Mathalon, Thomas McGlashan, Diana Perkins, Larry J . Seidman, Ming Tsuang, Elaine Walker, Scott Woods

W23 . Developmental Trajectory of Facial Emotion Recognition in Normal Development and Across Stages of Schizophrenia Cheryl M . Corcoran, Pamela Butler Kahn, Elisa Dias, Daniel C . Javitt

W24 . Adults Recovered from Anorexia Nervosa Show Altered Brain Response during Delayed Discounting in Fasted and Fed States Christina Wierenga, Amanda Bischoff-Grethe, Andrew Melrose, Laura Torres, Laura Irvine, Ursula F . Bailer, Walter Kaye

242

ACNP Annual Meeting Book 2013 rev8.indd 242 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W25 . Implicit Cognition towards Self-injury Among Teenage Suicide Attempters vs . Teens Engaged in Non-suicidal Self-injury Daniel P . Dickstein, Megan Puzia, Grace Cushman, Kerri Kim, Karen Seymour, Alexandra Weissman, Matthew Nock, Anthony Spirito

W26. Decision Making in Avoidance-reward Conflict: Behavioral Performance in Non-human Primates and Humans Darin Dougherty, Amanda R . Arulpragasam, Andrew K . Corse, Navneet Kaur, Demetrio Sierra-Mercado, Tina Chou, Alexandra Rodman, Amanda Duffy, Eric J . McDonald, Christine A . Eckhardt, Emad N . Eskandar, Thilo Deckersbach

W27 . The Effects of Tobacco Smoking Status on Theta-gamma Coupling in Patients with Schizophrenia and Non-psychiatric Controls Mera S . Barr, Kristen M . Mackowick, Reza Zomorrodi, Victoria C . Wing, Caroline Wass, Zafiris J . Daskalakis, Tony P . George

W28 . Baseline Neurocognitive Predictors of Responders to Treatment at 12 Month Follow-up for Major Depressive Disorder by Deep Brain Stimulation Shane McInerney, Sakina Rizvi, Heather McNeely, Helen S . Mayberg, Lozano Andres, Peter Giacobbe, Joseph Geraci, Sidney Kennedy

W29 . Relationship between Frontal P300 Event-related Potential and Brain Glutamine/Glutamate Ratio Measured In Vivo Mei-Hua Hall, Jordan W . Smoller, Deborah L . Levy, Mary Lohan, Kevin M . Spencer, Dost Ongur

W30 . Ethnic Differences in Physiological Responses to Fear Conditioned Stimuli Karen G . Martinez, Jose A . Franco, Mohammed R . Milad, Gregory J . Quirk

243

ACNP Annual Meeting Book 2013 rev8.indd 243 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W31 . Preventing the Return of Fear Using a Retrieval + Extinction Reconsolidation Update Mechanism: The Integration of Fear-potentiated Startle and US-expectancy Ratings Seth D . Norrholm, Victor T . Warren, Kemp Anderson, Cliffe Kwon, Lauren Bosshardt, Tanja Jovanovic, Bekh Bradley, Kerry J . Ressler

W32. Neural Correlates of Relational and Item-specific Encoding and Retrieval (RiSE) in Schizophrenia J . Daniel Ragland, Charan Ranganath, Deanna M . Barch, James M . Gold, Michael P . Harms, Evan Layher, Angus W . MacDonald, Joshua Phillips, Andrew Poppe, Steve M . Silverstein, Dennis Thompson, Cameron S . Carter

W33 . Differential Effects of Aging and High Fat Diet on Cognitive Function in Mice James Kesby, Svetlana Semenova, Jane J . Kim, Jerrold M . Olefsky, Cristian L . Achim, Virawudh Soontornniyomkij, Benchawa Soontornniyomkij, Dilip V . Jeste

W34 . Age-at-Onset and Cognitive Control-related Brain Circuitry in First Episode Schizophrenia Tara Niendam, Emilio Ferrer, Tyler A . Lesh, Stefania Ashby, Marjorie Solomon, J . Daniel Ragland, Jong Yoon, Michael J . Minzenberg, Cameron S . Carter

W35 . Ecologically-valid Assessment of Attention in Schizophrenia in a Virtual Environment George Foussias, Ishraq Siddiqui, Krysta McDonald, Eliyas Jeffay, Konstantine K . Zakzanis, Gary Remington

W36 . Effects of Amphetamine on Encoding and Retrieval of Memory for Emotional Stimuli Jessica Weafer, David Gallo, Harriet de Wit

244

ACNP Annual Meeting Book 2013 rev8.indd 244 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W37 . Training the Brain to Abstain from Alcohol: Towards the Neural Basis of Approach/Avoidance Training Effects in Hazardous Drinkers Charles Taylor, Akanksha Shukla, Karalani Cross, Nader Amir, Murray B . Stein, Martin Paulus

W38 . Steady-state Gamma-band Responses in Children with Autism Spectrum Disorders during an Auditory Oddball Task Kristina L . McFadden, Sarah Steinmetz, Susan Hepburn, Jason Tregellas, Donald Rojas

W39 . Variation in Serotonin Transporter Gene Predicts Neural Activation in a Response Inhibition Task Ranjani Prabhakaran, Roberta Rasetti, Ena Xiao, Bhaskar S . Kolachana, Daniel R . Weinberger, Venkata S . Mattay, Karen F . Berman

W40. Fear Learning Deficits in Women with PTSD: Estrogen Is Associated with Extinction of Fear-potentiated Startle but Not Dark-enhanced Startle Ebony Glover, Vas Michopoulos, Kristina B . Mercer, Seth D . Norrholm, Bekh Bradley, Kerry J . Ressler, Tanja Jovanovic

W41. Pattern Separation Bias Deficit in Patients with Schizophrenia Theo Van Erp, Adrian Preda, Steven Potkin, Lawrence Faziola, Lisa Thom, Dana Nguyen, Andrea Weideman, Charles Kessler, Craig Stark

W42 . Change in Functional Activation during Cognitive Control Across Childhood and Adolescence as Related to Risk Taking Behavior Katherine H . Karlsgodt, Bart D . Peters, Toshikazu Ikuta, Pamela DeRosse, Kimberly Cameron, Angelica Bato, Philip R . Szeszko, Anil Malhotra

245

ACNP Annual Meeting Book 2013 rev8.indd 245 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W43 . Learning in the Absence of Intact Cognitive Control: The Neural Substrates of Transitive Inference in Adolescents with Autism Spectrum Disorders Marjorie Solomon, Tyler A . Lesh, Tara Niendam, Jonathan Beck, John Matter, Nathan Whitmore, Cameron S . Carter, J Daniel Ragland

W44 . Attenuated Behavioral and Brain Responses to Trust Violations among Assaulted Adolescent Girls Josh Cisler, Jennifer Lenow, Scott Steele, Clinton D . Kilts

W45 . Independent and Additive Impact of Co-occurring Anxiety Disorders on Elevated Trait Impulsivity in Bipolar Alcoholics: Implications for Alcoholism Severity and Bipolar Course of Illness Bryan K . Tolliver, James J . Prisciandaro, Delisa G . Brown, Helena Brenner

W46. Fronto-parietal Dysfunction and Cognitive Control Deficits in First- episode Psychosis Patients with Schizophrenia and Bipolar Disorder Tyler A . Lesh, Benjamin Geib, Tara Niendam, Michael J . Minzenberg, Jong Yoon, J Daniel Ragland, Marjorie Solomon, Cameron S . Carter

W47 . Mismatch Negativity Predicts Psychosis Onset and Is Associated with Plasma Markers of Inflammation in Youth at Clinical High Risk for Psychosis Daniel H . Mathalon, Diana Perkins, Kristin Cadenhead, Gregory A . Light, Peter Bachman, Jason Johannesen, Aysenil Belger, Margaret Niznikiewicz, Erica Duncan, Ricardo Carrion , Jean Addington, Tyrone Cannon, Barbara A . Cornblatt, Larry J . Seidman, Elaine Walker, Scott Woods

246

ACNP Annual Meeting Book 2013 rev8.indd 246 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W48 . High-resolution fMRI Reveals Reward Anticipation Signaling of the Substantia Nigra that Is Modulated by Reward Magnitude in Healthy Subjects and Blunted Responses in Schizophrenia Jong Yoon, Anthony Grandelis, Edward D . Cui, Michael J . Minzenberg, Tara Niendam, J Daniel Ragland, Tyler A . Lesh, Marjorie Solomon, Cameron S . Carter

W49 . Acute and Non-acute Effects of Cannabis on Neurocognitive Functioning April D . Thames, Natalie Arbid

W50 . Anger in Body and Brain: Elevated Blood Pressure Impedes Reaction Time and Diminishes Neural Activity in Attention and Visual Areas during a Decision Making Task Sarah N . Garfinkel, Jos Brosschot, Julian Thayer, Hugo D . Critchley

W51 . Input-information Processing during Fear Acquisition in PTSD Using Dynamic Causal Modeling and fMRI Huijin Song, Mohammed R . Milad

W52. Deficits in Reward Prediction Error Signaling in Cocaine Addiction: Evidence from the Feedback Negativity and Relationship to Recency of Cocaine Use Muhammad Parvaz, Anna Konova, Jonathan P . Dunning, Greg H . Proudfit, Pias Malaker, Scott J . Moeller, Nelly Alia-Klein, Rita Goldstein

W53 . Genetic Factors Contributing to Body Weight in Anorexia Nervosa and Bulimia Nervosa Allan S . Kaplan, Zeynep Yilmaz, Arun K . Tiwari, Robert D . Levitan, Jo Knight, Sara Piran, Sarah Gagliano, Andrew Bergen, Walter H . Kaye, James Kennedy

247

ACNP Annual Meeting Book 2013 rev8.indd 247 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W54 . FKBP5 Moderates Alcohol Withdrawal Severity: Human Genetic Association and Functional Validation in Knockout Mice Ming-Chyi Huang, Melanie L . Schwandt, Julie A . Chester, Aaron M . Kirchhoff, Chung-Feng Kao, Tiebing Liang, Jenica Tapocik, Vijay A . Ramchandani, David T . George, Colin A . Hodgkinson, David Goldman, Markus Heilig

W55 . Haplotype and SNP Variation in Genes Implicated in GABA Synthesis, Synaptic Transmission and Re-uptake are Predictors for Alcoholism Mary-Anne Enoch, Colin A . Hodgkinson, Elena Gorodetsky, Cheryl Marietta, Alec Roy, David Goldman

W56 . Role of Genetic Variation in Host-parasite Interaction Associated with Major Mental Illness Shinichi Kano, Colin A . Hodgkinson, Lorraine V . Jones-Brando, Sharon Eastwood, Koko Ishizuka , Minae Niwa, Alec Roy, Nicola Cascella, Faith Dickerson, Anil Malhotra, David Goldman, Paul J . Harrison, Robert Yolken, Akira Sawa

W57 . Genome-wide Association Study of Superior Frontal Volumes in Schizophrenia Ryota Hashimoto, Masashi Ikeda, Fumio Yamashita, Kazutaka Ohi, Hedenaga Yamamori, Yuka Yasuda, Michiko Fujimoto, Masaki Fukunaga, Kiyotaka Nemoto, Kiyoto Kasai, Norio Ozaki, Nakao Iwata, Masatoshi Takeda

W58 . Withdrawn

W59 . A Trial Matching and Mismatching Ondansetron and Sertraline to 5-HTTLPR Alleles in Non-treatment Seeking Alcohol Dependent Individuals George Kenna, Lorenzo Leggio, Robert M . Swift, William H . Zywiak, John McGeary, James Clifford, Jessica R . Shoaff, Samuel R . Fricchione, Michael Brickley, Kayla Beaucage, Carolina Haass- Koffler, Cynthia Vuittonet

248

ACNP Annual Meeting Book 2013 rev8.indd 248 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W60 . Monoamine Polygenic Liability in Health and Cocaine Addiction: Imaging Genetics Study Scott J . Moeller, Muhammad Parvaz, Elena Shumay, Salina Wu, Nicassia Beebe-Wang, Anna Konova, Michail Misyrlis, Nelly Alia- Klein, Rita Goldstein

W61 . Brain eQTLs Shared by Multiple Psychiatric Diseases Chunyu Liu, Chunling Zhang, Chao Chen, Judith Badner, Ney Alliey-Rodriguez, Elliot Gershon, Eric Gamazon, IOCDF-GC, TSAICG, Nancy J . Cox

W62 . Combined Brain Transcriptome Meta-analysis and Genome-wide Association Studies Provide Evidence for Shared Genetic Risk between Depression and Other Brain Disorders Etienne Sibille, Ying Ding, Lun-Ching Chang, Xingbin Wang, Jean- Philippe Guilloux, Jenna Parrish, Hyunjung Oh, David A . Lewis, George C . Tseng

W63 . A Candidate Gene Analysis of Acoustic Startle Latency and Psychosis Lauren Gensler, Tanja Jovanovic, Alicia K . Smith, Lynn Almli, Seth D . Norrholm, Ebony Glover, Kerry J . Ressler, Bekh Bradley, Erica Duncan

W64 . DSM-IV and DSM-5 Alcohol, Cannabis, and Methamphetamine Use Disorders: Rates, Heritability, and Co-morbidity in an American Indian Community Sample David Gilder, Ian Gizer, Cindy L . Ehlers

W65 . A Second Large-scale Candidate Gene Analysis of Endophenotypes for Schizophrenia Further Implicates the Glutamate and Neuregulin-ErbB4 Signaling Pathways Tiffany A . Greenwood, Gregory A . Light, Neal R . Swerdlow, David L . Braff

249

ACNP Annual Meeting Book 2013 rev8.indd 249 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W66 . An Interactive Effect of the Two SNPs in the Catechol-O- Methyltransferase (COMT) Gene on Dopamine Concentration in the Prefrontal Cortex Elena Shumay, Joanna Fowler, Nora D . Volkow

W67 . Differential Allelic Expression and cis-regulatory Sites at Human Neuronal Genes Qiaoping Yuan, Seungeun Yeo, Zhifeng Zhou, Colin A . Hodgkinson, David Goldman

W68. Application of Sequencing, Fatty Acid Profiling, and Metabolomics Investigations to Explore Pathogenesis and Treatment Strategy for Anorexia Nervosa Pei-an Betty Shih, Jun Yang, Christophe Morisseau, Ashley Van Zeeland, Toni-Kim Clarke, Andrew W . Bergen, Pierre Magistretti, Katherine Ann Halmi, Wade Berrettini, Nicholas Schork, Walter H . Kaye, Bruce D . Hammock

W69 . Evidence for Epistatic Interactions between ANK3 and Voltage Gated Ion Channels in Influencing Schizophrenia Risk Rebecca Birnbaum, Fengyu Zhang, Daniel Weinberger

W70 . Suicidal Ideation and Suicidality in an American Indian Community: Comorbidity with Trauma Exposure, ASPD, Affective Disorders and Drug Dependence Cindy L . Ehlers, David Gilder

W71 . Whole Genome Sequencing of Schizophrenia in a Founder Population Todd Lencz, Semanti Mukherjee, Shai Carmi, Anil Malhotra, Itsik Pe’er, Ariel Darvasi

250

ACNP Annual Meeting Book 2013 rev8.indd 250 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W72 . A Genome-wide Association Study on Antipsychotic-induced Body Weight Gain Dissecting the CATIE Sample Daniel J . Mueller, Eva J . Brandl, Arun K . Tiwari, Clement C . Zai, Nabilah I . Chowdhury, Tamara Arenovich, Jiangshan J . Shen, James L . Kennedy

W73 . Pharmacogenetics of Obsessive-compulsive Disorder Candidate Genes and Antidepressant Response Gwyneth Zai, Clement C . Zai, Vanessa Goncalves, Eva J . Brandl, Karen Wigg, James L . Kennedy, Peggy M .A . Richter

W74 . The Genetic Basis of Neurocognitive Decline and Reduced White-matter Integrity in Normal Human Brain Aging David C . Glahn, Jack Kent, Rene L . Olvera, Laura Almasy, Peter Kochunov, Ravi Duggirala, John Blangero

W75 . Variation in the ZNF804A Gene Is Associated with Striatal Presynaptic Dopamine Function Catherine E . Hegarty, Daniel P . Eisenberg, Philip D . Kohn, Daniel R . Weinberger, Joseph C . Masdeu, Karen F . Berman

W76 . Pharmacoepigenetics of Depression - A Role of Monoamine Oxidase A DNA Hypomethylation? Katharina Domschke, Nicola Tidow, Jürgen Deckert, Volker Arolt, Peter Zwanzger, Bernhard Baune

W78 . High Transcriptional Plasticity of the AKT1 Gene Is Revealed by RNA Sequencing Analysis in the Brain Gianluca Ursini, Joo Heon Shin, Bin Xie, Giovanna Punzi, Yuan Gao, Joel E . Kleinman, Thomas M . Hyde, Keri Martinowich, Daniel R . Weinberger

251

ACNP Annual Meeting Book 2013 rev8.indd 251 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W79 . Oxytocin and Vasopressin Peptide Gene Region: Associations with Autism Related Phenotypes Sunday Francis, Emily Kistner-Griffin, Guter Stephen, Edwin H . Cook, Suma Jacob

W80 . Association of SCN2A Variants with Cognitive Ability in Schizophrenia, and Additional Support from Analyses of Unaffected Siblings, Independent Schizophrenia Samples, fMRI, and mRNA Expression in Brain Dwight Dickinson, Richard Straub, Joey W . Trampush, Yuan Gao, Ningping Feng, Gianluca Ursini, Kristin Bigos, Bhaskar Kolachana, Ryota Hashimoto, Masatoshi Takeda, Dan Rujescu, Joseph H . Callicott, Thomas M . Hyde, Karen F . Berman, Joel E . Kleinman, Daniel R . Weinberger

W81 . Variation in the Williams Syndrome GTF2i Gene and Anxiety-proneness Interactively Predict DLPFC Response to Aversive Social Stimuli in Humans Mbemba Jabbi, Qiang Chen, Nicholas Turner, Michael White, J . Shane . Kippenhan, Philip Kohn, Dwight Dickinson, Bhaskar Kolachana, Venkata Mattay, Daniel R . Weinberger, Karen Berman

W82 . Generation of Serotonin Transporter Knock-in Mice Carrying Ile425Val Coding Variant Associated with Obsessive-compulsive Disorder and Tourette Disorder Sammanda Ramamoorthy, Padmanabhan Mannangatti, Kamalakkannan Naidu, Lankupalle Jayanthi, Dennis L . Murphy

W83 . New Insight into Genetic Mechanism Underlying the Treatment Effect of Obsessive-compulsive Disorder Using SSRIs Haide Qin, Jack Samuels, Ying Wang, Gerald Nestadt, Yin Yao

W84 . The Utility of DNA Extracted from Saliva for Methylation Studies of Psychiatric Traits Alicia K . Smith, Varun Kilaru, Torsten Klengel, Kristina B . Mercer, Karen Conneely, Kerry J . Ressler, Elisabeth Binder

252

ACNP Annual Meeting Book 2013 rev8.indd 252 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W85 . ADRB2 Gene Polymorphism Interacts with Childhood Trauma in Conveying Risk for Adult Posttraumatic Stress Disorder (PTSD) Anthony P . King, Kerry J . Ressler, Lynn Almli, Greg Cohen, Marijo Tamburrino, Sandro Galea, Joseph R . Calabrese, Israel Liberzon

W86 . Variation in the Human Fatty Acid Amide Hydroxylase (FAAH) Gene and Threat Processing Francisco J . Amador, Andrew Holmes, Carmen L . Cadilla, Mohammed R . Milad, Karen G . Martinez, Gregory J . Quirk

W87 . Telomere Length Measurements in Post-mortem Human Brain in Major Depressive Disorder Firoza Mamdani, Brandi Rollins, William E . Bunney, Richard M . Myers, Jack David Barchas, Alan F . Schatzberg, Stanley J . Watson, Huda Akil, Marquis P . Vawter, Pedro A . Sequeira

W88 . Dynamics of Transcriptional Coexpression Brain Networks Over the Human Lifespan Claudia C . Wehrspaun, Wilfried Haerty, Danielle Bassett, Joo Heon Shin, Daniel R . Weinberger, Chris Ponting

W89 . Large-scale RNA-sequencing of Schizophrenia Brains by the CommonMind Consortium Pamela Sklar

W90 . Pharmacogenetics of Growth Effects Complicating ADHD Treatment Erika L . Nurmi, Allyson Mallya, Karyn S . Mallya, Gerhard S . Hellemann, James McGough, Sandra K . Loo, Robert M . Bilder, James T . McCracken

W91 . Obsessive-compulsive Traits in Children and Adolescents from the General Population: A Genome-wide Association Study Paul D . Arnold, Christine Burton, Laura Park, Bingbin Li, S-M Shaheen, Vanessa Sinopoli, Annie Dupuis, Andrew Paterson, Jennifer Crosbie, Russell Schachar

253

ACNP Annual Meeting Book 2013 rev8.indd 253 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W92 . Leveraging Hyperserotonemia and Whole Exome Sequencing in Autism Families to Identify Genetic Risk Factors James S . Sutcliffe, Nicholas Campbell, Emily L . Crawford, Bingshan Li, Lea K . Davis, Nancy J . Cox, Edwin H . Cook

W93. A Genome-wide Association Study Identifies a Genetic Locus in the GRB10-amino Acid Decarboxylase Region of 7p12 .2 Associated with Caucasian Treatment Resistant Schizophrenia Patients Herbert Y . Meltzer, Jiang Li

W94 . Characterization of Autism-associated De Novo Mutations Impacting Integrin Receptor Subunit Genes James S . Sutcliffe, Emily L . Crawford, Keaton Wadzinski, Ana Carneiro

W95 . RNA Editing Levels of 5-HT2C and GluA2 Are Increased in Suicides with Major Depression Monsheel Sodhi, Thomas M . Hyde, Stefan Green, Joel E . Kleinman

W96 . Deep RNA Seq Characterization of Novel Transcripts in CACNA1C Joo Heon Shin, Dewey Kim, Joshua Hurtado, Bin Xie, Thomas M . Hyde, Joel E . Kleinman, Daniel R . Weinberger

W97 . Genetic Pathway Analyses of the Endocannabinoid System in a Sample of Social Drinkers and Treatment-seeking Alcoholics Jia Yan, Bethany L . Stangl, Mark A . Reimers, Melanie L . Schwandt, Hui Sun, Colin A . Hodgkinson, David Goldman, Daniel W . Hommer, David T . George, Kenneth S . Kendler, Markus Heilig, Vijay A . Ramchandani

W98 . Clinical and Genetic Predictors of Length of Sobriety in Alcoholics Treated with Acamprosate Joanna Biernacka, Jennifer Geske, Gregory Jenkins, Mark A . Frye, Doo-Sup Choi, Daniel Hall-Flavin, Terry Schneekloth, Falk Kiefer, Karl F . Mann, Victor Karpyak

254

ACNP Annual Meeting Book 2013 rev8.indd 254 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W99 . Alterations of BDNF Signaling and Splicing in Violent Suicide Giovanna Punzi, Gianluca Ursini, Kristen Maynard, Joo Heon Shin, Bin Xie, Yuan Gao, Joel E . Kleinman, Thomas M . Hyde, Keri Martinowich, Daniel R . Weinberger

W100 . Potential Methylation in the 5HT System: Analysis in Suicidal Behavior Vincenzo de Luca, Ali Bani-Fatemi, Jiali Song, Aaron Howe, Nuwan Hettige, Ahmed Hassan

W101 . Discovery and Validation of Blood Biomarkers for Suicidality Alexander B . Niculescu, Helen Le-Niculescu, Daniel Levey, Mikias Ayalew, Nitika Jain, Evan Winiger, Ganesh Shankar, Mark Radel, Elizabeth Belanger, Hilary Duckworth, Robert Schweitzer, Michael Yard, George Sandusky, Anantha Shekhar, Nicholas Schork, Daniel Salomon

W102 . Growth Factors as Biomarkers of Major Depressive Disorder and Potential Predictors of Antidepressant Drug Response Angelos Halaris, Anne Clark-Raymond, Edwin Meresh, Aparna Sharma, Robin Kang, Brandon Hage, Kathryn Morrissey, Jawed Fareed, Ghanshyam Pandey

W103 . Task-related Brain Activation in Subjects with Chronic, Stable Schizophrenia and the Effects of a Single-dose α-7 Nicotinic Acetylcholine Receptor Agonist (AQW051): A Placebo-controlled, Double-blind, Randomized Study Deanna M . Barch, Stephen R . Marder, Michael P . Harms, Lars F . Jarskog, Will Cronenwett, Li-Shiun Chen, Markus Weiss, Ralph P . Maguire, Nicole Pezous, Dominik Feuerbach, Cristina Lopez-Lopez, Rhett B . Behrje, Baltazar Gomez-Mancilla, Robert W . Buchanan

W104 . Opioid Antagonism Decreases Hedonic Responses to Social Stimuli in Healthy Adults Margaret C . Wardle, Anya K . Bershad, Matt Pulaski, Harriet de Wit

255

ACNP Annual Meeting Book 2013 rev8.indd 255 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W105. Inpatient Resource Utilization and Cost-related Benefits of Long-acting Injectable Antipsychotics Across Different Age Groups of Medicaid- insured Schizophrenia Patients Craig Karson, Steve Offord, Ross A . Baker, Anna Eramo, Jay Lin, Siddhesh Kamat

W106. A Trial of D-cycloserine to Treat the Social Deficit in Older Adolescents and Young Adults with Autism Spectrum Disorders Maria R . Urbano, Leonore Okwara, Paul Manser, Kathrin Hartmann, Stephen Deutsch

W107 . Selective Effects of the 5-HT2C Receptor Agonist Meta- chlorophenylpiperazine (mCPP) on Intake of a Palatable Snack Food in Healthy Female Volunteers: Correlation with Regional Brain Activations Measured by BOPLD fMRI Colin T . Dourish, Jason M . Thomas, Suzanne Higgs

W108 . Measurement of Immune Activation via Blood Gene Expression Early and Accross Treatment of Major Depressive Disorder Marisa Toups, Thomas Carmody, Cobi Heijnen, Robert Dantzer, Madhukar Trivedi

W109 . Pregnenolone for Depression in Outpatients with Bipolar Disorder E . Sherwood Brown, John Park, Christine E . Marx, Linda Hynan, Domingo Davila, Alyson Nakamura, Prabha Sunderajan, Alexander Lo, Traci Holmes

W110 . Marijuana Withdrawal and Relapse in the Human Laboratory: Effect of Zolpidem Alone and in Combination with Nabilone Margaret Haney, Ziva Cooper, Gillinder Bedi, Stephanie Collins Reed, Divya Ramesh, Richard W . Foltin

W111 . Relationship between Tobacco Consumption and Lifetime Cannabis Use Status in Outpatients with Schizophrenia Tony P . George, Rachel A . Rabin

256

ACNP Annual Meeting Book 2013 rev8.indd 256 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W112 . Intravenous Methamphetamine Self-administration by Humans in a Modified Progressive-ratio Paradigm Rajkumar J . Sevak, Carmen Freire-Cobo, Eric Wagreich, Edythe D . London

W113 . Topiramate Treatment of Heavy Drinkers: Moderation by a GRIK1 Polymorphism Henry Kranzler, Jonathan Covault, Richard Feinn, Stephen Armeli, Howard Tennen, Albert Arias, Joel Gelernter, Timothy Pond, Cheryl Oncken, Kyle Kampman

W114. Onset of Efficacy of Long-acting Injectable Paliperidone Palmitate for Negative Symptoms and Anxiety/Depression in Subjects with Schizophrenia Dong-Jing Fu, Cynthia A . Bossie, Jennifer Kern Sliwa, Yi-Wen Ma, Larry Alphs

W115 . Effects of Varenicline on Neural Correlates of Motivation for Alcohol in Heavy Drinkers: The Alcohol-food Incentive Delay Task Vatsalya Vatsalya, Reza Momenan, Melanie L . Schwandt, Marion Coe, Selena Bartlett, Daniel W . Hommer, Markus Heilig, Vijay A . Ramchandani

W116 . Treatment with Paroxetine Increases Levels of Nociceptine in Cerebrospinal Fluid in Females with Fibromyalgia Lars H . Tanum, Morten Vinje, Gunnar Ordeberg, Fred Nyberg

W117. Efficacy of Lurasidone in the Treatment of Schizophrenia with Prominent Negative Symptoms: A Post-hoc Analysis of Short-term Trials Nina R . Schooler, Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Robert Goldman, Antony Loebel

257

ACNP Annual Meeting Book 2013 rev8.indd 257 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W118 . Critical Testing of the Alcohol Incentive-sensitization Model in Young Heavy Binge Drinkers Developing Symptoms of Alcohol Use Disorder Andrea King, Patrick McNamara, Dingcai Cao

W119 . Is Quality of Life Related to Cognitive Performance or Negative Symptoms in Patients with Schizophrenia? Results from a Double-blind, Active-controlled, Lurasidone Extension Study Philip D . Harvey, Antony Loebel, Josephine Cucchiaro, Debra Phillips, Cynthia Siu

W120 . Abuse Potential of Intranasal Buprenorphine versus Buprenorphine/ Naloxone in Buprenorphine-maintained Heroin Users Jermaine D . Jones, Maria A . Sullivan, Jeanne M . Manubay, Shanthi Mogali, Verena Metz, Sandra D . Comer

W121 . Positive Symptoms Respond to Add-on Aspirin in Schizophrenia Patients with High Sera CRP Levels: A Post-hoc Analysis of an RCT Mark Weiser, Shimon Burshtein, Liana Fodoreanu, Roxana Chiriță, Ghiorghe Talău, Diana Cirjaliu, Naama Fund, Robert Yolken, John M . Davis, M .D, Michael Davidson

W122 . Pharmacogenetics of CYP2C19 and Response to Escitalopram in Autism Spectrum Disorders (ASD) Jeffrey R . Bishop, Fedra Najjar, Thomas Owley, Guter Stephen, Edwin H . Cook

W123 . Implementation of Metabolic Monitoring Guidelines for Patients Receiving Antipsychotic Medications in a Large Outpatient Psychiatry Clinic: Interventions and Outcomes Jayesh Kamath, Rana Singh, Xuesong Chen, Helen Wu

W124 . Which Schizophrenia Subjects Relapse Despite Adherence to Long- acting Antipsychotic Therapy? Henry Nasrallah, Ibrahim Turkoz, Cynthia A . Bossie, Dong-Jing Fu, Srihari Gopal, Larry Alphs, David Hough

258

ACNP Annual Meeting Book 2013 rev8.indd 258 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W125 . Plasma Oxytocin Concentrations Following MDMA or Intranasal Oxytocin in Humans Matthew G . Kirkpatrick, Sunday M . Francis, Suma Jacob, Royce J . Lee, Harriet de Wit

W126 . Effects of MDMA and THC on Social Subjective States and Social Processing in Humans Gillinder Bedi, Daniel Burghart, Jenny Porter, Nicholas T . Van Dam, Kevin N . Ochsner, Margaret Haney

W127 . Pro-attentional Effects of Amphetamine in Healthy Adults Are Predicted by Levels of Sensorimotor Gating Neal R . Swerdlow, Savita G . Bhakta, Jo A . Talledo, Sarah N . Lamb, Bryan Balvaneda, Justin Kei, Hsun-Hua Chou

W128 . Cariprazine Demonstrates High Dopamine D3 and D2 Receptor Occupancy in Patients with Schizophrenia: A Clinical PET Study with [11C]-(+)-PHNO Mark Slifstein, Anissa Abi-Dargham, Deepak C . D’Souza, Richard E . Carson, István Laszlovszky, Suresh Durgam, Nika Adham, Béla Kiss, István Gyertyan, Margit Kapás, Yih Lee

W129 . Lack of Subjective Abuse-related Effects of Intranasal Eluxadoline: A Novel Mu-delta Opiate Modulator for Oral Use in IBS-d Naama Levy-Cooperman, Gail McIntyre, Laura Bonifacio, Mike Davenport, Paul Covington, Scott Dove, June Almenoff, Bijan Chakraborty, Kerri A . Schoedel, Michael McDonnell, Edward M . Sellers

W130 . The Effects of 5HT-7 Antagonism on Sleep in Humans: A Placebo- controlled Cross-over Study of Lurasidone Andrew Krystal, Gary Zammit, Andrei Pikalov, Antony Loebel

259

ACNP Annual Meeting Book 2013 rev8.indd 259 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W131 . Trajectories of Response to Repeat Dose of Intravenous Subanesthetic Ketamine in Treatment Resistant Depression Paulo R . Shiroma, Brian Johns, Michael Kuskowski, Paul Thuras, Kelvin O . Lim

W132 . Cognitive Training with Pharmacological Enhancement in Schizophrenia Ana D . Stan, Debra Bushong, Binu Thomas

W133 . Adverse Childhood Experiences Predict Heavier Drinking and Greater Alcohol Intake during Intravenous (IV) Alcohol Self-administration in Non-dependent Drinkers Bethany L . Stangl, Melanie L . Schwandt, Laura E . Kwako, Jia Yan, Molly Zametkin, Vijay A . Ramchandani

W134. Δ -THC Attenuates and d-amphetamine Potentiates Responses to a Psychosocial Stressor ⁹ Emma L . Childs, Harriet de Wit

W135 . Meta-analysis: Response Curve to SSRIs in OCD Michael H . Bloch, Yasmin Issari, Ewgeni Jakubovski

W136. A Pilot Study of a Dopamine β-hydroxylase Inhibitor, Nepicastat, in the Treatment of PTSD with Genotype Outcome Analysis Lori Davis, David P . Graham, Hamner Mark, David Nielson, Thomas Kosten, Iouri Makotkine, Rachel Yehuda

W137 . Preliminary Investigation of EEG Predictors in an Open-label, Flexible- dose, Repeated Infusions of Ketamine as Augmentation in Treatment Resistant Depression Cristina Cusin, Matthias Eikermann, Sebastian Zaremba, Kara Pavone, Kelley Durham, Trina Chang, Paolo Cassano, Christina Dording, David Soskin, David Mischoulon, Maurizio Fava

260

ACNP Annual Meeting Book 2013 rev8.indd 260 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W138 . Intranasal Methamphetamine Self-administration in Humans during D-amphetamine Maintenance Paul Glaser, Erika Pike, Lon Hays, William W . Stoops, Craig R . Rush

W139 . Lurasidone in the Treatment of Early-stage Schizophrenia: A Post-hoc Analysis of Three Pooled Acute Treatment Studies Jeffrey Lieberman, Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Fred Grossman, Antony Loebel

W140 . Perceptions of Obsessive Compulsive Disorder and Potential Impact on Treatment Outcome Michael Van Ameringen, William Simpson, Beth Patterson, Jasmine Turna

W141 . Do We Know Why There Are Regional Differences in Signal Detection in Global Neuroscience Clinical Trials? Amir Kalali

W142 . Trajectory of Neurocognition in First-episode Schizophrenia Joey W . Trampush, Delbert G . Robinson, Todd Lencz, John Kane, Anil Malhotra, Terry E . Goldberg, Danielle Beech

W143 . Withdrawn

W144 . Chronic High Dose Adjunctive Intranasal Oxytocin in Schizophrenia Patients David Feifel, Kai MacDonald, Cobb Patrice, Rebecca McKinney

W145 . The Impact of Cocaine Use Patterns, Demographic and Mood Variables, and Addiction Severity on Neurocognitive Functioning in Individuals with Cocaine Use Disorders James Mahoney, Ari Kalechstein, Christopher D . Verrico, Tabish Iqbal, Thomas Newton, Richard De La Garza

261

ACNP Annual Meeting Book 2013 rev8.indd 261 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W146. Efficacy and Safety of Treatment with Lurasidone Adjunctive to Lithium or Valproate in Bipolar I Depression: Results of Two 6-week Studies Joseph R . Calabrese, Trisha Suppes, Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro, Andrei Pikalov, Antony Loebel

W147 . Lurasidone Adjunctive Therapy with Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-blind, Placebo-controlled Study (PREVAIL 3) Trisha Suppes, Joseph R . Calabrese, Robert Silva, Hans Kroger, Josephine Cucchiaro, Andrei Pikalov, Antony Loebel

W148 . Lurasidone in Bipolar I Depression: A 24 Week, Open-label Extension Study Terence A . Ketter, Kaushik Sarma, Robert Silva, Jane Xu, Josephine Cucchiaro, Antony Loebel

W149 . Short- and Longer-term Treatment with Lurasidone in Patients with Bipolar I Depression: Effect on Metabolic Syndrome Susan McElroy, Andrei Pikalov, Josephine Cucchiaro, Jay Hsu, Hans Kroger, Debra Phillips, Antony Loebel

W150 . Early Improvement Predicts Endpoint Response to Lurasidone in Schizophrenia: Pooled Analysis of Five Double-blind Trials Christoph U . Correll, Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Robert Goldman, Antony Loebel

W151 . Neurocognitive Impairments as Putative Predictors of Neuroleptic- induced Movement Disorders in People with Schizophrenia Anthony Ahmed

W152 . Loss of Neural Signals Related to Cognitive Flexibility in the Rostral Caudate Following Short-term Cocaine Self-administration Brianna Sleezer, Benjamin Hayden

262

ACNP Annual Meeting Book 2013 rev8.indd 262 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W153 . Long-term Reduction of Cocaine Seeking in Rats and Monkeys by Viral Vector-delivered Cocaine Hydrolase (CocH) Marilyn E . Carroll, Natalie E . Zlebnik, Yang Gao, Stephen Brimijoin, Ph .D .

W154 . The Neurokinin-1 Receptor Mediates Stress-induced Reinstatement to Alcohol and Cocaine Seeking Jesse R . Schank, Courtney King, Kejun Cheng, Kenner C . Rice, David Weinshenker, Jason P . Schroeder, Markus Heilig

W155 . Chronic Nicotine Treatment Differentially Alters the Discriminative Stimulus Effects of Nicotine and Varenicline in Rhesus Monkeys Colin S . Cunningham, Lance McMahon

W156 . Antidepressant-like Effects of Buprenorphine Are Primarily Mediated through the Kappa Opioid Receptor Edgardo Falcon, Irwin Lucki

W157. Antidepressant and Anti-inflammatory Properties in the Action of Agomelatine Raffaella Molteni, Flavia Macchi, Andrea Carlo Rossetti, Elisa Colombo, Mario Dell’Agli, Marco A . Riva, Giorgio Racagni

W158 . Agomelatine Treatment Induces Early and Time-dependent Modulation of Rat Hippocampal MiRNome Daniela Tardito, Mara Seguini, Alessandra Mallei, Maurizio Popoli, Giorgio Racagni

W159 . Lurasidone Exerts Antidepressant Properties in the Chronic Mild Stress Model through the Regulation of Synaptic and Neuroplastic Mechanisms in the Prefrontal Cortex Marco A . Riva, Flavia Macchi, Mariusz Papp, Giorgio Racagni, Raffaella Molteni

263

ACNP Annual Meeting Book 2013 rev8.indd 263 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W160 . Selective Orexin-2 Receptor Antagonism as Adjunctive Therapy for Insomnia in Depression Timothy Lovenberg, Jonathan Shelton, SuJin Yun, Pascal Bonaventure, Brock Shireman, Christine Dugovic

W161 . Selective Blockade of 2-arachidonoylglycerol Hydrolysis Affects Learning and Memory Performance While Slowing Down Epileptogenesis in Rodents Guy Griebel, Philippe Pichat, Sandra Beeské, Bruno Biton, Dominique Françon, Richard Alonso, Dmitri Wiederschain, Heike Arlt, Bingzhi Zhang, Patrick Avenet, George F . Koob, Johanna Escoubet

W162 . Behavioral Effects of the Cannabinoid CB1 Receptor Negative Modulator ORG27569 in Rats Yuanyuan Ding, Yanyan Qiu, Yanan Zhang, Jun-Xu Li

W163 . Discovery and Characterization of a G Protein-biased Agonist that Inhibits β-arrestin Recruitment to the D2 Dopamine Receptor David R . Sibley, R . Benjamin Free, Lani Chun, Amy Moritz, Brittney Miller, Trevor Doyle, Jennie Conroy, Adrian Padron, Julie Meade, Jingbo Xiao, Yang Han, Lihua Duan, Marc Ferrer, Jonathan Javitch, Noel Southall, Juan Marugan

W164 . Morphine-induced Conditioned Place Preference and Effects of Morphine Pre-exposure in Adolescent and Adult Mice Wouter Koek

W165 . Therapeutic Potential of Selective Orexin-1 Receptor Antagonists Pascal Bonaventure, Diane Nepomuceno, Brian Lord, Leah Aluisio, Ian Fraser, James R . Shoblock, Tamara Berdyyeva, Brock Shireman, Christine Dugovic, SuJin Yun, Jonathan Shelton, Nicholas Carruthers, Timothy Lovenberg

264

ACNP Annual Meeting Book 2013 rev8.indd 264 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W166 . Improved Neuritogenesis and Mitochondrial Dynamics by Levetiracetam Might Explain Cognitive Improvement in Brain Aging and Animal Models of Alzheimer’s Disease Walter E . Mueller, Davide Miano, Carola Schiller, Kristina Leuner

W167 . Fluoxetine Exposure during Adolescence Alters Responses to Aversive Circumstances in Adulthood Sergio Iñiguez, Vincent Vialou, Brandon L . Warren, Lace Riggs, Mary Kay Lobo, Raisa Ahmed, Bryan Cruz, Eric Nestler, Carlos A . Bolanos-Guzman

W168 . A Role for Innate Immune Signaling in Microglia in Behavioral Changes Induced by Repeated Social Defeat Stress in Mice Xiang Nie, Shiho Kitaoka, Kohei Tanaka, Eri Segi-Nishida, Yuki Imoto, Atsubumi Ogawa, Shuh Narumiya, Tomoyuki Furuyashiki

W169 . Effects of Ethanol and Antidepressant on the Platelet BDNF Release Function in the Peripheral Blood: Implication in the Pathogenesis of Psychiatric Disease Toshikazu Saito, Eri Hashimoto, Wataru Ukai, Takao Ishii, Yoshiyasu Kigawa, Kengo Furuse, Hanako Tsujino

W170 . The M1 Muscarinic Receptor Subtype Regulates the Antidepressant-like Effects of the Rapidly-acting Antidepressant Scopolamine Jeffrey M . Witkin, Carl Overshiner, John Catlow, Douglas Schober, Beverly Heinz, Alexander Nikolayev, Tolstikov Vladimir, Wesley Anderson, Richard Higgs, Kuo Ming-Shang, Christian Felder

W171 . Adolescent Cannabis Exposure Differentially Affects Heroin Reinforcement and Accumbens Dopamine Transmission in Lewis and Fisher344 Rats Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Sandro Fenu

265

ACNP Annual Meeting Book 2013 rev8.indd 265 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W172 . Therapeutic Effects of TrkB Ligands on Depression-like Behaviors and Dendritic Changes in the Hippocampus and Nucleus Accumbens after Inflammation Kenji Hashimoto, Ji-Chun Zhang, Jin Wu, Qian Ren, Suxia Li, Yukihiko Shirayama

W173. Chronic Methamphetamine-induced Recognition Memory Deficits Are Associated with Impaired Long-term Depression and Decreased glun2b Surface Expression in the Perirhinal Cortex Michael D . Scofield, Heather Trantham-Davidson, Marek Schwendt, Ronald E . See, Carmela M . Reichel

W174 . Methylphenidate Enhancement of Early-stage Sensory Signal Processing Barry Waterhouse, Rachel Navarra, Gerard Zitnik, Brian Clark

W175 . Optogenetic Control of Central Serotonergic Neurons Affects Anxiety and Impulsivity Yu Ohmura, Kenji Tanaka, Iku Tsutsui-Kimura, Akihiro Yamanaka, Tomomi Tsunematsu, Mitsuhiro Yoshioka

W176 . Ketamine Is a Potent Antidepressant in Two Rodent Models of Depression Aleksander Mathé, Vasco Sousa, Christina Weide Fischer, Tiberiu Loredan Stan, Gregers Wegener, Andreas Lennartsson, Per Svenningsson

W177 . What’s Serotonin Got to Do with It? Studies on the Actions of SSRIs and Cocaine in SERT M172 Mice Linda D . Simmler, Alexander G . Nackenoff, Sonja J . Stutz, Noelle Anastasio, Kathryn Cunningham, Randy D . Blakely

W178 . Endocannabinoid Elevation Reverses Social Withdrawal and Normalizes Neuronal Activation Patterns in the PCP Rat Model of Schizophrenia Julien Matricon, Alexandre Seillier, Andrea Giuffrida

266

ACNP Annual Meeting Book 2013 rev8.indd 266 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W179 . Inhibition of Select Bromodomain Proteins Attenuates Cocaine Reward Gregory C . Sartor, Shaun P . Brothers, Claes Wahlestedt

W180 . Suppression of Drug-evoked Nucleus Accumbens Dopamine by Somatic Hyperpolarization James E . McCutcheon, Samantha M . Fortin, Jackson J . Cone, Christopher G . Sinon, Ilana B . Witten, Karl Deisseroth, Garret D . Stuber, Mitchell F . Roitman

W181 . Glucagon-like Peptide-1 Receptor Activation Reduces Cocaine Reward Gregg Stanwood, Devon Graham, India Reddy, Lynette Daws, Aurelio Galli

W182 . Lithium Ameliorates Rotenone-induced Methylation and Hydroxymethylation of DNA in Cortical Primary Neurons Gustavo Scola, L . Trevor Young, Helena Kim, Mirian Salvador, Ana Andreazza

W183 . A Microarray and Proteomics Study of Lithium-treated Mice and Knockout Mice with Lithium-like Behavior Reveals a Common Effect on Mitochondrial Function and Autophagy Galila Agam, Lilach Toker, Yuly Bersudsky, R .H . Belmaker, Inbar Plaschkes, Vered Chalifa-Caspi, Dieder Moechars, Roberto Buccafusca, Gerard T . Berry

W184 . ORM-12741: Receptor Pharmacology of a Novel Alpha2C-adrenergic Receptor Subtype Selective Antagonist with Multi-therapeutic Potential Jukka Sallinen, Juha Rouru, Jyrki Lehtimaki, Päivi Marjamäki, Merja Haaparanta-Solin, Eveliina Arponen, Semi Helin, Olof Solin, Frank Tarazi, Mohammed Shahid

W185 . Differential Effects of Vilazodone vs . Citalopram and Paroxetine on Serotonin Transporters and Receptors Yong Kee Choi, Ronald Oosting, Pradeep Banerjee, Frank Tarazi

267

ACNP Annual Meeting Book 2013 rev8.indd 267 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W186 . A Progressive Ratio Determination of the Relative Reinforcing Effect of Methylphenidate versus Cocaine by Intravenous Self-administration Testing in Rats David J . Heal, Niki Buckley, Emma L . Johnson, Jane Gosden, Sharon L . Smith

W187 . Neonatal SSRI Exposure Alters Neurodevelopment and Risk for Depression in Model Rats Sarah M . Clinton, Matthew E . Glover, Phyllis C . Pugh, Joshua Cohen, Huda Akil

W188 . Effects of Buprenorphine and ALKS 33, Alone and in Combination, on Monoamine Release within the Nucleus Accumbens Shell and Medial Prefrontal Cortex of Male Wistar Rats Daniel R . Deaver, Jacobi I . Cunningham, Reginald L . Dean, Mark Todtenkopf, David J . Eyerman

W189 . Investigating the Interaction between Lisdexamfetamine and S-citalopram on Monoamine Neurochemistry by Dual-probe Microdialysis in Freely Moving Rats: Evidence for Synergistic Augmentation of Serotonin and Dopamine Efflux Pete Hutson, Helen Rowley, Rajiv Kulkarni, David J . Heal

W190 . GLYX-13, a NMDA Receptor Glycine-site Functional Partial Agonist, Produces Long Lasting Antidepressant-like Effects through Modulation of Long-term Synaptic Plasticity Jeffrey Burgdorf, Xiao-lei Zhang, Amanda Gross, Roger Kroes, Patric Stanton, J . David Leander, Ronald M . Burch, Joseph Moskal

W191 . Levomilnacipran Inhibits Both Norepinephrine and Serotonin Reuptake Across the Clinical Dose Range Joann O’Connor, Laishun Chen, Carl Gommoll, Stephen R . Zukin

268

ACNP Annual Meeting Book 2013 rev8.indd 268 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W192 . Human Neuronal Precursors: Melatonin Abolishes Cytoskeletal Alterations and Promotes Neuronal Development in Olfactory Neuroepithelial Cells Obtained from Schizophrenic Subject Gloria Benítez-King, Tania Galván-Arrieta, Carlos Berlanga, Horacio Zamudio-Meza

W193 . The Effects of Gene Knockout of the Vesicular Monoamine Transporter 2 (VMAT2; SLC18A2) and the Dopamine Transporter (DAT; SLC3A6) on Ethanol Consumption and Escalation in Mice Frank S . Hall, Alexandra Houston-Ludlam, Zhicheng Lin, George Uhl

W194 . THC Elicits Temporary or Persistent Changes in Expression of Genes Implicated in Neurodevelopment in Adolescent Rat Brain Regions Bertha K . Madras, Gregory M . Miller, Lisa Ogawa, Josh Zimmer, Eric Vallender, Yasmin Hurd, Susan Westmoreland

W195. The Role of Efficacy on the Interaction between Mu Opioid Receptor Agonists and Cannabinoid Receptor Agonists David R . Maguire, Charles P . France

W196 . Dissecting Nucleus Accumbens Dynorphin Neurons in Aversion and Reward Ream Al-Hasani, Jordan G . McCall, Nicole Capik, Blessan Sebastian, Daniel Hong, Audra Foshage, Michael Krashes, Bradford Lowell, Thomas Kash, Michael R . Bruchas

W197 . Rapamycin, an Inhibitor of mTORC1 Signaling Activity, Improved Measures of Sociability in the BTBR T+ Itpr3tf/J Mouse Model of Autism Spectrum Disorder Jessica Burket, Andrew Benson, Amy Tang, Stephen Deutsch

W198 . MDPV has Potent and Atypical Effects on Dopamine Release in Adolescent and Adult Rats Cynthia M . Kuhn, Sabrina Ergun, Elizabeth Sears, Quentin Walker

269

ACNP Annual Meeting Book 2013 rev8.indd 269 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W199 . Chronic Lithium Treatment Diminishes the Amplitude of Electrically Evoked Dopamine Concentration Transients in the Nucleus Accumbens Core Adem Can, Roger Cachope, Douglas Frost, Joseph Cheer, Todd D . Gould

W200 . Effects of Monoamine Releasers with Varying Selectivity to Release Dopamine vs . Norepinephrine in Assays of Cocaine Discrimination and Cocaine vs . Food Choice Matthew L . Banks, Clayton Bauer, Bruce Blough, Richard B . Rothman, John Partilla, Steve Negus

W201 . NS1738, a Positive Allosteric Modulator of Alpha7 Nicotinic Receptors, as Adjunctive Treatment in Schizophrenia: An Experimental Study Monica M . Marcus, Åsa Konradsson-Geuken, Kristin Feltmann, Vladimir Ivanov, Björn Schilström, Kent Jardemark, Torgny H . Svensson

W202 . Acute Vilazodone Administration Induces Hypothermia in Mice through a 5-HT1A Mechanism Alvaro Garcia-Garcia, Pradeep Banerjee, E . David . Leonardo

W203 . Discovery of Metabotropic Glutamate Receptor Subtype 5 PAMs that Display Stimulus Bias Reveals that In Vivo Efficacy in Animal Models Can be Achieved without Direct Potentiation of NMDAR Currents Jerri M . Rook, Paige N . Vinson, Thomas M . Bridges, Shaun R . Stauffer, Ayan Ghoshal, J . Scott . Daniels, Colleen M . Niswender, Hilde Lavreysen, Claire Mackie, Jose Manuel . Bartolome, Gregor J . Macdonald, Thomas Steckler, Carrie K . Jones, Craig W . Lindsley, P . Jeffrey Conn

W204 . Want It, Need It, and Can’t Control It: The Dynamic Relationship between Impulsivity and the Propensity to Binge Eat Noelle Anastasio, Kathryn Cunningham

W205 . Withdrawn

270

ACNP Annual Meeting Book 2013 rev8.indd 270 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W206 . Electrophysiological Investigation of the Effects of a Subanesthetic Dose of Ketamine on Monoamine Systems Pierre Blier, Karim El Iskandarani, Chris Oosterhof, Mostafa El Mansari

W207 . The Effects of Methylphenidate and Atomoxetine on Glutamate in the Prefrontal Cortex of the Awake Spontaneously Hypertensive Rat Model of ADHD Paul Glaser, Erin Miller, Greg Gerhardt

W208 . Characterization of the Novel M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Vu0467154 in Animal Models of Antipsychotic-like Activity, Cognitive Enhancement and Changes in Sleep-wake Architecture Carrie K . Jones, Thomas M . Bridges, Michael Bubser, Robert W . Gould, Ditte Dencker Thorbek, Michael D . Grannan, J . Scott . Daniels, Meredith J . Noetzel, Colleen M . Niswender, Mark E . Duggan, Nicholas J . Brandon, John Dunlop, Michael W . Wood, Craig W . Lindsley, P . Jeffrey . Conn

W209 . Hypnotic and Anxiolytic Properties of the Selective Melatonin MT2 Receptor Partial Agonist UCM765 Stefano Comai, Rafael Ochoa-Sanchez, Quentin Rainer, Gabriella Gobbi

W210. Forebrain-specific CRF Overexpression during Early Life Increases Vulnerability for PTSD-like Symptoms in Adulthood Mate Toth, Maya Gross, Isabelle Mansuy, Emilio Merlo-Pich, Victoria Risbrough

W211. Transdermal Cannabidiol: Long-lasting Beneficial Actions in Animal Models of Drug Seeking, Anxiety, and Impulsivity Friedbert Weiss, Remi Martin-Fardon, Dana Hammell, Stan Banks, Rajita Sinha, Audra Stinchcomb, Gustavo Gonzalez-Cuevas

271

ACNP Annual Meeting Book 2013 rev8.indd 271 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W212 . Intranasal Delivery of an Interfering Peptide with Antidepressant-like Effect Fang Liu, Virginia Brown

W213 . Adenosine Receptor Involvement in Methamphetamine Conditioned Place Preference, Self-administration and Reinstatement Ryan Bachtell, Kevin Kavanagh, Sophia Levis, Casey O’Neill

W214 . Evaluating a Novel Brain-penetrant HDAC Inhibitor in Rat Behavioral Models in Relation to Target Occupancy Assessed by Pet Imaging Frederick A . Schroeder, Changning Wang, Misha M . Riley, Surya Reis, Yan-Ling Zhang, Stephen J . Haggarty, Jacob M . Hooker

W215. β-arrestin Dependence of the Putative Antipsychotics M100907 and LY379268, in Animal Models of Psychosis Caitlin E . McOmish, James Hanks, Elizabeth LaMarca, Molly Belkin, Elena Y . Demireva, Jay A . Gingrich

W216 . Development of a Novel Class of Antipsychotics: Multifunctional PAT Compounds (5HT2A Antagonists / 5HT2C Agonists) Ameliorate the Positive and Cognitive Disrupting Symptoms Associated with Psychosis Drake Morgan, Clinton Canal, Krishnakanth Kondabolu, Myong Kim, Kimberly Robertson, Neil E . Rowland, Glen M . Sizemore, Raymond G . Booth

W217 . Chronic Ethanol Increases Excitability in the Ventral Bed Nucleus of Stria Terminalis via Postsynaptic Serotonin2c Receptor Signaling Catherine Marcinkiewcz, Cayce Dorrier, Thomas L . Kash

W218 . Role of Central Amygdala PACAP in the Stress Response Valentina Sabino, Attilio Iemolo, Riccardo Dore, Xiaofan Wang, Pietro Cottone

272

ACNP Annual Meeting Book 2013 rev8.indd 272 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W219 . NMDA Receptors in the Nucleus Accumbens Shell Mediate Compulsive Eating of Palatable Food Pietro Cottone, Karen Smith, Rahul Rao, Marta Valenza, Clara Velazquez-Sanchez, Valentina Sabino

W220 . Panic Disorder and Agoraphobia: Novel Glutamate Mechanisms and Therapeutic Approaches from Preclinical Model Anantha Shekhar, Philip L . Johnson, Andrei Molosh, Stephanie D . Fitz, Amy Dietrich, William Truitt, Cris Barnaby, Luc Ver Donck

W221 . Subgrouping Central Serotonin Neurons by Their Networks Yue Ping Guo, Kathryn Commons

W222 . Kappa Opioid Receptors Inhibit Glutamatergic Transmission to the Extended Amygdala in an Input Specific Manner Thomas L . Kash, Nicole Capik, Michael R . Bruchas

W223 . Suicidal Ideation in Depressed New Mothers: Relationship with Childhood Trauma and Sleep Disturbance Dorothy Sit, James Luther, Jesse Dills, Heather Eng, Dan Buysse, Michele Okun, Stephen Wisniewski, Katherine L . Wisner

W224 . Gonadal Hormone Regulation of Stress Circuitry Activity in Healthy Women Is Disrupted in Major Depressive Disorder Emily G . Jacobs, Jill M . Goldstein, Laura M . Holsen, Katrina Lancaster, Anne Remington, Stephen Buka, Susan Whitfield- Gabrieli, Anne A . Klibanski

W225 . Linked Sex Differences in Cognition and Functional Connectivity in Youth Theodore D . Satterthwaite, Daniel Wolf, David Roalf, Kosha Ruparel, Guray Erus, Simon Vandekar, Efstathios Gennatas, Mark Elliott, Alex Smith, Hakon Hakonarson, Ragini Verma, Christos Davatzikos, Raquel E . Gur, Ruben C . Gur

273

ACNP Annual Meeting Book 2013 rev8.indd 273 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W226 . Sex Differences in Marijuana’s Positive Subjective Effects in Daily Marijuana Smokers Ziva D . Cooper, Margaret Haney

W227. Sex-specific Behavioral and Neuroanatomical Markers of Susceptibility to Failed Fear Suppression Tina Gruene, Elian Roberts, Rebecca Shansky

W228. Estrogen Influences C-fos Expression in the Fear Extinction Network in Female Rats Kara K . Cover, Lisa Maeng, Aaron Landau, Daria Turner, Mohammed R . Milad, Kelimer Lebron-Milad

W229 . Response to Yohimbine and Cocaine Cues in Cocaine-dependent Individuals Megan Moran-Santa Maria, Aimee McRae-Clark, Nate Baker, Viswanathan Ramakrishnan, Kathleen T . Brady

W230 . Sex Differences in Progesterone, Allopregnanolone, and ACTH Responses to Metyrapone in Men and Women with PTSD Sabra Inslicht, Erin Madden, Anne Richards, Evelyn Rucker, Aoife O’Donovan, Madhu Rao, Lisa Talbot, Thomas Metzler, Richard Hauger, Thomas Neylan

W231 . Diet-induced Obesity Alters Drug Reward Differentially in Males and Females Sari Izenwasser

W232 . Reduced Motivation to Self-administer Methamphetamine by Oxytocin in a Behavioral-economics Paradigm Predicts Reinstatement of Methamphetamine Seeking Brittney M . Cox, Brandon Bentzley, Carmela M . Reichel, Ronald E . See, Gary Aston-Jones

274

ACNP Annual Meeting Book 2013 rev8.indd 274 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Poster Session III—Wednesday W233 . Sex Differences in Corticotropin Release Factor-evoked Anxiety-related Behavior Debra Bangasser, Hannah Simko, Adam Hawkins, Brittany Wicks, Rob Cole, Jeremy Schmidt, Michelle Lerner

W234 . Contributions of Estrogen and Oral Contraceptive Use to Sex Differences in Functional Responding to Conditioned Cues during Fear Conditioning Moon Jung Hwang, Huijin Song, Rachel Zsido, Edward F . Pace- Schott, Karen Klahr K . Miller, Mohammed R . Milad

W235 . Sex Differences in the Neural Processing of Emotions within the Theoretical Framework of the Circumplex Model of Affect Jarod Peterson, James Russell, Yuankai Huo, Angela Tseng, Bradley S . Peterson, Zhishun Wang

W236 . Adolescent Sex Differences in Fronto-limbic Activity during Selective Attention and Emotion Processing Crystal E . Schiller, Joshua Bizzell, Sarah Hart, Ayse Belger

W237 . Is Alzheimer Disease a Different Disease in Men and Women? Observations from Autopsied Brains and Transgenic Studies Bradley Chaharyn, Paul Pennington, Kelsey Fehr, Zelan Wei, Jennifer Chlan, Darrell Mousseau

275

ACNP Annual Meeting Book 2013 rev8.indd 275 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program Notes

276

ACNP Annual Meeting Book 2013 rev8.indd 276 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Nika Adham Dewleen Baker Senior Director of Pharmacology Professor Forest Research Institute Deprtment of Psychiatry, University of Harborside Financial Buliding California San Diego Plaza V 9500 Gilman Drive (0603V) Jersey City, New Jersey 07311 La Jolla, California 92037

Susanne Ahmari Ross Baker Assistant Professor Director, CNS Global Medical Affairs Columbia University Otsuka Pharmaceutical Development & 1051 Riverside Drive Commercialization, Inc . Unit 87 100 Overlook Drive New York, New York 10024 Princeton, New Jersey 08540

Jorge Almeida Tracy Bale Resident Associate Professor of Neuroscience Brown University University of Pennsylvania 345 Blackstone Blvd 201E Vet, 6046 Providence, Rhode Island 02860 3800 Spruce St Larry Alphs Philadelphia, Pennsylvania 19104 Therapeutic Area Leader Psychiatry Medical Affairs, Central Nervous System Darrick Balu 40 Foxcroft Drive Instructor Princeton, New Jersey 08540 Psychiatry 115 Mill St Michal Arad MRC RM 114 Postdoctoral Fellow Mailstop 124 Department of Psychiatry, University of Belmont, Massachusetts 02478 Maryland School of Medicine 685 West Baltimore St . Debra Bangasser MSTF Bldg Rm . 934-F Assistant Professor Baltimore, Maryland 21201 Temple University Psychology 1701 North 13th Street Peter Bachman 873 Weiss Hall Research Psychologist Philadelphia, Pennsylvania 19122 Semel Institute 1826 S Bundy Dr Matthew Banks Apt 2 Research Assistant Professor Los Angeles, California 90025 Department of Pharmacology and Toxicology 410 North 12th Street Ryan Bachtell PO Box 980613 Assistant Professor Robert Blackwell Smith Bldg University of Colorado Richmond, Virginia 23298 Department of Psychology and Neuroscience UCB 345 Boulder, Colorado 80309-0345

277

ACNP Annual Meeting Book 2013 rev8.indd 277 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Estelle Barbier Carlos Blanco Post-doctoral Research Fellow Professor of Clinical Psychiatry National Institute of Health Columbia University 10 Center Drive 504 W 110th Street #5D Building 10-CRC, Room 1-5330 New York, New York 10025 Bethesda, Maryland 20892-1108 John Blangero Deanna Barch Director, AT&T Genomics Computing Center Professor Texas Biomedical Research Institue Departments of Psychology, Psychiatry and Department of Genetics Radiology 7620 NW Loop 410 Box 1125 San Antonio, Texas 78227-5301 One Brookings Drive Saint Louis, Missouri 63130 Jeffrey Borckardt Associate Professor Keri Barksdale Borckardt Lab Postdoctoral Fellow 507-North IOP University of Alabama, Birmingham 67 President Street 1720 7th Ave South Charleston, South Carolina 29425 Birmingham, Alabama 35243

Mera Barr Giulia Bracci Independent Scientist Postdoctoral Fellow Centre for Addiction and Mental Health Columbia University 250 College Street 1051 Riverside Drive #2917 Toronto, Ontario M5T1R8 Department of Psychiatry Canada New York, New York 10032

Gillinder Bedi Hans Breiter Assistant Professor of Clinical Psychology Professor of Psychiatry and Behavioral NYSPI Sciences 1051 Riverside Drive Feinberg School of Medicine, Northwestern New York, New York 10040 University 710 N . Lake Shore Dr Ruth Benca Abbott Hall 1301 Professor, Department of Psychiatry Chicago, Illinois 60611 Director, Center for Sleep Medicine and Sleep Research Jennifer Britton 6001 Research Park Blvd . Assistant Professor Madison, Wisconsin 53719-1176 University of Miami 5665 Ponce de Leon Blvd Jeffrey Bishop Flipse Building, 354 Associate Professor Coral Gables, Florida 33146 University of Illinois at Chicago College of Pharmacy 833 South Wood Street, RM164 MC886 Chicago, Illinois 60612

278

ACNP Annual Meeting Book 2013 rev8.indd 278 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Shaun Brothers Kwang Choi Assistant Professor Assistant Professor University of Miami Miller School of Uniformed Services University Medicine Dept . of Psychiatry 1501 NW 10th Ave 4301 Jones Bridge Rd Miami, Florida 33136 Bethesda, Maryland 20814

T.H. Eric Bui Hsun-Hua Chou Associate Director for Research, Center for Biological Psychiatry Research Fellow Anxiety and Traumatic Stress Disorders, Dept . of Psychiatry, MC 0804 Instructor in Psychiatry, Harvard Medical UCSD School 9500 Gilman Drive, MC 0804 Massachusetts General Hospital La Jolla, California 92093 One Bowdoin Sq, 6th floor Boston, Massachusetts 02114 Sandra Comer Professor of Clinical Neuroscience Ronald Burch Columbia University College of Physicians Chief Medical Officer and Surgeons Naurex, Inc 1051 Riverside Dr 433 West Morris Road Unit 120 Morris, Connecticut 06763 New York, New York 10032 Juan Bustillo Professor of Psychiatry & Neurosciences James Cornish University of New Mexico Associate Professor Dept Psychiatry MSC09 University of Pennsylvania Perelman School 1 University of NM of Medicine Albuquerque, New Mexico 87106 TRC 3900 Chestnut Street Alon Chen Philadelphia, Pennsylvania 19104 Associate Professor Department of Neurobiology Bernadette Cortese Weizmann Institute of Science Assistant Professor Rehovot 76100 Medical University of South Carolina Israel Institute of Psychiatry 100 Doughty Street Emma Childs Charleston, South Carolina 29425 Research Associate (Assistant Professor) University of Chicago Alan Cross 5841 S Maryland Ave MC3077 Senior Director Chicago, Illinois 60637 AstraZeneca, Wilmington Delaware 141 Portland St Doo-Sup Choi Cambridge, Massachusetts 02139 Associate Professor Mayo Clinic 200 Frist Street SW Rochester, Minnesota 55905

279

ACNP Annual Meeting Book 2013 rev8.indd 279 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Josephine Cucchiaro Robert Davis Vice President, Clinical Operations Senior Consultant Sunovion Pharmaceuticals, Inc Intra-Cellular Therapies, Inc . 1 Bridge Plaza North 3960 Broadway Suite 510 New York, New York 10032 Fort Lee, New Jersey 07024 Jacek Debiec Kathryn Cullen Assistant Professor Assistant Professor University of Michigan University of Minnesota Medical School The Molecular and Behavioral Neuroscience 4146 40th Avenue S Institute Minneapolis , Minnesota 55406 205 Zina Pitcher Place Ann Arbor, MI 48109-5720 Cristina Cusin Psychiatrist Thilo Deckersbach Department of Psychiatry- Massachusetts Director of Psychology General Hospital Bipolar Clinic and Research Program, One Bowdoin Sq Department of Psychiatry, Massachusetts 6th Floor General Hospital Boston, Massachusetts 02114 50 Staniford St Boston, Massachusetts 02114 Sara Czaja Professor of Psychiatry and Behavioral Kristina Deligiannidis Sciences Director, Depression Specialty Clinic; Asst . University of Miami Miller School of Professor of Psychiatry and Obstetrics & Medicine Gynecology Department of Psychiatry University of Massachusetts Medical School 1695 N .W . 9th Avenue Suite 3208H Dept . of Psychiatry Miami, Florida 33136 55 Lake Avenue, North Worcester, Massachusetts 01655 Zafiris Daskalakis Associate Professor of Psychiatry Andre Der-Avakian Centre for Addiction and Mental Health Assistant Research Scientist 1001 Queen Street West Department of Psychiatry Toronto, Ontario M6J1H4 9500 Gilman Drive Canada MC 0603 La Jolla, California 92093-0603 Richard Davidson Vilas Professor of Psychology and Psychiatry Christen Deveney Department of Psychology and Psychiatry Assistant Professor Center for Investigating Healthy Minds Wellesley College Waisman Center, Suite S119 Building 15K 1500 Highland Ave 10 Center Drive Madison, Wisconsin 53705 Bethesda, Maryland 20892

280

ACNP Annual Meeting Book 2013 rev8.indd 280 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Dwight Dickinson Jennifer Felger Chief, Neuropsychology Lab Senior Associate Clinical Brain Disorders Branch Emory University School of Medicine 10 Center Drive 1365-B Clifton Rd CRC, Rm 7-3335 5th Floor, B5204 Bethesda, Maryland 20892 Atlanta, Georgia 30322

Colin Dourish Deveroux Ferguson Chief Executive Officer Post Doc P1vital Icahn School of Medicine at Mount Sinai, Manor House Department of Neuroscience Howbery Park 301 East 110th Street Wallingford APT 1A United Kingdom New York, New York 10029

Suresh Durgam Susan Ferguson Senior Director- Clinical Development Assistant Professor Forest Research Institute Seattle Children’s Research Institute Harborside Financial Center 1900 Ninth Ave . Plaza V Seattle, Washington 98101 Jersey City, New Jersey 07311 Jamie Feusner Elliot Ehrich Associate Professor Senior Vice President, Research and UCLA Department of Psychiatry and Development, Chief Medical Officer Biobehavioral Sciences Alkermes Inc 300 UCLA Medical Plaza, Room 2345 852 Winter St Los Angeles, California 90095 Waltham, Massachusetts 02451 Francesca Filbey Daniel Eisenberg Assistant Professor Staff Clinician Center for BrainHealth, School of Behavioral NIMH and Brain Sciences 10 Center Drive, 10/3C-209 2200 West Mockingbird Lane Bethesda, Maryland 20892-1365 Dallas, Texas 75235

Anna Eramo Bernard Fischer Associate Medical Director Assistant Professor H . Lundbeck A/S Maryland Psychiatric Research Center 4 Parkway North 5900 Norway Court Deerfield, Illinois 60015 Columbia, Maryland 21044

Irina Esterlis Kate Fitzgerald Assistant Professor Assistant Professor of Psychiatry Yale University Department of Psychiatry University of Michigan 950 Campbell Ave . Dept . of Psychiatry West Haven, Connecticut 06514 4250 Plymouth Rd . Ann Arbor, Michigan 48104

281

ACNP Annual Meeting Book 2013 rev8.indd 281 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Shelly Flagel Juan Gallego Research Assistant Professor Psychiatrist Department of Psychiatry Hofstra North Shore LIJ School of Medicine 205 Zina Pitcher Place Zucker Hillside Hospital Ann Arbor, Michigan 48105 Psychiatry Research 75-59 263rd Street Aryandokht Fotros Glen Oaks, New York 11004 Graduate Student McGill Sarah Garfinkel 1033 Pine Ave West Senior Research Fellow Montreal, Quebec H3A 1A1 Brighton and Sussex Medical School Canada Sussex United Kingdom George Foussias Fellow, Schizophrenia Program David George Centre for Addiction and Mental Health Associate Clinical Director 250 College St . Section of Clinical Assessment and Treatment Rm . 722 Evaluation Toronto, Ontario M5T 1R8 9000 Rockville Pike Canada 10 CRC, Rm 2-2352 NE MSC 1540 Christie Fowler Bethesda, Maryland 20892-1540 Staff Scientist The Scripps Research Institute Sophie George 130 Scripps Way 2A2 Research Investigator Jupiter, Florida 33458 University of Michigan Dept of Psychiatry, Rachel Upjohn Building Andrew Fox 4250 Plymouth Road Graduate Student Ann Arbor, Michigan 48109 University of Wisconsin-Madison 344 State St . David Gilder Madison, Wisconsin 53703 Research Scientist The Scripps Research Institute Samantha Fung 10550 N Torrey Pines Road Postdoctoral Research Officer La Jolla, California 92037 Neuroscience Research Australia Barker St Jodi Gilman Sydney 2031 Instructor Australia Massachusetts General Hospital 120 2nd St 104C Maura Furey Charlestown, Massachusetts 02129 Staff Scientist National Institute of Mental Health Nicholas Gilpin 10 Center Drive Assistant Professor 10CRC, Room 7-3345 LSU Health Sciences Center Physiology Dept NIMH/NIH Dept of Physiology Room 7205 Bethesda, Maryland 20892 1901 Perdido Street New Orleans, Louisiana 70112

282

ACNP Annual Meeting Book 2013 rev8.indd 282 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Paul Glaser Guy Griebel Associate Professor Head Assets Valorization & Opportunities University of Kentucky, Dept . of Psychiatry Evaluation 245 Fountain Ct Sanofi, Exploratory Unit Lexington, Kentucky 40509 1 Avenue Pierre Brossolette Chilly-Mazarin Jesus Gomar France Postdoctoral Research Trainee Litwin-Zucker Alzheimer’s Disease Research Fred Grossman Center Senior Vice President, Clinical Development 350 Community Drive and Medical Affairs The Feinstein Institute for Medical Res Sunovion Pharmacueticals Manhasset, New York 11030 Fort Lee, New Jersey 07024

Raul Gonzalez Anett Gyurak Associate Professor Postdoctoral Fellow Florida International University Department of Psychiatry and Behavioral 11200 SW 8th Street Sciences AHC-1, Room 140 Stanford University School of Medicine Miami, Florida 33199 401 Quarry Road Stanford, California 94305 Danielle Graham Group Leader, Neurology Danella Hafeman EMD Serono Research & Development Child Psychiatry Fellow Institute Western Psychiatric Institute and Clinic, 45A Middlesex Turnpike University of Pittsburgh Medical Center Billerica, Massachusetts 01742 3811 O Hara St Pittsburgh, Pennsylvania 15213 Merida Grant Assistant Professor Ahmad Hameed University of Alabama-Birmingham Associate Professor Callahan Eye Foundation Hospital Penn State College of Medicine 1720 University Blvd Dept . of Psychiatry 305C 500 University Dr Birmingham, Alabama 35294 Hershey, Pennsylvania 17033

William Greenberg Robert Hamer Director, Clinical Development-Psychiatry Professor of Psychiatry, Research Professor Forest Research Institute of Biostatistics Harborside Financial Center Department of Psychiatry Plaza V, Suite 1900 336 Medical School Wing B Jersey City, New Jersey 07311-4994 Chapel Hill, North Carolina 27599

283

ACNP Annual Meeting Book 2013 rev8.indd 283 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Colleen Hanlon Ian Hickie Assistant Professor Professor of Psychiatry and Executive Hanlon Lab Director 67 President St Brain & Mind Research Institute, The Charleston, South Carolina 29425 University of Sydney 100 Mallett Street Paul Harrison Camperdown Professor of Psychiatry Sydney 2050 Department of Psychiatry Australia Neurosciences Building Warneford Hospital Yoji Hirano Oxford OX3 7JX Visiting Postdoctoral Fellow United Kingdom VA Boston Healthcare System / Harvard Medical School Kenji Hashimoto VA Boston Healthcare System Professor 150 S Huntington Ave Chiba University Center for Forensic Mental Research 151C Health Boston, Massachusetts 02130 1-8-1 Inohana Chiba 260-8670 Georgia Hodes Japan Post Doctoral Fellow Mount Sinai School of Medicine Gregor Hasler 1425 Madison Ave Professor of Psychiatry New York , New York 10029 UPD Waldau Psychiatric University Hospital Colin Hodgkinson University of Bern Staff Scientist Bolligenstrasse 111 Laboratory of Neurogenetics Bern 3000 National Institute on Alcohol Abuse and Switzerland Alcoholism National Institutes of Health Benjamin Hayden 5625 Fishers Lane, Room 3S-32:MSC 9412 Assistant Professor Rockville, Maryland 20852 University of Rochester Department of Brain and Cognitive Sciences Marcelo Hoexter 88 Lake Road MD PhD Rochester, New York 14627 IPQ Ovidio Pires de Campos 785 Sarah Heilbronner Sao Paulo 05403010 Postdoctoral Associate Brazil University of Rochester 601 Elmwood Ave Elizabeth Hoge Rochester, New York 14642 Psychiatrist, Center for Anxiety and Traumatic Stress Disorders, Assistant Professor, Harvard Medical School Massachusetts General Hospital One Bowdoin Square Boston, Massachusetts 02114

284

ACNP Annual Meeting Book 2013 rev8.indd 284 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Laura Holsen Yasmin Hurd Assistant Professor in Psychiatry Professor Harvard Medical School Icahn School of Medicine at Mount Sinai, Division of Women’s Health - BC-3 Department of Psychiatry 1620 Tremont St . One Gustave Levy Place Boston, Massachusetts 02120 Box 1603 New York, New York 10023 Daniel Hommer Chief, Section of Brain Electrophysiology Kazutaka Ikeda and Imaging Project Leader National Institute on Alcohol Abuse and Addictive Substance Project Alcoholism 2-1-6 Kamikitazawa, 10 Center Drive Setagaya-ku 10 CRC, 1-5330 Tokyo 156-8506 Bethesda, Maryland 20892 Japan

Guillermo Horga Dan Iosifescu Associate Research Scientist Associate Professor of Psychiatry and Columbia University and the New York State Neuroscience Psychiatric Institute Mount Sinai Medical Center 1051 Riverside Drive One Gustave Levy Place New York, New York 10032 Box 1230 New York, New York 10029 David Hsu Research Assistant Professor Elena Ivleva University of Michigan Assistant Professor 205 Zina Pitcher Place Department of Psychiatry, University of Ann Arbor, Michigan 48109 Texas Southwestern Medical Center 5323 Harry Hines Blvd ., NE5 .110H Zoe Hughes Dallas, Texas 75235-9127 Senior Principal Scientist Pfizer Inc. Jacob Jacobsen Eastern Point Road Research Associate Senior Groton, Connecticut 06340 Duke University DUMC, Box 3287 Tom Hummer Durham, North Carolina 27710 Assistant Professor Department of Psychiatry Philip Johnson Riley Hospital for Children Assistant Professor 705 Riley Hospital Drive Anatomy Room 4300 MS510, 635 Barnhill Drive Indianapolis, Indiana 46202-5200 Van Neys Medical Science Building Indiana University School of Medicine Indianapoilis, Indiana 46202

285

ACNP Annual Meeting Book 2013 rev8.indd 285 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Jussi Jokinen Thomas Kash Associate Professor, Senior Researcher Assistant Professor Department of Clinical Neuroscience, Pharmacology, Center for Alcohol Studies Karolinska Institutet UNC R5 Karolinska University Hospital 104 Manning Drive Stockholm 17176 CB 7178 Sweden 5023 Thurston Bowles Chapel Hill, North Carolina 27599 Carrie Jones Assistant Professor of Pharmacology Sarah Keedy Vanderbilt Center of Neuroscience Drug Assistant Professor Discovery University of Chicago Vanderbilt University Medical Center 5841 S Marylane Ave MC 3077 2220 Pierce Ave, 418 PRB Chicago, Illinois 60637 Nashville, Tennessee 37232 Mazen Kheirbek Sheena Josselyn Research Scientist/Assistant Professor Associate Professor New York State Psychiatric Institute/RFMH Hospital for Sick Children/University of 1051 Riverside Drive Toronto Unit 87 6018 McMaster Building New York, New York 10032 555 University Avenue Toronto, Ontario M5G1X8 Andrea King Canada Professor University of Chicago Tanja Jovanovic 5841 S . Maryland Avenue Assistant Professor Chicago, Illinois 60613 Emory University School of Medicine 49 Jesse Hill Jr Dr, Suite 331 Anthony King Atlanta, Georgia 30303 Research Assistant Professor University of Michigan Jayesh Kamath Department of Psychiatry Associate Professor of Psychiatry and 2707 Rachel Upjohn Blg Immunology 4250 Plymouth Road University of Connecticut Health Center Ann Arbor, Michigan 48105 10 Talcott Notch Road East Lobby 3rd Floor Matthew Kirkpatrick Farmington, Connecticut 06030 Postdoctoral Fellow University of Chicago Katherine Karlsgodt 5319 South Kimbark Ave Apt 2B Assistant Investigator Chicago, Illinois 60615 The Zucker Hillside Hospital 75-59 263rd St Torsten Klengel Glen Oaks, New York 11004 Post-Doc Max Planck Institute of Psychiatry Kraepelinstrasse 2-10 Munich 80804 Germany

286

ACNP Annual Meeting Book 2013 rev8.indd 286 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Bhaskar Kolachana Matthew Mosconi Staff Scientist Assistant Professor NIMH Psychiatry 10 Center Drive 5323 Harry Hines Blvd Building 10, Room 4N312, MSC 1385 Dallas, Texas 75390-9086 Bethesda, Maryland 20892 James Murrough Thomas Lanz Assistant Professor of Psychiatry and Principal Scientist Neuroscience Pfizer Mount Sinai Medical Center 700 Main St 1 Gustave L . Levy Place Lab 219-1 Dept . of Psychiatry Cambridge, Massachusetts 02139 Box 1230 New York, New York 10029 Charles Marmar Lucius N . Littauer Professor of Psychiatry; Charles Nichols Chair of Psychiatry Associate Professor New York University Langone Medical Louisiana State University Health Sciences Center Center NYU Department of Psychiatry Pharmacology Department 550 First Avenue, OBV A643 1901 Perdido St . New York, New York 10016 New Orleans, Louisiana 70112

Rachel Marsh Antonio Noronha Assistant Professor of Clinical Psychology Director, Division of Neuroscience & (in Psychiatry) Behavior The New York State Psychiatric Institute NIAAA, NIH 1051 Riverside Drive DNB, NIAAA, NIH Unit 74 5635 Fishers Lane New York, New York 10032 Room 2061 Bethesda, Maryland 20892 Tsuyoshi Miyakawa Professor Sachin Patel Fujita Health University Assistant Professor 1-98 Dengakugakubo Vanderbilt University School of Medicine Kutsukakecho 1601 23rd Ave South Toyoake 470-1192 Nashville, Tennessee 37232 Japan Paul Patterson Anne P . and Benjamin F . Biaggini Professor of Biological Sciences California Institute of Technology 216-76 Caltech Pasadena, California 91125

287

ACNP Annual Meeting Book 2013 rev8.indd 287 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Julia Sacher Joseph Taylor Senior Research Fellow MD/PhD Student Max Planck Institute for Human Cognitive Brain Stimulation Lab and Brain Sciences 4006 Radcliffe Place Drive Stephanstr . 1A Unit 2 Leipzig Charleston, South Carolina 29414 Germany Panayotis Thanos Theodore Satterthwaite Scientist Instructor State University of New York, Stony Brook Department of Psychiatry, University of Medical Department,BNL Pennsylvania Perelman School of Medicine Upton, New York 11973 Hospital of the Univ of PA 10th Floor, Gates Bldg Eric Vermetten 34th & Spruce St Military Mental Health - Research, Defense Philadelphia, Pennsylvania 19104 Lundlaan 1 Utrecht 3584 CX Eric Schadt Netherlands Chairman and Professor, Department of Genetics and Genomic Sciences; Director, Ken Warren Institute for Genomics and Multiscale Director Biology NIAA Icahn School of Medicine at Mount Sinai 5635 Fishers Lane 1425 Madison Avenue Bethesda, MD 20892 Box 1498 New York, New York 10029 Douglas Williamson Dielmann Professor of Genetic and Dorothy Sit Environmental Risk Assistant Professor of Psychiatry The University of Texas Health Science Western Psychiatric Institute and Clinic Center at San Antonio University of Pittsburgh, School of Medicine, 7703 Floyd Curl Drive, MC772E Dept of Psychiatry San Antonio, Texas 78229 3811 O’Hara Street, Oxford Building Suite 410 Victoria Wing Pittsburgh, Pennsylvania 15213 Medical Student Imperial College London Michael Taffe 250 College St Associate Professor Room 730 The Scripps Research Institute Toronto, Ontario M5S 2S1 CNAD; MailCode SP30-2400 Canada 10550 North Torrey Pines Road La Jolla, California 92037 Daniel Wolf Assistant Professor of Psychiatry University of Pennsylvania Department of Psychiatry 10 Gates Bldg . Philadelphia, Pennsylvania 19104

288

ACNP Annual Meeting Book 2013 rev8.indd 288 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan . 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan . 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan . 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company . 2013 Program Committee Disclosures

Anissa Abi-Dargham: Part 1: Otsuka, Shire, Roche, BMS, Pfizer, Takeda, Amgen, Forest, Pierre Fabre, Part 4: Pierre Fabre, Forest

Randy Blakely: Part 1: Lundbeck Amgen, Part 4: Amgen

Ariel Deutch: Part 1: Eli Lilly

Paul Kenny: Part 1: Eolas Therapeutics

Henry Kranzler: Part 1: Lundbeck, Pfizer, Lilly Consultant: Alkermes, Lundbeck, RochePart 2: Lundbeck, Part 4: Pfizer

Pat Levitt: Part 1: Scientific Advisory Board for Pediatric Biosciences

Stephen Marder: Part 1: Abbott, Roche, Genentech, Otsuka, Shire, EnVivo, Targacept, Pfizer, Lundbeck, Bristol Meyers Squibb ., Part 4: Sunovion, Novartis, Amgen, Psychogenics

Barbara Mason: Part 1: Johnson & Johnson Pharmaceutical Research & Development, LLC, Lohocla Research Corporation; Arkeo Pharmaceuticals, Inc ., Addex Pharmaceuticals; Part 4: Corcept .

Daniel Mathalon: Part 1: I am a consultant for Bristol-Myers Squibb I am a consultant for Amgen, Part 4: 2011-AstraZeneca investigator initiated grant

Colleen McClung: Part 1: I received honorarium for a seminar given at Johnson & Johnson in 2012 . , Part 4: I received a grant from IMHRO partnered with Johnson & Johnson in 2012 (Rising Star Translational Research Award) .

Kalpana Merchant: Part 5: Eli Lilly and Company

Andreas Meyer-Lindenberg: Part 1: Speaker and Advisory boards: AstraZeneca, J+J, Lundbeck, Servier, Lilly

289

ACNP Annual Meeting Book 2013 rev8.indd 289 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

2013 Program Committee Disclosures (continued)

Lisa Monteggia: Part 1: Speaker’s bureau, Roche .

Akira Sawa: Part 4: Astellas Pharm ., Dainippon Sumitomo, Mitsubishi-Tanabe Pharm ., Takeda, Johnson and Johnson, Asubio, Sucampo, Eli Lilly, Taisho, Pfizer, Afraxis, Sanofis- Aventis

Darryle Schoepp: Part 1: Merck and Company, Inc ., Part 2: Merck and Company, Inc ., Part 3: Merck and Company, Inc ., Part 4: Merck and Company, Inc ., Part 5: Merck and Company, Inc .

Thomas Schulze: Part 1: Almirall (Neurofarmagen/genetic testing)

Pamela Sklar: Part 4: Sage BioNetworks

Matthew State: Part 1: Pfizer pharmaceuticals SynapDx, Part 2: Pfizer pharmaceuticals

Trisha Suppes: Part 1: Sunovion Pharmaceuticals Inc, Jones and Bartlett, Part 4: AstraZeneca, National Institute of Mental Health, Pfizer, Inc., Sunovion Pharmaceuticals Inc., Elan Pharma International Limited, and VA Cooperative Studies Program .

Audrey Tyrka: Part 1: Medtronic, Neuronetics, NeoSync, Part 4: Medtronic, Neuronetics, NeoSync

Jeremy Veenstra-Vander Weele: Part 1: Novartis, Seaside Therapeutics, Roche Pharmaceuticals, Forest, SynapDx .

Daniel Weinberger: Part 1: AstraZeneca, Johnson & Johnson, Lundbeck, Servier, and Lilly

Carlos Zarate: Part 1: co-inventor - patent application for the use of ketamine and its metabolites in major depression . Patent rights assigned to U .S . government; will receive a percentage of any royalties received by the government .

NOTHING TO DISCLOSE Ted Abel Rita Goldstein Kerry Ressler Gary Aston-Jones David Grandy John Rubenstein Hilary Blumberg Robert Greene Etienne Sibille John Bruno Kalpana Merchant Arielle Stanford Kristin Cadenhead Karoly Mirnics James Sutcliffe Joe Callicott Bita Moghaddam Rachel Yehuda Stephen Deutsch Uma Rao

290

ACNP Annual Meeting Book 2013 rev8.indd 290 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures Vanderbilt CME has determined that there is no conflict of interest.

Abel, Ted : Part 2: Editor, Neurobiology of Learning and Memory, Elsevier

Abi-Dargham, Anissa: Part 1: Pierre Fabre, Pfizer, Takeda, Otsuka, Amgen, Roche, Part 4: Pierre Fabre

Alexopoulos, George: Part 1: I have a research grant from Forest; have consulted for Hoffman- LaRoche, Janssen, Lilly, Navidea, Pfizer, and Otsuka; and have been on speakers’ bureaus for Astra Zeneca, Avanir, Merck, Novartis, and Sunovion ., Part 2: Astra Zeneca, Forest, Merck, Sunovion, Part 4: I have received grant support from Forest

Alphs, Larry: Part 1: Janssen Scientific Affairs Employment and Stock, Part 2: 2011-2013 Employed buy Janssen Scientific Affairs a division of Johnson & Johnson; I also received stock from them ., Part 3: Janssen Scientific Affaris, Part 4: None, Part 5: Johnson & Johnson

Appelbaum, Paul: Part 1: Equity interest in COVR, Inc . (violence prediction software) ., Part 2: Professor, Columbia University, Research Scientist, NY State Psychiatric Institute, Private practice of general and forensic psychiatry

Arnsten, Amy: Part 1: I have recently had conversations with Pfizer, Merck, Shire and Evotec, and received a small grant from Pfizer to perform physiological assessments of one of their compounds in primate prefrontal cortex . Part 2: Yale University and I receive royalties from the sales of Intuniv from Shire Pharmaceuticals .

Banks, Matthew: Part 1: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates . Part 4: Collaborator on a grant from Perdue Pharmaceuticals related to opioid pharmacology in nonhuman primates .

Baram, Tallie Z.: Part 1: Baram’s institution (UCI) received travel & consultanship; Questcor, Part 2: stock ownership, TEVA

Barch, Deanna: Part 1: Consultant for Pfizer and Amgen, Research Grants from Novartas and Dainippon Sumitomo Pharma Co ., Ltd, Part 4: Research Grants from Novartas and Dainippon Sumitomo Pharma Co ., Ltd

Becker, Howard: Part 1: Dr . Becker has conducted contractual work and served as a consultant for Eli Lilly and Company, but those activities have no relationship to work that will be presented in this symposium ., Part 4: Dr . Becker engaged in a research contract with Eli Lilly and Company .

Bergen, Andrew : Part 1: Dr . Bergen has had research supported by an Agreement with Perlegen Biosciences, by an Agreement with Medco Health Solutions, and with loans of equipment and reagents from Affymetrix and from Genisphere .

Bikson, Marom: Part 1: Marom Bikson has equity in Soterix Medical Inc ., Part 4: Marom Bikson recieved grant support from Soterix Medical Inc .

Blennow, Kaj: Part 1: Innogenetics, Kyowa Kirin Pharma, Roche, Pfizer, BMS.

291

ACNP Annual Meeting Book 2013 rev8.indd 291 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Blier, Pierre: Part 1: I participated in advisory boards, gave presentations, and/or received research grants (without a salary portion and administered by my institution) from Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Forest, Lundbeck, Merck, Otsuka, Pfizer, Roche, Takeda, and Servier

Boettiger, Charlotte: Part 1: I own shares in the following companies: Becton Dickinson Co ., Bio Rad Laboratories Inc. CL A, Sigma Aldrich Corp., Thermo Fisher Scientific Inc. , Part 2: Becton Dickinson Co ., Sigma Aldrich Corp .

Brandon, Nicholas: Part 1: AstraZeneca, Part 2: AstraZeneca, Part 3: AstraZeneca, Part 5: AstraZeneca .

Buchanan, Robert: Part 1: Advisory Boards: Abbott; Amgen; Janssen Pharmaceutical, Inc .; NuPathe; Pfizer; Roche; Takeda, Consultant: Abbott; Amgen; Bristol-Myers Squibb; EnVivo; Omeros; Pfizer, DSMB: Otsuka; Pfizer

Bustillo, Juan: Part 1: Speakers Bureau and advisory consulting for Otsuka America Pharmaceutical Inc

Carlezon, William: Part 1: I am a consultant for Concert Pharmaceuticals . My spouse is a full-time employee of EMD Serono ., Part 2: My spouse is a full-time employee of EMD Serono ., Part 3: My spouse is a full-time employee of EMD Serono .

Carter, Cameron: Part 1: Grant funding from GSK 2011, Part 4: GSK 2011

Casey, Daniel: Part 1: Consultant/advisory board: Bristol-Myers Squibb, Genentech and Merck; Speaker’s bureau: Bristol-Myers Squibb, Merck and Sunovion

Chappell, Phillip: Part 5: Pfizer Inc

Charney, Dennis: Part 1: Dr . Charney has been named as inventors on a pending use-patent of ketamine for the treatment of depression . If ketamine were shown to be effective in the treatment of depression and received approval from the Food and Drug, Administration for this indication, Dr. Charney and Mount Sinai School of Medicine could benefit financially.

Coccaro, Emil: Part 1: Scientific Avisory Board for Azivan Pharmaceuticals.

Correll, Christoph: Part 1: Dr . Correll has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Lundbeck, Merck, Janssen/J&J, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda. He has received grant support from BMS, Janssen/J&J, and Otsuka . , Part 2: Bristol-Myers Squibb, Cephalon, Merck, Otsuka, Pfizer, ProPhase Part 4: BMS, Janssen/J&J, and Otsuka

Cross, Alan: Part 5: Current employee of AstraZeneca Pharmaceuticals, in Wilmington DE, the company that sponsored/funded the study reported here .

Dalmau, Josep: Part 1: JD receives royalties from Athena Diagnostics for a patent for the use of Ma2 as an autoantibody test, and licensing fees from Euroimmun for a patent for the use of NMDAR as an autoantibody test .

292

ACNP Annual Meeting Book 2013 rev8.indd 292 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Daskalakis, Zafiris: Part 1: Received external funding through Neuronetics and Brainsway Inc . ZJD has also served on the advisory board for Hoffmann-La Roche Limited . This work was supported by the Ontario Mental Health Foundation (OMHF), the Canadian Institutes of Health Research (CIHR), the Brain and Behaviour Research Foundation and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health (CAMH) Foundation and the Campbell Institute ., Part 4: Brainsway Inc .

Davis, Kenneth: Part 1: My wife, Bonnie M . Davis, MD is a patent holder on the use patent for galantamine for Alzheimer’s disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson . She receives royalty income from this license, Part 2: My wife, Bonnie M . Davis, MD is a patent holder on the use patent for galantamine for Alzheimer’s disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson . She receives royalty income from this license, Part 3: My wife, Bonnie M . Davis, MD is a patent holder on the use patent for galantamine for Alzheimer’s disease and dementias that has been licensed to Janssen-Pharma, a subsidiary of Johnson & Johnson . She receives royalty income from this license .

de Wit, Harriet: Part 1: I conducted a research study funded by Unilever in 2011 .

Dourish, Colin: Part 1: Employee, Director and shareholder of P1vital, Part 2: Employee, Director and shareholder of P1vital, Part 3: Employee, Director and shareholder of P1vital, Part 5: P1vital

Dubocovich, Margarita: Part 1: Takeda Pharmaceuticals North America, Inc .

Duman, Ronald: Part 1: Lilly, Forest, Bristol Myers Sqibb, Taisho, Johnson & Johnson, Pfizer, Lundbeck, Part 4: Lilly, Forest, Lundbeck, Johnson & Johnson

Duncan, Erica: Part 4: Grant support from Brain Plasticity, Inc .

Elliott, Mark: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Evins, A. Eden: Part 1: Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence, Part 4: Pfizer: Supplemental research support for the NIDA funded trial: R01 DA021245 Extended Duration Varenicline for Prevention of Smoking in Schizophrenia, Envivo Pharmaceuticals: Supplemental research support for the NIDA funded R01 DA030992 Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence, GSK: Supplemental research support for NIDA funded U01 DA019378 Cooperative Drug Discovery Group for Nicotine Dependence

Fan, Xiaoduo: Part 1: Eli Lilly - advisory board, Part 4: Eli Lilly - investigator initiated clinical trial grant

293

ACNP Annual Meeting Book 2013 rev8.indd 293 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Fava, Maurizio: Part 1: Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc .; Amarin Pharma Inc .; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc .; BioMarin Pharmaceuticals, Inc .; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc .; CNS Response, Inc .; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc .; DiagnoSearch Life Sciences (P) Ltd .; Dinippon Sumitomo Pharma Co . Inc .; Dov Pharmaceuticals, Inc .; Edgemont Pharmaceuticals, Inc .; Eisai Inc .; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc .; ePharmaSolutions; EPIX Pharmaceuticals, Inc .; Euthymics Bioscience, Inc .; Fabre-Kramer Pharmaceuticals, Inc .; Forest Pharmaceuticals, Inc .; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc .; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp .; Labopharm Inc .; Lorex Pharmaceuticals; Lundbeck Inc .; MedAvante, Inc .; Merck & Co ., Inc .; MSI Methylation Sciences, Inc .; Naurex, Inc .; Neuralstem, Inc .; Neuronetics, Inc .; NextWave Pharmaceuticals; Novartis AG; NuPathe;Nutrition 21; Orexigen Therapeutics, Inc .; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc .; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc .; Rexahn Pharmaceuticals, Inc .; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc .; Somaxon Pharmaceuticals, Inc .; Somerset Pharmaceuticals, Inc .; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc .; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc .; Tetragenex Pharmaceuticals, Inc .; Teva; TransForm Pharmaceuticals, Inc .; Transcept Pharmaceuticals, Inc .; Vanda Pharmaceuticals, Inc .; Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc .; CME Institute/Physicians Postgraduate Press, Inc .; Eli Lilly and Company; Forest Pharmaceuticals, Inc .; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/ Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories; Equity Holdings: Compellis; PsyBrain, Inc .; Royalty/patent, other income: Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of azapirones and bupropion in Major Depressive Disorder (MDD) .; Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd. , Part 2: Belvoir Media Group for editing a newsletter: 2011-$12,000 ., Part 4: Abbott Laboratories; Alkermes, Inc .; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc .; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc .; Clintara, LLC; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc .; Euthymics Bioscience, Inc .; Forest Pharmaceuticals, Inc .; Ganeden Biotech, Inc .; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmavite® LLC; Photothera; Roche; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories

294

ACNP Annual Meeting Book 2013 rev8.indd 294 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Fleischhacker, W. Wolfgang : Part 1: Amgen, Lundbeck, Roche, Bristol-Myers Squibb, Otsuka, Janssen, MedAvante, Merck, Vanda, Endo, Takeda, Pfizer, Reckitt-Benckiser, Part 3: Janssen, Otsuka, Reckitt-Benckiser

Frail, Donald: Part 1: I am an employee of AstraZeneca . , Part 2: I am an employee of AstraZeneca . , Part 3: I am an employee of AstraZeneca and was an employee of Pfizer. , Part 5: I am an employee of AstraZeneca .

Gainetdinov, Raul: Part 4: I have research grants from F . Hoffmann La-Roche (Basel, Switzerland) on the topic of this presentation .

George, Tony: Part 1: Grant support from Pfizer, Speakers Bureau Pfizer, 2011 and 2012, Data Monitoring Committee, Novartis, 2011-present, Part 4: Pfizer - for studies of varenicline in smokers with mental illness, including schizophrenia

Geyer, Mark: Part 1: Consulting compensation from Abbott, Acadia, Addex, Cerca, Lundbeck, Merck, Neurocrine, Omeros, San Diego Instruments , Takeda, DART and Teva, Part 2: Equity interest in San Diego Instruments, Part 3: Equity interest in San Diego Instruments, Part 4: Research grant support from Intracellular Therapeutics, Johnson & Johnson, NIDA, NIMH, and the U .S . Veteran’s Administration VISN 22 Mental Illness Research, Education, and Clinical Center .

Glatt, Stephen: Part 1: I serve as a scientific consultant to SynapDx Corp.

Gobbi, Gabriella: Part 1: Lilly, Astra-Zeneca, Lundbeck, Cosmas Therapeutics

Goff, Donald: Part 1: DSMB member: Otsuka Pharmaceuticals, Part 4: PamLab, Pfizer, Novartis, GSK

Gold, Lisa: Part 1: Full-time employee of Merck and Co, Inc, Part 2: Full-time employee of Merck and Co, Inc, Part 3: Full-time employee of Merck and Co, Inc, Part 5: Full-time employee of Merck and Co, Inc

Gopal, Srihari: Part 2: Shareholder Johnson & Johnson (JNJ), Shareholder Merck (MRK), Part 5: Full time employee Johnson & Johnson (JNJ)

Gordon, Joshua: Part 1: Speaker at Pfizer Basic Research Division Neuroscience Symposium, honorarium, 2011

Gründer, Gerhard: Part 1: Dr . Gründer has served as a consultant for Bristol-Myers Squibb (New York, NY), Cheplapharm (Greifswald, Germany), Eli Lilly (Indianapolis, Ind), Forest Laboratories (New York, NY, USA), Lundbeck (Copenhagen, Denmark), Otsuka (Rockville, Md .), Roche (Basel, Switzerland), and Servier (Paris, France) . He has served on the speakers’ bureau of Bristol-Myers Squibb, Eli Lilly, Gedeon Richter (Budapest, Hungary), Otsuka, Roche, and Servier . He has received grant support from Alkermes, Eli Lilly, and Roche . He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf . , Part 2: 2011: Eli Lilly, Part 3: 2011: Eli Lilly, Part 4: Dr . Gründer has received grant support from Alkermes, Eli Lilly, and Roche . He is co-founder of Pharma-Image – Molecular Imaging Technologies GmbH, Düsseldorf .

295

ACNP Annual Meeting Book 2013 rev8.indd 295 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Grace, Anthony : Part 1: Johnson & Johnson, Lundbeck, Pfizer, GSK, Puretech Ventures, Merck, Takeda, Dainippon Sumitomo, Otsuka, Lilly, Roche, Asubio, Part 4: Lilly, Lundbeck

Graham, Danielle: Part 5: I am a full time employee of EMD Serono Research & Development Institute .

Greenberg, Benjamin: Part 1: Meeting Travel Expense, Medtronic Inc, Part 4: Research Grant Support, Hoffman-LaRoche, Inc .

Greist, John : Part 1: eResearch Technology, Healthcare Technology Systems, Pfizer, Part 2: eResearch Technology, Healthcare Technology Systems, Possibly Pfizer, though I expect something less than $10,000 ., If I own any stock in any pharmaceutical or device company it would be in retirement accounts such as the State of Wisconsin Retirement Plan over which I have no control . I have never purchased or held any pharmaceutical stocks in my personal investment account, nor has my spouse ., Part 3: Please see #2 above ., Part 4: AstraZeneca, eResearch Technology, Forest, Lilly, Novo Nordisk, Otsuka, Pfizer, Takeda, Transcept, UCB, Part 5:Healthcare Technology Systems is a medical assessment company . Though it is not technically a pharmaceutical/biotech/medical device company, I list it here to avoid any possible misunderstanding .

Gur, Raquel: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Gur, Ruben: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Gurney, Mark: Part 1: Dr . Gurney is an employee of Tetra Discovery Partners ., Part 2: Dr . Gurney is an employee of Tetra Discovery Partners ., Part 3: Dr . Gurney is an employee of Tetra Discovery Partners ., Part 5: Tetra Discovery Partners .

Haber, Suzanne: Part 1: Dr . Haber has received consultation fees from Medtronic, Inc and Pfizer, Inc.

Harrison, Paul : Part 1: Advisory board, Sunovion (2013), Honorarium for educational talks, Otsuka (2013), Part 2: Employment: University of Oxford, Expert witness work for Pinsent Masons, London, Deputy Editor Honorarium, Biological Psychiatry, Part 4: Unrestricted educational grant from Takeda (Cambridge) 2012-13

Hasler, Gregor : Part 1: Servier (Suisse) SA , Lundbeck (Schweiz) AG, Schweizerische Gesellschaft für Bipolare Störungen, AstraZeneca, Eli Lilly (Suisse) SA , Part 4: Novartis Switzerland

Hen, Rene: Part 1: Serve on Scientific Advisory Boards for Roche Pharmaceuticals, Lundbeck and Servier

296

ACNP Annual Meeting Book 2013 rev8.indd 296 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Heres, Stephan: Part 1: I have received honoraria from Janssen-Cilag, Eli Lilly, Sanofi-Aventis and Johnson & Johnson . I have accepted travel or hospitality payment from Janssen-Cilag, Sanofi-Aventis, Johnson & Johnson, Pfizer, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis and Eli Lilly . I have participated in clinical trials sponsored or supported by Eli Lilly, Janssen Cilag, Johnson & Johnson, Bristol-Myers-Squibb, AstraZeneca, Lundbeck, Novartis, Servier, Pierre Fabre, Pfizer, Organon, Roche and Merck. I have participated in advisory activities and boards for Janssen, Johnson & Johnson, Eli Lilly, Lundbeck and Roche .

Hermanson, Daniel : Part 1: DJH, LJM and SP have submitted a patent application entitled “Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation,” which includes the compound LM-4131 .

Hickie, Ian: Part 1: Servier, Astrazeneca, Pfizer, Janseen, Eli Lilly, Part 4: Servier Laboratories

Higgs, Suzanne: Part 1: Academic Supervisor of PhD studentship part funded by P1vital, Part 4: Academic Supervisor of PhD studentship part funded by P1vital

Hollander, Eric: Part 1: research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences, consultant: Roche, Coronado Biosciences, Part 4: research grants: Simons Foundation, Roche, Transcept, Forest, Coronado Biosciences,

Hyman, Steven: Part 1: Member - Novartis Science Board, Consultant - AstraZeneca, iMed, Scientific Advisory Board - Fidelity Biosciences, Part 2: Novartis Science Board, Scientific Advisory Board - Fidelity Biosciences

Innis, Robert: Part 1: Eli Lilly has provide funds to NIMH to support my research, Part 4: Eli Lilly has provide funds to NIMH to support my research .

Iosifescu, Dan: Part 1: In the previous 36 months, Dr . Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion ., Part 4: In the previous 36 months, Dr . Iosifescu has received research funding through Mount Sinai School of Medicine from AstraZeneca, Brainsway, Euthymics, Neosync, and Roche; he has received consulting fees from CNS Response, Otsuka, Servier and Sunovion .

Jarskog, Lars: Part 1: Research grants from Sunovion, Amgen, Roche . DSMB board member - Janssen .

Javitt, Daniel: Part 1: Honoraria from Sunovion, BMS, Eli Lilly, Takeda, Omeros, Otsuka, Consensus Medical Communications, Guidepoint global, American Capital, Clearpoint communications, Vindico Medical Communication, and Clearview Healthcare . Research support from Pfizer and Roche; equity in, Glytech, Inc. and AASI; intellectual property rights for use of glycine, D-serine and glycine transport inhibitors in schizophrenia, and serves, on the advisory board of Promentis, Part 2: Columbia, NYS OMH, Glytech, Part 4: Pfizer, Roche

297

ACNP Annual Meeting Book 2013 rev8.indd 297 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Kalin, Ned: Part 1: Honorariums: CME Outfitters, Elsevier, Letters & Sciences; Scientific Advisory Board, Corcept Therapeutics, Neuronetics, CeNeRx BioPharma, Neurocrine Biosciences, Neuronetics, LLC, Medivation, Janssen; Stockholder, Equity Options, Corcept Therapeutics, CeNeRx BioPharma; Owner, Promoter Neurosciences, LLC; Patents, Promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences: U .S . Patent issued on 07-04-06; patent #7071323, U .S . Patent issued on 05-12-09; patent #7,531,356, Promoter sequences for urocortin II and the use thereof: U .S . Patent issued on 08-08-06; patent #7087385, Promoter sequences for corticotropin-releasing factor binding protein and use thereof: U .S . Patent issued on 10-17- 06; patent #7122650, Part 2: Elsevier, Part 4: Project Investigator: Neurobehavioral Bases of Emotion Regulation and Dysregulation in Adolescence . P50 MH84051, National Institute of Mental Health/National Institute of Health, $234,757,00 2008-2013, Principal Investigator: Developmental Mechanisms Underlying the Risk to Develop Anxiety and Depression . Subproject on a Silvio O . Conte Center for Interdisciplinary Research on Brain, Behavior & Mental Health, National Institute of Mental Health, $1,855,782, 2008-2013, Principal Investigator: Development and regulation of emotion in primates . R01 MH046729, National Institute of Mental Health/National Institute of Health, $425,841 .00, 2012-2017, Principal Investigator: Brain mechanisms underlying childhood anxiety . R21MH092581, National Institute of Mental Health/National Institute of Health, $125,000, 2012-2014, Principal Investigator: Brain Mechanisms Mediating Genetic Risk Factors for Anxiety and Depression . DHHS, PHS R01 MH081884 . National Institute of Mental Health, $4,472,284, 2008-2012, Principal Investigator: Defining corticotropin-releasing factor (CRF) system changes in amygdala and medial temporal cortex in association with depression and suicide . The Stanley Medical Research Institute, $150,000, 2009-2011, Principal Investigator: Development and Regulation of Emotion in Primates . R01 MH046729, National Institute of Mental Health,$2,743,637, 2005-2011, Principle Investigator: Combining mouse and monkey models to understand human risk for psychopathology . MH091550 . National Institute of Mental Health, $275,000, 2010-2012, Co-Principal Investigator: Neural Substrates of Affective Style and Emotion Regulation . R01, MH043454, National Institute of Mental Health, $150,000 Supplement, 2008-2011, APIRE/Janssen Resident Psychiatric Mentor Grant,

Kantrowitz, Joshua: Part 1: Dr . Kantrowitz reports having received consulting payments within the last 2 years from Otsuka Pharmaceuticals, Quadrant Health, RTI Health solutions, the Healthcare Advisory Board, Vindico Medical Education, Health Advances, LLC, Strategic Edge Communications . He owns a small number of shares of common stock in GlaxoSmithKline ., Part 2: NYS OMH, Columbia, RFMH, St Luke’s-Roosevelt, Part 4: He has conducted clinical research supported by the NIMH, the Stanley Foundation, Roche-Genetech, EnVivo, Psychogenics, Sunovion, Novartis, Pfizer, Lilly and GlaxoSmithKline.

Kenny, Paul : Part 1: Consultant to Pfizer, Inc., Co-founder of Eolas Therapeutics.

Kinon, Bruce: Part 1: Employee of Eli Lilly and Company, Shareholder of Eli Lilly and Company, Part 2: Employee of Eli Lilly and Company, Shareholder of Eli Lilly and Company, Part 3: Employee of Eli Lilly and Company, Part 5: Employee of Eli Lilly and Company

298

ACNP Annual Meeting Book 2013 rev8.indd 298 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Klann, Eric: Part 1: I am a consultant for Takeda Pharmaceuticals . My wife is employed by Takda Pharmaceuticals, Part 2: Consultant for Takeda Pharmaceuticals ., Part 3: Consultant for Takeda Pharmaceuticals during sabbatical of 2012-13 academic year .

Knight, Scott: Part 5: Sigma Aldrich

Kohler, Christian: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Krystal, John: Part 1: Abbott, Amgen, AstraZeneca, BMS, Eisei, Estellas, Forest, Johnson and Johnson, Lilly, Lohocla, Mnemosyne, Naurex, Novartis, Pfizer, Shire, Sunovion, Takedam, Teva, Part 4: AstraZeneca, Pfizer

Lanz, Thomas: Part 1: Employee of Pfizer, Part 3: Employee of Pfizer, Part 5: Pfizer

Lapidus, Kyle: Part 1: Dr . Lapidus has received support for this project from the Brain and Behavior Research Foundation’s Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award and serves as scientific advisor for Halo Neuro, Inc. He also participated in an interview on the future of antidepressants with LCN Consulting, Inc ., Part 4: Dr . Lapidus has received support for this project from the Brain and Behavior Research Foundation’s Young Investigator Award and Apire Janssen Psychiatric Resident Research Scholars Award .

Lavretsky, Helen: Part 1: Rsearch grants from Forest Research Institute and Alzheimer’s Research and Prevention foundation, Part 4: Forest Research Institute- research grants

Lisanby, Sarah: Part 4: Research Grants to my institution from Brainsway, NeoSync, ANS/St . Jude . Equipment support from Magstim, Magventures .

Malhotra, Anil: Part 1: Genomind

Mann, J. John: Part 2: Royalties from Research Foundation for Mental Health for C-SSRS, Part 4: Unrelated past grants from GSK and Novartis

March, Mary: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Markou, Athina: Part 4: Bristol-Myers-Squibb .

Marnett, Lawrence: Part 1: DJH, LJM and SP have submitted a patent application entitled “Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation,” which includes the compound LM-4131 .

Marx, Christine: Part 1: Applicant or co-applicant, pending patents on the use of neurosteroids and derivatives in CNS disorders and for lowering cholesterol (no patents issued, no licensing in place). Unpaid scientific advisor, Sage Therapeutics.

299

ACNP Annual Meeting Book 2013 rev8.indd 299 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Mathalon, Daniel: Part 1: Consultant for Amgen, Consultant for Bristol Myers Squibb

Matsumoto, Mickey: Part 1: I am an employee of Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc ., Part 2: Astellas Research Institute of America LLC ., Part 3: Astellas Research Institute of America LLC ., Part 5: Astellas Research Institute of America LLC .

McCracken, James: Part 1: Research Contracts: Roche, Seaside Therapeutics, Otsuka, Consultant Income: Roche, BioMarin, PharmaNet, Speaker Honoraria: Tourette Syndrome Association, Part 2: Research Contracts: Roche, Seaside Therapeutics

McCullumsmith, Cheryl: Part 1: Jansenn Pharmaceuticals : Suicide Advisory Board

McGorry, Patrick: Part 1: I have received honoraria for educational and consultancy activities and/or travel support to attend such consultancy meetings from Janssen Cilag, Servier and Roche and unrestricted research grant support from Janssen Cilag and Astra Zeneca, Part 4: Unrestricted research grant support from Janssen Cilag and Astra Zeneca

Meyer-Lindenberg, Andreas: Part 1: Speaker and Advisory boards: AstraZeneca, J+J, Lundbeck, Servier, Lilly

Miller, Andrew: Part 1: Abbott Laboratories, AstraZeneca, Centocor Inc ., GlaxoSmithKline, Lundbeck Research USA, F . Hoffmann-La Roche Ltd ., Schering-Plough Research Institute and Wyeth/Pfizer Inc., Part 4: Centocor Inc ., GlaxoSmithKline, and Schering-Plough Research Institute

Miyakawa, Tsuyoshi: Part 1: Advisor/Consultant for Astellas Pharma Inc .

Murrough, James: Part 1: Dr . Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals, Part 4: Dr . Murrough has received research support from Janssen Pharmaceuticals and Avanir Pharmaceuticals .

Nemeroff, Charles: Part 1: Skyland Trail, Cenerx, Novadel Pharma, Takeda, Revaax Pharma, Xhale, Allergan, Lilly, Roche, Shire, SK Pharma, PharmaNeuroboost, Part 2: Cenerx, Novadel Pharma, PharmaNeuroboost, Xhale, Part 3: Xhale, PharmaNeuroboost, Cenerx, Novadel Pharma

Nuechterlein, Keith: Part 1: Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc ., Consultant and research grant, Genentech, Consultant, Otsuka, Part 4: Investigator-Initiated Research Grant from Janssen Scientific Affairs, LLC, Research grant from Brain Plasticity, Inc., Research grant from Genentech

Nye, Jeffrey: Part 1: Employee of Janssen/J&J, Part 2: Employee of Janssen/J&J, Part 3: Employee of Janssen/J&J, Part 4: Employee of Janssen/J&J, Part 5: Employee of Janssen/ J&J

300

ACNP Annual Meeting Book 2013 rev8.indd 300 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

O’Malley, Stephanie: Part 1: ACTIVE workgroup supported be Eli Lilly, Lundbeck, Alkermes, Pfizer, Johnson and Johnson, GSK, Abbott, Hazelden Foundation, Applied behavior research, Pfizer, Part 4: Eli Lilly contract, Pfizer medication supplies

Patel, Maxine: Part 1: Consultancy: Janssen; Endo; Amgen; Lundbeck, Principal or Chief Investigator for clinical studies: Amgen; Lundbeck, Part 4: Principal or Chief Investigator for clinical studies: Amgen; Lundbeck,

Patel, Sachin: Part 1: DJH, LJM and SP have submitted a patent application entitled “Compositions and Methods for Substrate-Selective Inhibition of Endocannabinoid Oxygenation,” which includes the compound LM-4131 .

Paul, Steven: Part 1: Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner), Part 2: Alnylam Pharmaceuticals (Board of Directors), Constellation Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Karuna Pharmaceuticals (Board of Directors), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Tal Medical Pharmaceuticals (Scientific Advisory Board and Board of Directors), Third Rock Ventures (Venture Partner), Part 3: Alnylam Pharmaceuticals (Board of Directors), Eli Lilly (Stockholder), Sage Therapeutics (Founder and shareholder), Sigma Aldrich Company (Board of Directors), Third Rock Ventures (Venture Partner), Part 4: Alzheimer’s Drug Discovery Foundation, AstraZeneca Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Alzheimer’s Drug Discovery Foundation, NIH R01 grant .

Pearlson, Godfrey: Part 1: Consultant BMS 2012

Pelham, William: Part 1: Gave a talk at a conference in Japan that was sponsored by Janssen Pharmaceuticals

Perkins, Diana: Part 1: Consultant: Genentech/Roche, Sunovion, Otsuka

Peterchev, Angel: Part 1: Dr . Peterchev is inventor on patents and patent applications on TMS technology assigned to Columbia University and Duke University, including technology licensed to Rogue Research; was Principal Investigator on a research grant to Duke from Rogue Research and equipment donations to Columbia and Duke by Magstim, MagVenture, and ANS/St . Jude Medical; has received patent royalties from Rogue Research through Columbia for TMS technology; and has received travel support from Rogue Research through Duke, Part 3: Dr . Peterchev has received patent royalties from Rogue Research through Columbia University for TMS technology that he invented, Part 4: Dr . Peterchev was Principal Investigator on a research grant to Duke from Rogue Research and of equipment donations to Columbia and Duke by Magstim and MagVenture .

Phillips, Mary: Part 2: I have been a consultant for Cardiff University, Department of Psychological Medicine, UK . This relationship is due to end in 2013 .

Pletcher, Mathew: Part 1: Employee of Pfizer, Part 5: Pfizer

301

ACNP Annual Meeting Book 2013 rev8.indd 301 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Posner, Kelly: Part 1: Dr . Posner is the director of the Center for Suicide Risk Assessment . The Center, as part of an effort to help execute the FDA suicidality classification mandates, has received support from the following pharmaceutical companies: Abbott, Aerial Biopharma, Albany Molecular Research, Alder Biopharma, Alfresa, Alkermes, Amgen, Astellas Pharm, Astra Zeneca, Biogen, Biomarin Pharmaceutical, Biovail Technologies, Boehringer Ingelheim, Bracket, Bristol Myers Squibb, Cato Research, Celerion, Cephalon, Cetero Research, Chiesi Pharmaceuticals, Covance, CRI Worldwide, Daiichi Sankyo Company, Depomed, Douglas Pharmaceuticals/VersaPharm, EISAI, Elan, EnVivo, Epiomed, Forest, Gilead, GlaxoSmithKline, Grunenthal, GW Pharma Limited, Human Genome Sciences, i3 International, i3 Research, i3 Pharmaceutical Services, ICON Development Solutions, Impax Laboratories, INC Research, Ingenix, IntelGenx Corp, IntraCellular Therapies, Ironwood, IRIS, Isis, Ivax, Janssen, Jazz, Johnson & Johnson, Lilly USA, Lotus, Lundbeck, MedAvante, MedImmune, Merck, Mochida, Neurocrine Biosciences, Neuronex, Neurosearch, NextWave Pharma, Novartis, Noven, NovoNordisk, Omeros, Orexigen Therapeutics, Orion, Otsuka, Pamlab, Parexel, Pfizer, PGx Health, Pharmaceutical Research Associates, Pharmanet i3, Pierrel Research, PPD, Prana Biotechnology, ProPhase, Psyadon, QED Pharmaceuticals, Quintiles, Receptos, Reckitt Benckiser, Rho, Rhythm, Roche, Sanofi-Aventis, Schering-Plough, Schwarz Biosciences, SCOPE International, Sepracor, Shionogi, Shire, Siena Biotech, SK Life Science, Sunovion, Supernus Pharmaceuticals, Synosia Therapeutics, Takeda Global Research & Development Center, Takeda Pharmaceuticals, TauRx Therapeutics, Theravance, UCB Biosciences, UCB Korea, UCB Pharma, United BioSource Corp, Upsher-Smith Laboratories, Vaccinex, Valeant Pharmaceuticals, Vernalis, Vivus, WorldWide Clinical Trials, Wyeth Ayerst, Wyeth Pharmaceuticals, Wyeth Research, Xenoport and Zalicus . Dr . Posner receives royalty payments from the e-CSSRS, which are distributed to her by her employer, the Research Foundation for Mental Hygiene .

Potenza, Marc: Part 1: Consulting to Boehringer-Ingelheim and Lundbeck; financial interests in Somaxon . Grant from Psyadon, Part 4: Grant from Psyadon .

Rauch, Scott: Part 1: 2011 NIMH RDoC - honorarium, 2011 & 2012 - Oxford University Press - royalty, 2011 & 2012 - APPA - royalty, Part 2: None other than my primary employer: McLean Hospital/Partners Healthcare, Part 3: None other than my primary employer: McLean Hospital/Partners Healthcare, Part 4: Cyberonics, Medtronic

Ray, Lara: Part 1: I am a paid consultant for GSK .

Reynolds, Charles: Part 2: I receive an honorarium from the American Association for Geriatric Psychiatry, for service as associate editor of the American Journal of Geriatric Psychiatry, Part 4: During the past three years I have received pharmaceutical supplies for my NIH sponsored clinical trials from Pfizer (venlafaxine, aripiprazole, donepezil) and Eli Lilly (duloxetine), Part 5: not applicable; primary employer = University of Pittsburgh and UPMC

Risbrough, Victoria: Part 4: Research grants awarded from Johnson and Johnson, Omeros Pharmaceuticals , Sunovion Pharmaceuticals, and Johnson and Johnson .

302

ACNP Annual Meeting Book 2013 rev8.indd 302 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Robbins, Trevor: Part 1: Consultancy: Cambridge Cognition, Lilly, Merck, GlaxoSmithKline, Lundbeck, Teva, Shire Pharmaceuticals, ChemPartners, Royalties: Cambridge Cognition (CANTAB), Editorial Honoraria: Springer Verlag (Psychopharmacology), Part 2: Cambridge Cognition, Part 3: Cambridge Cognition, Part 4: Lilly, Lundbeck, GlaxoSmithKline

Roffman, Joshua: Part 4: Pamlab

Rogawski, Michael: Part 1: Marinus Pharmaceuticals, Sage Therapeutics, Eisai, UCB, Upsher- Smith, Part 2: University of California, Davis, Sage Therapeutics, Part 4: Gilead Sciences, Eisai, UCB

Ruparel, Kosha: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Russo, Scott: Part 4: Dr Russo receives laboratory support from Johnson and Johnson to study IL-6 and depression .

Sablinski, Tomasz: Part 5: Auven Therapeutics, Transpartency Life Sciences

Sahakian, Barbara: Part 1: Cambridge Cognition Limited, Lundbeck, Janssen/ J&J, Roche, Part 2: Cambridge Cognition Limited, Part 4: Janssen/J&J, Foresight, BIS, Government Office for Science

Sanchez, Raymond : Part 1: Employee of Otsuka Pharmaceutical Development and Commercialization (Vice President, Global Clinical Development CNS), Part 2: Employee of Otsuka Pharmaceutical Development and Commercialization, Part 5: Otsuka Pharmaceutical Development and Commercialization

Satterthwaite, Theodore: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Sawa, Akira: Part 4: Research Support:, Astellas Pharm ., Dainippon Sumitomo, Mitsubishi- Tanabe Pharm., Takeda, Johnson and Johnson, Consultant:, Pfizer, Asubio, Sucampo, Eli Lilly, Taisho, Collaboration:, Pfizer, Afraxis, Astellas Pharm., Dainippon Sumitomo, Mitsubishi- Tanabe Pharm., Takeda, Sanofis-Avenis, Johnson and Johnson

Schadt, Eric: Part 1: SAB for Pacific Biosciences and SAB for Berg, Part 2: SAB for Pacific Biosciences and SAB for Berg .

Schork, Nicholas: Part 1: Dr . Schork is a founder of CypherGenomics (http://www . cyphergenomics .com/) and on the board of MD Revolution (http://mdrevolution .com/) and has stock as a result .

303

ACNP Annual Meeting Book 2013 rev8.indd 303 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Sheehan, David: Part 1: Advisory Board membership to Roche, Sagene Pharma, Otsuka, Forest, Novadel, Labopharm, Neuronetics, International Society for CNS Drug Development (ISCDD) . Consultant to Sagene Pharma, Janssen (JNJ), MAPI, Prime Education, Neuronetics, ProPhase, Novadel, xCenda, Targacept, PharmaNeuroBoost . Payments for lectures from Pfizer, Eli Lilly, Glaxo, LaboPharm Angelini, Merck, PharmaNeuroBoost, Quintiles, Hikma, United BioSource, Janssen (JNJ), IncResearch, Otsuka . Payment for manuscript preparation from Quadrant HealthCom Inc. Royalties from eResearch Technology, Pfizer and Simon and Schuster . Stock in Medical Outcomes Systems . Travel Expenses to two ISCDD meetings paid by ISCDD, Part 2: Sagene Pharma, Labopharm, Neuronetics, MAPI, Pfizer, Eli Lilly, Glaxo.

Shelton, Richard: Part 1: Bristol-Myers Squibb, Cyberonics, Inc ., Elan, Corp ., Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Medtronic, Inc., Naurex, Inc., Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Inc., Pfizer, Inc ., Repligen, Corp ., Ridge Diagnostics, St . Jude Medical, Inc ., Takeda Pharmaceuticals, Part 2: Pamlab, Inc ., Part 4: Bristol-Myers Squibb, Elan, Corp ., Eli Lilly and Company, Euthymics Bioscience, Forest Pharmaceuticals, Janssen Pharmaceutica, Naurex, Inc ., Novartis Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab, Inc ., Repligen, Corp ., Ridge Diagnostics, St . Jude Medical, Inc ., Takeda Pharmaceuticals

Simpson, Helen: Part 1: Consultation for Quintiles, Inc . (on therapeutic needs for OCD), 9/2012, Part 4: Research support from Transcept Pharmaceuticals for ondansetron study 2011- 2013, Research support for medication at no-cost from Janssen Pharmaceuticals 2006-2012 for NIMH funded study in OCD

Smith, Mark: Part 5: Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the company that funded/sponsored the study reported here . Current employee of Shire Pharmaceuticals in Wayne, PA .

Stein, Murray: Part 1: Care Management Technologies (Consultant), Up-to-Date (Co-Editor- in-Chief, Psychiatry), Depression and Anxiety [Wiley] (Associate Editor), Part 2: University of California San Diego, Va San Diego Healthcare System, Up-To-Date, Part 3: Up-To-Date,Part 4: Janssen (Co-Investigator on Research Contract)

Stephens, David: Part 1: Research Contract with GSK, Cambridge, UK, Consultant with Merz & Co, Frankfurt, Germany, Part 2: Research Contract with GSK, Cambridge, UK

Svensson, Torgny: Part 1: Consultant/advisory board: AstraZeneca, Janssen, Lundbeck, Otsuka, Merck Sharp and Dome . , Part 4: The Swedish Research Council, The Karolinska Institutet, Stockholm (Sweden), The Brain Foundation (Sweden), AstraZeneca, Organon, Schering-Plough, Merck Sharp and Dome, Lundbeck, Otsuka, Astellas

Swanson, James: Part 1: I have been a consultant with Noven Pharmaceuticals and BLK Pharma, and I recieved indirect support from pharmaceutucal companies from a professional organzation, the European Network of Hyperkinetic Disorders (EUNETHYDIS), to make presentations at annual meetings .

Sweeney, John: Part 1: Consultant to Lilly, Takeda, Roche and BMS

304

ACNP Annual Meeting Book 2013 rev8.indd 304 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Swift, Robert: Part 1: Consultant to Transcept Pharmaceuticals - received fee, Scientific Advisory Board for D&A Pharma - received honorarium and travel expenses to meeting, Consultant to Pharmaceutico CT - received fee and travel expense reimbursement, Part 2: Consultant to Pharmaceutico CT - fee and travel expense reimbursement

Tamminga, Carol: Part 1: Astellas; Eli Lilly; Intra-Cellular Therapies; Kaye Scholer LLP; Lundbeck; PureTech Ventures; NIMH; Am J Psychiatry; Part 2: Am J Psychiatry; KayeScholer LLP; IntraCellular Therapies, Part 4: Sunovion

Thomas, Jason: Part 1: PhD studentship part funded by P1vital, Part 3: PhD studentship part funded by P1vital, Part 4: PhD studentship part funded by P1vital

Trivedi, Madhukar: Part 1: Madhukar H . Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc ., Cerecor, Concert Pharmaceuticals, Inc ., Eli Lilly & Company, Evotec, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, Sunovion, Takeda, Targacept, Transcept, and Wyeth-Ayerst Laboratories ., Part 4: Dr . Trivedi has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse .

Turetsky, Bruce: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Uchida, Hiroyuki: Part 1: Dr . Uchida has received speaker’s honoraria from Otsuka Pharmaceutical, Janssen Pharmaceutical, Novartis Pharma, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, and Janssen Pharmaceutical within the past two years . Part 4: Dr. Uchida has received grants from Pfizer, Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, and Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma, Janssen Pharmaceutical, and Yoshitomi Yakuhin within the past two years .

Uher, Rudolf: Part 1: Dr Uher co-chairs a steering board of a research project initiated and funded by Bristol Myers Squibb and collaborates with Pfizer, Glaxo-Smith Kline and Roche as part of the European Union Innovative Medicine Initiative funded NEWMEDS project . Dr Uher has received no personal income from any pharmaceutical or biotech industry and holds no equity in companies active in medicine, pharmaceuticals or biotechnology .

Van Zeeland, Ashley: Part 1: Dr . Van Zeeland is a Co-founder and CEO of CypherGenomics (http://www .cyphergenomics .com/) and has stock as a result, Part 5: Cypher Genomics

Vinogradov, Sophia: Part 1: consultant to BrainPlasticity Institute

Wahlestedt, Claes: Part 1: Pfizer, OPKO

Walker, Brendan: Part 4: Completed a cooperative research agreement on 9/24/2011 with H . Lundbeck A/S, Copenhagen on the kappa-opoid mechanisms of nalmefene .

305

ACNP Annual Meeting Book 2013 rev8.indd 305 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Warden, Melissa: Part 1: Stanford University has filed for patent protection on technology invented by Dr . Melissa R . Warden and Dr . Karl Deisseroth .

Waxmonsky, James: Part 1: Research Contract Noven Pharmaceuticals, Research Contract Janssen, Research Contract Shire Inc ., Advisory Board Noven Pharmaceuticals (<$5,000), Part 4: Research Contract Noven Pharmaceuticals, Research Contract Janssen, Research Contract Shire Inc .

Wigal, Tim: Part 1: Otsuka and McNeil, Part 4: Eli Lilly, Noven, Shire and Rhodes Pharamceuticals

Wing, Victoria: Part 4: Pfizer IIR Operating Grant 2012-2014 ($50,000), Pfizer IIR 2010-2013 (medication supply only), Pfizer GRAND Operating Grant 2013-2015 ($20,000)

Winterer, Georg: Part 1: PharmaImage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Boehringer Ingelheim (consulting), UCB Pharma (consulting, services), Pfizer (speaker bureau, grant), Focus Drug Development (consulting, services), Dritte Patent Portfolio Beteiligungsgesellschaft mbH & Co KG (consulting), Ratiopharm (consulting), Part 2: PharmaImage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), UCB Pharma (consulting, services), Focus Drug Development (consulting, services), Part 3: PharmaImage - Biomarker Solutions GmbH (CEO), Janssen Pharmaceutica (consulting, services) , Lundbeck (consulting, services), Focus Drug Development (consulting, services), Part 4: Pfizer/McNeill

Wolf, Daniel: Part 4: The study reported here was sponsored and funded by AstraZeneca Pharmaceuticals .

Wolf, Marina: Part 1: I have 50,000 shares (~$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329 . I do not receive any income at this time. There is no linkage to my research or to ACNP., I have 50,000 shares (~$50,000) in a non-publicly traded entity: CIS BIotech Inc, 2701 North Decatur Rd, Decatur, GA 30033 . I do not receive any income at this time . There is no linkage to my research or to ACNP ., Part 2: I have 50,000 shares (~$50,000) in a non-publicly traded entity: Grace Laboratories LLC, 1755 Logans Knoll NE, Atlanta GA 30329 . I do not receive any income at this time . There is no linkage to my research or to ACNP., I have 50,000 shares (~$50,000) in a non-publicly traded entity: CIS BIotech Inc, 2701 North Decatur Rd, Decatur, GA 30033 . I do not receive any income at this time . There is no linkage to my research or to ACNP .

Wong, Dean: Part 1: Consultant for Amgen and Concert Pharmaceuticals, Part 2: Johns Hopkins University, School of Medicine, Part 4: Avid, Biotie, GE, Intracellular, J+J, Lilly, Lundbeck, Merck, NIH, Otsuka, Roche, Sanofi-Aventis, Synosia

Woods, Scott: Part 1: Investigator-initiated grant from Pfizer, Part 4: Investigator-initiated grant from Pfizer

Yates III, John R.: Part 1: ThermoFisher, Part 2: ThermoFisher, Part 4: Roche

306

ACNP Annual Meeting Book 2013 rev8.indd 306 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Youngstrom, Eric: Part 1: Eric Youngstrom has consulted with Lundbeck and received past travel support from Bristol-Myers Squibb . He has consulted with Penn State about analyses for a grant funded by Pfizer, and received grant funding from NIMH.

Zarate, Carlos: Part 1: Dr . Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression . Dr . Zarate has assigned his rights in the patent to the U .S . government but will share a percentage of any royalties that may be received by the government .

Zhang, H. Steve: Part 5: Sangamo Biosciences

Zorumski, Charles: Part 1: I serve on the Scientific Advisory Board of Sage Therapeutics.

Zukin, Stephen: Part 5: Former employee of AstraZeneca Pharmaceuticals in Wilmington DE, the company that funded/sponsored the study reported here ., Current employee of Forest Research Institute in Jersey City, New Jersey .

Following Faculty Had Nothing to Disclose:

Dean Acheson Jake Bosin Toni-Kim Clarke Jean Addington Jennifer Bossert Paula Clayton Susanne Ahmari Kathleen Brady Brett Clementz Schahram Akbarian Linda Brady Christine Colvis Martin Alda Jess Brallier Wilson Compton Ream Al-Hasani David Bredt Mark Connelly Susan Amara Timothy W . Bredy Robin Cooper Mala Ananth Truman Brown Cheryl Corcoran Katrin Arelin Michael Bruchas Barbara Cornblatt Amy Arnsten Han Brunner Kathryn Cunningham Peter Bachman Katherine Burdick Megan Davis Dewleen Baker Inga Burmann Michael De Bellis Tracy Bale Meryl Butters Jacek Debiec Ruben Baler Dan Buysse Karl Deisseroth Elizabeth Balough Kristin Cadenhead Mauricio Delgado Michael Baumann Catherine Cahill Christine Denny Jaime Becnel Tyrone Cannon Pamela DeRosse Gillinder Bedi Melanie Canterberry Jordan DeVylder Odeta Beggel Nicole Capik Brian Dias Aysenil Belger Facundo Carillo Elisa Dias Sabina Berretta Marlene Carlson Jesse Dills Wade Berrettini Ricardo Carrion Yan Dong Timothy Bestor Hannah Cates Glenn Doyle Bruno Biagianti Guillermo Cecchi Liam Drew James Bibb Moses Chao Manoranjan D’Souza Elisabeth Binder Joseph Cheer Elizabeth Duval James Bjork Alon Chen John Edwards Jeffrey Borckardt Brandon Chuang Igor Elman

307

ACNP Annual Meeting Book 2013 rev8.indd 307 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Following Faculty Had Nothing to Disclose:

Mark Emmett Amanda Guyer Sung Won Kim Heather Eng Victoria Haghighi Jonathan Kipnis Michael Epstein Maureen Hahn Robin Kleiman Monique Ernst Tomas Hajek Joel Kleinman Emad Eskandar Batsheva Halberstam Torsten Klengel Irina Esterlis Katherine Ann Halmi Rebecca Knickmeyer Amit Etkin Ahmad Hameed Harold Koenigsberg Gary Evans Robert Hamer David Kokel Jennifer Felger Bruce D . Hammock Genevieve Konopka Deveroux Ferguson Colleen Hanlon George Koob Russell Ferland Nolan Hartley Michael Krashes Diego Fernandez Slezak Karen Hartwell Annegret Krause-Utz Francesca Filbey Elizabeth Heller Adrienne Lahti Erika Forbes J . Dee Higley Wanda Lai Audra Foshage Noboru Hiroi Olivia Lam Joanna Fowler Georgia Hodes Salomon Langer Andrew Fox Rachel Hodge Ruth Lanius Nathan Fox Daniel Hong Janine LaSalle Paul Frankland Hailan Hu Hilde Lavreysen Joseph Friedman Z . Josh Huang Francis Lee Henn Fritz Thomas Hyde Thomas Lehner Flavio Frohlich Thomas Insel Ellen Leibenluft Brian Frosh Michael Irwin Todd LeMatty Julie Fudge Koko Ishizuka Bernard Lerer Dan Fulford Jacob Jacobsen Marc Lerner Chris Fussell Andrew Jaffe David Leung Aurelio Galli J . David Jentsch Cara Levitch Joyonna Gamble-George Jarcho Johanna Kun Li Sarah Garfinkel Jason Johannesen Xingbao Li Xiujuan Geng Oralee Johnson Lujian Liao Mark George Sara Jones Israel Liberzon Susan George Sheena Josselyn Gregory Light Vincent Giguere Peter Kalivas Kelvin Lim John Gilmore Yeona Kang Ryan Logan Jay Gingrich Thomas Kash Falk Lohoff Santhosh Girirajan Siegfried Kasper Edythe London Nitin Gogtay Walter Kaye Miguel Lopez-Teledono Rita Goldstein Matthew Kayser Francis Lotrich Raul Gonzalez Edmund Kerut David Lovinger David Grandy Matcheri Keshavan Bradford Lowell Kathleen Grant Mazen Kheirbek Bai Lu Steven Grant Janice Kiecolt-Glaser Bruce Luber Rachel Greene Dohyun Kim Farah Lubin Nuria Gresa-Arribas Ronald Kim Alice Luo Clayton

308

ACNP Annual Meeting Book 2013 rev8.indd 308 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Following Faculty Had Nothing to Disclose:

James Luther Antonio Noronha Barry Setlow Angus MacDonald Aoife O’Donovan Carla Shatz Pierre Magistretti Kevin Ochsner Tomer Shechner Zana Majeed Anne O’Donnell Pei-an Betty Shih Roberto Malinow Michele Okun Sarah Short Daniel Margulies Max Owens David Shurtleff Sander Markx Angela Ozburn Larry Siever Charles Marmar Andre Pampel Mariano Sigman Rachel Marsh Carlos Pardo Gail Silipo Keri Martinowich Puja Parekh Jogender Singh Tushir Jordan McCall Michael Parides Dorothy Sit Colleen McClung Ramin Parsey Phil Skolnick Robert McCullumsmith Paul Patterson Vikaas Sohal Christopher McDougle Tomas Paus Laili Soleimani Bruce McEwen Catherine Pena Chandra Sripada Jacqueline McGinty Andrew Perez Beth Stevens Vinod Menon M . Mercedes Perez- Camilla Stoltenberg Valentina Mercaldo Rodriguez Scott Stroup Kathleen Merikangas Phillip Phan Garret Stuber Roger Meyer Marina Picciotto Regina Sullivan Klaus Miczek David Pickar Haosheng Sun Arthur Mikhno Daniel Pine Lawrence Sung Mohammed Milad Linda Porrino Ezra Susser Maria Milekic James Prisciandaro James Swain Brooke Miller Gregory Quirk Jonathan Sweedler Gregory Miller Ralf Regenthal Peter Szatmari James Moeller Kerry Ressler Philip Szeszko Bita Moghaddam Stephan Ripke Karen Szumlinski Suman Mohanty Oliver Robinson Michael Taffe Megan Moran-Santa Maria Stephanie Rohrig John Talpos Christophe Morisseau Jerrold Rosenbaum Joseph Taylor Matthew Mosconi Bryan Roth Panayotis Thanos Felix Muchomba Richard Rothman Paul Thompson Karim Nader Laura Rowland Wesley Thompson Kazuhiko Nakamura Andrey Rzhetsky Maarten Titulaer Sneha Narasimhan Julia Sacher Vi Tran Eric Nelson Michael Saladin Gina Turrigiano Eric Nestler Derya Sargin David Vaillancourt Thomas Neylan Nayla Scaramello Edwin van den Oord Charles Nichols Alexander Schäfer Ashlee Van’t Veer Philip Nielsen Christian Schmahl Joris Veltman Caroline Nievergelt Lauren Schmitt Eric Vermetten Carol Nilsson Blessan Sebastian Arno Villringer Margaret Niznikiewicz Larry Seidman Susanna Visser

309

ACNP Annual Meeting Book 2013 rev8.indd 309 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

ACNP 2013 Presenter Disclosures (continued)

Following Faculty Had Nothing to Disclose:

Aristotle Voineskos Katherine Wisner Soojin Yi Nora Volkow Stephen Wisniewski Adelaide Yiu Mark Von Zastrow Catherine Wong Bangning Yu Terry Vrijenhoek Marcelo Wood Deborah Yurgelun-Todd Elaine Walker Josh Woolley Kate Yurgil Ken Warren Sandra Woolson Andrew Zalesky Christopher Watkins Yurong Xin Zane Zeier Daniel Weinberger Jun Yang Tai Zhou Anne West Zhongfei Yang Xianjin Zhou Douglas Williamson Rachel Yehuda

310

ACNP Annual Meeting Book 2013 rev8.indd 310 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Abazyan, Bagrat 210 Aluisio, Leah 264 Abazyan, Sofya 210 Alvarado-Alanis, Patricia 174 Abbott, Chris 235 Alvarenga, Pedro de 228 Abbott, Thomas 196 Amador, Francisco J . 253 Abdallah, Chadi 179 Amara, Susan G . 81 Abdullah, Saeed 191 Ambrosia, Marigrace 185, 242 Abelson, James L . 240 Ameis, Stephanie 175 Abel, Ted 1, 78 Ameringen, Michael Van 261 Abi-Dargham, Anissa 1, 129, 184, 259 Amiaz, Revital 221 Acheson, Dean 18, 46, 47, 241 Amir, Nader 245 Achim, Cristian L . 244 Amole, Marlissa 185 Acierno, Ron 171 An, Yang 182 Adams, Philip 172, 222, 227 Anand, Amit 174 Addington, Jean 40, 242, 246 Ananth, Mala 33, 199 Adham, Nika 259, 277 Anastasio, Noelle 266, 270 Adinoff, Bryon 183 Andersen, Susan L . 202 Adler, Caleb 168, 189 Anderson, Kemp 244 Aeinehband, Shahin 166 Anderson, Wesley 265 Agam, Galila 267 Andreazza, Ana 267 Agee, Elisha R . 241 Andres, Lozano 243 Aghajanian, George 196 Andrews, Howard 191 Agorastos, Stergiani 188 Ankri, Yael 191, 221 Ahmari, Susanne 136, 277 Ansari, Amber 202 Ahmed, Anthony 262 Anticevic, Alan 182 Ahmed, Raisa 265 Anton, Raymond F . 176, 181 Ajilore, Olusola 172, 176, 178, Appelbaum, Paul S . 85 181, 220, 241 Arad, Michal 230, 277 Akbarian, Schahram 138, 212 Arango, Victoria 215, 216 Akil, Huda 74, 202, 206, 253, Arbid, Natalie 247 268 Arelin, Katrin 99, 229 Alcantara, Lyonna F . 204 Arenovich, Tamara 251 Alda, Martin 82, 228 Arguello, Amy A . 197 Aldridge-Gerry, Arianna 219 Argyelan, Miklos 178 Aleksandrova, Lily 194 Arias, Albert 257 Alexander, Jon C . 210 Arion, Dominique 167 Alexopoulos, George S . 156, 194 Arlt, Heike 264 Algorta, Guillermo Perez 231 Armeli, Stephen 257 Al-Hasani, Ream 38, 269 Arndt, Stephan 183 Alia-Klein, Nelly 239, 247, 249 Arnold, Eugene 173 Al-Jadiri, Aseel 202 Arnold, Paul D . 175, 253 Allam, Farida 202 Arnsten, Amy 67, 73 Allen, Nicholas 242 Arolt, Volker 251 Alliey-Rodriguez, Ney 249 Arponen, Eveliina 267 Almasy, Laura 251 Arreola, Adrian 208 Almeida, Jorge 171, 172, 173, Artigas, Francesc 195 174, 277 Arulpragasam, Amanda R . 234, 243 Almenoff, June 259 Åsberg, Marie 166 Almli, Lynn 176, 249, 253 Ashby, Stefania 244 Alonso, Richard 264 Ashe-McNalley, Cody 181, 196 Alphs, Larry 86, 190, 257, 258, Aslam, Haris 171 277 Asor, Eyal 206 Altman, Daniel E . 201 Aston-Jones, Gary 1, 197, 274 Altshuler, Lori 181 Augier, Eric 210

311

ACNP Annual Meeting Book 2013 rev8.indd 311 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Auta, James 166 Bartlett, Selena 257 Avena, Nicole M . 204 Bartolome, Jose Manuel 206, 270 Avenet, Patrick 264 Barton, Bruce A . 231 Avery, Jason 186 Bartz, Jennifer 163, 201, 239 Avital, Avi 206 Bass, Christina 228 Ayalew, Mikias 255 Bassett, Danielle 253 Ayutyanont, Napatkamon 190 Bato, Angelica 245 Baaré, Wim 193 Bauer, Clayton 270 Baba, Akemichi 206 Baumann, Michael H . 90 Bachman, Peter 40, 246, 277 Baune, Bernhard 251 Bachtell, Ryan 272, 277 Bearden, Carrie 180, 241, 242 Bader, Verian 214 Beas, Sofia 240 Badner, Judith 249 Beaucage, Kayla 248 Baena, S . 233 Beaver, Kathryn 233 Baganz, Nicole 165 Bebko, Genna 173 Bailer, Ursula F . 187, 242 Beck, Jonathan 246 Bain, Earle 225 Becker, Howard C . 155 Bakalian, Mihran J . 215, 216 Becnel, Jaime 25, 191 Baker, Amanda M . 240 Bedi, Gillinder 36, 224, 256, 259, Baker, Dewleen 46, 95, 241, 277 278 Baker, Maggie B . 232 Bednarski, Sarah 182 Baker, Nate 274 Beebe-Wang, Nicassia 249 Baker, Ross 227, 256, 277 Beech, Danielle 261 Bakshi, Vaishali 163, 201, 239 Beeghly, James 235 Baldwin, Philip 188, 189 Beesdo-Baum, Katja 181 Baler, Ruben 84 Beeské, Sandra 264 Bale, Tracy 158, 277 Beesley, Stephen 212 Ballinger, Michael 210 Begemann, Marieke 168 Balough, Elizabeth 59, 204 Beggel, Odeta 110, 223 Balu, Darrick 206, 277 Behrens, M . Margarita 210 Balvaneda, Bryan 259 Behrje, Rhett B . 255 Bame, Monica 214 Belanger, Elizabeth 255 Banerjee, Pradeep 267, 270 Belfort-Deaguiar, Renata 182 Bangasser, Debra 275, 277 Belger, Ayse 40, 179, 246, 275 Bani-Fatemi, Ali 255 Belin, David 197 Banks, Matthew 90, 270, 277 Belkin, Molly 272 Banks, Stan 271 Belmaker, R .H . 267 Bansal, Ravi 173 Benanzer, Tessa 168 Banuelos, Cristina 240 Benca, Ruth 176, 278 Baram, Tallie Z . 158 Bender, Julian 176 Barbarich-Marstellar, Nicole 204 Benedek, David M . 233 Barbier, Estelle 214, 215, 278 Benes, Francine M . 216 Barchas, Jack David 253 Benítez-King, Gloria 269 Barch, Deanna 131, 189, 193, Benkelfat, Chawki 188 244, 255, 278 Bennett, Vann 204 Barham, Terrika 230 Ben-Shachar, Dorit 206 Barksdale, Keri 167, 278 Benson, Andrew 269 Barnaby, Cris 273 Benton, Tami D . 217 Barnett, Alan S . 178 Bentzley, Brandon 274 Barr, Christina 163, 165, 201, Benveniste, Helene 191 232, 239 Ben-Yoav, Hadar 192 Barr, Mera 243, 278 Berdyyeva, Tamara 264 Barrett, Ruth 213 Berent-Spillson, Alison 232

312

ACNP Annual Meeting Book 2013 rev8.indd 312 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Berg, Louise 222 Blakely, Randy 1, 17, 18, 19, 165, Bergen, Andrew 31, 247, 250 266 Berger, Rebecca 198 Blakeman, Sam 216 Berger, Stefan 213 Blanco, Carlos 228, 278 Berk, Michael 234 Blangero, John 251, 278 Berlanga, Carlos 269 Blennow, Kaj 7, 13, 14, 176 Berman, Karen 1, 74, 167, 178, Blier, Pierre 150, 222, 271 186, 187, 232, Bloch, Michael H . 182, 184, 260 245, 251, 252 Blom, Thomas 189, 223 Berman, Rebecca A . 180 Blood, Anne 186 Bernert, Rebecca 186, 226 Blough, Bruce 270 Bernhardt, Elisabeth 234 Blumberg, Hilary 1 Bernstein, Ira 234 Boada, Fernando 217 Berretta, Sabina 77, 166 Bodkin, J . Alexander 192 Berrettini, Wade 31, 250 Bodurka, Jerzy 177 Berridge, Kent 209 Boehm, Peter 190 Berry, Gerard T . 267 Boeke, Emily A . 184 Bershad, Anya K . 255 Boettiger, Charlotte A . 152 Bersudsky, Yuly 267 Boger, Heather A . 209 Bertenthal, Daniel 230 Bohannon, Andrew S . 210 Bertocci, Michele A . 173 Boileau, Isabelle 182 Besheer, Joyce 214 Boksay, Istvan 234 Bestor, Timothy 43, 207 Bolanos-Guzman, Carlos A . 204, 265 Bethea, Cynthia L . 164 Boldrini, Maura 215, 216 Bhakta, Savita G . 259 Bonar, Lisa 173 Bharadwaj, Rahul 212 Bonaventure, Pascal 264 Bhattacharjee, Abesh 175 Bonifacio, Laura 259 Biagianti, Bruno 113, 236 Bonne, Omer 197 Bibb, James A . 151, 211 Bonyadi, Mariam 196 Bidesi, Anup S . 173 Booth, Raymond G . 272 Biernacka, Joanna 254 Borckardt, Jeffrey 24, 120, 172, 233, Biggio, Giovanni 240 278 Bigos, Kristin 252 Bortnova, Ana 225 Bijanki, Kelly Rowe 183 Bortolozzi, Analia 233 Bikson, Marom 91 Bortz, Dave 163 Bilder, Robert M . 226, 253 Bos, Dienke 169 Bilgel, Murat 182 Bosin, Jake 101, 208 Billingslea, Eileen 182 Bossert, Jennifer M . 137 Binder, Elisabeth 153, 163, 201, Bosshardt, Lauren 244 239, 252 Bossie, Cynthia A . 190, 257, 258 Birmaher, Boris 173 Boules, Sylvia 166, 221 Birnbaum, Rebecca 250 Boulter, Jim 164 Birnbaum, Shari 205 Bové, Jordi 233 Bischoff-Grethe, Amanda 242 Bracci, Giulia 216, 278 Bishop, Jeffrey 242, 258, 278 Bradley, Bekh 176, 231, 244, Biton, Bruno 264 245, 249 Bizon, Jennifer 240 Bradshaw, Mark 222 Bizzell, Joshua 275 Brady, Kathleen T . 120, 233, 274 Bjork, James M . 139 Brady, Linda S . 1, 74, 144 Blackburn, Elizabeth 218 Braff, David L . 249 Blackistone, Kevin 165, 217 Bralet, Marie-Cecile 175 Blacktop, Jordan M . 196 Brallier, Jess W . 62, 221 Blady, Shira J . 188 Brandl, Eva J . 251

313

ACNP Annual Meeting Book 2013 rev8.indd 313 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Brandon, Nicholas 124, 159, 214, 271 Buckner, Randy 184, 227 Bredy, Timothy W . 158 Bui, T .H . Eric 212, 241, 279 Breiter, Hans 186, 278 Buka, Stephen 273 Brenner, Helena 246 Bukhari, Noreen 217 Bressan, Rodrigo 183 Bunney, William E . 253 Brewster, Ryan 181 Burant, Charles 188 Briand, Lisa A . 164, 203 Burch, Ronald 268, 279 Brickley, Michael 248 Burdick, Katherine 89, 163, 201, 239 Bridges, Thomas M . 270, 271 Burgdorf, Jeffrey 268 Briggs, Richard W . 183 Burggren, Alison 177 Brimijoin, Stephen 263 Burghardt, Kyle 163, 192 Britton, Jennifer 180, 278 Burghardt, Paul 188 Brodie, Jonathan D . 188 Burghart, Daniel 259 Brodsky, Matthew 217 Burke, Ainsley 220 Brody, Arthur 170 Burket, Jessica 269 Bronstein, Kathryn 192 Burmann, Inga 99, 229 Brooks, Julie 213 Burman, Poromendro 217 Brosschot, Jos 247 Burnham, Veronica 215 Brothers, Shaun 215, 267, 279 Burrows, Kaiping 186 Brotman, Melissa A . 168, 193 Burshtein, Shimon 258 Brown, Alan 228 Burton, Christine 253 Brown, Angelo 230 Busatto, Geraldo 183 Brown, David 220 Bushong, Debra 260 Brown, Delisa G . 246 Bustillo, Juan 132, 279 Brown, E . Sherwood 256 Butters, Meryl 156 Brown, Jacquelyn 201 Buysse, Dan 57, 273 Brown, Jesse 169 Byun, Janet 164 Brown, Lawrence 209 Cachope, Roger 270 Brown, Richard 166 Cackowski, Sylvia 167 Brown, Robyn M . 207, 219 Cadenhead, Kristin 1, 40, 242, 246 Brown, Solange P . 204 Cadilla, Carmen L . 253 Brown, Truman 24, 172, 181 Cadoni, Cristina 265 Brown, Virginia 272 Cahill, Catherine 152 Brown, Walter A . 221 Calabrese, Joseph R . 253, 262 Brown, William 190 Calhoun, Vincent 179, 185, 198 Bruce, Douglas 174 Calkin, Cynthia 228 Bruchas, Michael 18, 38, 39, 269, Callicott, Joseph 1, 252 273 Cameron, Kimberly 245 Bruder, Gerard 222, 223, 227 Campbell, Nicholas 254 Bruggemann, Jason 195 Can, Adem 270 Bruijnzeel, Adrie 210 Canal, Clinton 272 Brunner, Han G . 33, 199 Canetta, Sarah E . 228 Bruno, Davide 176 Cañive, José 174 Bruno, John 1, 163, 207 Cannon, Tyrone 40, 242, 246 Brutsche, Nancy 227 Canterberry, Melanie 24, 120, 172, 233 Bryan, Angela 185 Cantley, Brian 192 Bubenzer, Sarah 170 Cao, Dingcai 258 Bubser, Michael 271 Caparelli, Elisabeth 168 Buccafusca, Roberto 267 Capik, Nicole 38, 269, 273 Buchanan, Robert W . 77, 127, 193, 236, Caravaggio, Fernando 193 255 Carballo-Carbajal, Iria 233 Buchsbaum, Monte S . 175 Carella, Morgan 202 Buckley, Niki 268 Carillo, Facundo 36, 224

314

ACNP Annual Meeting Book 2013 rev8.indd 314 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Carlezon Jr ., William 97, 98, 131, 209 Cheer, Joseph 125, 270 Carlson, Marlene 110, 223 Chen, Alon 133, 279 Carmi, Shai 250 Chen, Ashley C . 185 Carmody, Thomas 173, 222, 227, 256 Chen, Changzheng 222 Carmona, María del Carmen 233 Chen, Chao 249 Carneiro, Ana 202, 254 Chen, Dalei 224 Carpenter, Linda 163, 177, 201, Chen, Gang 180 231, 239 Chen, Guang 166, 208 Carrasco, Melisa 240 Chen, Haiming 214 Carrion, Joseph 188 Chen, Kewei 190 Carrion, Ricardo 40, 246 Chen, Laishun 268 Carroll, Marilyn E . 263 Chen, Li-Shiun 255 Carruthers, Nicholas 264 Chen, Qian 203 Carson, Richard 173, 182, 184, 259 Chen, Qiang 252 Carter, Cameron S . 131, 244, 246, 247 Chen, Xiangchuan 189 Carter, Howard 187 Chen, Xuesong 258 Carver, Frederick W . 187 Chen, Yue 239 Casaus, Laurie R . 241 Chen, Yu-Han 174 Cascella, Nicola 216, 248 Cheng, Kejun 263 Casey, Daniel E . 92 Chester, Julie A . 248 Casey, David 194 Chhatre, Sumedha 174 Cassano, Paolo 260 Chiara, Gaetano Di 265 Cassiello, Clair 184 Chica, M Rosario 233 Castellanos, Francisco Xavier 180 Childress, Anna R . 176, 179, 180, 188 Castrillon, Gabriel 180 Childs, Emma 260, 279 Caterson, Bruce 166 Chi, Ming 183 Cates, Hannah 54, 212 Chintoh, Araba 163 Catherine, Demers 183 Chiriță, Roxana 258 Catlow, John 265 Chlan, Jennifer 275 Catts, Stanley V . 195 Chocron, Sheryl 192 Cecchi, Guillermo 36, 224 Choi, Doo-Sup 254, 279 Celada, Pau 195 Choi, Kwang 189, 279 Cezar, Raony Cassab 228 Choi, Michelle 188 Chaharyn, Bradley 275 Choi, Yong Kee 267 Chakraborty, Bijan 259 Cho, Raymond 163, 201, 239 Chakravarty, Mallar 168 Chott, Robert 221 Chalifa-Caspi, Vered 267 Chou, Hsun-Hua 259, 279 Chambers, Micah C . 181 Chou, Tina 243 Chan, Larry 191 Choudhry, Sreyan 213 Chandra, Ramesh 213 Choudhury, Tanzeem 191 Chang, Chun-hui 203 Chowdhury, Nabilah I . 251 Chang, Kiki 190 Christensen, Kara 175 Chang, Lee C . 179 Christoffel, Daniel J . 215 Chang, Lin 196 Chuang, Brandon 113, 236 Chang, Lun-Ching 249 Chun, Lani 264 Chang, Trina 260 Chung, Lisa 196 Chao, Moses V . 135 Chung, Youjin 216 Chappell, Phillip 86 Cintron, Dahima 229 Charlton, Rebecca 172 Cirjaliu, Diana 258 Charney, Dennis S . 62, 92, 221 Cirrito, John 221 Chase, Henry 171, 172, 173, 174 Cisler, Josh 246 Chaudhury, Dipesh 215 Citrome, Leslie 220 Chaudhury, Sraboni 206 Clark, Brian 266

315

ACNP Annual Meeting Book 2013 rev8.indd 315 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Clarke, Toni-Kim 31, 250 Cornblatt, Barbara A . 40, 242, 246 Clark-Raymond, Anne 255 Cornish, James 188, 279 Clayton, Alice Luo 78 Correll, Christoph 127, 202, 262 Clayton, Paula J . 86 Corse, Andrew K . 234, 243 Clement, Ashley 198 Corsi-Travali, Stefani 173 Clemente, Jessica 165 Cortese, Bernadette 171, 279 Clementz, Brett A . 126, 173 Costafreda, Sergi 215, 217 Clerkin, Suzanne 171 Cottone, Pietro 272, 273 Clifford, James 248 Covault, Jonathan 257 Clinton, Sarah M . 268 Cover, Kara K . 274 Coccaro, Emil F . 83, 85 Covington, Paul 259 Coe, Marion 257 Cowell, Rita M . 210 Cohen, Beth 230 Cowen, Philip 170, 241 Cohen, Bruce 167, 179, 212, 224 Cox, Brittney M . 197, 274 Cohen, Greg 253 Cox, Nancy J . 249, 254 Cohen, Hagit 206, 234 Coykendall, Lizz 182 Cohen, Jamie 172, 220 Coyle, Joseph T . 206, 209, 216 Cohen, Jonathan 234 Crane, Natania 241 Cohen, Joshua 268 Crawford, Cynthia 163, 201, 239 Cohen, Lee S . 232 Crawford, Emily L . 254 Cohen, Shlomi 206 Crawford, Sybil 232 Colangelo, Christopher 196 Crews, Fulton T . 215 Cole, Michael 182 Critchley, Hugo D . 247 Cole, Rob 275 Crnic, Agnes 222 Collins, Gregory T . 205 Croarkin, Paul 234 Colombo, Elisa 263 Crockett, Molly 170 Colvis, Christine 144 Croft, Harry A . 224 Comai, Stefano 271 Cronenwett, Will 255 Comer, Sandra 258, 279 Crosbie, Jennifer 253 Commons, Kathryn 273 Cross, Alan 27, 124, 171, 225, Compton, Wilson M . 84 279 Cone, Jackson J . 267 Cross, Karalani 245 Conejero-Goldberg, C . 229 Crowell, Susanna 184 Conlin, Sarah 230 Crowley, David I . 174 Conneely, Karen 252 Cruz, Bryan 265 Connelly, Mark 30, 170 Csernansky, John G . 1 Conn, Jeffrey 206, 270, 271 Cucchiaro, Josephine 220, 226, 257, Conroy, Jennie 264 258, 261, 262, 280 Convit, Antonio 166 Cui, Edward D . 247 Cook, Edwin H . 252, 254, 258 Cui, Huxing 205 Cook, Jason B . 214 Cui, Lihong 176 Coombs, Garth 184 Cullen, Kathryn 182, 225, 280 Cooper, Crystal 171, 172, 173, Cullum, C . Munro 234 174, 222, 223 Cunningham, Colin S . 263 Cooper, Kimberly N . 227 Cunningham, Jacobi I . 268 Cooper, Robin L . 25, 191 Cunningham, Kathryn 7, 143, 266, 270 Cooper, Thomas 197 Cunningham, Robin 163, 201, 239 Cooper, Ziva 256, 274 Cushman, Grace 243 Coplan, Jeremy 179 Cusin, Cristina 260, 280 Coppola, Richard 187 Cuthbert, Bruce 190 Corcoran, Cheryl 18, 36, 37, 224, Cutler, Andrew J . 224 242 Cyranowski, Jill M . 185 Corey-Lisle, Patricia 193 Czaja, Sara 192, 193, 280

316

ACNP Annual Meeting Book 2013 rev8.indd 316 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Czarapata, Jasmin 186 Deligiannidis, Kristina 231, 280 D’Agati, Douglas 234 Dellagioia, Nicole 184 Dagher, Alain 188 Dell’Agli, Mario 263 Dahmen, Brigitte 170 DeLong, Cynthia J . 214 Dalgard, Clifton L . 197 DeLorenzo, Christine 184 Dalmau, Josep 105, 229 del Re, Elisabetta 242 Daly, Ella 222 de Luca, Vincenzo 255 Damadzic, Ruslan 210 Demars, Michael 217 Damaraju, Eswar 198 Demirakca, Traute 167 Daniels, J . Scott . 270, 271 Demireva, Elena Y . 272 Dantzer, Robert 177, 256 DeModena, Anna 175 Darvasi, Ariel 250 den Hollander, Jan A . 177 da Silva, Pedro Vieira 234 Denny, Christine A . 59, 204 Daskalakis, Zafiris 91, 243, 280 Der-Avakian, Andre 208, 280 Datta, Dibyadeep 167 DeRosier, Melissa 182 Davatzikos, Christos 273 DeRosse, Pamela 89, 179, 245 Davenport, Mike 259 Deshpande, Gopikrishna 185 David, Lisa 202 de Souza, Angelica 214 Davidson, Michael 199, 258 Deutch, Ariel 1 Davidson, Richard 239, 280 Deutsch-Feldman, Molly 233 Davidson, Samuel E . 179 Deutsch, Stephen 1, 256, 269 Davies, Peter 229 Devanand, Davangere P . 191 Davila, Domingo 256 Deveney, Christen 168, 193, 280 Davis, Andrew 189 DeVivo, Immaculata 212 Davis, F . Caroline 187 Devous, Michael D . 183 Davis, John M . 166, 221, 258 DeVylder, Jordan E . 36, 224 Davis, Kenneth L . 85 Dewey, Stephen L . 188 Davis, Lea K . 254 de Wit, Harriet 96, 244, 255, 259, Davis, Lori 260 260 Davis, Megan 20, 170 Dias, Alexandra A . 230 Davis, Michael C . 223 Dias, Brian 138 Davis, Robert 225, 280 Dias, Elisa 110, 223, 242 Daws, Lynette 267 Dickerson, Faith 248 Dayrit, Genesis 213 Dickinson, Dwight 252, 281 Dazzi, Laura 240 Dickstein, Daniel P . 243 DeAlmeida, Nancy 233 Dickstein, Susan 198 Dean, Reginald L . 268 Dietrich, Amy 273 Deaver, Daniel R . 268 Dillon, Daniel 222, 223 De Bellis, Michael D . 89 Dills, Jesse 57, 273 Debiec, Jacek 138, 280 Dima, Danai 196 De Bruecker, Geert 222 Ding, Ying 216, 249 Deckersbach, Thilo 171, 172, 174, Ding, Yuanyuan 264 183, 234, 243, 280 Ding, Yu-Shin 182, 217 Deckert, Jürgen 251 Diniz, Juliana Belo . 183 Deehan, Gerald A . 198 Diwadkar, Vaibhav 173 Deep-Soboslay, Amy 167 Dobson, Jennifer 186 De Francisco, Don F . 224 Dockstader, Colleen 175 Deisseroth, Karl 136, 193, 267 Domino, Edward F . 230 De Jager, Phil 194 Domschke, Katharina 251 deJong, Loek 210 Donahue, Rachel 209 DelBello, Melissa 168, 189, 223 Donati, Robert 215, 217 Deldin, Patricia J . 222, 223 Donckels, Tess 211 Delgado, Mauricio 125 Donck, Luc Ver 273

317

ACNP Annual Meeting Book 2013 rev8.indd 317 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Dong, Yan 129 Dykhuis, Kate 188 Dording, Christina 260 Eagle, Andrew 214 Dore, Riccardo 272 Eastwood, Sharon 248 Dorrier, Cayce 272 Eberly, Lynn 225 Dor, Rivka Ben 229 Ebert, Daniel 217 Dougherty, Darin 183, 234, 243 Eckhardt, Christine A . 243 Dougherty, Sarah E . 210 Economou, Nicole 232 Douglas, Steven D . 217 Edelson, Jessica R . 165 Dourish, Colin 19, 51, 52, 53, Edgar, J Christopher 174 256, 281 Edwards, John 43, 207 Dove, Scott 259 Edwards, Robert 212 Dowd, Emily D . 188 Egerton, Greg 192 Doyle, Glenn 118, 229 Ehlers, Cindy L . 249, 250 Doyle, Trevor 264 Ehrich, Elliot 192, 220, 281 Dragheim, Marianne 221 Ehrman, Ronald 180 Drevets, Wayne 173, 177, 222 Eidelman, Ofer 197 Drew, Liam J . 59, 204 Eijk, Julia van 167 Drgonova, Jana 165 Eikermann, Matthias 260 Drinkenberg, Pim 197 Einstein, Emily 216 Driscoll, Carlos 165 Eisenberg, Daniel 167, 187, 251, 281 Driver, David I . 228 Eisert, Albert 170 Dryman, Taylor 212 Ekuta, Victor 232 Drysdale, Andrew T . 185 el-Guebaly, Nady 194 D’Souza, Deepak C . 259 Eliassen, James 189 D’Souza, Manoranjan S . 141, 208 Elkarim, Gad 176 Du, Fei 167, 179 Ellingrod, Vicki 163, 192 Du, Yangchun 220 Elliott, Mark 27, 171, 273 Duan, Lihua 264 Elman, Igor 152, 188 Dubé, Benoit 217 Elmer, Greg I . 203, 207 Dubin, Marc J . 185, 234 Emmett, Mark 7, 8, 9 Dubocovich, Margarita L . 150 Ende, Gabriele 167 Ducat, Elizabeth 233 Eng, Heather 57, 273 Duckworth, Hilary 255 Engleman, Eric A . 198 Duffy, Amanda 243 Enkhuizen, Jordy van 209 Duggan, Mark E . 271 Enoch, Mary-Anne 248 Duggirala, Ravi 251 Enrique, Nicole 241 Dugovic, Christine 264 Epel, Elissa S . 218 Dulcis, Davide 209 Epperson, C . Neill 230 Duman, Ronald S . 1, 135, 196 Epping, Eric 183 Duncan, Erica 40, 190, 246, 249 Epstein, Michael 110, 223 Duncan, Wallace C . 226 Eramo, Anna 227, 256, 281 Dunlop, John 271 Ergun, Sabrina 269 Dunning, Jonathan P . 247 Erhardt, Keeley 230 Dunn, Leslie 182 Ernst, Monique 125 Dupuis, Annie 253 Erp, Theo Van 179, 245 Duran, Luis R . Patino 168, 223 Ersahin, Devrim 182 Durgam, Suresh 224, 259, 281 Erus, Guray 273 Durham, Kelley 260 Escobar, Javier I . 180 Durkee, Caitlin 167 Escoubet, Johanna 264 Durston, Sarah 169 Eskandar, Emad N . 80, 243 Duval, Elizabeth 98, 116, 117, 229 Eslinger, Nicole M . 198 Dwivedi, Yogesh 166, 212 Espy, Kimberly 193 Dwork, Andrew J . 215, 216 Esterlis, Irina 134, 184, 281

318

ACNP Annual Meeting Book 2013 rev8.indd 318 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Etkin, Amit 79, 163, 178, 183, Feuerbach, Dominik 255 185, 186, 188, Feusner, Jamie 169, 176, 181, 281 191, 201, 239 Fiedorowicz, Jess 183 Evans, Dwight L . 217 Fields, Howard 212 Evans, Gary W . 116, 229 Filbey, Francesca 139, 281 Everheart, Monica 201 Fillman, Stu 195 Everitt, Barry J . 197 Findling, Robert 173 Evins, A . Eden 134 Finkel, Eric 213 Eyerman, David J . 268 Fischer, Bernard 236, 281 Falcon, Edgardo 263 Fischer, Christina Weide 266 Fani, Negar 176, 181 Fisher, Kristen R . 214 Fan, Jin 171 Fisher, Patrick 193 Fan, Xiaoduo 127 Fish, Kenneth 211 Farabaugh, Amy 184 Fitzgerald, Daniel 178 Fareed, Jawed 255 Fitzgerald, Kate 188, 281 Farmer, Madison 228 Fitzpatrick, Christopher 207 Farmer, Stacey 170 Fitz, Stephanie D . 273 Farnum, Michael 197, 198 Flagel, Shelly 206, 282 Fatemi, S . Hossein 213 Flavin, Karen 223 Faucett, James 221 Fleck, David 189 Faulkner, Paul 170 Fleischhacker, W . Wolfgang 87, 227 Fausett, Jennifer S . 183 Fleisher, Adam S . 190 Fava, Maurizio 150, 171, 172, Fletcher, Paul 163 173, 174, 184, Floresco, Stan B . 206 192, 212, 222, Fodoreanu, Liana 258 223, 227, 260 Folsom, Timothy 213 Favila, Rafael 174 Foltin, Richard W . 256 Faziola, Lawrence 245 Forbes, Erika 123, 163, 185, Fears, Scott C . 180 201, 239, 242 Featherstone, Robert 205 Ford, Judith M . 179, 182 Febo, Marcelo 189 Fortin, Samantha M . 267 Fedgchin, Margaret 222 Foshage, Audra 38, 269 Fehr, Kelsey 275 Fote, Gianna 216 Feifel, David 261 Fotros, Aryandokht 188, 282 Feinn, Richard 257 Fournier, Jay 172, 174 Felder, Christian 265 Foussias, George 244, 282 Feldman, Stephanie 192 Fowler, Christie 164, 165, 282 Felger, Jennifer 83, 281 Fowler, Joanna 22, 166, 185, 191, Felsky, Daniel 179 250 Feltmann, Kristin 270 Fox, Andrew 153, 282 Feng, Ningping 252 Fox, Nathan 20, 170 Fenu, Sandro 265 Frail, Donald 144 Ferenczi, Emily 193 France, Charles P . 205, 269 Ferguson, Deveroux 54, 212, 215, 281 Francis, Alan 175 Ferguson, Susan 211, 281 Francis, Sunday 252, 259 Ferland, Russell J . 123 Francis, T . Chase 213 Fernandez, Joseph M . 210 Franco, Jose A . 243 Fernandez-Mendoza, Julio 195 Françon, Dominique 264 Ferrario, Carrie R . 209 Frangou, Sophia 196 Ferrer, Emilio 244 Frank, Ellen 191, 234 Ferrer, Marc 264 Frank, Guido K .W . 195 Ferrés-Coy, A . 233 Frankland, Paul 48, 213 Ferretti, Casara J . 226, 235 Franklin, Teresa R . 176, 179, 180

319

ACNP Annual Meeting Book 2013 rev8.indd 319 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Fraser, Ian 264 Gallego, Juan 178, 192, 218, 282 Frazer, Alan 1 Gallegos, Jesus 234 Frazier, Thomas 173 Gallezot, Jean-Dominique 182 Frederick, Blaise 170, 184 Galli, Aurelio 127, 267 Fredericks, Peter 163 Gallo, David 244 Frederiksen, Christine 221 Galofré, Mireia 233 Freedman, Robert 181, 219 Galván-Arrieta, Tania 269 Freedman, Sara 191, 221 Gamazon, Eric 249 Freeman, Andrew 231 Gamble-George, Joyonna 122, 235 Freeman, Ellen 230 Gamo, Nao 218 Freeman, Marlene 163, 192, 201, Gao, Yang 263 222, 232, 239 Gao, Yuan 251, 252, 255 Free, R . Benjamin 264 Garbett, Krassimira 201 Freimer, Nelson 180 Garcia, Nacire 231 Freire-Cobo, Carmen 257 Garcia-Garcia, Alvaro 270 Fricchione, Samuel R . 248 Garcia-Keller, Constanza 219 Friedman, Allyson 215 Garfinkel, Sarah 116, 229, 247, 282 Friedman, Joseph 18, 33, 34, 35, 199 Garlow, Steven 233 Friedman, Kent 217 Garnham, Julie 228 Fristad, Mary 173 Garza, Richard De La 227, 261 Fritz, Henn 194, 195 Garzio, Lori M . 190 Froehlich, Janice C . 194 Gauchan, Sangeeta 201 Frohlich, Flavio 91 Gehring, William J . 240 Frokjaer, Vibe 193 Geib, Benjamin 246 Frosh, Brian 85 Gelenberg, Alan J . 195, 231 Frost, Douglas 270 Gelernter, Joel 257 Frye, Mark A . 254 Geng, Xiujuan 30, 170 Fu, Cynthia 215, 217 Gennatas, Efstathios 273 Fu, Dong-Jing 257, 258 Genovese, Raymond F . 201 Fuchs, Rita A . 197 Gensler, Lauren 249 Fudge, Julie L . 125, 187 Genzlinger, Jacquelynne 192 Fuente, Camilo de la 174 George, David 225, 248, 254, 282 Fujimoto, Michiko 248 George, Mark 24, 120, 172, 233 Fujita-Hirasawa, Mika 230 George, Sophie 205, 282 Fukunaga, Masaki 248 George, Susan R . 7, 12, 211 Fulford, Dan 113, 236 George, Tony P . 134, 182, 243, 256 Fund, Naama 258 Geraci, Joseph 226, 243 Fung, Samantha 211, 282 Gerbarg, Patricia L . 166 Furey, Maura 227, 282 Gerhardt, Greg 271 Furuse, Kengo 265 Gerretsen, Philip 193 Furuyashiki, Tomoyuki 265 Gershon, Elliot 249 Fussell, Chris 113, 236 Geske, Jennifer 254 Gabbay, Vilma 177 Gess, Jennifer L . 183 Gaber, Tilman J . 170 Gettes, David 217 Gabriel, Laura 240, 241 Gevorgyan, Lilit 220 Gadelkarim, Johnson 181 Geyer, Mark A . 46, 96, 149, 209, Gaden, Christian 193 241 Gaffrey, Michael 189 Ghahremani, Dara 184 Gagliano, Sarah 247 Ghimire, Santosh 234 Gainetdinov, Raul R . 81 Ghodssi, Reza 192 Gajewski, Paula 214 Ghose, Subroto 205 Galatzer-Levy, Isaac 191, 221 Ghosh, Doel 166 Galea, Sandro 253 Ghoshal, Ayan 270

320

ACNP Annual Meeting Book 2013 rev8.indd 320 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Giacca, Adria 163 Gonzales, Natalia M . 165 Giacobbe, Peter 243 Gonzalez-Cuevas, Gustavo 271 Giedd, Jay 168 Gonzalez, Raul 84, 283 Giese-Davis, Janine 219 Goodkind, Madeleine 186 Giguere, Vincent 33, 199 Goodman, Wayne K . 240 Gilad, Moran 191, 221 Gopal, Shruti 235 Gilbert, Ryan 240 Gopal, Srihari 87, 258 Gilder, David 249, 250, 282 Gordon, Joshua A . 136 Gillis, Timothy E . 209 Gordon, Rebecca 234 Gilman, Jodi 186, 282 Gorlyn, Marianne 220 Gilmore, John 17, 30, 164, 170 Gorodetsky, Elena 248 Gilpin, Nicholas 203, 282 Gosden, Jane 268 Gingrich, Jay A . 43, 207, 272 Goswami, Samridhi 219 Gipson, Cassandra 201 Gotlib, Ian 190 Giraldez, Antonio J . 210 Gould, Robert W . 271 Girirajan, Santhosh 78 Gould, Thomas J . 164 Gitlin, Michael J . 240 Gould, Todd D . 230, 270 Giuffrida, Andrea 266 Gourley, Shannon L . 214 Gizer, Ian 249 Grace, Anthony A . 129, 203 Glabe, Charles 218 Graff, Ariel 174, 193 Glahn, David C . 251 Graham, Danielle 147, 283 Glaser, Paul 261, 271, 283 Graham, David P . 260 Glatt, Stephen J . 95 Graham, Devon 267 Gleason, Kelly 205 Grammer, Geoffrey G . 233 Glorioso, Danielle 218 Grandelis, Anthony 247 Glover, Ebony 176, 245, 249 Grandy, David 1, 81 Glover, Matthew E . 268 Grannan, Michael D . 271 Gobbi, Gabriella 150, 271 Grant, Jon E . 219 Godlewska, Beata 241 Grant, Kathleen A . 155 Goel, Kapil 234 Grant, Merida 185, 283 Goelman, Gadi 206 Grant, Steven 85, 139 Goetz, Stefan M . 194 Gray, Jason 211 Goff, Donald 94 Gray, John 211 Gogtay, Nitin 82, 180, 228 Green, Michael F . 182, 193, 223 Gold, James 193, 244 Green, Stefan 254 Gold, Lisa 85 Greenberg, Benjamin 80, 225 Goldberg, Terry E . 229, 261 Greenberg, Michael E . 217 Golden, Sam 209, 215 Greenberg, Tsafrir 171, 172 Goldman, David 168, 195, 214, Greenberg, William 222, 283 217, 248, 250, 254 Greene, Rachel K . 103, 227 Goldman, Robert 257, 262 Greene, Robert 1 Goldstein, David S . 166 Greengard, Paul 222, 225 Goldstein, Jill M . 175, 242, 273 Greenlee, Jeremy 235 Goldstein, Kim 168 Greenstein, Deanna 168, 180, 228 Goldstein, Michael 176 Greenwood, Tiffany A . 249 Goldstein, Rita 1, 137, 239, 247, Gregory, Michael D . 186 249 Greist, John 86 Golomb, James 234 Gresa-Arribas, Nuria 105, 229 Gomar, Jesus 229, 283 Gretchen-Doorly, Denise 240, 241 Gomez-Mancilla, Baltazar 255 Griebel, Guy 264, 283 Gommoll, Carl 222, 224, 268 Grieve, Stuart 188 Goncalves, Vanessa 251 Grill, Warren M . 194 Gong, Qiyong 169 Grim, Andrea 209

321

ACNP Annual Meeting Book 2013 rev8.indd 321 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Grodin, Erica N . 167, 181 Hall, Frank S . 165, 269 Gross, Adam 203 Hall, Geoffrey 178 Gross, Amanda 268 Hall, Janet E . 232 Gross, James 191, 226 Hall, Mei-Hua 243 Gross, Maya 271 Hall-Flavin, Daniel 254 Gross, Robert 233 Halmi, Katherine Ann 31, 250 Grossman, Fred 226, 261, 283 Hamann, Stephan 233 Grosz, Daniel E . 224 Hameed, Ahmad 86, 231, 283 Grove, Tyler 163 Hamer, Robert 30, 164, 170, 283 Gruene, Tina 274 Hammell, Dana 271 Gründer, Gerhard 141 Hammock, Bruce D . 31, 250 Grunebaum, Michael 220 Han, Ming-Hu 215 Gruner, Patricia 182 Han, Yang 264 Guerra, Valerie 210 Haney, Margaret 163, 201, 239, Guerrieri, Gioia 229 256, 259, 274 Guha, Saurav 179 Hanford, Lindsay 178 Guidotti, Alessandro 166, 221 Hanks, James 272 Guilloux, Jean-Philippe 249 Hanlon, Colleen 24, 98, 120, 121, Gulcicek, Erol E . 196 172, 233, 284 Guo, Nannan 213 Hanna, Gregory L . 240 Guo, Yue Ping 273 Hanna, Harlington 178 Gupta, Arpana 181, 196, 199 Hao, XueJun 169 Gupta, Swapnil 179 Hard, Marjie 220 Gur, Raquel 1, 27, 74, 148, Harmer, Catherine J . 241 171, 225, 273 Harms, Michael P . 244, 255 Gur, Ruben C . 27, 171, 273 Haroon, Ebrahim 189 Gurney, Mark 151 Harrell, Constance 232 Gutman, David 176 Harrington, Gloria 240 Guyer, Amanda E . 125, 193 Harris, Josette 181 Gyertyan, István 259 Harris, Margret 242 Gyurak, Anett 183, 191, 283 Harrison, Paul 159, 248, 284 Haahr, Mette 193 Hart, John 228 Haaparanta-Solin, Merja 267 Hart, Sarah 275 Haas, Magali 194 Hartley, Nolan 122, 235 Haass-Koffler, Carolina 248 Hartmann, Kathrin 256 Haba, Ryota 206 Hartwell, Karen 120, 233 Habel, Ute 170 Harvey, Philip 192, 193, 230, 258 Haber, Suzanne 1, 80, 198 Hasan, Khader M . 187 Hablitz, John J . 210 Hasbi, Ahmed 211 Hadley, Jennifer 185 Hashimoto, Eri 265 Haerty, Wilfried 253 Hashimoto, Hitoshi 206 Hafeman, Danella 173, 283 Hashimoto, Kenji 266, 284 Hage, Brandon 255 Hashimoto, Ryota 248, 252 Haggarty, Stephen J . 186, 272 Hasler, Gregor 141, 284 Haghighi, Victoria Fatemeh . 43, 207 Hassan, Ahmed 255 Hagino, Yoko 202 Hauger, Richard 274 Hahn, Margaret 163 Hauser, Sheketha R . 198 Hahn, Maureen K . 149 Hawkins, Adam 275 Haig, George 225 Hayden, Benjamin 198, 262, 284 Hajek, Tomas 82, 228 Hayes, Matthew 208 Hakonarson, Hakon 273 Hays, Lon 261 Halaris, Angelos 255 Hazlett, Erin 168 Halberstam, Batsheva 110, 223 Hazlett, Kathleen E . 171

322

ACNP Annual Meeting Book 2013 rev8.indd 322 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

He, Yong 169 Hirano, Yoji 187, 242, 284 Heal, David J . 268 Hiroi, Noboru 78 Heendeniya, Nuwanthi 196, 199 Hirvonen, Jussi 169 Hegarty, Catherine E . 251 Hjelmstad, Gregory 212 Heijnen, Cobi 256 Hnasko, Thomas S . 212 Heilbronner, Sarah 198, 284 Ho, S 177 Heilig, Markus 203, 210, 214, Hodes, Georgia 147, 284 215, 225, 248, Hodge, Clyde 214 254, 257, 263 Hodge, Rachel 118, 229 Heimer, Hakon 163, 201, 239 Hodges, Matthew A . 197 Heinz, Beverly 265 Hodgkinson, Colin 168, 195, 248, Heitzeg, Mary 172 250, 254, 284 Helin, Semi 267 Hoexter, Marcelo 183, 228, 284 Hellemann, Gerhard S . 240, 241, 253 Hof, Patrick R . 240 Heller, Elizabeth 19, 54, 55, 56, Hoffman, Ellen J . 210 212, 215 Hoge, Elizabeth 212, 284 Heller, Sloane 234 Hollander, Eric 157, 226, 235 Helmbold, Katrin 170 Hollimon, John J . 210 Hen, René 59, 150, 204, 213, Hollis, Jeffrey 190 215, 216 Holmes, Andrew 253 Henderson, Sarah E . 177 Holmes, Avram J . 184 Henderson, Scott 176 Holmes, Traci 256 Hendrickson, Margo 225 Holsen, Laura M . 175, 273, 285 Henn, Fritz 19, 64, 65 Holson, Edward 186 Henry, Mellissa M . 224 Holt, Daphne J . 184 Hepburn, Susan 245 Holtzheimer, Paul 163, 201, 239 Heres, Stephan 87 Hom, Melanie 186 Herkenham, Miles 213 Hommer, Daniel W . 225, 254, 257, 285 Hermanson, Daniel 122, 235 Hong, Daniel 38, 269 Hernandez, Adan 211 Hooker, Jacob M . 186, 272 Herpertz-Dahlmann, Beate 170 Hoon, Mark 219 Herron, Todd J . 214 Horan, William 182, 193, 223 Herscovitch, Peter 169 Horga, Guillermo 184, 285 Hettige, Nuwan 255 Horn, John D . Van 181 Heusner, Carrie 203 Horvath, Szatmar 201 Hewlett, William 165 Horwitz, Sarah 173 Hibbeln, Joseph R . 169 Hosokawa, Taiga 187 Hickie, Ian 148, 284 Hough, David 258 Higgs, Richard 265 Houle, Sylvain 180 Higgs, Suzanne 51, 256 Houri, Alaa 182, 225 Higley, J . Dee 85, 165, 232 Houston-Ludlam, Alexandra 269 Higuchi, Makoto 175 Howe, Aaron 255 Hilbert, Kevin 181 Howe, Meghan 190 Hillhouse, Maureen 174 Howell, Breannan 174 Hill, Julia 202 Howell, Kristy R . 207 Hill, Shirley Y . 187 Howes, Oliver 170 Hines, Michael 190 Hsu, David 171, 285 Hinkka-Yli-Salomäki, Susanna 228 Hsu, Jay 226, 257, 261, 262 Hinton, Elizabeth A . 214 Hsu, Timothy 222 Hinton, Kendra 168 Hu, Sien 182 Hipolito-Cubedo, Lucia 201 Hu, Willie 194 Hipolito, Maria 216 Hu, Xiaoping 189 Hirai, Hiroyuki 206 Huang, Ming-Chyi 248

323

ACNP Annual Meeting Book 2013 rev8.indd 323 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Huang, Mingxiong 174 Ivleva, Elena 173, 285 Huang, Yiyun 173 Iwata, Nakao 248 Huang, Z . Josh 67, 69, 70 Izenwasser, Sari 274 Hughes, Zoe 214, 285 Jabbi, Mbemba 252 Hu, Hailan 64, 194 Jackowski, Andrea 179 Hummer, Tom 184, 285 Jackson, Jenna 165 Hunter, Michael 174 Jackson, Nateka 208 Hunter, Sharon 219 Jacob, Suma 252, 259 Huo, Yuankai 169, 275 Jacobowitz, David 197 Hurd, Yasmin 212, 269, 285 Jacobs, Andrew 195 Hurtado, Joshua 254 Jacobs, Emily G . 273 Husain, Mustafa 234, 235 Jacobs, Petra 174 Hussein, Ayan 217 Jacobs, Rachel 240, 241 Huston, Joseph 214 Jacobsen, Jacob 149, 285 Hutchison, Amanda 219 Jacquelyn, Braud 183 Hutchison, Kent 185 Jaffe, Andrew 159, 218 Hutson, Pete 268 Jagannathan, Kanchana 176, 179, 180, 188 Hwang, Janice 182 Jain, Nitika 255 Hwang, Moon Jung 275 Jain, Sonia 233 Hyde, Thomas M . 159, 167, 218, Jakubovski, Ewgeni 260 251, 252, 254, 255 James, George A . 183 Hyman, Steven E . 7, 15, 126, 142 Janes, Amy 170 Hynan, Linda 256 Jaquet, Florian 166 Iadarola, Michael 219 Jarcho, Johanna M . 17, 20, 21, 170 Ibrahim, Amira 241 Jardemark, Kent 270 Iemolo, Attilio 272 Jarskog, Lars F . 127, 255 Iguchi, Yoshio 204 Jasielec, Mateusz S . 221 Ikeda, Kazutaka 202, 285 Javitch, Jonathan 264 Ikeda, Masashi 248 Javitt, Daniel C . 110, 223, 242 Ikuta, Toshikazu 178, 179, 245 Jayanthi, Lankupalle 252 Imoto, Yuki 265 Jayaram, Geetha 234 Indurkhya, Xela 218 Jeffay, Eliyas 244 Iñiguez, Sergio 213, 265 Jegga, Anil G . 166 Inman, Cory 233 Jenkins, Gregory 254 Innis, Robert 85, 151 Jensen, J . Eric 174, 209 Insel, Thomas 16, 79 Jentsch, J . David 96 Inslicht, Sabra 274 Jessen, Tammy 202 Iosifescu, Dan 62, 221, 285 Jeste, Dilip V . 207, 218, 244 Iqbal, Tabish 227, 261 Jhou, Thomas C . 219 Irimia, Andrei 181 Ji, Bin 175 Irvine, Laura 242 Ji, Yue 210 Irwin, Michael R . 83 Jimenez, Dennisse 202 Ishibashi, Kenji 184 Jin, Chelsea 228 Ishii, Takao 265 Jin, Hua 221 Ishizuka, Koko 151, 216, 218, 248 Jin, Tony 173 Iskandarani, Karim El 271 Jo, Booil 219 Israeli-Shalev, Yossi 221 Joffe, Hadine 232 Issari, Yasmin 260 Johannesen, Jason 40, 246 Isung, Josef 166 John, Majnu 179 Ito, Hiroshi 175 Johns, Brian 260 Ito, Koki 210 Johnson, Barbara 176 Ivanov, Iliyian 171 Johnson, Emma L . 268 Ivanov, Vladimir 270 Johnson, Hans 183

324

ACNP Annual Meeting Book 2013 rev8.indd 324 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Johnson, Jacqueline 231 Kasai, Shinya 202 Johnson, Oralee 25, 191 Kash, Thomas 38, 269, 272, 273, Johnson, Philip 273, 285 286 Johnson, Zachary 232 Kasper, Siegfried 92 Johnstone, Andrea L . 214, 215 Kass, Robert E . 236 Jokinen, Jussi 166, 286 Kassel, Michelle 241 Jonaris, Johnson 176 Kauer, Julie 211 Jones-Brando, Lorraine V . 248 Kaufman, Aaron 235 Jones, Carrie 206, 270, 271, 286 Kaufman, Marc J . 209 Jones, Jermaine D . 258 Kaur, Navneet 234, 243 Jones, Penelope 228 Kavanagh, Kevin 272 Jones, Sara R . 155 Kaye, Walter 31, 154, 187, 242, Jones, Thomas 235 247, 250 Jordan, Kelsey 219 Kayser, Jürgen 223 Jorgensen, Christinna 163 Kayser, Matthew 97, 105, 106, 229 Josselyn, Sheena 18, 48, 49, 50, Kearney-Ramos, Tonisha 183 213, 286 Keats, Matthew 192 Jovanovic, Tanja 176, 181, 231, Kechner, Megan 204 244, 245, 249, 286 Keedy, Sarah 242, 286 Jozwik, Catherine 197 Keffler, Carrie 195 Juarez, Barbara 215 Kegeles, Lawrence S . 172, 197 Kaczmarzyk, Jakub 188 Kei, Justin 259 Kahn, Pamela Butler 242 Keilp, John 220 Kalali, Amir 226, 261 Keller, William R . 236 Kalechstein, Ari 261 Kelley, Ryan G . 169, 190 Kalin, Ned H . 153 Kellner, Charles 235 Kaliora, Styliani 178 Kelly, Clare 180 Kalivas, Peter W . 1, 129, 195, 201, Kelly, Deanna L . 192 207, 209, 219 Kelsoe, John 175 Kamath, Jayesh 258, 286 Kendler, Kenneth S . 254 Kamat, Siddhesh 256 Kenna, George 248 Kamenski, Mary E . 210 Kenna, Heather 169 Kamiya, Atsushi 210 Kennedy, James 179, 194, 247, 251 Kamkamidze, George 220 Kennedy, Pamela 214 Kampman, Kyle 176, 225, 257 Kennedy, Robert 214 Kanba, Shigenobu 187, 242 Kennedy, Sidney 226, 243 Kane, John 178, 202, 227, 261 Kenny, Paul 1, 133, 164, 165 Kang, Robin 255 Kenowsky, Sunnie 234 Kang, Yeona 22, 185 Kent, Jack 251 Kano, Shinichi 248 Kerley, Kimberly 231 Kantrowitz, Joshua 97, 110, 111, 112, Kerman, Ilan A . 208 223 Kerr, Kara 186 Kao, Chung-Feng 248 Kerstetter, Kerry 211 Kapara, Ori 199 Kerut, Edmund K . 25, 191 Kapás, Margit 259 Kesby, James 244 Kaplan, Allan S . 247 Keshavan, Matcheri 126, 173, 224 Kapoor, Sandeep 202 Keshaviah, Aparna 212 Karlsgodt, Katherine 178, 241, 245, 286 Kessler, Charles 245 Karne, Harish 174 Kessler, Daniel 172 Karpyak, Victor 254 Ketter, Terence A . 220, 262 Karson, Craig 256 Khalil, Iya 194 Karstoft, Karen-Inge 191 Khalsa, Sahib 239 Kasai, Kiyoto 248 Khan, Arif 221

325

ACNP Annual Meeting Book 2013 rev8.indd 325 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Kheirbek, Mazen 19, 59, 60, 61, Knapp, Rebecca 235 204, 286 Knickmeyer, Rebecca 30, 164, 170 Kiecolt-Glaser, Janice 83 Knight, David C . 185 Kiefer, Falk 254 Knight, Jo 194, 247 Kievit, Paul 164 Knight, Scott 54, 212 Kigawa, Yoshiyasu 265 Knox, Dayan K . 205 Kilaru, Varun 252 Knudsen, Gitte M . 193 Killgore, William 177 Kochunov, Peter 251 Kilpatrick, Lisa 196, 199 Koek, Wouter 264 Kilts, Clinton D . 183, 246 Koenig, Jim 203 Kim, Byoung Woo 186 Koenigsberg, Harold W . 160 Kim, Dewey 254 Koerner, Frederick S . 236 Kim, Dohyun 22, 185 Koga, Minori 218 Kim, Eunkyoung 192 Kogan, Jeffrey 203 Kim, Helena 267 Kohler, Christian 27, 171, 225 Kim, Jane J . 244 Kohn, Philip 167, 251, 252 Kim, Kerri 243 Kokel, David 97, 108, 109, 203 Kim, Myong 272 Kolachana, Bhaskar 167, 186, 232, Kim, Pearl K . 216 245, 252, 287 Kim, Ronald 33, 199 Kondabolu, Krishnakanth 272 Kim, Semmie 232 Konopaske, Glenn 216 Kim, Suck Won 219 Konopka, Genevieve 138 Kim, Sung Won 22, 185 Konova, Anna 239, 247, 249 Kim, Yunbok 236 Konrad, Kerstin 170 Kimmey, Blake 208 Konradsson-Geuken, Åsa 270 King, Andrea 258, 286 Koo, Ja Wook 215 King, Anthony 253, 286 Koob, George F . 131, 264 King, Courtney 203, 263 Koola, Maju 190 Kingsley, Peter B . 178 Koopman, Cheryl 219 King, Tricia 181 Kopin, Irwin J . 166 Kinkead, Becky 219 Korb, Alexander S . 182 Kinon, Bruce J . 124 Korgaonkar, Mayuresh 188 Kipnis, Jonathan 157 Korth, Carsten 214, 218 Kippenhan, J . Shane 186, 232, 252 Korthuis, P . Todd 174 Kirchhoff, Aaron M . 248 Kosten, Thomas 260 Kirkpatrick, Matthew 259, 286 Kostic, Dusan 227 Kirsch, Jonathan 226, 235 Kouwe, Andre van der 186 Kiss, Béla 259 Kowatch, Robert 173 Kistner-Griffin, Emily 252 Kozel, F . Andrew 228 Kitaoka, Shiho 265 Kozyrkov, Cassie I . 194 Kitzinger, Melanie 219 Kraemer, Helena 182, 219 Klann, Eric 78 Kraguljac, Nina V . 177, 185 Klasen, Martin 170 Kranzler, Henry 1, 257 Kleiman, Robin 107, 213 Krashes, Michael 38, 269 Klein, Ehud 206 Krause-Utz, Annegret 140, 167 Klein, Rachel G . 177, 180 Kraut, Michael 182 Kleinman, Joel E . 77, 159, 167, 218, Kreek, Mary Jeanne 233 232, 251, 252, Kritz, Steven 209 254, 255 Kroes, Roger 268 Klengel, Torsten 128, 252, 286 Kroger, Hans 262 Klibanski, Anne A . 175, 273 Kroll-Desrosiers, Aimee R . 231 Klimes-Dougan, Bonnie 225 Krystal, Andrew 259 Klumpp, Heide 178 Krystal, John 1, 67, 124, 182, 184

326

ACNP Annual Meeting Book 2013 rev8.indd 326 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Ku, Stacy 215 Lee, Alycia 208 Kucinski, Aaron 201 Lee, Brian 165 Kuhn, Cynthia M . 205, 269 Lee, Francis 135 Kulkarni, Rajiv 268 Lee, Hedok 191 Kumar, Anand 172, 176, 178, Lee, Jin-Moo 221 181, 220 Lee, Junghee 182, 223 Kunii, Yasuto 167 Lee, Myung Joo 186 Kuo, Susie 178 Lee, Royce J . 232, 259 Kupchik, Yonatan M . 195, 201, 207, 219 Lee, Sang 186 Kupfer, David J . 1, 182 Lee, Wendy 190 Kurian, Benji T . 171, 172, 173, Lee, Yih 259 174, 222, 223, 227 Leggio, Lorenzo 230, 248 Kuskowski, Michael 235, 260 Lehel, Szabolz 193 Kuster, John 186 Lehmann, Michael 213 Kwako, Laura 225, 260 Lehner, Thomas 142 Kwon, Cliffe 244 Lehtimaki, Jyrki 267 Labus, Jennifer 181, 196, 199 Leibenluft, Ellen 20, 123, 168, 170, Lahti, Adrienne C . 132, 167, 177, 185 193 Lai, Wanda 113, 236 Leider, Harry 192 Lajtha, Abel 166, 221 Leigh-Pemberton, Richard 192 Lam, Olivia 113, 236 LeMatty, Todd 120, 233 LaMarca, Elizabeth 272 Lemke, Nicholas T . 235 Lamar, Melissa 172, 220 Lencz, Todd 178, 192, 250, 261 Lamberty, Gregory 235 Le-Niculescu, Helen 255 Lamb, Sarah N . 259 Lennartsson, Andreas 266 Lancaster, Katrina 273 Lenow, Jennifer 246 Landau, Aaron 274 Lenroot, Rhoshel 195 Landén, Mikael 164 Lenz, Jeffrey D . 213 Lan-Feng, Tsai 227 Leonard, Maggie N . 214 Langbaum, Jessica 190 Leonardo, E . David . 270 Langenecker, Scott 171, 172, 240, 241 Leonard, Sherry 219 Langer, Salomon Z . 92 León-Ortiz, Pablo 174 Langleben, Daniel D . 180, 188 Leow, Alex D . 169, 176, 181 Lang, Mary Anne 192 Lerch, Jason 168 Lanius, Ruth 140 Lerer, Bernard 123, 206 Lanz, Thomas 107, 213, 287 Lerman, Mark 220 Lapidus, Kyle 19, 62, 63, 221 Lerner, Marc 84 Larcher, Kevin 188 Lerner, Michelle 275 LaRiviere, Lori 225 Leserman, Jane 231 Larsen, Bridget 230 Lesh, Tyler A . 244, 246, 247 LaSalle, Janine 94 Leslie, Kimberly 171 Lasko, Natasha B . 187, 196 Lesort, Mathieu 210 Lasseter, Heather C . 197 Le, Thien 189 Laszlovszky, István 224, 259 Lett, Tristram 179 Lavretsky, Helen 156 Leuner, Benedetta 163 Lavreysen, Hilde 124, 270 Leuner, Kristina 265 Layher, Evan 244 Leung, David K . 33, 199 Le, Ngoc-Anh 190 Levey, Daniel 255 Leach, Prescott 164 Levin, Bruce 191 Leander, J . David 268 Levinson, Amanda 172 Lebron-Milad, Kelimer 274 Levis, Sophia 272 Lecca, Daniele 265 Levitan, Robert D . 247 Leckman, James 228 Levitch, Cara F . 62, 221

327

ACNP Annual Meeting Book 2013 rev8.indd 327 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Levitt, Pat 1, 17, 18, 19 Liu, Changlu 208 Levy-Cooperman, Naama 259 Liu, Chunyu 249 Levy, Deborah L . 243 Liu, Fang 175, 192, 272 Lewandowski, Kathryn E . 179, 224 Liu, Peng 215, 217 Lewis, David 1, 16, 67, 165, Liu, Rong-Jian 196 167, 211, 216, 249 Liu, Xiaofen 190 Lewis, Jada 189 Liu, Xun 171 Leyton, Marco 188 Liu, Yan 215 Li, Bingbin 253 Liu, Yanni 188 Li, Bingshan 254 Liu, Yashu 197 Li, Bo 195 Liu, Yi 208 Li, Chiang-shan Ray 182 Liv, Clasen 168 Li, Chunbo 221 Lizarraga, Sofia 211 Li, Jiang 254 Lo, Alexander 256 Li, Jun-Xu 264 Lobach, Iryna 234 Li, Kun 64, 194 Lobo, Daniela S . S . 194 Li, Li 212 Lobo, Mary Kay 213, 265 Li, Lina 207 Loebel, Antony 220, 226, 257, Li, Suxia 266 258, 259, 261, 262 Li, Xia 208 Loewenstein, David 192 Li, Xingbao 24, 120, 172, 176, Logan, Ryan 101, 208 233 Lohan, Mary 243 Li, Yin 179, 180 Lohoff, Falk 98, 118, 119, 229 Li, Zhi 175 London, Edythe D . 154, 177, 184, 257 Liang, Lidia 170 Loo, Sandra K . 253 Liang, Tiebing 248 Lopera, Francisco 190 Liao, Lujian 64, 194 Lopez-Jaramillo, Carlos 180 Liberzon, Israel 116, 128, 205, Lopez-Lopez, Cristina 255 229, 253 Lopez-Teledono, Miguel 107, 213 Lieberman, Jeffrey 224, 261 Lophaven, Soren 224 Lifschytz, Tzuri 206 Lord, Brian 264 Light, Gregory 40, 163, 201, 239, Lord, Catherine 240 246, 249 Lory, Omer 206 Lim, Bernard 225 Lotan, Amit 206 Lim, Kelvin O . 132, 182, 194, Lotfipour, Shahrdad 164 225, 235, 260 Lotrich, Francis E . 156, 172 Lin, Amy 203 Louie, Ben 209 Lin, Chi Ying 218 Lovenberg, Timothy 208, 264 Lin, Jay 256 Love, Raymond 192 Lin, Jue 218 Love, Tiffany 171, 172, 195 Lin, Melissa 209 Lovinger, David 155 Lin, Robert 205 Lowell, Bradford 38, 269 Lin, Sandra 216 Lowen, Steven 202 Lin, Zhicheng 269 Loweth, Jessica A . 218 Lindell, Courtney 165 Lowy, Adam 220 Lindell, Stephen 165, 232 Lu, Bai 135 Lindler, Kathryn M . 165 Lu, Hanzhang 173, 174 Lindsley, Craig W . 270, 271 Luber, Bruce 91, 194, 234 Ling, Walter 174 Lubin, Farah 158 Lipska, Barbara 167, 232 Luby, Joan 189 Lisanby, Sarah 91, 194, 234, 235 Lucero, Jacinta 210 Liston, Conor 185 Luckenbaugh, David 226, 227 Litvin, Yoav 202 Lucki, Irwin 263

328

ACNP Annual Meeting Book 2013 rev8.indd 328 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Lueken, Ulrike 181 Mallei, Alessandra 263 Lui, Ge 169 Mallya, Allyson 253 Lui, Su 169 Mallya, Karyn S . 253 Lu, Kaifeng 224 Mamdani, Firoza 253 Lukas, Scott 167, 170 Mamo, David 193 Luo, Ji 190 Mamoun, Michael 170 Luo, John S . 241 Mandelkern, Mark 170, 184 Lury, Kenneth 164 Manfro, Gisele 228 Luther, James 57, 273 Manji, Husseini 85, 197, 222 Lutter, Michael L . 205 Mann, Claire 167 Lutterveld, Remko van 168 Mann, J . John 86, 197, 215, 216, Luu, Trinh 170 220 Lynch, Kevin 217, 225 Mann, Karl F . 254 Lytton, William 190 Mann, Steve W . 163 Ma, Yi-Wen 257 Mannangatti, Padmanabhan 252 Maayan, Lawrence 221 Mannes, Andrew 219 Mabbott, Don 175 Mansari, Mostafa El 222, 271 Mabrouk, Omar 214 Manser, Paul 256 Macchi, Flavia 263 Mansuy, Isabelle 271 MacDonald, Angus W . 131, 244 Mantsch, John R . 196 Macdonald, Gregor J . 270 Manubay, Jeanne M . 258 MacDonald, Kai 261 Mao, Xiangling 172, 174, 179, 197 MacDonald, Matthew L . 211, 216 Marandi, Morteza 220 Mackie, Claire 270 Marangell, Lauren 215, 217 Mackowick, Kristen M . 243 Maras, Pamela 202 Madden, Erin 274 March, Mary 27, 171, 225 Madras, Bertha K . 269 Marcinkiewcz, Catherine 272 Madray, Charles 209 Marcus, Monica M . 270 Madsen, Karine 193 Marder, Stephen 1, 223, 255 Maeda, Jun 175 Marenco, Stefano 178 Maeng, Lisa 274 Marengo, Laura 188 Magistretti, Pierre 31, 250 Margulies, Daniel 99, 229 Maglinte, Gregory 193 Maria, Megan Moran-Santa 120, 233, 274 Magnotta, Vincent A . 183 Marietta, Cheryl 248 Maguen, Shira 230 Marin, Marie-France 196 Maguire, David R . 269 Marjamäki, Päivi 267 Maguire, Ralph P . 255 Mark, Hamner 260 Mahableshwarkar, Atul 221 Markou, Athina 141, 208 Maher, Brady J . 218 Markx, Sander 33, 199 Mahler, Stephen V . 197 Marmar, Charles 128, 287 Mahoney, Elizabeth 225 Marnett, Lawrence 122, 235 Mahoney, James 227, 261 Marshall, Randall 192 Majeed, Zana 25, 191 Marsh, Courtney 232 Makotkine, Iouri 260 Marsh, Rachel 154, 169, 287 Makris, Nikos 175, 186 Marsit, Carmen J . 231 Malaker, Pias 247 Martinez, Karen G . 243, 253 Maldonado-Devincci, Antoniette M . 214 Martinez, Pedro 229 Malenka, Robert C . 1 Martin-Fardon, Remi 271 Malhotra, Anil 77, 178, 179, 192, Martiniuk, Frank T . 176 218, 245, 248, Martinowich, Keri 135, 202, 251, 255 250, 261 Martin, Stacy 185 Malinger, Alan 222 Marugan, Juan 264 Malinow, Roberto 64, 194 Maruyama, Masahiro 175

329

ACNP Annual Meeting Book 2013 rev8.indd 329 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Marx, Christine E . 93, 256 McGeary, John 248 Masdeu, Joseph C . 167, 251 McGinty, Jacqueline F . 143 Maseda, Tess 218 McGlashan, Thomas 242 Mason, Barbara 1 McGough, James 253 Mates, Sharon 225 McGrath, Patrick J . 171, 172, 173, Mathalon, Daniel 1, 18, 40, 41, 42, 174, 222, 223, 227 113, 179, 236, McHugh, Meredith J . 183 242, 246 McInerney, Shane 243 Mathé, Aleksander 206, 231, 234, 266 McInnis, Melvin 173, 174, 214, 222 Matheos, Dina 213 McIntyre, Gail 259 Mathew, Sanjay J . 179, 188 McIntyre, Roger S . 224 Mathews, Maju 224 McKenzie, Courtney 173 Mathis, Chester A . 187 McKinney, Anthony 222 Matricon, Julien 266 McKinney, Ericka 192 Matsui, Joy 183 McKinney, Rebecca 261 Matsumoto, Mickey 77, 203 McLean, Charlee 216 Mattay, Venkata 186, 232, 245, 252 McLzorry, Patrick 148 Matter, John 246 McMahon, Brenda 193 Matthews, Daniel 222 McMahon, Francis J . 193 Matthews, Mark 191 McMahon, Lance 263 Mayberg, Helen S . 183, 233, 243 McMahon, Robert P . 192, 236 Mayer, Emeran A . 181, 196, 199 McMeekin, Laura J . 210 Mayford, Mark 207 McNamara, Patrick 258 Maynard, Kristen 255 McNamara, Robert 223 Mayo, Cheryl 203 McNeely, Heather 243 Mazei-Robison, Michelle 204, 215 McNutt, Marcia 230 McAdams, Harrison 180 McOmish, Caitlin E . 272 McAvoy, Kathleen 213 McPhie, Donna L . 212 McBride, William J . 198 McQuail, Joseph 240 McCall, Jordan G . 38, 269 McRae-Clark, Aimee 274 McCall, W . Vaughn 235 McRae, Kateri 226 McCarley, Robert 187, 242 McTeague, Lisa 183 McCarthy, Lizbeth 219 Meade, Julie 264 McCarthy, Margaret M . 230 Meda, Shashwath A . 173 McCarthy, Michael J . 175, 212 Mehta, Sarah 207 McClintock, Shawn M . 234 Meinhardt, Markus 215 McClung, Colleen 1, 101, 208, 218 Mei, Si .Tian 221 McCormick, Laurie M . 183, 235 Melman, Caroline 222 McCown, Thomas J . 214 Melrose, Andrew 242 McCracken, James T . 84, 253 Meltzer-Brody, Samantha 164 McCullumsmith, Cheryl 86 Meltzer, Carolyn C . 187 McCullumsmith, Robert E . 132 Meltzer, Herbert Y . 254 McCutcheon, James E . 267 Memisoglu, Asli 192 McDonald, Brenna C . 184 Mendlowitz, Sandra 175 McDonald, Eric J . 243 Menon, Vinod 160 McDonald, Krysta 244 Mercaldo, Valentina 48, 213 McDonnell, Michael 259 Mercer, Kristina B . 245, 252 McDougal, Robert 190 Merchant, Kalpana 1 McDougle, Christopher 147 Meresh, Edwin 255 McElroy, Susan 262 Merikangas, Kathleen Ries 84, 148, 176 McEwen, Bruce 93, 153, 202, 211, Merlo-Pich, Emilio 271 231 Merrill, David A . 187, 235 McFadden, Kristina L . 245 Mervis, Carolyn 186

330

ACNP Annual Meeting Book 2013 rev8.indd 330 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Mesholam-Gately, Raquelle 242 Mobarrez, Fariborz 166 Mettlach, Gabriel 211 Moechars, Dieder 267 Metzger, David S . 174, 217 Moeller, James R . 33, 199 Metzler, Thomas 274 Moeller, Scott J . 247, 249 Metz, Verena 258 Mogali, Shanthi 258 Meyer, Christian 178 Moghaddam, Bita 1, 123, 236 Meyer, Jeffrey H . 180 Mohanty, Suman 103, 227 Meyer, Roger 86, 231 Molosh, Andrei 273 Meyer, Walter 236 Molteni, Raffaella 263 Meyer-Lindenberg, Andreas 1, 131, 140 Momenan, Reza 167, 181, 225, 257 Meyers, Kortni 171 Monge, Zachary A . 179, 180 Miake-Lye, Sam 213 Monte, Fabricio H . Do 205 Miano, Davide 265 Montefeltro, Andrés P . 233 Michopoulos, Vas 245 Monteggia, Lisa 1, 163, 201, 239 Mickey, Brian J . 171, 172 Monterosso, John 184 Miczek, Klaus A . 96 Montojo, Caroline A . 241 Migliore, Raffaele 224 Moody, Teena 169, 181 Miguel, Euripedes C . 183, 228 Moondra, Priyanka 175 Mihara, Takuma 205 Moore, Nicole L .T . 201 Mikhno, Arthur 33, 199 Moorman, David 197 Miklowitz, David 234 Moran, Amy 235 Milad, Mohammed R . 137, 196, 243, Mordi, Isioma 217 247, 253, 274, 275 Morgan, Cassie Rae 228 Milak, Matthew 172, 197 Morgan, Drake 272 Milekic, Maria 18, 43, 44, 45, 207 Morgan, Judith 185 Milella, Michele 188 Morimoto, Sarah Shizuko 194 Miller, Andrew H . 147, 189 Morishita, Hirofumi 217 Miller, Brittney 264 Morisseau, Christophe 31, 250 Miller, Brooke 97, 107, 213 Moritz, Amy 264 Miller, Erin 271 Moriyama, Tais 228 Miller, Gregory 81, 174, 269 Moron-Concepcion, Jose 201 Miller, Karen Klahr K . 275 Morris, David W . 222 Miller, Michael 225, 236 Morris, John C . 221 Miller, Shefali 183 Morris, Matthew C . 230 Minabe, Yoshio 204 Morrissey, Judy L . 224 Mineur, Yann S . 216 Morrissey, Kathryn 255 Ming-Shang, Kuo 265 Morrow, A . Leslie 214 Mintun, Mark A . 221 Morrow, Eric M . 211 Mintzopoulos, Dionyssios 209 Morrow, Jonathan D . 207 Minuzzi, Luciano 178 Morrow, Leslie 229 Minzenberg, Michael J . 244, 246, 247 Mosconi, Matthew 97, 103, 104, 227, Mirnics, Karoly 1, 201, 212 287 Mirrione, Martine 195 Moseman, Scott 186 Mischoulon, David 212, 219, 260 Moser, David J . 183 Mishra, Santosh 219 Moskal, Joseph 268 Misyrlis, Michail 249 Mouchlianitis, Elias 170 Mitchell, Amanda 212 Moussa, Malaak N . 183 Mitchell, Michael 231 Mousseau, Darrell 275 Mitelman, Serge 175 Muchomba, Felix M . 36, 224 Miyakawa, Tsuyoshi 77, 287 Mueller, Bryon 179, 182, 225 Miyake, Shinichi 203 Mueller, Daniel J . 251 Miyoshi, Sosuke 203 Mueller, Walter E . 265 Mizrahi, Romina 180 Muir, Owen 202

331

ACNP Annual Meeting Book 2013 rev8.indd 331 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Mukherjee, Semanti 250 Nepomuceno, Diane 264 Mukhin, Alexey 170 Neri, Eric 219 Mulhern, Stephanie 197 Nestadt, Gerald 252 Mullin, Danielle 188 Nestler, Eric 1, 54, 133, 209, Mumma, Joel 176 212, 215, 265 Muratore, Alexandra F . 240 Neumaier, John F . 211, 217 Murphy, Dennis L . 252 Neumeister, Alexander 173 Murphy, Eleanor 193 New, Antonia S . 168 Murphy, Niall 164 Newcomer, John W . 164, 223 Murphy, Susan 185 Newcorn, Jeffrey 171 Murray, Jennifer E . 197 Newman, Jason 211, 216 Murray, Susan 204 Newton, Thomas 227, 261 Murrough, James 62, 221, 287 Neylan, Thomas 95, 230, 274 Muschamp, John 209 Neymotin, Samuel 190 Musselman, Dominique L . 230 Nguyen, Dana 245 Musselman, Samuel 185 Nguyen, Thai 234 Muzik, Maria 177 Nguyen, Tuong-Vi 232 Mwangi, Benson 186, 187 Nichols, Charles 17, 25, 26, 191, Myers, Richard M . 253 287 Myrick, Hugh 176 Nickerson, Lisa 170 Naber, Dieter 221 Nicol, Ginger E . 164, 223 Nabulsi, Nabeel B . 184 Nicoll, Roger 211 Nackenoff, Alexander G . 266 Niculescu, Alexander B . 255 Nader, Karim 140 Nielsen, Philip 30, 170 Naganawa, Mika 173 Nielson, David 260 Nagata, Kin-ya 206 Nieman, Lynnette K . 229 Naidu, Kamalakkannan 252 Niendam, Tara 244, 246, 247 Najjar, Fedra 258 Nierenberg, Andrew A . 219, 234 Nakajima, Shinichiro 193 Nierenberg, Jay 176 Nakamura, Alyson 256 Nievergelt, Caroline 46, 241 Nakamura, Kazuhiko 157 Nie, Xiang 265 Nakamura, Masataka 206 Nikolayev, Alexander 265 Narasimhan, Sneha 118, 229 Nilsson, Carol 7 Narayan, Soumya 216 Nishimura, Shintaro 203 Narayan, Vaibhav 166, 197, 198 Niswender, Colleen M . 270, 271 Narendran, Rajesh 172 Niwa, Minae 203, 248 Narumiya, Shuh 265 Niznikiewicz, Margaret 40, 242, 246 Nasca, Carla 231 Nobile, Cameron 209 Nasrallah, Henry 173, 258 Nobrega, Jose 163, 194 Nathan, Pradeep J . 239 Nock, Matthew 243 Navarra, Rachel 266 Noetzel, Meredith J . 271 Neary, Meaghan 170 Noone, Rachel 226, 235 Nedergaard, Maiken 191 Nopoulos, Peggy C . 183 Negus, Steve 270 Norbury, Ray 241 Neigh, Gretchen 232 Nordström, Peter 166 Neill, Joanna 204 Noronha, Antonio 155, 287 Nelson, Brent G . 194 Norremolle, Anne 193 Nelson, Eric 20, 170 Norrholm, Seth D . 176, 181, 231, Nelson, Katharine 225 244, 245, 249 Nelson, Mark 213 Norton, Daniel 239 Nemeroff, Charles B . 83, 153 Nosal, Eryka 232 Németh, György 224 Nouriani, Bita 219 Nemoto, Kiyotaka 248 Nuechterlein, Keith H . 87, 240, 241

332

ACNP Annual Meeting Book 2013 rev8.indd 332 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Nugent, Allison C . 227 Ormerod, Brandi 210 Nunez, Rene 224 Orr, Scott 187 Nurmi, Erika L . 253 Orsini, Caitlin 205 Nurnberger, John 216 Ortinski, Pavel I . 203 Nwulia, Evaristus 216 Ortiz, Abigail 228 Nyberg, Fred 257 O’Shea, K Sue 214 Nye, Jeffrey 144 Oskooilar, Nader 224 Nyer, Maren 184 Ota, Kristie 196 Nylocks, Karin M . 231 Otiashvili, David 220 Oathes, Desmond 178, 186 Otto, Michael 234 O’Brien, Charles P . 176, 179, 180, Ouyang, Qing 211 188, 225 Overshiner, Carl 265 O’Buckley, Todd K . 214 Owens, Max 120, 233 Ochoa-Sanchez, Rafael 271 Owley, Thomas 258 Ochsner, Kevin 160, 259 Oxenkrug, Gregory F . 164 O’Connell, Patrick 165 Ozaki, Norio 248 O’Connor, Joann 268 Ozbek, Umut 234 O’Connor, Margaret 175 Ozburn, Angela 97, 101, 102, 208, Odlaug, Brian 219 218 O’Donnell, Anne 43, 207 Pace-Schott, Edward F . 275 O’Donnell, Maryann 195 Pace, Thaddeus W . 219 O’Donnell, Patricio 213 Packard, Mark J . 169 O’Donovan, Aoife 95, 230, 274 Pacult, Mark 230 O’Donovan, Claire 228 Padron, Adrian 264 O’Dowd, Brian F . 211 Palacio, Juan 180 Offord, Steve 256 Palesh, Oxana 219 Ogawa, Atsubumi 265 Palmer, Abraham A . 165 Ogawa, Lisa 269 Palmer, Barton W . 218 Ogden, Todd 172, 197 Palzes, Vanessa 179 Oh, Hyunjung 249 Pampel, Andre 99, 229 Ohi, Kazutaka 248 Pandey, Ghanshyam 166, 212, 255 Ohmura, Yu 266 Pandey, Subhash C . 218 Ojserkis, Rebecca A . 212 Pantazopoulos, Harry 166 Okun, Michele 57, 273 Papp, Mariusz 263 Okwara, Leonore 256 Parade, Stephanie H . 198 Olefsky, Jerrold M . 244 Paradiso, Sergio 183 Olincy, Ann 181 Pardo, Carlos 157 Olsen, Christina K . 224 Parekh, Puja 101, 208 Olvera, Rene L . 251 Parides, Michael K . 62, 221 O’Malley, Stephanie 152 Parise, Eric M . 204 Onaka, Yusuke 206 Parker, Clarissa C . 165 Oncken, Cheryl 257 Park, John 256 Ondrus, Matej 219 Park, Laura 253 O’Neill, Casey 272 Parks, Stephanie A . 190 Ongur, Dost 167, 179, 224, 243 Parrish, Jenna 249 Onitsuka, Toshiaki 187 Parsey, Ramin V . 79, 171, 172, 173, Oosterhof, Chris 271 174, 184, 222, Oosting, Ronald 267 223, 227 Oot, Emily N . 230 Parter, Amy 197 Oquendo, Maria 173, 174, 197, Partilla, John 270 220, 227 Parvaz, Muhammad 239, 247, 249 Ordeberg, Gunnar 257 Patel, Krishna 188 Oribe, Naoya 187, 242 Patel, Maxine X . 87

333

ACNP Annual Meeting Book 2013 rev8.indd 333 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Patel, Sachin 98, 122, 235, 287 Phillip, Shaw 168, 195 Patenaude, Brian 183 Phillips, Debra 258, 262 Paterson, Andrew 253 Phillips, Joshua 244 Patki, Gaurav 202 Phillips, Lawrence 230 Patrice, Cobb 261 Phillips, Mary L . 82, 160, 171, 172, Patterson, Beth 261 173, 174, 227 Patterson, Paul 157, 287 Piantadosi, Patrick B . 206 Paul, Steven 85, 93 Picciotto, Marina 143, 216 Paulus, Martin 245 Pichat, Philippe 264 Paus, Tomas 82 Pickar, David 85 Pavone, Kara 260 Piehl, Fredrik 166 Payer, Doris E . 182 Pierce, R . Christopher 164, 203 Payne, Gregory 192 Pietrzak, Robert 173 Pearlson, Godfrey 126, 173, 198 Pikalov, Andrei 257, 259, 261, 262 Pechtel, Pia 222, 223 Pike, Erika 261 Pecina, Marta 195 Pillai, Anilkumar 207 Pedersen, Cort 231 Pincus, Alexandra 210 Pedrelli, Paola 184 Pine, Daniel S . 20, 168, 170, 180 Pe’er, Itsik 250 Pinto, Jayant 232 Peeters, Pieter J . 197 Piralishvili, Gvantsa 220 Pelham, William 84 Piran, Sara 247 Pelic, Christopher G . 233 Pisoni, Angela 184 Pelton, Gregory 191 Pitman, Roger K . 187, 196 Pena, Catherine 54, 212 Pittenger, Christopher 182, 207 Peng, Kathy 186 Pizzagalli, Diego A . 208, 222, 223, 227 Pennington, Paul 275 Plaschkes, Inbar 267 Penzes, Peter 211 Plattner, Florian 211 Perez, Andrew M . 62, 221 Plebani, Jennifer G . 225 Perez, Pablo 189 Pletcher, Mathew 107, 213 Perez-Rodriguez, M . Mercedes 140, 168 Pletnikov, Mikhail 204, 210 Perier, Celine 233 Pocivavsek, Ana 163, 207 Perkins, Diana 40, 242, 246 Pogorelov, Vladimir 207 Perlman, Susan 173 Poldrack, Russell 184 Perreault, Melissa L . 211 Pollard, Harvey B . 197 Persad, Carol 232 Pomara, Nunzio 176, 224 Pershing, Michelle 163 Pond, Timothy 257 Persson, Jennie 219 Ponting, Chris 253 Peskind, Elaine R . 194 Poole, Sabrina 174, 220 Peterchev, Angel V . 91, 194, 234 Popescu, Marlene 219 Peters, Amy 234, 240 Popoli, Maurizio 263 Peters, Bart D . 179, 245 Popp, Danielle 190 Peterson, Bradley S . 169, 173, 184, 275 Poppe, Andrew 244 Peterson, Jarod 275 Porcu, Patrizia 214 Peters-Strickland, Timothy 227 Porrino, Linda 139, 183 Petkova, Eva 223, 227 Porter, Jenny 259 Petrides, Georgios 178, 235 Posner, Kelly 86 Petti, Alexander 172 Posse, Patricio Riva 233 Pettinati, Helen M . 225 Post, David 178 Pezous, Nicole 255 Potenza, Marc N . 143 Pfefferbaum, Adolf 189 Potkin, Steven 179, 218, 245 Phan, K . Luan 178, 240 Powell, Susan B . 210 Phan, Phillip 85 Power, Jonathan 189 Philip, Noah S . 177, 231 Pozo, Karine 211

334

ACNP Annual Meeting Book 2013 rev8.indd 334 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Prabhakaran, Ranjani 245 Rao, Rahul 273 Preda, Adrian 179, 245 Rao, Uma 1, 230 Preer, Lily I . 174 Rapaport, Mark Hyman 219 Prescot, Andrew 181 Rapoport, Judith L . 74, 180, 195, 228 Prescott, Jennifer 212 Rapoport, Stanley 169 Price, Julie C . 187 Rasenick, Mark M . 215, 217 Price, Lawrence H . 177, 231 Rasetti, Roberta 245 Prikulis, Ingrid 214 Rasgon, Natalie 169 Primeau, Michelle 186 Rashid, Barnaly 198 Prisciandaro, James J . 120, 181, 233, 246 Raskind, Murray A . 194 Proper, Caitlin 197 Rasmussen, Dennis D . 194 Propper, Lukas 228 Rasmussen, Steven 225 Proudfit, Greg H. 247 Rauch, Scott 80 Pugh, Phyllis C . 208, 268 Ravindran, Arun 226 Puhl, Matthew D . 209 Ravishankar, Harshita 221 Pulaski, Matt 255 Ray, Brenda 233 Punzi, Giovanna 251, 255 Ray, Lara 152 Puzia, Megan 243 Raznahan, Armin 168 Qi, Xiaoli 210 Reamer, Elyse 188 Qian, Meng 221 Recasens, Ariadna 233 Qin, Haide 252 Reddy, Arubala P . 164 Qin, Liya 215 Reddy, Felice 193 Qiu, Yanyan 264 Reddy, India 267 Quintero, Gabriel 207 Reed, Brian 233 Quirk, Gregory J . 80, 137, 205, 243, Reed, Stephanie Collins 256 253 Regenthal, Ralf 99, 229 Raalten, Tamar van 169 Reichel, Carmela M . 266, 274 Rabiner, Eugenii Alfredovich 193 Reichert, Chelsea 176 Rabinowitz, Jonathan 223 Reid, Meredith A . 177 Rabinowitz, Yaacov Z . 223 Reilly, James 242 Rabin, Rachel A . 256 Reiman, Eric 190 Racagni, Giorgio 263 Reimers, Jeremy M . 218 Racine, Emma 226, 235 Reimers, Mark A . 254 Rada, Pedro 204 Reis, Surya 272 Radel, Mark 255 Reisberg, Barry 234 Ragland, J . Daniel 244, 246, 247 Reiss, Allan 169 Rai, Narayan 216 Reissner, Kathryn 207 Rainer, Quentin 271 Reissner, Kathryn J . 209 Raines, Jeffrey 190 Rekshan, William 226 Raji, Cyrus A . 187, 235 Remington, Anne 273 Ramakrishnan, Viswanathan 274 Remington, Gary 163, 193, 244 Ramamoorthy, Sammanda 252 Ren, Juanjuan 221 Raman, Rema 233 Ren, Qian 266 Ramchandani, Vijay A . 167, 225, 230, Ren, Xinguo 166 248, 254, 257, 260 Ren, Yan 189 Ramesh, Divya 256 Renner, Brian 177 Rana, Samir 208 Renshaw, Perry F . 181 Randall, Patrick 176 Repovs, Grega 182 Randolph, Christopher 190 Resnick, Susan M . 182 Ranganath, Charan 244 Ressler, Kerry 1, 128, 138, 176, Rannals, Matthew D . 218 181, 231, 244, Ranscht, Barbara 165 245, 249, 252, 253 Rao, Madhu 274 Reti, Irving M . 234

335

ACNP Annual Meeting Book 2013 rev8.indd 335 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Revilla, R . 233 Rosas-Vidal, Luis E . 205 Reyes-Madrigal, Francisco 174 Rose, Jed 170 Reynolds, Charles 156 Rosen, Tove 173 Rice, Kenner C . 263 Rosenbaum, Jerrold 85 Richards, Anne 274 Rosenblum, Katherine 177 Richter, Peggy M .A . 251 Rosoklija, Gorazd B . 215, 216 Riedner, Brady 176 Ross, Christopher A . 204 Rienas, Christopher A . 215 Ross, Randal 219 Riga, Maurizio 195 Ross, Robert 170 Riggs, Lace 265 Rosser, Tena 241 Riley, John 205 Rossetti, Andrea Carlo 263 Riley, Misha M . 272 Rosso, Isabelle I . 174 Ringrose, Rachel 240 Roth, Bryan L . 25, 191 Ripke, Stephan 159 Rothberg, Amy 188 Risbrough, Victoria 46, 95, 149, 208, Rothman, Richard B . 90, 270 241, 271 Rothschild, Anthony J . 231 Risinger, Robert 220 Rouru, Juha 267 Riva, Marco A . 263 Rowland, Laura M . 132 Rizavi, Hooriyah S . 166 Rowland, Neil E . 272 Rizvi, Sakina 226, 243 Rowley, Helen 268 Roach, Brian J . 179, 182 Roy, Alec 248 Roalf, David 273 Roy, Amy K . 180 Robbins, Trevor 84, 154 Royster, Erica 230 Roberson, Chelsea 184 Rubenstein, John 1 Roberts, Charles T . 164 Rubinow, David 229 Roberts, Elian 274 Rubinstein, Dani 187 Robertson, Kimberly 272 Rubin, Todd 211 Roberts, Rosalinda C . 167 Rucker, Evelyn 274 Robinson, Delbert G . 178, 261 Rudrauf, David 239 Robinson, Michael J .F . 209 Rujescu, Dan 252 Robinson, Oliver J . 125 Runeson, Bo 166 Robinson, Terry E . 207 Ruparel, Kosha 27, 171, 273 Robison, Alfred Jay 214 Rupprecht, Laura 208 Robson, Matthew J . 165 Rush, Craig R . 261 Rodd, Zachary A . 198 Rusjan, Pablo 180 Rodman, Alexandra 243 Russell, James 275 Rodriguez, Carolyn 172, 197 Russo, Scott 147, 209, 215 Rodriguez, Mariana 205 Ruth, Adam 222 Rodríguez-Mayoral, Oscar 174 Ruzicka, W . Brad 216 Roe, Katherine 186 Ruzickova, Martina 228 Roffman, Joshua L . 94 Ryan, Kelly 240, 241 Rogawski, Michael A . 93 Rzhetsky, Andrey 142 Rohan, Michael 202 Sabbag, Samir 193 Rohrig, Stephanie 110, 223 Sabbineni, Amithrupa 185 Roiser, Jonathan 170 Sabino, Valentina 272, 273 Roitman, Mitchell F . 267 Sablinski, Tomasz 144 Rojas, Donald 245 Sacher, Julia 97, 99, 100, 229, Rollins, Brandi 253 288 Rombouts, Serge 169 Sachs, Gary S . 226 Rook, Jerri M . 270 Safadi, Ziad 198 Roontiva, Auttawut 190 Sahakian, Barbara J . 84 Rosa-Neto, Pedro 188 Sahara, Naruhiko 175, 189 Rosario, Maria Conceicao 228 Sahay, Amar 213

336

ACNP Annual Meeting Book 2013 rev8.indd 336 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Saito, Atsushi 210 Schiller, Crystal E . 275 Saito, Toshikazu 265 Schilström, Björn 270 Sajitharan, Deena 211 Schlaggar, Bradley 189 Sakharkar, Amul J . 218 Schloesser, Robert 202 Saladin, Michael 120, 233 Schmahl, Christian 140, 167 Salas, Ramiro 179, 188, 189 Schmidt, Heath D . 203, 208 Salem Jr, Norman 169 Schmidt, Jeremy 275 Salim, Samina 202 Schmidt, Matthew 233 Salles, Juliette 241 Schmidt, Peter 229, 232 Sallinen, Jukka 267 Schmitt, Lauren 103, 227 Salmeron, Betty J . 183 Schmitz, Anja 176 Salomon, Daniel 255 Schneekloth, Terry 254 Salvador, Mirian 267 Schneider, Andrea 182 Sammel, Mary 230 Schneider, Marguerite R . 168 Samuels, Jack 252 Schober, Douglas 265 Sanacora, Gerard 184 Schoedel, Kerri A . 259 Sanchez, Connie 195 Schoepp, Darryle 1 Sanchez, Cristina L . 170, 205 Schooler, Nina R . 257 Sanchez, Raymond 87, 227 Schork, Nicholas 31, 250, 255 Sanders, Jeff 207 Schramm-Sapyta, Nicole L . 205 Sandusky, George 255 Schraufnagel, Caitlin D . 228 Sanford, Benjamin J . 171 Schroeder, Frederick A . 186, 272 Santiago, Adrienne N . 215 Schroeder, Jason P . 263 Santoro, Giovanni 188 Schuebel, Kornel 217 Santos, M . I . 233 Schulze, Thomas 1, 163, 201, 239 Sargin, Derya 48, 213 Schulz, Kurt 171 Sarma, Kaushik 262 Schulz, S . Charles 182, 225 Sarpal, Deepak 178 Schwandt, Melanie L . 165, 225, 230, Sarter, Martin 201 248, 254, 257, 260 Sartor, Gregory C . 267 Schwarcz, Robert 163, 207 Sassi, Roberto 178 Schwartz, Danielle 219 Sato, João R 179, 183 Schwarz, Noah 212 Satterthwaite, Theodore 27, 171, 273, 288 Schweiger, Julia A . 164, 223 Saunders, Erika F .H . 195 Schweitzer, Robert 255 Savic, Aleksandar 182 Schwendt, Marek 266 Savitz, Jonathan 177 Scobie, Kimberly 213 Sawa, Akira 1, 151, 203, 216, Scofield, Michael D. 209, 266 218, 248 Scola, Gustavo 267 Saxon, Andrew J . 174 Seal, Karen 230 Saykin, Andrew J . 184 Seaman, Scott 195 Scalice, Stephanie 230 Sears, Christopher 241 Scaramello, Nayla 110, 223 Sears, Elizabeth 269 Schäble, Sandra 214 Seay, Julia 230 Schachar, Russell 175, 253 Sebastian, Blessan 38, 269 Schachter, Reva 175 Sedlak, Tom 218 Schacht, Joseph P . 176, 181 See, Ronald E . 266, 274 Schadt, Eric 142, 288 Segi-Nishida, Eri 265 Schäfer, Alexander 99, 229 Seguini, Mara 263 Schank, Jesse 203, 214, 263 Seidman, Larry J . 40, 242, 246 Schatzberg, Alan F . 178, 182, 253 Seifer, Ronald 198 Scherrer, Sandy 188 Seillier, Alexandre 266 Schettler, Pamela 219 Sellers, Edward M . 259 Schiller, Carola 265 Selvaraj, Sudhakar 170

337

ACNP Annual Meeting Book 2013 rev8.indd 337 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Selwyn, Reed 189 Shoaff, Jessica R . 248 Semenova, Svetlana 244 Shoblock, James R . 208, 264 Sequeira, Pedro A . 253 Short, Sarah 30, 170 Sershen, Henry 166, 221 Shott, Megan 195 Sethi, Adhiraaj 178 Shuhui, Wang 187 Setiawan, Elaine 180 Shukla, Akanksha 245 Setlow, Barry 154, 205, 240 Shuman, Joshua R . 185 Sevak, Rajkumar J . 257 Shumay, Elena 166, 249, 250 Seymour, Karen 243 Shungu, Dikoma 172, 174, 179, 197 Shaheen, S-M 253 Shurtleff, David 81 Shahid, Mohammed 267 Sibille, Etienne 1, 249 Shalev, Arieh Y . 191, 221 Sibley, David R . 264 Shan, Zhiying 210 Siddarth, Prabha 187, 235 Shankar, Ganesh 255 Siddiqui, Ishraq 244 Shanks, Marcus 205 Sidtis, John J . 176 Shansky, Rebecca 274 Siegel, Steven J . 205 Sharma, Aparna 255 Siekmeier, Peter J . 199 Sharp, Wendy 195 Sienaert, Pascal 222 Shatz, Carla 67, 71, 72 Sierra-Mercado, Demetrio 243 Shavitt, Roseli G . 183 Siever, Larry 140, 168 Shea, Stephen 195 Sigman, Mariano 36, 224 Sheau, Kristen 169 Sikharulidze, Zura 220 Shechner, Tomer 20, 170, 180 Silipo, Gail 110, 223 Sheeber, Lisa 242 Silk, Jennifer 185, 242 Sheehan, David V . 86 Silk, Kenneth 172 Shekhar, Anantha 255, 273 Silva, Alcino 241 Sheline, Yvette 221 Silva, Robert 226, 262 Shelton, Jonathan 264 Silveri, Marisa 174 Shelton, Micah 211 Silverman, Rebecca 188 Shelton, Richard C . 86, 185 Silverstein, Steve M . 244 Shen, Jiangshan J . 251 Simko, Hannah 275 Shen, Jun 178 Simmler, Linda D . 266 Shen, Maurice 211 Simmons, William K . 186 Shenton, Martha 187, 242 Simon, Naomi M . 212 Shepherd, Timothy 217 Simon, Nicholas 236 Sheridan, Eva 202 Simpson, Helen Blair 136, 169, 172 Sherif, Mohamed A . 190 Simpson, William 261 Sherwin, Robert 182 Singer, Zachary D . 179, 180 Shieh, Jennifer 170 Singh, Jaskaran 222 Shih, Pei-an Betty 17, 31, 32, 250 Singh, Manpreet K . 190 Shillan, Brittney 198 Singh, Rana 258 Shimada, Hitoshi 175 Singh, Tanvir 211 Shin, Joo Heon 251, 253, 254, 255 Singley, Erick 210 Shin, Lisa M . 187, 196 Sinha, Rajita 271 Shin, Rick 203 Sinon, Christopher G . 267 Shinn, Ann K . 179 Sinopoli, Vanessa 253 Shinotoh, Hitoshi 175 Sit, Dorothy 19, 57, 58, 273, Shintani, Norihito 206 288 Shiovitz, Thomas 220 Siu, Cynthia 226, 258 Shiovitz, Zoe 220 Sizemore, Glen M . 272 Shirayama, Yukihiko 266 Sklar, Pamela 1, 253 Shireman, Brock 264 Skolnick, Phil 22, 185 Shiroma, Paulo R . 260 Slagle, Anna 178

338

ACNP Annual Meeting Book 2013 rev8.indd 338 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Slaney, Claire 228 Spirito, Anthony 243 Sleezer, Brianna 198, 262 Spiro, Carolyn 180 Slezak, Diego Fernandez 36, 224 Spitsin, Sergei 217 Slifstein, Mark 259 Spitzer, Nicholas 209 Sliwa, Jennifer Kern 257 Sreenivasan, Karthik R . 185 Slome, Mary 225 Sripada, Chandra 116, 172, 229 Small, Gary 187, 235 Srivastava, Amita 181 Smith, Alex 273 Srivastava, Meera 197 Smith, Alicia K . 249, 252 Stahl, Lauren 223 Smith, Karen 273 Stan, Ana D . 260 Smith, Keith 164 Stanford, Arielle 1 Smith, Leslie 229 Stangl, Bethany L . 254, 260 Smith, Mark 27, 171, 225 Stankeviciute, Neringa 201 Smith, Robert C . 166, 221 Stansbury, Melissa 231 Smith, Sharon L . 268 Stan, Tiberiu Loredan 266 Smith, Yolanda 232 Stanton, Patric 268 Smits, Anouk 169 Stanwood, Gregg 267 Smoller, Jordan W . 243 Staples, Lindsay K . 187, 196 Smucny, Jason 181 Stark, Craig 245 Soares, Jair C . 186, 187 State, Matthew 1, 210 Sobota, Rosanna 205 Statnikov, Alexander 191 Sodhi, Monsheel 254 Stauffer, Shaun R . 270 Sohal, Vikaas S . 136 Steckler, Thomas 197, 206, 270 Solanki, Naimesh 202 Steele, Scott 246 Soleimani, Laili 62, 221 Stein, Elliot A . 183 Solin, Olof 267 Steinmetz, Sarah 245 Solis-Vivanco, Rodolfo 174 Stein, Murray B . 128, 160, 233, 245 Solomon, Marjorie 244, 246, 247 Stephen, Guter 252, 258 Sommer, Iris 168 Stephens, David 96 Sommer, Wolfgang H . 215 Stephen, Strakowski 168, 189 Song, Huijin 196, 247, 275 Stern, Chantal 170 Song, Jiali 255 Stern, Emily R . 240 Sonntag, Kai 202 Stevens, Angie 223 Soontornniyomkij, Benchawa 244 Stevens, Beth 147 Soontornniyomkij, Virawudh 244 Stevens, Jennifer 176, 231 Sorensen, James L . 174 Stevens, Karen 219 Sorenson, Andrea 165 Stiffler, Richelle 171, 172 Sorkin, John 190 Stigler, Kimberly A . 184 Soskin, David 260 Stinchcomb, Audra 271 Sottile, Melanie 186, 232 Stock, Veronika 192 Sourander, Andre 228 Stoeckel, Luke 194 Sousa, Vasco 266 Stohler, Christian 195 Southall, Noel 264 Stokes, Karen 233 Spagnolo, Primavera 225 Stoltenberg, Camilla 94 Spann, Marisa N . 173 Stone, Kathryn 196 Speirs, Ian 208 Stool, Louis 234 Spence, Jeffrey 228 Stoops, William W . 261 Spencer, Kevin M . 187, 242, 243 Strakowski, Stephen 223 Spencer, Sade 207, 209, 219 Straub, Richard 252 Sperry, Sarah H . 224 Strawn, Jeffrey 168, 223 Spiegel, Chad 233 Stromeyer, Charles 239 Spiegel, David 219 Stroup, Scott 127 Spiker, Danielle 186 Stuber, Garret D . 143, 267

339

ACNP Annual Meeting Book 2013 rev8.indd 339 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Stutz, Sonja J . 266 Talău, Ghiorghe 258 Subburaju, Sivan 216 Talbot, Lisa 274 Subotnik, Kenneth 240, 241 Talledo, Jo A . 259 Suckow, Raymond 197 Talloen, Willem 197 Sugar, Catherine A . 170 Talpos, John 149 Suhara, Tetsuya 175 Tamburrino, Marijo 253 Suh, Jesse J . 176, 179, 180 Tam, Clara 175 Sullivan, Edith V . 189 Tamminga, Carol 74, 126, 173 Sullivan, Jane 217 Tamura, Kouichi 203 Sullivan, Kelli M . 192 Tan, Chunfeng 211 Sullivan, Maria A . 258 Tan, Zhiqun 218 Sullivan, Patti 166 Tanaka, Kenji 266 Sullivan, Regina M . 153 Tanaka, Kohei 265 Summergrad, Paul 164 Tang, Amy 269 Sunderajan, Prabha 256 Tang, Lei 218 Sung, Lawrence M . 85 Taniguchi, Yu 210 Sun, Haosheng 54, 212, 215 Tanum, Lars H . 257 Sun, Hui 254 Tao, Ran 218 Sun, Xiaoying 233 Tapocik, Jenica 203, 214, 215, 248 Sun, Yu 198 Tarazi, Frank 267 Suomi, Stephen 165, 232 Tardito, Daniela 263 Suppes, Trisha 1, 262 Tariot, Pierre 190 Surcel, Helja-Marja 228 Tau, Gregory Z . 169 Susser, Ezra 94 Taylor, Bonnie P . 226, 235 Sutcliffe, James 1, 254 Taylor, Charles 245 Svenningsson, Per 222, 231, 266 Taylor, Jane R . 196 Svensson, Torgny H . 92, 270 Taylor, Joseph 17, 24, 172, 288 Swain, James E . 116, 177, 229 Taylor, Stephan 163, 188, 240 Swanson, Andrew M . 214 Teague, Kent 177 Swanson, James 84 Tenke, Craig E . 223 Swarm, Robert A . 221 Tennen, Howard 257 Swartz, Holly A . 185 Teo, Celine 163 Sweedler, Jonathan 7, 10, 11 Teppen, Tara 218 Sweeney, John A . 103, 173, 227, 242 Terwillinger, Robert 187 Sweet, Lawrence H . 177 Thada, Shantalaxmi 169 Sweet, Robert A . 211, 216 Thaker, Gunvant K . 173 Swerdlow, Neal R . 249, 259 Thambisetty, Madhav 182 Swift, Robert M . 152, 248 Thames, April D . 247 Sylvester, Chad 189 Thanos, Panayotis 33, 199, 288 Sylvia, Louisa 234 Thase, Michael E . 164, 192, 221 Szatmari, Peter 148 Thayer, Julian 247 Szczepanik, Joanna 227 Thida, Thida 179 Szeszko, Philip 77, 163, 178, 179, Thiyyagura, Pradeep 190 201, 239, 245 Thomas, Binu 260 Szumlinski, Karen K . 137 Thomas, Charmaine 241 Tabibnia, Golnaz 184 Thomas, Jason M . 51, 256 Tadayon-Nejad, Reza 178 Thomas, Jennifer 217 Tadic, Andre 222 Thomas, Laura A . 168 Taffe, Michael 90, 288 Thom, Lisa 245 Tajinda, Katsunori 203 Thompson, Britta S . 202 Takagi, Shunsuke 206 Thompson, Dennis 244 Takano, Harumasa 175 Thompson, Karla 229 Takeda, Masatoshi 248, 252 Thompson, Leslie 218

340

ACNP Annual Meeting Book 2013 rev8.indd 340 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Thompson, Paul 142, 176 Turetsky, Bruce 27, 171, 225 Thompson, Wesley 156, 218 Turkheimer, Federico 170 Thorbek, Ditte Dencker 271 Turkoz, Ibrahim 258 Thuras, Paul 260 Turna, Jasmine 261 Tidow, Nicola 251 Turncliff, Ryan 220 Tillisch, Kirsten 181 Turner, Cortney 202 Titulaer, Maarten 105, 229 Turner, Daria 274 Tiwari, Arun K . 247, 251 Turner, Jessica 179 Toda, Shigenobu 204 Turner, Mary B . 228 Todtenkopf, Mark 268 Turner, Nicholas 252 Toker, Lilach 267 Turrigiano, Gina 67, 68 Tolliver, Bryan K . 246 Turski, Waldemar 164 Tomasi, Dardo 166, 168 Tushir, Jogender Singh 138 Tomlinson, Anneka 204 Tustin, Nancy 217 Tong, My-Linh 224 Tyrka, Audrey 1, 177, 198, 231 Tong, Yunjie 184 Uchida, Hiroyuki 87 Tong, Yunxia 186 Uetani, Noriko 165 Torgerson, Carinna 181 Uhde, Thomas W . 171 Torossian, Carol 234 Uher, Rudolf 79 Torregrossa, Mary M . 196 Uhl, George 165, 269 Torres-Gil, Fernando 235 Ukai, Wataru 265 Torres, Laura 242 Umhau, John C . 169 Toth, Mate 271 Urbano, Maria R . 256 Toups, Marisa 222, 227, 256 Ursano, Robert 189, 197 Towbin, Kenneth 193 Ursini, Gianluca 251, 252, 255 Towle, Vernon 232 Vaidya, Jatin 179 Trampush, Joey W . 252, 261 Vaidya, Punit 234 Tranel, Daniel 239 Vaillancourt, David E . 103, 227 Tran, Phuong K . 209 Valentine, Thomas R . 177 Tran, Pierre 222 Valenza, Marta 273 Trantham-Davidson, Heather 266 Valera, Eve 175 Tran, Vi 25, 191 Valjakka, Risto 219 Tregellas, Jason 181, 245 Vallejo, Ana 177 Trevino, Kenneth 234 Vallender, Eric 269 Tripathi, Adarsh 234 van Belle, Janna 169 Trivedi, Hersh 205 Van Dam, Nicholas T . 259 Trivedi, Jitendra 234 Vandekar, Simon 273 Trivedi, Madhukar 79, 171, 172, 173, van den Oord, Edwin 142 174, 192, 222, VanElzakker, Michael B . 187, 196 223, 227, 256 vanMaanen, David 199 Tronson, Natalie 208 Van Meter, Anna 192, 231 Trossbach, Svenja 214 Van Nueten, Luc 222 Truitt, William 198, 273 Vanover, Kimberly E . 225 Tsai, Guochuan Emil 226 Vargas Upegui, Cristian David 180 Tseng, Angela 275 Varlamov, Oleg 164 Tseng, George C . 249 Varney, Seth 202 Tseng, Kuei Y . 218 Vaska, Paul 191 Tseng, Wan-Ling 193 Vatsalya, Vatsalya 257 Tsuang, Ming 242 Vawter, Marquis P . 253 Tsujimura, Tsuyoshi 218 Veer, Ashlee Van’t 131 Tsujino, Hanako 265 Veith, Christina 188 Tsunematsu, Tomomi 266 Velasquez, Kenia 188 Tsutsui-Kimura, Iku 266 Velazquez-Sanchez, Clara 273

341

ACNP Annual Meeting Book 2013 rev8.indd 341 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Veltman, Joris A . 33, 199 Wang, Harold 193 Ventura, Joseph 240, 241 Wang, Xiaofan 272 Verchinski, Beth A . 232 Wang, Xingbin 249 Verma, Ragini 273 Wang, Yang 184 Vermetten, Eric 95, 288 Wang, Ying 252 Verrico, Christopher D . 227, 261 Wang, Ze 180 Very, Etienne 241 Wang, Zhishun 169, 275 Vetreno, Ryan P . 215 Warden, Melissa R . 136, 193 Vialou, Vincent 265 Wardle, Margaret C . 255 Victor, Teresa 177 Ward, Maeve 184 Vieta, Eduard 180 Warren, Brandon L . 204, 265 Villa, Kathleen F . 240, 241 Warren, Ken 16, 288 Villringer, Arno 99, 229 Warren, Victor T . 244 Vinje, Morten 257 Waselus, Maria 206 Vinogradov, Sophia 113, 236 Wass, Caroline 243 Vinson, Paige N . 270 Wasylink, Suzanne 182 Visser, Susanna N . 84 Waterhouse, Barry 266 Viswanath, Humsini 188 Watkins, Christopher 144 Vladimir, Tolstikov 265 Watson, Stanley J . 202, 206, 253 Vogel-Ciernia, Annie 213 Waxmonsky, James G . 84 Vogel, Octavia 230 Weafer, Jessica 244 Voida, Stephen 191 Weber, Wade 168, 189 Voineskos, Aristotle 77, 179 Weele, Jeremy Veenstra-Vander 1 Volk, David W . 165 Wegbreit, Ezra 175 Volkow, Nora 16, 17, 22, 23, Wegener, Gregers 266 139, 166, 168, Wehring, Heidi J . 192 185, 191, 250 Wehrspaun, Claudia C . 253 Von Zastrow, Mark 123 Wei, Hongbing 212 Voyvodic, James 179 Wei, Zelan 275 Vranjkovic, Oliver 196 Weickert, Cynthia S . 195, 211 Vrijenhoek, Terry 33, 199 Weickert, Thomas W . 195 Vuittonet, Cynthia 248 Weideman, Andrea 245 Vunck, Sarah 163 Weiden, Peter J . 242 Vyas, Gopal 192 Weiland, Barbara 185 Wadzinski, Keaton 254 Weinberger, Daniel 218, 250 Wagner, Angela 187 Weinberger, Daniel R . 124, 167, 178, Wagner, Brandie 219 186, 187, 232, Wagreich, Eric 257 245, 251, 252, Wahlestedt, Claes 107, 133, 213, 253, 254, 255 214, 215, 267 Weinshenker, David 263 Wakschlag, Lauren 193 Weinstock, Joel 164 Walker, Brendan 131 Weisenbach, Sara 240, 241 Walker, Elaine 40, 242, 246 Weiser, Mark 199, 221, 258 Walker, N . Robrina 183 Weiss, Friedbert 271 Walker, Quentin 269 Weiss, Markus 255 Wallin, Anna 166 Weissman, Alexandra 243 Wall, Melanie 228 Weissman, Myrna M . 171, 172, 173, Walsh, Jessica 215 174, 222, 223, 227 Walton, Noah 203 Welge, Jeffrey 168, 189, 223 Walton, Zandra 212 Wells, Audrey M . 197 Wang, An-Li 188 Welsh, David 212 Wang, Changning 186, 272 Welsh, Robert 185, 188, 240 Wang, Gene-Jack 166, 168, 191 Welty, Natalie 208

342

ACNP Annual Meeting Book 2013 rev8.indd 342 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Werbeloff, Nomi 199 Wood, Jesse 236 Werner, David F 214 Wood, Kimberly 185 West, Andrew B . 210 Wood, Marcelo A . 158, 213 West, Anne E . 133 Wood, Michael W . 271 West, Tim 221 Woods, Scott 40, 242, 246 Westlund, Melinda 225 Woody, George E . 174, 188, 220 Westmoreland, Susan 269 Woolley, Josh 98, 113, 114, 115, Wetherill, Reagan R . 176, 179 236 Wexler, Bruce E . 194 Woolson, Sandra 30, 164, 170 Weyandt, Sarah 171, 172, 173, Woolwine, Bobbi 189 223, 227 Wootton, Cassandra 174 Wheelock, Muriah 185 Worthington, John 212 White, David 177, 185, 232 Wright, Jane 165 White, Michael 252 Wroolie, Tonita 169 Whitfield-Gabrieli, Susan 273 Wu, Helen 258 Whitmore, Nathan 246 Wu, Jin 266 Whittle, Catheryne 212 Wu, Minjie 172 Whyte, Alonzo 202 Wu, Salina 249 Wicks, Brittany 275 Wunsch, Amanda 211 Widjaja, Elysa 175 Wynn, Jonathan K . 182, 193, 223 Wiederschain, Dmitri 264 Xi, Liwen 222 Wiegand, Frank 222 Xiao, Ena 186, 245 Wierenga, Christina 242 Xiao, Jingbo 264 Wigal, Tim 84 Xiao, Yuan 169 Wigenstrand, Mattis 216 Xie, Bin 251, 254, 255 Wigg, Karen 251 Xie, Xiaohu 197 Wilcox, Charles S . 224 Xin, Yurong 43, 207 Wilden, Jessica A . 198 Xu, Jane 262 Williams, Janet B .W . 219 Xu, Meiyu 207 Williams, Katherine 169 Xu, Mengyuan 193 Williams, Leanne 183, 188, 226 Yamamori, Hedenaga 248 Williamson, Douglas 128, 288 Yamanaka, Akihiro 266 Williams, Wendol 184 Yamashita, Fumio 248 Williams, Wilbur 218 Yang, Jun 31, 250 Wilson, Alan A . 180, 193 Yang, Qing X . 171 Winek, Nathan 234 Yang, Shaolin 172, 176, 178 Wing, Victoria 134, 182, 243, 288 Yang, Tao 197 Winiger, Evan 255 Yang, Zhongfei 64, 194 Winkler, Thomas 192 Yanhong, Liu 221 Winterer, Georg 134 Yan, Jia 254, 260 Wisner, Katherine L . 57, 273 Yao, Li 169 Wisniewski, Stephen 57, 273 Yao, Xiang 166, 197 Witkin, Jeffrey M . 265 Yao, Yin 193, 252 Wittenberg, Gayle 166, 197, 198 Yarasheski, Kevin 221 Witten, Ilana B . 267 Yard, Michael 255 Wolf, Daniel 17, 27, 28, 29, Yasuda, Yuka 248 171, 225, 273, 288 Yates III, John R . 64, 194 Wolf, Marina E . 129, 218 Yates, Nathan 216 Wolkowitz, Owen M . 218 Ye, Jieping 197 Wong, Catherine 64 Yeckel, Catherine 182 Wong, Christopher 166 Yehuda, Rachel 1, 138, 260 Wong, Dean F . 85, 141, 182 Yeo, Seungeun 250 Wong, Kwok-Kin 212 Yi, Jennifer 168, 193

343

ACNP Annual Meeting Book 2013 rev8.indd 343 11/15/13 4:10 PM ACNP 52nd Annual Meeting • Final Program

Yi, Soojin V . 138 Zevallos, Carlos R . 171 Yieh, Lynn 166, 197 Zgrajka, Wojciech 164 Yilmaz, Zeynep 247 Zhang, Aifeng 176 Yingling, Michael D . 164, 223 Zhang, Bingzhi 264 Yiu, Adelaide 48, 213 Zhang, Chunling 249 Yoffe, Rinat 199 Zhang, Fengyu 250 Yolken, Robert 248, 258 Zhang, H . Steve 54, 212 Yoo, Ji Hoon 212 Zhang, Huaibo 218 Yoon, Jong 244, 246, 247 Zhang, Hui 212 Yoshioka, Mitsuhiro 266 Zhang, Ji-Chun 266 Young, Jared 193, 209, 210 Zhang, Jihui 176 Young, Kimberly A . 176, 179, 180 Zhang, Ming-Rong 175 Young, L . Trevor 267 Zhang, Sheng 182 Young, Robert 235 Zhang, Xiao-lei 268 Youngstrom, Eric 86, 173, 192, 231 Zhang, Yan 178 Yu, Bangning 25, 191 Zhang, Yanan 264 Yuan, Qiaoping 168, 214, 217, Zhang, Yan-Ling 272 232, 250 Zhan, Liang 169, 176 Yuksel, Cagri 167 Zhou, Tai 64, 194 Yun, SuJin 264 Zhou, Weiyin 169 Yurgelun-Todd, Deborah 139 Zhou, Xianjin 149 Yurgil, Kate 46, 241 Zhou, Yun 182 Zahr, Natalie M . 189 Zhou, Zhifeng 168, 214, 232, 250 Zai, Clement C . 251 Zhu, Chong-Bin 165 Zai, Gwyneth 251 Zhu, Shanshan 204 Zakzanis, Konstantine K . 244 Zia, Mohammad 174 Zalesky, Andrew 139 Ziemer, David 230 Zametkin, Molly 260 Zimmer, Josh 269 Zammit, Gary 259 Zitnik, Gerard 266 Zamudio-Meza, Horacio 269 Zlebnik, Natalie E . 263 Zandi, Peter 234 Zoghbi, Huda 75, 76 Zarate, Carlos 1, 151, 222, 226, Zohar, Joseph 206, 234 227 Zomorrodi, Reza 243 Zaremba, Sebastian 260 Zorumski, Charles 93 Zarrow, Marlene 220 Zsido, Rachel 275 Zavala, Roberto 209 Zubieta, Jon-Kar 171, 172, 188, Zebley, Benjamin 185 195, 232, 240, 241 Zeeland, Ashley Van 31, 250 Zucker, Nancy 186 Zeier, Zane 107, 213 Zukin, Stephen R . 27, 171, 224, 225, Zeitzer, Jamie 219 268 Zelli, Danielle 231 Zunta-Soares, Giovana B . 186 Zeng, Huadong 189 Zvyagintsev, Michael 170 Zepf, Florian Daniel . 170, 205 Zwanzger, Peter 251 Zetterberg, Henrik 176 Zywiak, William H . 248

344

ACNP Annual Meeting Book 2013 rev8.indd 344 11/15/13 4:10 PM Annual Meeting Evaluation

CME Credit

All meeting attendees are urged to complete an evaluation.

Attendees who are requesting CME credit for the meeting are required to complete the evaluation. This form is available online only.

To complete the online form while at the meeting, visit the ACNP Computer Center located in the Diplomat 1 & 2 Foyer

You may also access the evaluation on the ACNP website (www.acnp.org) under the “Annual Meeting” tab.

There will be a $40.00 charge for scientific registrants to obtain CME credits. The evaluation must be completed by January 23, 2014 in order to receive CME credit. ACNP phone: (615) 324-2360 5034A Thoroughbred Lane fax: (615) 523-1715 Brentwood, Tennessee 37027 email: [email protected] www.acnp.org